CLINICAL STUDY PROTOCOL  
 
 
Study ID: [REMOVED] 
 Study Title:  A Prospective, Open -label, Long -term Safety and Efficacy Study of  Teduglutide in 
Pediatric Patients with Short Bowel Syndrome Who  Completed TED -C14-006 
 Study Number:   SHP633 -304 
  
Protocol Version  and Date :   
Original Protocol :  08 Apr  2016 
Amendment 1 :  22 Nov 2016  
Amendment 2:   23 Mar 2017 
Amendment 3:   16 May 201 8 
Amendment 4:   [ADDRESS_482844]  2019 
 
PROTOCOL: SHP633 -304
TITLE: A Prospective, Open -label, Long-term Safet y and Efficacy  Study of 
Teduglutide in Pediatric Patients with Short Bowel Syndrome Who 
Completed TED -C14-006
DRUG: Teduglutide
IND: IND# [ADDRESS_482845] NO.: 2016-000849-30
SPONSOR: Shire Human Genetic Therapi[INVESTIGATOR_014], Inc.
[ADDRESS_482846] , Lexington, MA [ZIP_CODE] [LOCATION_003]
PROTOCOL 
HISTORY:Original Protocol: 08April [ADDRESS_482847] party witho ut the express written 
consent of Shire.
For non-commercial use only
Shire 
Protocol SHP633-304 CONFIDENTIAL Page2 
08 Apri12016 
PROTOCOL SIGNATURE [CONTACT_64783]'s (Shire) Approval 
 
Global Clinical Development 
Investigator's Acknowledgement 
I have read this protocol for Shire Study SHP633-304. ! Date: 
Title: A prospective, open label, long-term safety and efficacy study of teduglutide in pediatric 
patients with short bowel syndrome who completed TED-Cl4-[ADDRESS_482848] fully discussed the objective(s) of this study and the contents of this protocol with the 
sponsor's representative. 
I understand that the information in this protocol is confidential and should not be disclosed, 
other than to those directly involved in the execution or the scientific/ethical review of the study, 
without written authorization from the sponsor. It is, however, permissible to provide the 
information contained herein to a subject in order to obtain their consent to participate. 
I agree to conduct this study according to this protocol and to comply with its requirements, 
subject to ethical and safety considerations and guidelines, and to conduct the study in 
accordance with International Conference on Harmonization (ICH) guidelines on Good Clinical 
Practice (GCP) and with the applicable regulatory requirements. 
I understand that failure to comply with the requirements of the protocol may lead to the 
termination of my participation as an investigator for this study. 
I understand that the sponsor may decide to suspend or prematurely terminate the study at any 
time for whatever reason; such a decision will be communicated to me in writing. Conversely, 
should I decide to withdraw from execution of the study I will communicate my intention 
immediately in writing to the sponsor. 
Investigator Name [CONTACT_1781]: 
(please hand print or type) 
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_482849] IN FORMA TION
In the event of a serious adverse event (SAE), the investigator must fax or e-mail the Shire 
Clinical Study  Adverse Event Form forSerious Adverse Events (SAEs) and Non-serious AEs as 
Required by [CONTACT_230478] 24 hours to the Shire Global Pharmacovigilance and Risk 
Management Department. Applicable fax numbers and e-mail address can be found on the form 
(sent under separate cover). A copy of this form must also be sent to the contract research 
organization Shire Medical Monitor by  [CONTACT_3719] e -mail using the details below.
, MD PhD
Email: 
Fax: 
For protocol -or safety- related issues during no rmal business hours ([ADDRESS_482850] Time) ,the investigator must contact [CONTACT_317344]:
, MD PhD, 
Phone: 
Mobile: 
Email: 
Fax: 
For protocol -or safety- related issues outside of normal business hours , the investigator 
must contact [CONTACT_319404]:
, MD, 
Phone:  (medical emergencies –US & Canada)
Phone:  (medical emergencies –global)
Email: 
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_482851] 
(marketed or investigational) does not meet expectations (eg, inadequate or faulty  closure, 
product contamination) or that the product did not meet the specifications defined in the 
application for the produc t (eg, wrong product such that the label and contents are different 
products). For instructions on reporting AEs related to product complaints, see Section 8.
Please use the information below as applicable to report the Pr
oduct Quality Complaint:
Origin of Product Quality Complaint E-mail Address
North and South America
European Union and Rest of World
Telephone numbers (provided for reference): 
 Shire ([LOCATION_003]) 
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_482852] OF FIGURES .........................................................................................................................9
ABBREVIAT IONS .......................................................................................................................10
STUDY SYNOPSI S
......................................................................................................................12
STUDY SCHEDULE(S) ...............................................................................................................[ADDRESS_482853] Background .................................................................................................22
2STUDY OBJECTIVES AND PURPOSE ..............................................................................24
2.1 Rationale for the Study .............................................................................................24
2.2 Study  Objectives ......................................................................................................24
2.2.1 Primary  Objectives .................................................................................................24
2.2.2 Secondary  Objectives .............................................................................................24
3STUDY DESIGN ...................................................................................................................25
3.1 Study  Design and Flow Chart ..................................................................................25
3.2 Duration and Study  Completion Definition .............................................................27
4STUDY POPUL ATION.........................................................................................................28
4.1 Study  Inclusion Eligibility Criteria ..........................................................................28
4.2 Study  Exclusion Eligibility  Criteria
.........................................................................28
4.3 Teduglutide Eligibility  Criteria ................................................................................28
4.4 Teduglutide Treatment Inclusion Criteria
................................................................28
4.5
Teduglutide Treatment Exclusion Criteria...............................................................29
4.6 Follow -up Period Escape Criteria ............................................................................30
4.7 Reproductive Potential ................................ ................................ ............................. 30
4.7.1 Female Contraception ................................ ................................ ............................ 30
4.8 Discontinuation of Subjects ................................ ................................ ..................... 31
4.8.1 Teduglutide Discontinuation..................................................................................31
4.8.2 Study  Withdrawal ................................ ................................ ................................ ..31
4.8.3 Reasons for Discontinuation ................................ ................................ .................. 31
[IP_ADDRESS] Subjects ‘L ost to Follow -up’ Prior to Last Scheduled Visit ..................[ADDRESS_482854](s) ...........................................................34
6.2.1 Interactive Response Technology  (IRT) for Investigational Product 
Management ...........................................................................................................[ADDRESS_482855] Compliance ..................................................................................................37
7
STUDY PROCEDURES........................................................................................................38
7.1 Study  Schedule .........................................................................................................38
7.1.1 Screening ................................................................................................................38
7.1.2
Visits for Subjects Not Receiving Teduglutide .....................................................38
7.1.3
Visits for Subjects Receiving Teduglutide ............................................................39
[IP_ADDRESS] Pre-treatment Visit .................................................................................39
[IP_ADDRESS] Teduglutide Treatment Period (CxD1 -CxW24) .....................................40
[IP_ADDRESS] Site Visits during Teduglutide Treatment Period ...................................40
[IP_ADDRESS] Phone Visits ............................................................................................41
7.1.4 Teduglutide Follow -up Period ...............................................................................41
[IP_ADDRESS] Study  Completion/Earl y Termination Visit (EOS/ET Visit) .................41
7.2 Study  Evaluations and Procedures ...........................................................................42
7.2.1 Demographics, Medical History , and SBS History ...............................................42
7.2.2 Physical Examination .............................................................................................42
7.2.3 Vital Signs, Bod y Weight, Height, Head Circumference and Body  Mass 
Index (BMI) ...........................................................................................................42
7.2.4 Clinical L aboratory  Tests ................................ ................................ ....................... 43
7.2.5 Serum Sampling ................................ ................................ ................................ .....44
7.2.6 Pregnancy  Testing ................................ ................................ ................................ ..45
7.2.7 Antibody  Testing ................................ ................................ ................................ ...45
7.2.8 Volume of Blood ................................ ................................ ................................ ....45
7.2.9 Gastrointestinal -specific Testing ................................ ................................ ........... 46
[IP_ADDRESS] Fecal Occult Blood Testing ................................ ................................ ....46
For non-commercial use only
Shire CONFIDENTIAL Page 7
Protocol SHP633 -304 08April 2016
[IP_ADDRESS] Colonoscopy ................................ ................................ ........................... 46
7.2.10 Nutritional Support ................................................................................................46
7.2.11 Intake Diary ...........................................................................................................46
7.2.12 Output Diary ..........................................................................................................47
7.2.13 Health
-related Quality  of L ife Assessments ..........................................................47
[IP_ADDRESS] Pediatric Quality  of Life Generic Core Scale (PedsQL ™), Acute 
version ....................................................................................................48
[IP_ADDRESS] Pediatric Quality  of Life Family  Impact Module (PedsQL™), Acute 
version ....................................................................................................49
[IP_ADDRESS] PedsQL  Gastrointestinal Sy
mptoms Module (PedsQL ™), Acute 
version ....................................................................................................[ADDRESS_482856] ...........................................................................55
8.4
Dose Interruption and Permanent Discontinuation ................................ .................. 56
8.4.1 Dose Interruption Criteria Based on Known or Possible Risks of 
Teduglutide ............................................................................................................56
8.4.2 Dose Interruption Criteria Based on Drug -Induced L iver Injury .......................... 58
8.5 Early Termination of the Clinical Study ..................................................................59
9DATA MANAGEMENT AND STATISTICAL METHODS
................................ ............... 60
9.1 Data Collection ................................ ................................ ................................ ......... 60
9.2 Clinical Data Management ................................ ................................ ....................... 60
For non-commercial use only
Shire CONFIDENTIAL Page 8
Protocol SHP633 -304 08April 2016
9.3 Statistical Analy sis Process ......................................................................................60
9.4 Planned Interim Anal ysis, and Data Monitoring Committee ...................................60
9.5
Sample Size Calculation and Power Considerations................................................61
9.6 Study  Population ......................................................................................................61
9.7 Efficacy  Anal yses.....................................................................................................61
9.7.1 Efficacy  Endpoints .................................................................................................61
9.8 Safety  Anal yses........................................................................................................61
9.8.1 Safety  Endpoints ....................................................................................................61
9.9 Other Anal yses.........................................................................................................62
9.9.1 Health
-related Quality  of L ife Anal yses................................................................62
10SPONSOR’S AND I NVEST IGATOR’S RESPONSIBIL
ITIES...........................................64
10.1
Sponsor’s Responsibilities .......................................................................................64
10.1.1 Good Clinical Practice Compliance .......................................................................64
10.1.2 Indemnity /Liability  and Insurance .........................................................................64
10.1.3 Public Posting of Study  Inf
ormation......................................................................64
10.1.4 Submission of Summary  of Clinical Study  Report (CSR) to Competent 
Authorities of Member States Concerned and Ethics Committees ........................64
10.1.5 Study  Suspension, Termination, and Completion ..................................................65
10.2
Investigator’s Responsibilities .................................................................................65
10.2.1 Good Clinical Practice Compliance .......................................................................65
10.2.2 Protocol Adherence and Investigator Agreement ..................................................65
10.2.3 Documentation and Retention of Records .............................................................66
[IP_ADDRESS] Case Report Forms .................................................................................66
[IP_ADDRESS] Recording, Access, and Retention of Source Data and Study  
Documents ..............................................................................................66
[IP_ADDRESS] Audit/I nspection .....................................................................................66
[IP_ADDRESS] Financial Disclosure ...............................................................................[ADDRESS_482857] or Ethics Committee ................................ .................. 67
10.4 Privacy  and Confidentiality ......................................................................................68
10.5 Study  Results / Publication Policy ................................ ................................ ........... [ADDRESS_482858]  OF TABLES
Table 1-1: Schedule of Events Required for All Subjects ..............................................17
Table 1
-2: Schedule of Events for Subjects Not Receiving Teduglutide .......................18
Table 1
-3: Schedule of Events for Subjects While Receiving Tedug lutide ....................19
Table 5
-1: Prohibited Treatment .....................................................................................33
Table 7
-1: Approximate Volume of Blood to be Drawn from Each Subject 
Annually ........................................................................................................45
Table 7
-2: Developmentall y Appropriate PedsQL™Generic Core Scales .....................48
Table 8
-1: CTCAE Criteria for Adverse Events that May  Lead to Dose 
Interruption ....................................................................................................[ADDRESS_482859]  OF FIGURES
Figure 3 -
1: Study  Desig n Flow Chart ..............................................................................[ADDRESS_482860] aspartate aminotransferase
-HCG beta-human chorionic gonadotropin
BMI body mass index
CRA clinical research associate
CRO contract research organization
CSR clinical study report
CTCAE common terminology criteria for adverse events
DILI drug-induced livery injury
DMC data monitoring committee
DPP-[ADDRESS_482861]
IRT interactive response technology
IV intravenous
IWRS interactive web -based response system
MedDRA Medical Dictionary for Regulatory Activities
NCI National Cancer Institute
NDA new drug application
For non-commercial use only
Shire CONFIDENTIAL Page 11
Protocol SHP633 -304 08April 2016
NTT no-teduglutide treatment
PDA patent ductus arteriosus
PedsQL Pediatric Quality of Life inventory
PS parenteral support
PT/INR prothrombin time/international normalized ratio
QD once daily
SAE serious adverse event
SAP statistical analysis plan
SBS short bow el syndrome
SC subcutaneous
SOC standard of care
t1/[ADDRESS_482862] upper limit of normal
US [LOCATION_002]
WHO -DD World Health Organization –Drug Dictionary
For non-commercial use only
Shire CONFIDENTIAL Page 12
Protocol SHP633 -304 08April 2016
STUDY  SYNOPSIS
Protocol num ber: SHP633 -304 Drug: Teduglutide
Title of the study: A Prospective, Open -label, Long -term Safety and Efficacy Study of Teduglutide in Pediatric 
Patients with Short Bow el Syndrome (SBS) Who C ompleted TED -C14-006
Number of subjects (total and for each treatm ent arm):
Approximately 34subjects who completed the TED -C14-[ADDRESS_482863] of care 
treatment arm, are expected to enroll in this extension study. This study will enroll up to as many subjects as 
complete the TED -C14-006 study.
Investigator(s): Multicenter study
Site(s) and Region(s): 
Approximately 28 investigational sites in North America and Europe w ill participate in this extension study
Study period (planned):
October 2016 –September 2019Clinical phase: 3 Extension
Objectives:
Prim ary: To evaluate the long -term safety and tolerability of teduglutide treatment in pediatric subjects w ith SBS.
Secondary: To evaluate long -term efficacy of teduglutide treatment in pediatric subjects with SBS.
Rationale:
This is a Phase 3, prospective, open -label, long-term extension study to evaluate the safety and efficacy of 
teduglutide in pediatric subjects with short bowel syndrome (SBS) who completed the TED -C14-006 study (the 
core study). In addition to evaluating the long-term safety and durability of efficacy after 24-weeks of treatment, 
this extension study will evaluate the need for additional teduglutide treatment in these 
subjects, and will allow 
the study of first-time treatment of teduglutide -naïve subjects who participated in the standard of care (SOC) 
treatment arm in TED -C14-006. 
Investigational product, dose, and m ode of administration:
This study will allow repeat doses of teduglutide 0.05 mg/kg subcutaneous (SC) once daily (QD) injection for 
eligible p ediatric subjects. There is no active comparator or reference product.
Methodology:
This is a Phase 3, prospective, open -label, long-term extension study to evaluate the safety and efficacy of 
teduglutide in pediatric subjects who completed the TED -C14-006 study (core study).
Once the inform ed consent (and if applicable, informed assent) have been revie wed and signed , demographics, 
medical history , and short bowel syndrome 
history will be obtained .Subjects not receiving teduglutide treatment 
(ie, in a no-teduglutide treatment [NTT] period), will be seen every 12 weeks for safety, parenteral support (PS) 
requirements, and quality of life. The first NTT visit will occur approximately 12 weeks after the screening visit. 
At any point after screening, includin g during a NTT period, subjects who meet ≥[ADDRESS_482864], and parent 
agree to proceed with teduglutide therapy .
After the pre -treatment visit, sub jects who meet ≥1 of the teduglutide treatment inclusion criteria, and meet none 
of the teduglutide treatment exclusion criteria, will start a 28 -week cy cle, consisting of 24 weeks of teduglutide 
treatment at 0.05 mg/kg SC once daily, followed by a 4 -week follow -up period (during which no teduglutide is 
administered) ( Figure 3-1). During the [ADDRESS_482865] may "escape" the follow -up period early and proceed immediately to another pre -treatm ent visit. 
Follow ing com pletion of the [ADDRESS_482866] that completes a treatment cycle, will occur approximately 12 w eeks after the Week 28 (CxW28) 
visit.     
Atallsitevisits andtelephone contacts, safety will bemonitored andnutritional support will bereviewed and
adjusted as needed. Tomaintain consistency across centers, allattempts should bemade tofollow thenutritional
support adjustment guidelines (developed withSBS expert input and provided intheprotocol) fordecisions
regarding PSsupport reduction andadvances inenteral feeds based onweight gain, urine andstool output, and
clinical stability. Departure from theguidelines, however, isnotconsidered aprotocol deviation. (Appendix 1).
Study Design Flow Chart 
Figure legend: Safety and efficacy data for subjects not receiving teduglutide treatment are captured every 12 weeks, but 
subjects may proceed to the pre-treatment visit at any time in order to assess eligibility for teduglutide therapy. Eligible 
subjects will enter a 28-week teduglutide cycle. During this cycle, subjects will return to the site for safety and efficacy 
assessments at weeks 1, 2, 4, 6, 9, 12, 16, 20, and 24 ( solid black lines ).Phone visits are required approximately 1 week 
after adjustments in PS during the intervening weeks between weeks 2 and 24 ( dashed grey lines ). Subjects discontinue 
teduglutide at week 24 and enter a 4 -
week follow -up (no -treatment) period, during which ph one visits will be performed 
weekly (solid grey lines ). If an escape criterion is met during the follow -up period, subjects may proceed directly to 
another pre -treatment visit.
Study Inclusion Criteria: 
The subject will be considered eligible for the study if they meet allof the study inclusion criteria. Teduglutide 
treatment eligibility does not impact study eligibility.
1.Subject provides written inform ed consent (subject, parent or legal guardian and, as appropriate, 
informed assent) to participate in the study before completing any study -related procedures.
2.Subject completed the TED -C14-006 study (including subjects in the standard of care treatment arm).
3.Subject understands and is willing and able to fully adhere to study requirements as defined in this 
protocol. 
Study Exclusion Criteria: There are no exclusion criteria for this study.
Teduglutide Eligibility Criteria: Subjects are eligible for teduglutide treatment if at least one (≥1) of the 
teduglu tide treatment inclusion criteria, and none of the teduglutide treatment exclusion criteria, are met. In 
addition, the investigator and the subject (and/or parent or legal guardian, as appropriate) must agree to proceed 
with treatment.
Teduglutide Treatmen t Inclusion Criteria :
1.Subject is teduglutide -naïve, receiving PS, and unable to significantly reduce PS or advance enteral feeds 
(eg, 10% or less change in PS or advance in feeds) for at least 3months prior to and during the 
For non-commercial use only
Shire CONFIDENTIAL Page 14
Protocol SHP633 -304 08April 2016
teduglutide pre-treatment visit, as assessed by [CONTACT_093]. Transient instability for events such as 
interruption of central access or treatment for sepsis is allow ed if the PS returns to within 10% of 
baseline prior to the event.
2.Subject w as previously treated w ith tedugluti de and at least one of the following criteria is satisfied:
a.Increasing PS requirements follow ing teduglutide discontinuation.
b.Decreased PS requirement during prior teduglutide treatment, followed by [CONTACT_385952] n.
c.Deteriorating nutritional status (eg, weight loss or grow th failure) despi[INVESTIGATOR_319360].
d.Deteriorating fluid or electrolyte status despi[INVESTIGATOR_319361].
e.Severe diarrhea related to teduglutide discontinuation.
Teduglutide Treatment Exclusion Criteria:
1.Body  weight <10 kg at the pre- treatment visit.
2.Unresected gastrointestinal (GI) polyp, known polyposis condition , pre-malignant change, or 
malignancy, in the GI tract.
3.History of cancer in the previous 5 years except surgically curative skin cancers.
4.Serial transverse enteroplasty or other major intestinal surgery within 3 months preceding the teduglutide 
pre-treatm ent visit. Insertion of a feeding tube, anastom otic ulcer repair, minor intestinal resections ≤10 
cm, and endoscopic procedures are allow ed.
5.Intestinal or other major surgery planned or scheduled to occur during the 28 -week cycle.
6.Clinically significant in testinal stricture or obstruction.
7.Clinically significant, active or recurrent pancreatic or biliary disease.
8.Active, severe, or unstable, clinically significant hepatic impairment or injury, including the following 
laboratory values at the pre- treatm ent v isit:
a.Total bilirubin ≥2× upper limit of normal (ULN)
b.Aspartate aminotransferase (AST) ≥7 × ULN
c.Alanine aminotransferase (ALT) ≥7 × ULN
9.Renal dysfunction shown by [CONTACT_319406] (eGFR) below 
50mL/min/1.[ADDRESS_482867] repair, or patent ductus arteriosus (PDA) ligation.
11.Participation in a clinical study using an experimental drug (other than glutamine or Omegaven) within 
3months or 5.5 half-lives of the experimental drug, whichever is longer, prior to the pre-treatment visit 
and for the duration of the 28 -week cycle.
12.Treatment with analogs of glucag on-like peptide -1 (GLP -1), glucagon -like peptide -2 (GLP -2) (not 
including teduglutide), insulin -like grow th 
factor -1 (IGF -1), or grow th horm one, within 1 month 
preceding the teduglutide pretreatment visit.
13.Treatment with octreotide or dipeptidyl peptidase 4 (DPP -4) inhibitors within [ADDRESS_482868], closely -related 
compounds, or any of the stated ingredients.
15.Known history of alcohol or other substan ce abuse within 1 year prior to the pre-treatment visit.
16.Pregnant or lactating female subjects.
For non-commercial use only
Shire CONFIDENTIAL Page 15
Protocol SHP633 -304 08April 2016
17.Sexually active female subjects of child -bearing potential unwilling to use approved contraception 
during teduglutide treatment and for 30 days after the treat ment period.
18.Any condition, disease, illness, or circumstance that in the investigator’s opi[INVESTIGATOR_319362], prevents completion of the study, or interferes with analysis of the study results.
Follow -up Period Escape Criteria: At the discretion of the investigator, the follow -up period may be interrupted 
and the subject may proceed directly to the pre -treatment visit, if 1 of the following criteria is met:
1.Increasing PS requirements follow ing teduglutide discontinuation
2.Deteriorati ng nutritional status (eg, weight loss or grow th failure) despi[INVESTIGATOR_319363].
3.Deteriorating fluid or electrolyte status despi[INVESTIGATOR_319364].
4.Severe diarrhea related to teduglutide discontinuation.
Maximum duration of subject involvem ent in the study:
A subject will be considered enrolled in the study once the subject has provided signed consent, and meets all of 
the Study Inclusion Criteria . Subjects may participate in multiple NTT periods and/or multiple [ADDRESS_482869] has access (as needed) to teduglutide. 
The subject’s maximum durati on of participation is expected to be approximately [ADDRESS_482870] has not withdrawn early from thestudy for any reason 
prior to completing End of Study (EOS) visit.
Planned duration of no teduglutide treatment periods : variable, depending on disease course 
Planned duration of the teduglutide pre -treatm ent visit: 1 to 21 days
Planned cycle duration : 28 weeks. Each cycle consists of 24 w eeks of teduglutide treatment followed 
by a 4 -week follow -up period (no treatment)
Endpoints and statistical analysis: 
The safety population will consist of all enrolled subjects. The safety population will be used for both 
safety and efficacy analysis.
Efficacy Endpoints
The follow ing efficacy/PD endpoi nts will be measured. For each endpoint, analys es will be performed using the 
baseline of this extension study at the following time points: 1) End of each teduglutide treatment period (week 
24 or EOT), and 2) each study visit. In addition, the Efficacy/PD endpoints will be analyzed using the baseline of 
the Core study (TED -C14-006) and the baseline of each treatment cycle. The derivations of the weekly PS 
volume and 3 baselines will be described in the study Statistical Analysis Plan (SAP) in detail. 
Reduction in PS volume of at least 20%
Absolute and relative change in PS volume
Com plete weaning off PS
Change in days per w eek of PS
Health Econom ics and Outcom es Research (HEOR) Endpoints 
The following HEOR endpoints will be measured. For each endpoint , analyses will be performed using the 
Baseline of this extension study. In addition, the HEOR endpoints will be analyzed using the Baseline of each 
treatment cycle at approximately 12 week intervals (weeks 12 and 24 of each teduglutide treatment cycle, and 
every 12 w eeks for subjects not on teduglutide).
Change in Pediatric Quality of Life Inventory (PedsQL) score
Change in PedsQL Family Impact Module score
Change in PedsQL Gastrointestinal Symptoms Module Sub -Scales scores: 
For non-commercial use only
Shire CONFIDENTIAL Page 16
Protocol SHP633 -304 08April 2016
Food and Drink Limits
Diarrhea 
Safety Endpoints 
The follow ing safety endpoints will be measured. For each endpoint, analyses will be performed using the 
Baseline of this extension study. In addition, the safety endpoints will be analy zed using the Baseline of the Core 
study (TED -C14-006).
Adverse events , including those pertaining to GI symptoms
Vital signs, including temperature, heart rate, blood pressure
Body  weight, height (or length), head circumference (up to 36 months of age) trends on grow th charts, 
BMI; z -scores will be calculated for height (or length), weight, head circumference and BMI
Laboratory safety data ( ie, clinical chemistry, hematology, and urinalysis)
Urine output
Stool output
Antibodies to teduglutide
Gastrointestinal -specific testing (teduglutide treatment eligible subjects only) including colonoscopy or 
sigmoidoscopy, abdominal ultrasound, and FOBT, upper GI series with small bow el follow through 
Statistical Methodology for Efficacy Analysis
No claims of statistical significance will be made; however, 95% confidence intervals will be provided, if 
applicable. Continuous variables, including those assessed on a discrete scale, will be summarized using 
descriptive statistics including number of subjects, mean, median, standard deviation , maximum, and minimum. 
For categorical variables, statistical summaries will include number of subjects and percentages.
Statistical Methodology for Safety Analysis 
Safety data, including laboratory tests and vital signs assessments, will be summarized by [CONTACT_765]. AEs will also be 
collected and summarized. Descriptive statistics will be calculated for quantitative safety data as well as for the 
difference from baseline, if applicable. Frequency counts will be compi[INVESTIGATOR_78415].
Sample Size Justification 
As this is an extension study, the maximum number of subjects will be determined by [CONTACT_319407] -C14-006.
For non-commercial use only
Shire CONFIDENTIAL Page 17
Protocol SHP633 -304 08April 2016
STUDY  SCHEDULE(S) 
Table 1-1: Schedule of Events Required for All Subjects 
PeriodScreening End of Study or Early Termination
Scr EOS/ET
Visit Type Site Site
Informed consent/assentaX
Study eligibility X
Demographics, Medical historyb, SBS historycX
Dispense intake and output diaries X
Evaluate teduglutide treatment inclusion criteriadX
Adverse events X X
Concomitant medications and GI procedureseX X
Physical examination and vital signs, including weight X
Height and head circumferencefX
Review intake and output diariesg X
Record PS and EN prescriptions, and adjust as neededhX
Safety laboratory testsiX
PedsQL Generic Core Scale/ PedsQL Family Impact Module/ 
PedsQL Gastrointestinal Symptoms Module Sub -ScalesX
Antibodies to teduglutidejX
Fecal occult blood testingk(X)
Colonoscopyl(X)
Pregnancy testingm(X)
EN=enteral nutrition; EOS =end of study; ET=early termination; GI=gastrointestinal; NTx= no treatment; 
PedsQL= Pediatric Quality of Life Inventory; PS=parenteral support; SBS=Short Bowel Syndrome; Scr =Screening.
Note: (X) denotes conditional requirement for a given assessment if the subject meets certain conditions per protocol.
aInformed Consent (and informed assent, if applicable) must be obtained prior to performing any study -related procedures; con sent (and 
informed assent, if applicable) may be obtained anytime during the Week 28 (or EOS) visit for the TED -C14-[ADDRESS_482871] has any changes to the SBS history that had been collected at the baseline of the TED -C14-006, then the updated SBS 
history will be collected .
dSubjects who meet ≥[ADDRESS_482872], and 
parent or legal guardian agrees to proceed with teduglutide therapy. (Table 1 -3).
eConcomitant GI procedures include (but are not limited to) endoscopy, radiographic studies, GI and liver biopsies and associa ted 
pathology results.
fHead circumference will be measured in subjects [ADDRESS_482873] actual PS volume and hours per day, and actual EN volume per day, completed daily for a minimum of 2 
weeks prior to each site visit (Section 7.2.11 ). Urine and stool output should be recorded in the output diary over a 48 -hour period of PS 
and EN stabi lity before every clinic visit (See Section 7.2.12 for more detail).
hPS adjustments should be made after review of the intake and output diaries and the safety lab data according to the guidance for 
nutrition support adjustment provided in Appendix [ADDRESS_482874] received the equivalent of 2 treatment cycles 
(48 weeks of study drug exposure), and subjects who continue to receive teduglutide will undergo colonoscopy at [ADDRESS_482875] 30 days after study drug 
discontinuation.
For non-commercial use only
Shire CONFIDENTIAL Page 18
Protocol SHP633 -304 08April 2016
Table 1-2: Schedule of Events for Subjects Not Receiving Teduglutide 
Visit Number NTx
Visit Type Site
Visit Frequency Every 12 weeks 
Window (days) ±[ADDRESS_482876] as neededeX
Safety laboratory testsfX
PedsQL Generic Core Scale/PedsQL Family Impact Module/ 
PedsQL Gastrointestinal Symptoms Module Sub-ScalesX
Antibodies to teduglutideg(X)
Fecal occult blood testinghAnnually 
Colonoscopyi(X)
Serum samplejEvery 24 w eeks
EN=enteral nutrition; NTT = no teduglutide treatment; PedsQL = Pediatric Quality of Life Inventory; PS= 
parenteral support.
Note: (X) denotes conditional requirement for a given assessment if the subject meets certain conditions per 
protocol.
aSubjects who meet ≥[ADDRESS_482877], and parent or guardian agree to proceed w ith teduglutide therapy ( Table 1 -3).
bConcomitant GI procedures include (but are not limited to) endoscopy, radiographic studies, GI and liver biopsies 
and associated pathology results.
cHead circumference will be measured in subjects [ADDRESS_482878] actual PS volume and hours per day, and a ctual EN volume per day, completed daily for 
a minimum of 2 weeks prior to each study visit (Section 7.2.11 ). Urine and stool output should be recorded in the 
output diary over a 48 -hour period of PS and EN stability before every clinic visit (See Section 7.2.12 for more 
detail).
ePS adjustments should be made after review of the intake and output diaries and the safety lab data according to 
the guidance for nutrition support adjustment provided in Appendix [ADDRESS_482879] positive/specific for TED antibodies should have follow -up 
samples collected every [ADDRESS_482880] received 
the equivalent of 2 treatment cycles (48 w eeks of study drug exposure) and subjects who continue to receive 
teduglutide will undergo colonoscopy at 5 year intervals or more oft en as needed. See Section 7.2.9 for details.
j Lack of collection of serum samples will not constitute a protocol deviation.
For non-commercial use only
Shire CONFIDENTIAL Page 19
Protocol SHP633 -304 08April 2016
Table 1-3:Schedule of Events for Subjects While Receiving Teduglutide
PeriodPre-
treat mentTeduglutide Treat mentFollow -up
Visit Number PxCx
D1Cx
W1Cx
W2
Phone contact [CONTACT_319408] [ADDRESS_482881] is required approximately 1 week after PS adjustmentCxW24 
(EOT)CxW25 
CxW26 
CxW27CxW28
EOS/ET
Visit Type Site Site Site Site Site Site Site Site Site Site Site PhoneaSite
Cycle Day -21 to 0 1 8 15 29 43 64 85 113 141 169176
197 183
190
Window  (days) -21 to 0 ±2 ±2 ±2 ±2 ±4 ±4 ±4 ±4 ±4 ±2 ±2
Evaluate teduglutide 
eligibility (inclusion 
and exclusion) criteriaX Xb
Dispense intake and 
output diariesX X X X X X X X X X X
Adverse events X X X X X X X X X X X X X
Concomitant 
medications and GI
procedurescX X X X X X X X X X X X X
Physical examination 
and vital signs, 
including weightX X X X X X X X X X X X
Height and head 
circumferenced X X X X
Review intake and 
output diariese X X X X X X X X X X X X X
Record PS and EN Rx, 
and adjust as neededf X X X X X X X X X X X X X
Safety laboratory 
testsg XhX X X X X X X X X X (X) X
PedsQL Generic Core 
Scale/ Family Impact 
Module/ GI 
Symptoms Module 
Sub-ScalesX X X
Antibodies to 
teduglutideX X X X
Fecal occult blood 
testingh X X X
Colonoscopyi(X) (X) (X)
Pregnancy testingjX X X X X X X X X
Serum samplekX X
For non-commercial use only
Shire CONFIDENTIAL Page 20
Protocol SHP633 -304 08April 2016
Table 1-3:Schedule of Events for Subjects While Receiving Teduglutide
PeriodPre-
treat mentTeduglutide Treat mentFollow -up
Evaluate escape 
criterial X X
Dispense study drugmX X X X X X X X X
EN=enteral nutrition; EOF = end of follow -up; EOS = end of study; EOT = end of treatment; ET = early termination; FOBT = fecal occult blood test; FU = follow -up; GI = 
gastrointestinal; PedsQL = Pediatric Quality of Life Inventory; PS= parenteral support; SBS =Short Bowel Syndrome; SC = subcutaneous; Scr =Screening; TED = Teduglutide; 
Tx = treatment.
Note: (X) denotes conditional requirement for a given assessment if the subject meets certain conditions per protocol.
aPhone visits are required approximately 1 week after adjustments in PS. The assessments to be performed at phone visits are the same as those described for CxW25 -27 (except 
for evaluation of escape criteria). 
b Eligibility will need to be re -confirmed prior to the first dose in the cycle. Negative urine pre gnancy test is required prior to the first dose of teduglutide, but results of other labs 
obtained at the CxD1 visit are not required to determine teduglutide treatment eligibility.
cConcomitant GI procedures include (but are not limited to) endoscopy, ra diographic studies, GI and liver biopsies and associated pathology results.
dHead circumference will be measured in subjects [ADDRESS_482882] actual PS volume and hours per day, and actual EN volume per day. Two weeks of intake diary data are required before drug is administered at 
CxD1 .Diaries should be completed daily from CXD1 up to CXW6 visit during Teduglutide treatment. After CXW6 visit, diaries should be completed daily for a minimum of 2 
weeks prior to ea ch study visit during Teduglutide treatment ( Section 7.2.11 ). During the 24 week teduglutide treatment period, the intake diary will also be completed for 1 week 
following PS adjustment, and daily during the 4 -week follow -up period. Urine and stool output should be recorded in the output diary over a 48-hour period of PS and EN stability 
before every clinic visit, and within 1 week of implementing a change in the PS prescription (See Section 7.2.11 for more detail).
fPS adjustments should be made after rev iew of the intake and output diaries and the safety lab data according to the guidance for nutrition support adjustment provi ded in
Appendix [ADDRESS_482883] PT/INR at the pre -treatment 
visit. Additional collection will occur if a potential drug -induced liver injury signal is observed. For pediatric subjects in diapers, urine specimen collection should be attempted as 
part of the safety labs, but lack of urinalysis will not constitute a protocol deviation.
hFOBT should be performed on teduglutide -exposed subjects on an annual basis.
i The Teduglutide -naïve subjects age 12 and older will undergo colonoscopy at the pre-treatment visit if one has not been performed within 1 year. Subjects of any age with newly 
positive FOBT results at the pre -treatment visit for which a rea dily detectable cause cannot be identified (eg, anal fissure) will undergo a colonoscopy prior to receiving 
teduglutide. If newly positive FOBT results (for which a readily detectable cause cannot be identified) are obtained at the e nd of a teduglutide tre atment cycle (CxW24/EOT), 
colonoscopy will be performed. The need for colonoscopy in response to positive FOBTs at CxW12 is at the discretion of the in vestigator. Teduglutide -exposed subjects who have 
received the equivalent of 2 treatment cycles (48 weeks of study drug exposure) will undergo colonoscopy. See Section 7.2.[ADDRESS_482884] is performed on all females of child-bearing potential (FOCBP) at the teduglutide pre -treatment visit. Urine pregnancy tests will be administered at all 
other visits according to the study schedules, or if pregnancy is suspected, or as specified per protocol upon withdrawal of the subject from the study
k Lack of collection of serum samples will not constitute a protocol deviation
l If escape criteria are met, the subject may proceed directly to another pre -treatment visit at the discretion of the investigator
m The first SC injection of teduglutide in treatment -naïve subjects will be administered under the supervision of the investigator/designee after which the subject will be observed 
For non-commercial use only
Shire CONFIDENTIAL Page 21
Protocol SHP633 -304 08April 2016
Table 1-3:Schedule of Events for Subjects While Receiving Teduglutide
PeriodPre-
treat mentTeduglutide Treat mentFollow -up
for hypersensitivity reactions for at least 4 hours. The site of administration (arm, thigh, abdomen) of the first teduglutide dose must be specified and recorded in the eCRF
For non-commercial use only
Shire CONFIDENTIAL Page 22
Protocol SHP633 -304 08April 2016
1BACKGROUND INFORMATI ON
1.1 Indication and Current Treatment Options 
Short bowel sy ndrome (SBS) is a rare disorder resulting from congenital abnormalities or severe 
intestinal diseases that result in major surgical resections of the small intestine. I t is estimated 
that, at most, there are a few hundred pediatric subjects 1 year and older with ( Khan et al. 
2015; Wales et al. 2004 ) .Unlike the adult population, the majority  of cases of SBS in pediatric 
subjects are due to congenital anomalies or catastrophic events that occur during infancy . 
Although the small intestine is capable of remarkable adaptation, excessive loss of absorptive 
surface area or specialized functions can lead to dependence on parenteral nutrition or 
intravenous (IV) fluids (parenteral support [PS]). Treatment of both pediatric and adult patients 
is focused on achieving adequate intestinal absorpt ion to allow for minimization or 
discontinuation of PS. About 30% of infants with SBS become independent of PS requirements 
by 12months of age, and an additional 10% wean off PS by  24 months of age. After this time, 
linear intestinal growth slows. About 60% of pediatric subjects with SBS are able to become 
independent of PS within 5 years of the initial diagnosis (Khan et al. 2015 ).Nevertheless, despi[INVESTIGATOR_115047], many  pediatric subjects remain dependent on PS. Complications 
of long -term PS include liver disease, catheter -related blood stream infections, central line -
associated venous thrombosis and dwindling central venous access. Sepsis is the leading cause of 
death in these pat ients and quality  of life is poor (Squires et al. 2012 )
.Accelerating the adaptive 
process and achieving enteral autonom y is an urgent goal for all patients with SBS who are 
dependent on PS (Khan et al. 2015 ;Squires et al. 2012 ).
Intestinal adaptation is driven by  [CONTACT_319436] (Drucker 
and Yusta 2014). Chief among th ese is hormones glucagon -like peptide 2 (GL P-2), which is 
secreted from L- type enteroendocrine cells that reside in the intestinal epi[INVESTIGATOR_319365]. Resection of these regions impairs the adaptive response b y limiting endogenous 
production of GLP -2. 
1.[ADDRESS_482885] Background 
Teduglutide is a novel, recombinant analog of naturally  occurring human GLP -2 that regulates 
the functional and structural integrity  of the cells lining the gastrointestinal (GI) tract. 
Teduglutide is a 33 -amino acid peptide that differs from native GLP- 2 in the substitution of 
glycine for alanine at the second position at the N -terminus. As a result, teduglutide demonstrates 
resistance to degradation by  [CONTACT_20597] l peptidase- IV (DPP -4) and therefore maintains a longer 
elimina tion half -life (t 1/2) in adults of approximately 2 hours compared to the native peptide, 
which has a t 1/2 of approximately  7 minutes. Teduglutide has been shown in animal studies and 
previous human clinical trials to increase villus height and cry pt depth in the intestinal 
epi[INVESTIGATOR_2130], thereb y increasing the absorptive surface area of the intestines (Tappenden et al. 
2013; Thymann et al. 2014 ). The European Commission granted a centralized marketing 
authorization valid throughout the European Union (EU) for tedu glutide ( REVESTIVE™) on [ADDRESS_482886] 2012 and a New Drug Application (NDA) for teduglutide (G ATTEX®) was approved by  
[CONTACT_24623] (US) Food and Drug Administration (FDA) on 21 December 2012 for the 
treatment of adult patients with SBS who are dependent o n PS. Teduglutide is not currently  
approved for use in pediatric subjects. 
For non-commercial use only
Shire CONFIDENTIAL Page 23
Protocol SHP633 -304 08April 2016
1.3 Clinical Studies with Teduglutide in Pediatric subjects
One Phase 3 stud y, TED -C13-003, was completed in pediatric SBS subjects in the US and 
[LOCATION_008] ([LOCATION_006]). In this study , teduglutide was administered to 3 cohorts of pediatric 
subjects from age s 1-17. Thirty -seven pediatric subjects received teduglutide at doses of 0.0125, 
0.025, or 0.05 mg/kg/day for [ADDRESS_482887] of care (SOC) cohort. There were clear dose -dependent effects of 
teduglutide seen at the 0.025 and 0.05 mg/kg/day  doses compared to SOC and the 0.0125 
mg/kg/day  dose. In the 0.025 mg/kg/day  cohort there was a reduction in PS volume a t Week 12 
of 37%, including complete independence from PS support in [ADDRESS_482888], and a reduction of 3.94 
hours per day  infusion time. I n the 0.05 mg/kg/day  cohort there was a reduction in PS volume at 
Week 12 of 39%, including complete independence from PS support in 3 subjects, and a 
reduction of 4.18 hours per day  infusion time. Teduglutide was generally  safe and well tolerated 
by [CONTACT_385953]. There were no deaths during the study  and no 
treatment -emergent serious adverse event s (TESAEs) related to teduglutide were reported. No 
discontinuations from study  were due to adverse events (AEs).
TED -C14-006 is an ongoing study  which includes 2 treatment arms: a teduglutide treatment arm 
and a standard of care treatment arm. Subjects in both arms participate in a [ADDRESS_482889] medical therap y for SBS; while 
those in the teduglutide treatment arm will receive daily  subcutaneous (SC) injections of 
teduglutide (stud y drug) in addition to standard medical therap y. The subjects enrolling in the 
tedugl utide treatment arm will be randomized 1:1 in a double -blinded manner into 2 parallel dose 
groups: 0.025 mg/kg/day or 0.05 mg/kg/day  of teduglutide administered subcutaneousl y for [ADDRESS_482890] version of the investigator’s brochure
for the overall risk/benefit 
assessment and the most accurate and current information regarding the drug metabolism, 
pharmacokinetics, efficacy  and safet y of teduglutide (SHP633). 
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_482891]- time treatment of teduglutide -naïve subjects who participated in the 
SOC treatment arm in TED -C14-006.
2.2 Study Ob jectives
2.2.1 Primary Objectives
The primary  objective of the study  is to evaluate the long -term safet y and tolerability of 
teduglutide treatment in pediatric subjects with SBS who completed TED -C14-006.
2.2.2 Secondary Objectives
The secondary  objective of this stud y is to evaluate the long -term efficacy  of teduglutide 
treatment in pediatric subjects with SBS who completed TED -C14-006.
For non-commercial use only
Shire CONFIDENTIAL Page 25
Protocol SHP633 -304 08April 2016
3STUDY DESIGN
3.1 Study Design and Flow Chart
This is a Phase 3, prospective, open -label, long -term extension study  to evaluate the safety and 
efficacy  of teduglutide in pediatric subjects who completed the TED -C14-006 study  (core stud y). 
At the time of entry  into the TED- C14-[ADDRESS_482892] 30% of their caloric or fluid needs, and had 
not been able to significantly  reduce PS for at least 3 months prior to enrollment. During the core 
study , pediatric subjects in the teduglutide treatment arm were randomized to 0.025 mg/kg or 
0.05 mg/kg QD dosing in a double -blinded manner. The TED -C14-[ADDRESS_482893] meet ≥1 of the teduglutide treatment inclusion 
criteria and none of the teduglutide treatment exclusion criteria.
Re-challenge
Subjects not receiving teduglutide treatment ( ie, in a “no teduglutide treatment period”), will be 
seen every  12 weeks for safet y, parenteral support (PS) requirements, and quality of life. At any  
point during a no teduglutide treatment period, subjects who meet ≥[ADDRESS_482894], and parent 
agree to proceed with teduglutide therapy .
Ration ale: Some pediatric subjects may have a durable beneficial effect after 24 weeks of 
teduglutide treatment and thus long -term follow -up without additional teduglutide treatment may 
be appropriate. However, there may be some pediatric subjects who deteriorat e or stop 
improving after discontinuation of teduglutide treatment. In these pediatric subjects, additional 
teduglutide treatment may be beneficial. 
Dose Selection 
Analy sis suggested that pediatric patients, ages 1 to 17 y ears old, are likel y to require the same 
dose as used in adults, namely  0.05 mg/kg/day (Mouksassi et al. 2009 ).In this extension study  to 
TED -C14-006, repeat doses of teduglutide 0.05 mg/kg QD will be administered to eligible 
pediatric subjects who previously  received teduglutide 0.05 or 0.025 mg/kg in Study  TED -C14-
006.
Rationale: Teduglutide is approved for adult use in the [LOCATION_002] and European Union at a 
dose of 0.05 mg/kg SC once daily. The completed 12- week pediatric study (TED -C13-003) 
demonstrated that teduglutide dosing at 0.025 and 0.05 mg/kg/day was associated with a 
favorable benefit/risk profile . In addition, population pharmacokinetic modeling and simulations 
were conducted to determine the effective dose to be used in pediatric subjects using data from 8 
adult clinical studies including adult Phase 1 studies and Phases 2/3 studies as well as th e 
pediatric study (TED -C13-
003) and suggested that the dose in pediatric subjects is likely to be 
same as the dose in adults (O'Keefe et al. 2006 ). 
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_482895] may  be evaluated immediately  for 
additional ted uglutide treatment. Subjects who clinically  deteriorate or stop improving at any  
time after the end of the follow- up period will also be assessed for additional treatment.
Rationale: During the teduglutide treatment cycle, visit frequency is similar to frequencies 
performed in TED- C13-[ADDRESS_482896] medical practices.
Measures and Parameter s
Following the review and signing of the informed consent (and informed assent, if applicable), 
screening visit procedures will begin including demographics, medical history , and short bowel 
syndrome history . Subjects who meet ≥1 of the teduglutide treatment inclusion criteria may 
proceed to the pre -treatment visit.
Afterthe pre -treatment visit, subjects who still meet ≥1 of the teduglutide treatment inclusion 
criteria, and meet none of the teduglutide treatment exclusion criteria, will start a 28 -week cy cle, 
consisting of 24 weeks of teduglutide treatm ent at 0.05 mg/kg SC once daily , followed by  a 4-
week follow -up (no treatment) period ( Figure 3-1). During the 28 -week cycle, clinic visits will 
occur at weeks 1, 2, 4, 6, 9, 12, 16, 20, 24, and 28. Phone vi sits are required approximately  1 
week after adjustments in PS during the TED treatment period, between weeks 1- 24, and weekl y 
during the TED follow -up period, between weeks 24 and 28.
Safety  and PS requirements will be evaluated on a weekl y basis, and qua lity of life assessments 
will be made approximately  every  12 weeks. At all site visits and telephone contacts, safety  will 
be monitored and nutritional support will be reviewed and adjusted as needed. To maintain 
consistency  across centers, all attempts sh
ould be made to follow the nutritional support 
adjustment guidelines (developed with SBS expert input and provided in the protocol) for 
decisions regarding PS reduction and advances in enteral feeds based on weight gain, urine and 
stool output, and clinica l stability . Departure from the guidelines, however, is not considered a 
protocol deviation ( Appendix 1 ).
Rationale: Measures of long term safety will include adverse events, growth parameters and 
anti-drug antibodies. Measure of long term efficacy will in clude durability of effect as measured 
by [CONTACT_319411] (PedsQL, PedsQL 
Family Impact Module) . A reduction in PS volume of at least 20% at end of treatment ( EOT )was 
used as the primary endpoint in pi [INVESTIGATOR_30338] 3 adult clinical trials and the completed phase 3 
pediatric study (TED -C13-003), and will be used as an endpoint in this extension study. In 
previous clinical studies, a reduction of this magnitude was associated with a reduction in the 
number of days per week of PS, and increases in enteral intake. Reduction in volume and time of 
PS due to improved enteral absorption may provide a pediatric subject with opportunities for 
more age -appropriate activities including oral rehabilitation. Quality of life assessments will be 
performed in this study to quantitate this effect.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_482897] of teduglutide, GI -specific screening tests, 
including fecal occult blood testing and colonoscopy, which are commonly part of the routine 
care of these subjects, will be performed to ensure safety. This study captures long -term safety 
data on polyps and other colonic mucosal changes in tedugl utide -exposed subjects using the 
surveillance strategy proposed in Section 7.2.9 . 
Figure 3-1: Study Design Flow Chart
Figure legend: Safety and efficacy data for subjects not receiving teduglutide treatment are captured every 12 weeks, but subjects 
may proceed to the pre -
treatment visit at any time in order to assess eligibility for teduglutide therapy. Eligible subjects will enter 
a 28-week teduglutide cycle. During this cycle, subjects will return to the site for safety and efficacy assessments at weeks 1, 2, 4, 
6, 9, 12, 16, 20, and 24 ( solid black lines ). Phone visits are required approximately 1 week after adjustments in PS during the 
intervening weeks between weeks 2 and 24 ( dashed grey lines ). Subjects discontinue teduglutide at week 24 and enter a 4 -week 
follow -up (no -treatment) period, during which phone visits will be performed weekly ( solid grey lines ). If an escape criterion is 
met during the follow -up period, subjects may proceed directly to another pre -treatment visit.
3.[ADDRESS_482898]’s maximum duration of participation is 
expected to be approximately  [ADDRESS_482899] has not withdrawn 
early from the stud y for any reason, and has completed the End of Stud y (EOS) visit.
The study  completion date is defined as the date the final subject, across all sites, completes their 
final protocol -defined as sessment. Please note that this includes the follow -up visit or contact 
(last safet y contact), whichever is later. The stud y completion date will be used to ascertain 
timing for study  results posting and reporting.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_482900] review and sign the informed consent (and informed assent, if applicable) 
before an y stud y-related procedures specified in the protocol are performed. Teduglutide 
treatment eligibility  does not impact study  eligibility .
4.[ADDRESS_482901] will not be considered eligible for the study  without meeting all of the criteria below:
1. Subject provides written informed consent (subject, parent or legal guardian and, as 
appropriate, subject informed assent) to participate in the study  before completing any  
study -related procedures. 
2. Subject completed the TED- C14-006 study  (including subje cts in the standard of care 
treatment arm).
3. Subject understands and is willing and able to fully  adhere to study  requirements as 
defined in this protocol.
4.[ADDRESS_482902] 1 ( ≥1) of the teduglutide treatment 
inclusion criteria, and none of the teduglutide treatment exclusion criteria can be met. In 
addition, the investigator and the subject (and/or parent or legal guardian, as appropriate) must 
agree to proceed with treatment.
4.[ADDRESS_482903] is teduglutide -naïve, receiving PS, and unable to significantl y reduce PS or 
advance enteral feeds ( eg, 10% or less change in PS or advance in feeds) for at least 
3months prior to and during the teduglutide pre -treatment visit, as assessed by  [CONTACT_1275]. Transient instability  for events such as interruption of central access or 
treatment for sepsis is allowed if the PS ret urns to within 10% of baseline prior to the 
event.
2.Subject was previousl y treated with teduglutide and at least 1 of the following criteria is 
satisfied :
a.Increasing PS requirements following teduglutide discontinuation.
b.Decreased PS requirement during prio r teduglutide treatment, followed by  
[CONTACT_319412].
c.Deteriorating nutritional status eg, weight loss or growth failure) despi[INVESTIGATOR_319366].
d.Deteriorating fluid or electroly te status despi[INVESTIGATOR_319367].
e.Severe diarrhea related to teduglutide discontinuation.
For non-commercial use only
Shire CONFIDENTIAL Page 29
Protocol SHP633 -304 08April 2016
4.5 Teduglutide Treatment Exclusion Criteria
1.Body weight <[ADDRESS_482904]
3.History  of cancer in the previous 5 y ears except surgically  curative skin cancers
4.Serial transverse enteroplasty  or other major intestinal surgery  within 3 months 
preceding the teduglutide pre -treatment visit. I nsertion of a feeding tube, anastomotic 
ulcer repair, minor intestinal resections ≤10 cm, and endoscopic procedures are 
allowed.
5.Intestinal or other major surgery  planned or scheduled to occur during the 28 -week 
cycle
6.Clinically  significant intestinal stricture or obstruction
7.Clinically  significant, active or recurrent pancreatic or biliary  disease
8.Active, severe, or unstable, clinically  significant hepatic impairment o r injury , 
including the following laboratory  values at the pre -treatment visit:
a.Total bilirubin ≥2× upper limit of normal (ULN)
b.Aspartate aminotransferase (AST) ≥7 × ULN
c.Alanine aminotransferase (ALT) ≥7 × ULN
9.Renal dy sfunction shown by  [CONTACT_385954] (eGFR) 
below 50 mL /min/1.[ADDRESS_482905] repair, or 
patent ductus arteriosus (PDA) ligation
11.Participation in a clinical study  using an experimental drug (other than glutamine or 
Omegaven) within 3 months or 5.5 half-lives of the experimental drug, whichever is 
longer, prior to the pre- treatment visit and for the duration of the 28 -week cy cle
12.Treatment with analogs of glucagon -like peptide -1 (GL P-1), glucagon -like peptide -2 
(GLP-2) (not including teduglutide), insulin -like growth factor -1 (IGF -1), or growth 
hormone , within 1 month preceding the teduglutide pretreatment visit.
13.Treatment with octreotide or dipeptidy l peptidase 4 (DPP -4) inhibitors within [ADDRESS_482906], 
closely -related compounds, or a ny of the stated ingredients
15.Known history  of alcohol or other substance abuse within 1year prior to the pre -
treatment visit
16. Pregnant or lactating female subjects 
17.Sexually  active female subjects of child -bearing potential unwilling to use approved 
contra ception during teduglutide treatment and for 30 day s after the treatment period 
For non-commercial use only
Shire CONFIDENTIAL Page 30
Protocol SHP633 -304 08April 2016
18.Any condition, disease, illness, or circumstance that in the investigator’s opi[INVESTIGATOR_319368] y undue risk, prevents completion of the study, or interferes with 
analysis of the study  results.
4.[ADDRESS_482907] may  
proceed directl y to the pre -treatment visit, if 1of the following criteria is met:
1.Increasing PS requirements following teduglutide discontinuation .
2.Deteriorating nutritional status (eg, weight loss or growth failure) despi[INVESTIGATOR_319369] .
3.Deteriorating fluid or electroly te status despi[INVESTIGATOR_319370] .
4. Severe diarrhea related to teduglutide discontinuation.
4.[ADDRESS_482908]. 
To be eligible for treatment with teduglutide, female pediatric subjects and adolescent subjects 
should be either:
Pre-menarchal and either Tanner Stage 1 or less than age 9 years, or
Females of child -bearing potential (FOCBP) wit h a negative serum beta -human chorionic 
gonadotropin ( -HCG) pregnancy  test at the teduglutide pre -treatment visit .Females of 
child- bearing potential must agree to abstain from sexual activity  that could result in 
pregnancy  or agree to use acceptable meth ods of contraception.
Acceptable methods of contraception are:
Abstinence
Intrauterine devices plus condoms
Double- barrier methods ( eg, condoms and diaphragms with spermicidal gel or foam)
Hormonal contraceptives (oral, depot, patch, injectable, or vaginal ring), stabilized for at 
least 30 day s prior to the pre -treatment visit, plus condoms. Note: if subject becomes 
sexually  active during the study , they  should use one of the other acceptable methods 
noted above in addition to the hormonal contraceptive until it has been stabilized for 
30days.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_482909] who remains in the study  would enter a no -teduglutide treatment 
(NTT) period and could be evaluated for sub sequent teduglutide treatment eligibility  according 
to the study  schedules. Comments (spontaneous or elicited) or complaints made b y the subject 
must be recorded in the source documents. The reason for permanent treatment discontinuation, 
dates of investig ational product administered (including last date of treatment), and amount of 
investigational product taken must be recorded in the electronic case report form (eCRF) and 
source documents, as described in Section 4.8.3. The investigator is encouraged to d iscuss 
withdrawal of a subject from investigational product with the medical monitor, when possible.
4.8.[ADDRESS_482910] will 
then be asked to return 4 weeks later for the earl y termination (ET) visit, and will be contact[CONTACT_319413] y by [CONTACT_319445] -up.
If a subject withdraws from the study  during a NTT period, the evaluations listed for the ET visit 
are to be performed as completely  as possible. 
Subjects who withdraw from the study will not be replaced.
4.8.3 Reasons for Discontinuation
The reason(s) for permanent discontinuation of treatment and/or withdrawal from the study  must 
be determined b y the investigator, and recorded in the subject’s medical record and in the eCRF. 
If a subject is withdrawn for more than [ADDRESS_482911] clinically  relevant reason should be entered in the eCRF.
Reasons for discontinuation include, but are not limited to:
Adverse event 
Protocol deviation
Lack of efficacy  
Physician decision 
Withdrawal by  [CONTACT_1130] 
Lost to follow -up
Pregnancy  (Discontinuation of treatment on ly) 
Death 
 Other 
For non-commercial use only
Shire CONFIDENTIAL Page 32
Protocol SHP633 -304 08April 2016
[IP_ADDRESS] Subjects ‘Lost to Follow -up’ Prior to Last Scheduled Visit
A minimum of [ADDRESS_482912] (office visit or telephone contact) . At least [ADDRESS_482913]’s last 
known address via courier or mail (with an acknowledgement of receipt request) asking that they  
return to the site for final safet y evaluations, and r eturn an y unused investigational product.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_482914] be recorded on the appropriate eCRF 
page. Concomitant treatments will be assessed at each site visit, and include all non -study  
treatments (medications, herbal treatments, vitamins, invasive and diagnostic procedures). 
Concomitant GI  procedures include (bu t are not limited to) endoscopy , radiographic studies, GI 
and liver biopsies and associated pathology  results. Concomitant treatment information must be 
recorded on the appropriate eCRF page. Details of medication changes and/or dosages will be 
recorded on the eCRF.
The mechanism of action of teduglutide may increase absorption of drugs ( eg, motility  
medication including narcotics and opi[INVESTIGATOR_20574], Coumadin, 
psychotropi[INVESTIGATOR_1102], metronidazole, and digoxin). Accordingl y, due consideration should be given to 
modify ing concomitant medication regimens. Down -titration of concomitant medications should 
be considered when drugs, especiall y those with a narrow therapeutic range, are prescribed at 
dosages that are higher than usual.
5.1.[ADDRESS_482915] medical therapy for SBS should be continued.
5.1.2 Prohibited Treatment
The mechanism of action of teduglutide may  increase enteral absorption of drugs ( eg, motility  
medication including narcotics and opi[INVESTIGATOR_20574], Coumadin, 
psychotropi[INVESTIGATOR_1102], metronidazole, digoxin), so consideration should be given to modify ing 
concomitant enteral medication regimens. Down -titration of concomitant enteral medications 
should be considered when drugs, especially  those with a narrow therapeutic range, are given at 
dosages that are higher than usual.
The following medications are prohibited during teduglutide treatment and within the provided 
timeframe prior to the pre -treatment visit:
Table 5-1: Prohibited Treatment
Prior Therapy Time Restriction Prior to 
the Pre -Treatment Visit
Native/synthetic glucagon -like peptide -2 (not -including teduglutide) Any
Glucagon-like peptide- 1 analog or human growth hormone 1 month
Octreotide or dipeptidyl peptidase 4 inhibitors 3 months
Biological therapy ( eg, antitumor necrosis factor) [ADDRESS_482916] is teduglutide, which will be provided in sterile, single -use 3 mL  vials 
containing 5 mg or 1.25 mg teduglutide as a white ly ophilized powder to be reconstituted before 
use with 0.5 mL  sterile water for injection. In addition to the active ingredient (teduglutide), each 
vial of teduglutide contains L -histidine, mannitol, monobasic sodium phosphate monohy drate, 
and dibasic sodium phosphate as excipi[INVESTIGATOR_840]. Additional information is provided in the current 
SHP633 i nvestigator’s brochure.
6.1.[ADDRESS_482917](s)
6.2.1 Interactive Response Technology (IRT) for Investigational Product 
Management
An interactive web -based response s ystem (IWRS) will be used for screening and enrolling 
subjects, recording subject visits, investigational product supply dispensat ion and management, 
inventory  management and supply  ordering, investigational product expi[INVESTIGATOR_49093], and return of investigational product. Please refer to the Study Manual for 
additional details regarding the IWRS. 
The I WRS will also be used for creating, tracking, and confirming investigational product 
shipments. A user manual with specific functions and instructions for the IWRS will be provided 
to the site, and site personnel will receive training.
6.2.[ADDRESS_482918], and /or parent/guardian agree 
to proceed with treatment, a formal evaluation of teduglutide inclusion and exclusion criteria will 
be performed at the pre -treatment visit ( Table 1-3 ). 
6.2.[ADDRESS_482919] will start a teduglutide treatment period, consisting of 24 weeks 
of teduglutide treatment at 0.05 mg/kg SC once daily . The initial dose will be calculated based 
on body  weight measured a t the teduglutide pre -treatment visit, and adjusted as needed, based on 
body  weight measured at Week 12 (CxW12). No other adjustments to dose will be made during 
the teduglutide treatment period, unless discussed with the sponsor’s medical monitor. 
Follow ing reconstitution, teduglutide will be administered by  [CONTACT_385955] 1 of the 4 
quadrants of the abdomen (in subjects without a stoma) or into either the thigh or arm. For 
subjects with a stoma, the quadrant of the abdomen containing the stoma shou ld not be used. 
Teduglutide should be used as soon as possible after reconstitution, but no more than [ADDRESS_482920] 
4 hours during thei r initial dosing visit. The site of administration (arm, thigh, and abdomen) of 
the first teduglutide dose must be specified and recorded in the eCRF. 
Detailed instructions for reconstitution and injection of the investigational product can be found 
in the I nstructions for Use. 
Following each [ADDRESS_482921] may  proceed 
directly  to another Pre -Treatment visit to assess treatment eligibility  for another cy cle 
(Section 4.6). Following the completion of the 4- week follow -up, the subject will continue in the 
study  off teduglutide. Additional [ADDRESS_482922](s) container. 
The study  drug will be packaged, labeled, and shipped to the study  site by  [CONTACT_98634]. Kits containing [ADDRESS_482923] is packaged in the following conditions:
Teduglutide will be provided in a sterile, single -use, glass vial as a l yophilized powder, to be 
reconstituted with 0.[ADDRESS_482924] be kept in a locked area with access restricted to specific study  personnel. Study  
drug will be stored refr igerated at a temperature between 2 to 8°C (35.6 to 46.4°F) until 
dispensed to a subject. Once dispensed to a subject, the study  drug can be stored refrigerated or 
up to a controlled room temperature (acceptable range of 2 to 25°C, or 35.6 to 77°F). 
Parent /guardian will be instructed to keep the subject’s study  drug and sterile water diluent at 
controlled room temperature. If there are concerns that the controlled room temperature cannot 
be maintained, the stud y drug may  be refrigerated.
Investigational pro duct must be stored in accordance with labeled storage conditions. 
Temperature monitoring is required at the storage location to ensure that the investigational 
product is maintained within an established temperature range. The investigator is responsible 
for ensuring that the temperature is monitored throughout the duration of the study and that 
records are maintained; the temperature should be monitored continuously  by [CONTACT_3570]-house sy stem, a mechanical recording device such as a calibrated cha rt recorder, or b y manual 
means, such that both minimum and maximum thermometric values over a specific time period 
can be recorded and retrieved as required. Such a device ( ie, certified min/max thermometer) 
would require manual resetting upon each record ing. The sponsor must be notified immediately  
upon discovery  of any  excursion from the established range. Temperature excursions will require 
site investigation as to cause and remediation. The sponsor will determine the ultimate impact of 
excursions on the investigational product and will provide supportive documentation as 
necessary . Under no circumstances should the product be dispensed to subjects until the impact 
has been determined and the product is deemed appropriate for use b y the sponsor.
The sponsor should be notified immediately  if there are an y changes to the storage area of the 
investigational product that could affect the integrity  of the product(s), eg, fumigation of a 
storage room.
Investigational products are distributed b y the pharmacy or nominated member of the study  
team. The pharmacist/nominated team member will enter the unique subject identifier on the 
investigational product bottle/carton labels, as they are distributed.
6.[ADDRESS_482925] will be made available to the sponsor’s site monitor for the purpose of accounting for 
all clinical supplies. Any  discrepancy  or deficiency  will be recorded and will include an 
explanation. All supplies sent to the investigator must be accounted for and in no case will 
clinical supplies be used in any  unauthorized situation.
The investigator has overall responsibility  for administering/dispensing investigational product. 
Where permissible, tasks may  be delegated to a qualified designee ( eg, a pharmacist) who is 
adequatel y trained in the protocol and who works under the direct supervision of the investigator. 
This delegation must be documented in the applicable st udy delegation of authority  form.
The investigator or his/her designee (as documented by  [CONTACT_49121] y form) will dispense the investigational product only to subjects eligible 
for teduglutide treatment fo llowing the procedures set out in the study  protocol. All dispensed 
For non-commercial use only
Shire CONFIDENTIAL Page 37
Protocol SHP633 -304 08April 2016
study  medication will be documented in the eCRFs and/or other investigational product record 
(eg, investigation product accountability  form). The investigator is responsible for assuring t he 
retrieval of all study  supplies from subjects.
All used and unused study  drug vials must be returned by  [CONTACT_20608]/or parent/guardian, 
and will be retained at the site. All original containers, whether empt y or containing study drug 
will be return ed to the pharmacy . Returned study  drugs will NOT be relabeled or reassigned for 
use by  [CONTACT_23837]. Contents of the study  drug containers will not be combined. All used and 
unused vials must be returned to the distribution center according to the spons or’s instruction. 
No vial/kit may  be destroy ed on site without approval by  [CONTACT_456]. 
Please see the Pharmacy  Manual for additional information.
6.[ADDRESS_482926] and empty /used
investigational product packaging to every  visit. Drug accountability  will be assessed at the 
container/packaging level for unused investigational product that is contained within the original 
tamper -evident sealed container ( eg, bottles, tray s, vials) or at the individual count level for 
opened containers/packaging. The pharmacist/nominated person will record details on the drug 
accountability  form.
Of those subjects eligible for teduglutide treatment, subjects who have received 80% of the 
planned doses a dministered will be assessed as being compliant with the study  protocol.
For non-commercial use only
Shire CONFIDENTIAL Page 38
Protocol SHP633 -304 08April 2016
7STUDY PROCEDURES
7.1 Study Schedule
Detailed study  procedures and assessments to be performed for subjects throughout the study  are 
outlined in the Schedule of Assessments ( Table 1 -1,Table 1 -2, and Table 1 -3) and must be 
referred to in conjunction with the instructions provided in this section. 
7.1.1 Screening 
Prior to performing an y study-related procedures (including those related to screening), the 
investigator or his/her designee must obtain written informed consent (and assent, as applicable) 
from the subject. A subject will have up to [ADDRESS_482927] visit after screening (either a 
no-teduglutide treatment visit or a pre-treatment visit), must occur within 12 weeks of screening.
The screening visit (Scr) assessments and procedures, beginning with informed consent, will be 
performed as outlined in Table 1
-1, and as detailed below :
 Inform ed consent, and informed assent (if applicable), is obtained
 Study  eligibility  is determined. A screen failure is a subject who has given informed 
consent and failed to meet the Study  Inclusion Eligibility  Criteria. Subjects cannot be 
rescreened once they  have been designated as a screen failure. 
 Demographics, medical history , and SBS history
 Intake and output diaries are dispensed
 Evaluate teduglutide treatment inclusion criteria 
 Adverse events , concomitant medications and concomitant GI  procedures
7.1.2 Visit s for Subjects Not Receiving Teduglutide
While outside of the 28-week teduglutide -treatment cycle, subjects will be followed every 
12weeks for safet y and efficacy  assessments. No-
teduglutide treatment visits are numbered 
sequentially  (NT1, NT2, etc.), even if interrupted by [CONTACT_385956]. Assessments will be 
performed as outlined in Table 1-2 and described below .
 Intake and output diaries are dispensed
 Evaluate teduglutide treatment inclusion criteria
 Adverse events , concomitant medications and concomitant GI  procedures
 Physical examination and vital signs, including weight
 Height and head circumference
 Review intake and output diaries
 Record PS and enteral nutrition ( EN)prescriptions, and adjust as needed
 Safety  Laboratory  Tests ( ie, clinical c hemistry , hematology , and urinaly sis)
For non-commercial use only
Shire CONFIDENTIAL Page 39
Protocol SHP633 -304 08April 2016
 PedsQL  Generic Core Scale/PedsQL Family  Impact Module/ PedsQL  Gastrointestinal 
Symptoms Module Sub- Scales
 Antibodies to teduglutide, if and when required
 Fecal occult blood testing , as indicated (see S ection [IP_ADDRESS])
 Colonoscopy , as indicated (see Section [IP_ADDRESS])
 Serum sample , as indicated
Teduglutide treatment may  be considered at any  time during the NTT period. If the investigator 
and the subject (and parent or legal 
guardian, as appropriate) agrees to proceed with t reatment if 
the subject is eligible, the subject may  proceed to the pre -treatment visit to determine eligibility .
The pre -treatment visit must occur within 12 weeks of a given NTT visit.
7.1.3 Visits for Subjects Receiving Teduglutide
[IP_ADDRESS] Pre-treatment Visit
Subjects who meet at least [ADDRESS_482928] 
and parent agree to proceed with teduglutide therapy . Similarly , subjects who meet escape 
criteria during the teduglutide follow- up period may  proceed to the pre -treatment visit.
The pre -treatment visit may  also be combined with screening visit, and if the pre -treatment visit 
assessments occur within 7 day s of th e TED -C14-006 EOS visit (Week 28), both sets of 
assessments can be combined. A subject must have [ADDRESS_482929] dose administration (CxD1) during an y teduglutide treatment cy cle. I n general, pre -
treatment assessm ents may  occur over a period of up to 21 day s. The teduglutide pre -treatment 
visit (Px) assessments and procedures will be performed in Table 1-3 and as described below :
 Evaluate teduglutide eligibility  (treatment inclusion/exclusion criteria) 
 Dispense intake and output diaries
 Adverse events , concomitant medications and concomitant GI  procedures
 Fecal occult blood testing 
 Gastrointestinal -specific testing, including colonoscopy  or sigmoidoscopy  as indicated
 Physical examination and vital signs, including weight
 Height and head circumference
 Review intake and output diaries
 Record PS and EM prescriptions, and adjust as needed.
 Safety  Laboratory  Tests 
(In addition to clinical chemistry , hematology , and urinaly sis, labs at this visit include 
prothrombin tim e [PT] international normalized ratio [I NR]. Subsequent prothrombin 
time/ international normalized ratio (PT/I NR) measurement is only  required to evaluate 
for suspected drug -induced liver injury  [DILI]). 
For non-commercial use only
Shire CONFIDENTIAL Page 40
Protocol SHP633 -304 08April 2016
 Pregnancy  testing (serum)
 Serum sample 
[IP_ADDRESS] Teduglutide Treatment Period (CxD1 -CxW24)
The open- label teduglutide treatment period will comprise [ADDRESS_482930] administrati on (Visit CxD1). 
VISIT CXD1
Assessments and procedures at this visit will be performed as outlined Table 1 -3and as 
described below. 
2 weeks of intake diary  data are required before drug is administered at CxD1.
 Confirm teduglutide eligibility
 Dispense intake and output diaries
 Adverse events , concomitant medications and concomitant GI  procedures
 Physical examination and vital signs, including weight
 Height and head circumference
 Review intake and output diaries
 Record PS and EN prescriptions, and adjus t as needed 
 Safety  laboratory  tests
 Quality  of life measurements 
 Antibodies to teduglutide
 Pregnancy  testing (urine)
 Dispense study  drug
[IP_ADDRESS] Site Visits during Teduglutide Treatment Period
Subjects will return for clinic visits on cy cle weeks 1, 2, 4, 6, 9, 12, 16, 20, and 24 /EOT . 
Assessments and procedures at these visits will be performed as outlined in Table 1-3 and as 
described below:
 Dispense /review intake and output diaries
 Physical examination and vital signs, including weight
 Record PS and EN prescriptions, and adjust as needed
 Safety  laboratory tests 
 Urine pregnancy  testing for FOCBP (CxW4, CxW9, CxW12, CxW16, CxW20, 
CxW24)
For non-commercial use only
Shire CONFIDENTIAL Page 41
Protocol SHP633 -304 08April 2016
 Study  drug dispensation (except for CxW24)
 Adverse events , concomitant medications and concomitant GI  procedures
In addition, at CxW12 and CxW24 Visits ONLY , the following procedures will be performed:
 Height and head circumference
 Antibodies to teduglutide
 Fecal occult blood testing (FOBT)
 GI-specific testing, including colonoscop y or sigmoidoscopy  as indicated 
 Quality of life measurements 
At CxW24 ONLY , a serum sample is collected and stored for future analysis. This sample will 
not be used for genetic testing and lack of collection will not constitute a protocol deviation.
[IP_ADDRESS] Phone Visits 
Phone visits are required approximately  1 week after adjustments in PS during the teduglutide 
treatment period. Phone visit assessments and procedures are ou
tlined in Table 1 -3and described 
below:
 Review intake and output diaries
 Safety  laboratory  tests (clinical chemistry  and urinaly sis)
 Record PS and EN prescriptions, and adjust as needed
 Obtain AEs, concomitant medications, and concomitant GI  procedures   
 Evaluate escape criteria
7.1.4 Teduglutide Follow -up Period
The safet y follow -up period for this protocol is 4 weeks (Weeks 25 – 28 of the cy cle). Phone 
visits will occur on cycle weeks 25, 26, and [ADDRESS_482931] may  
proceed directl y to another pre -treatment visit at the investigator’s discretion. 
At cy cle week 28 (CxW28), subjects will return to the study  site. In addition to the assessments 
performed at weeks 25 -27, the following procedures will be performed at CxW28 ONLY:
 Physical examination and vital signs, including weight
 Antibodies to teduglutide
 Pregnancy  testing (urin e)
 Evaluate escape criteria
[IP_ADDRESS] Study Completion/Early Termination Visit (EOS/ET Visit) 
All subjects will return to the study  site for the end of study /early termination visit (EOS/ET). 
Assessments and procedures at this visit will be performed as outlined in Table 1-[ADDRESS_482932] discontinues the study prematurel y, the assessments for the EOS/ET 
Visit are to be performed as completel y as possible.
 Adverse events , concomitant medications and concomitant GI  procedures   
 Physical examination and vital signs, including weight
 Height and head circumference
 Review intake and output diaries
 Record PS and EN prescriptions, and adjust as needed
 Safety  laboratory tests 
 Fecal occult blood testing, as indicated
 Gastrointestinal -specific te sting, including colonoscopy  or sigmoidoscopy  as 
indicated. 
 Quality  of life measurements 
 Antibodies to teduglutide
 Pregnancy  testing, as needed
7.[ADDRESS_482933] of the following:
 Adverse events that were ongoing at the time of completion of TED -C14-006
 Events that occurred during the period between com pletion of TED -C14-006 and 
informed consent to SHP -633-304
 Gestational age at birth and parental heights. 
This medical history  information will supplement the medical history  information collected at 
the start of the TED -C14-[ADDRESS_482934] has an y changes to the SBS history  
collected at the baseline visit of the TED
-C14-006 study , that information (updated SBS history ) 
will be collected.
7.2.2 Physical Examination
Physical examinations will be performed according to the study  schedules. Any  new c linicall y 
significant findings noted during ph ysical examinations should be recorded on the appropriate 
AE page of the eCRF. 
7.2.3 Vital Signs, Body Weight, Height, Head Circumference and Body Mass 
Index (BMI)
Vital signs will be measured according to the study schedules. Measurements will include 
systolic and diastolic blood pressure (mmHg), pulse (beats per minute), and body  temperature 
(°C/°F). Blood pressure should be determined b y cuff (using the same method, the same arm, 
and in the same position throughou t the study ).
For non-commercial use only
Shire CONFIDENTIAL Page 43
Protocol SHP633 -304 08April 2016
Body weight will also be recorded in the eCRF; subjects should be weighed on the same scale at 
each stud y visit. Height (or length) and head circumference (for subjects ≤36 months of age) will 
be measured at selected visits. A height z- score, weight z -score, BM I, and BMI z -score will be 
calculated b y the sponsor using the site -provided height and weight data collected at each site 
visit
New clinicall y significant vital sign abnormalities should be recorded on the appropriate AE 
page of the eCR F.
7.2.[ADDRESS_482935] of clinical chemistry , hematology , 
and urinal ysis and will be performed as outlined in the study  plan ( Table 1-1, Table 1-2, and 
Table 
1-3) Scheduled laboratory  testing will be processed by  a central lab. All laboratory  assay s 
will be performed according to the central laboratory ’s normal procedures. Reference ranges are 
to be supplied by  [CONTACT_25699] . The investigator should assess out
-of-range clinical laboratory  
values for clinical significance, indicating if the value(s) is/are not clinically  significant or 
clinically  significant. Abnormal clinical laboratory  values, which are unexpected or not 
explained by  [CONTACT_423]’s clinical condit ion, may , at the discretion of the investigator or sponsor, 
be repeated as soon as possible until confirmed, explained, or resolved. 
During the teduglutide treatment period, subjects will also have safet y labs within approximately  
5-[ADDRESS_482936] of clinical chemistry  and urinal ysis and may  be processed by  [CONTACT_319438] a local laboratory . Local lab results will not be entered in the eCRFs; however, i f the local lab 
results indicate an y new clinically  significant changes, they  must be reported as an adverse event 
(see Section 8.1). For pediatric subjects in diapers, urine specimen collection should be 
attempted as part of the safet y labs, but lack of u rinaly sis will not constitute a protocol deviation.
New clinicall y significant labs should be reported as AEs.
The following clinical laboratory
 assessments will be performed according to the study  
schedules: 
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_482937] of Laboratory Tests 
Hematology :
Hematocrit 
Hemoglobin 
Platelet count
Red blood cell count 
Red blood cell morphology, if needed
White blood cell count with differential
Coagulation :
Prothrombin time/I nternational normalized ratio
Urinalysis : 
Blood
Glucose
Leucocytes
Microscopic analysis
pH and osmolality
Protein
Sodium
Specific gravity
Pregnancy tests (females of childbearing 
potential):
oSerum β -HCG (screening)
oUrine β -HCG (all other visits)Biochemistry :
Albumin 
Alkaline phosphatase 
Alanine aminotransferase 
Amy lase
Aspartate aminotransferase 
Bicarbonate
Bilirubin (total and indirect)
Blood urea nitrogen 
Calcium (total)
Chloride
Cholesterol
C-reactive protein 
Creatinine
Estimated Glomerular Filtration Rate 
(Schwartz formula)
Gamma -glutamyl transferase 
Glucose
Lipase
Magnesium
Phosphorus
Potassium 
Sodium 
Triglycerides
Uric acid
7.2.5 Serum Sampling
Serum samples will be collected and stored for future anal ysis at the following times: 
 During Teduglutide treatment period: at the pretreatment and CxW24 ( EOT) visits.
 During NTT: Approximately  every  24 weeks. 
The serum sample will not be used for genetic testing. Lack of collection will not constitute a 
protocol deviation.
The sponsor, sponsor’s representatives, biorepositories, and an y specialt y laboratories will be 
blinded to the subject’s identity . The sample and/or extracted material will otherwise be stored 
for up to [ADDRESS_482938] their 
sample and/or extracted material destro yed. An y results alread y generated from the samples will 
not be removed from an y anal yses that have already  been performed.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_482939] from the 
study .
7.2.7 Antibody Testing
Blood samples will be drawn for the anal ysis of positive/specific antibodies to teduglutide 
according to the Schedule of Assessments ( Table 1 -1,Table 1 -2,and Table 1 -3). Blood samples 
for antibodies may  be drawn from a central line or f rom peripheral access. The sample drawn on 
CxD1 must be drawn prior to administration of the first dose of teduglutide.  Once the subject 
has started teduglutide treatment, samples must be drawn at least [ADDRESS_482940] positive/sp
ecific for antibodies to teduglutide will also be tested for neutralizing 
antibody . Subjects who have been previousl y treated with teduglutide, and who test 
positive/specific for antibodies to teduglutide, will have follow -up blood draws for 
positive/speci fic antibodies to teduglutide every  12weeks while on stud y until a negative result 
is obtained.
7.2.[ADDRESS_482941] annuall y are shown 
in the following table.
Table 7-1: Approximate Volume of Blood to be Drawn from Each Subject Annually 
AssessmentSample 
Volume (mL)No. Sam ples per two 28 -week 
Teduglutide CyclesTotal 
Volume (mL)
Subjects Receiving Teduglutide Treatment 
Safety Biochemistry and -hCGa2.5 24 60
Hem atology 2 24 48
Coagulation Param eters 1 2 2
Antibodies 2 8 16
Serum storage samples 3 4 12
Total mL per 2, 28 -week Treatment Cycles (Approximate Annual Volume): 138
Subjects Not Receiving Teduglutide Treatmentb
AssessmentSample 
Volume (mL)No. Sam ples per 4 NTT VisitsTotal 
Volume (mL)
Safety Biochemistry 2.5 4 10
Hem atology 2 4 8
Serum storage samples 3 2 6
Total mL per 4 “No Teduglutide Treatment” Visits 48 -week period: 24
Abbreviations: β -hCG=beta -human chorionic gonadotropin
a β-hCG testing will only be administered to females who are eligible for teduglutide treatment.
bSubjects not receiving TED treatment, but who were exposed to it previously and tested positive for anti -TED antibodies will 
require blood samples for antibody testing every [ADDRESS_482942] negative.
For non-commercial use only
Shire CONFIDENTIAL Page 46
Protocol SHP633 -304 08April 2016
Note: The amount of blood to be drawn for each assessment is an estimate. The amount of blood 
to be drawn may  vary  according to the instructions provided by  [CONTACT_10190]. When more than 1 blood assessment is to be done at the time 
point/period, if they  require the same t ype of tube, the assessments should be combined. Blood 
volume estimates do not include safet y labs performed after PS adjustment, and anti -teduglutide 
antibody  testing du ring no -teduglutide treatment.
7.2.9 Gastrointestinal- specific Testing
[IP_ADDRESS] Fecal Occult Blood Testing
Fecal occult blood testing must be performed on all subjects at the pre-treatment visit, week 12, 
and week [ADDRESS_482943] be performed on 
teduglutide -exposed subjects (subjects who have received teduglutide an y time in the past and 
are therefore not teduglutide -naïve) on a roughl y annual basis (approximately every 48 -60 
weeks). Actions to be taken in response to a posit ive FOBT are described below.
[IP_ADDRESS] Colonoscopy
Teduglutide -naïve subjects age 12 and older will undergo colonoscopy at the pre -treatment visit 
if one has not been performed within 1 y ear. 
Subjects of an y age with newly positive FOBT results at the pre -treatmen t visit for which a 
readil y detectable cause cannot be identified ( eg, anal fissure) will undergo a colonoscopy  prior 
to receiving teduglutide. If newl y positive FOBT results (for which a readily detectable cause 
cannot be identified) are obtained at the e nd of a teduglutide treatment cy cle (CxW24/EOT), 
colonoscop y will be performed. The need for colonoscopy in response to positive FOBTs at an y 
other point during the study , or to re -evaluate persistently  positive FOBTs is at the discretion of 
the investigat or. 
Teduglutide -exposed subjects who have received the equivalent of 2 treatment cy cles (48 weeks 
of study  drug exposure) will undergo colonoscopy . While receiving additional teduglutide 
treatment, subjects will undergo colonoscop y at 5 year intervals or more often as needed. 
Upper endoscopy may be performed along with any  colonoscopy  at the investigator’s discretion. 
If a pol yp is found, adherence to current pol yp follow -up guidelines is recommended. Subjects 
with unresected GI pol yps, poly posis conditions, pre -malignant change or malignancy  in the GI 
tract will be excluded from teduglutide treatment.
7.2.10 Nutritional Support
Nutritional support includes PS, EN, and other food and fluids. Advances in EN and/or 
reductions to PS will be based on clinical status, including weight, linear growth, hy dration 
status, and safet y laboratory  results. Intake and output diaries will include data to be considered 
in the adjustment of each subject’s nutritional support. Guidelines for nutritional support 
management and weani ng algorithms are provided in Appendix 1.
7.2.[ADDRESS_482944]’s nutritional support. The 
subject/parent/guardian will complete the appropriate fields of the PS and enteral nutrition 
(formula) sectio ns of the intake diary  2 weeks prior to ALL scheduled site visits. During the 24-
week teduglutide treatment period, the intake diary will also be completed for 1 week following 
For non-commercial use only
Shire CONFIDENTIAL Page 47
Protocol SHP633 -304 08April 2016
PS adjustments. The intake diary  will also be completed daily  during the 4-week follow -up 
period. The 
following data will be captured in the intake diaries:
 Parenteral support volume and infusion duration
 Enteral nutrition (formula) volume
 Site personnel will determine the actual PS and EN daily  calories based on diary  
entries.
7.2.12 Output Diary
Urine and stool output should be recorded in the output diary  over a 48- hour period of PS and 
EN stability  before every clinic visit; in addition, output should be recorded for subjects that are 
in a teduglutide treatment cy cle within 1 week of implementing a change in the PS prescription, 
regardless of previous teduglutide exposure.
Urine data:
 Toilet -trained subjects (who do not wear diapers)
 Measure and record all urine output in mL  or cc. The subject or parent will perform 
dipstick specifi c gravit y tests on the first urine produced after the daily  infusions of 
PS.
Nontoilet- trained subjects (who wear diapers)
 Measure and record the weight of all urine -only diapers. Urine volume will be 
calculated using the following formula: 1 g (scale weig ht) = [ADDRESS_482945] void after the 
daily  PS infusion to measure specific gravit y.
Stool data (includes diapers with mixed urine and stool):
 Toilet -trained subjects WHO DO NO T WEAR DIAPERS
Record the occurrence of each bowel movement and score the stool consistency  
using the Bristol Stool Form Scale (see Output diary )
 Nontoilet- trained subjects WHO WEAR DI APERS
Record the weight of diapers containing stool (including diapers with mixed urine 
and stool) as stool output and score the stool consistency  using the Bristol Stool 
Form Scale (see Output diary ). Stool volume will be calculated using the formula: 
1 g (scale weight)=[ADDRESS_482946] mont h, and parent -report of 
problems pursuing their normal work routine and concentrating at work. The PedsQL Generic 
Core Scales are also responsive to clinical change, as demonstrated in field trials.
[IP_ADDRESS] Pediatric Quality of Life Generic Core Scale (PedsQL™), A cute version
The PedsQL Generic Core Scale is designed to measures health -related quality  of life (HRQoL) 
in pediatric subjects and adolescents (2 -18 years of age). The developmentally  appropriate 
PedsQL  Generic Core Scale will be completed by  [CONTACT_319416] 7 -2at the time points as outlined inTable 1-1, Table 1 -2and Table 1 -3.
Table 7-2: Developmentally Appropriate PedsQL™Generic Core Scales
Report Completed by
[CONTACT_319417] (ages 2 -4) Parent or Legal Guardian
Child Self Report and Parent Proxy -Report for Young Pediatric subjects 
(ages 5 -7)Subject and Parent or Legal Guardian
Child Self Report and Parent Proxy -Report for Pediatric subjects (ages 
8-12)Subject and Parent or Legal Guardian
Child Self Report and Parent Proxy -Report for Teens (ages 13 -18) Subject and Parent or Legal Guardian
Abbreviations: PedsQL=Pediatric Quality of Life Inventory
The Parent Report for Toddlers (ages 2 -4) of the PedsQL Generic Core Scale is composed of 21 
items comprising 4 dimensions as follows: 1) Physical Functioning (8 items), 2) Emotional 
Functioning (5 items), 3) Social Functioning (5 items), 4) School Functio ning (3 items). 
The Child and Parent Reports of the PedsQL Generic Core Scale for Young Pediatric subjects 
(ages 5 -7), Pediatric subjects (ages 8- 12), and Teens (ages 13 -18) are composed of 23 items 
comprising 4 dimensions as follows: 1) Physical Function ing (8 items), 2) Emotional 
Functioning (5 items), 3) Social Functioning (5 items), 4) School Functioning (5 items).
For non-commercial use only
Shire CONFIDENTIAL Page 49
Protocol SHP633 -304 08April 2016
[IP_ADDRESS] Pediatric Quality of Life Family Impact Module (PedsQL™), Acute 
version
The PedsQL Family  Impact Module is a parent -report multidimensional instrument that will be 
completed b y the parent or legal guardian, as outlined in Table 1-1, Table [ADDRESS_482947] of pediatric chronic health condit ions on parents and the family (Varni et al. 2004 )
. 
The 36- item PedsQL Family  Impact Module consists of 6 scales measuring parent self -reported 
functioning as follows: 1) Physical Functioning (6 items), 2) Emotional Functioning (5 items), 3) 
Social Functioning (4 items), 4) Cognitive Fun ctioning (5 items; worries about treatment and 
disease), 5) Communication (3 items), 6) Worry  (5items). Two additional scales measure parent -
reported family  functioning as follows: 1) Dail y Activities (3 items), and 2) Family  Relationships 
(5 items). The PedsQL Family  Impact Module should take the parent or legal guardian 
approximately  5 to 10 minutes to complete.
[IP_ADDRESS] PedsQL Gastrointestinal Symptoms Module (PedsQL™), Acute version
The PedsQL Gastrointestinal Sy mptom Module is a disease -specific 58- item module , comprised 
of 10 differe nt symptom scales that assess gastrointestinal sy mptom -related quality  of life: food 
and drink limits, trouble swallowing, heartburn and reflux, nausea and vomiting, gas and 
bloating, constipation, blood in poop, and diarrhea. The PedsQL Gastrointestinal Sy mptoms 
Module was designed to allow the selection and scoring of individual scales from the Module. 
The scales of Food and Drink L imits (6 items) and Diarrhea (7 items) were identified as 
clinically  relevant and appropriate for th e symptoms experienced in this pediatric study  
population, and therefore, are the onl y scales used in this study . The scales will be completed by  
[CONTACT_319418] [ADDRESS_482948] a causal relationship with this 
treatment. An AE can therefore be an y unfavorable and unintended sign (including an abnormal 
laboratory  finding), s ymptom, or disease temporally  associated with the use of a medicinal 
(investigational) product, whether or not related to the medicinal (investigational) product (ICH 
Guidance E2A 1995). 
All AEs are collected from the time the informed consent is signed until the defined follow -up 
period stated in Section 7.1. 4. This includes events occurring during the screening phase of the 
study , regardless of whether or not investigational product is administered. Where possible, a 
diagnosis rather than a list of sy mptoms should be recorded. If a diagnosis has not been made
, 
then each s ymptom should be listed individually . All AEs should be captured on the appropriate 
AE pages in the eCRF and in source documents. In addition to untoward AEs, unexpected 
benefits outside the investigational product indication should also be ca ptured on the AE eCRF.
All AEs must be followed to closure (the subject’s health has returned to his/her baseline status 
or all variables have returned to normal), regardless of whether the subject is still participating in 
the study . Closure indicates that an outcome is reached, stabilization achieved (the investigator 
does not expect any  further improvement or worsening of the event), or the event is otherwise 
explained. When appropriate, medical tests and examinations are performed so that resolution of 
event(s) can be documented.
8.1.[ADDRESS_482949] be 
recorded as new AEs (for example, if a subject experiences mild intermittent dy spepsia prior to 
dosing of investigational product, but the dy spepsia becomes severe and more frequent after first 
dose of investigational product has been administered, a new AE of severe dy spepsia [with the 
appropriate date of onset] is recorded on the appropriate eCRF).
The medical assessment of severit y is determined by [INVESTIGATOR_1477]:
Mild: A type of AE that is usually  transient and may require only minimal treatment or 
therapeutic intervention. The event does not generall y interfere with usual 
activities of daily  living.
Moderate: A type of AE that is usually  alleviated with specific therapeutic intervention. The 
event interferes with usual activities of daily  living, causing discomfort but poses 
no significant or permanent risk of harm to the research subject.
Severe: A type of AE that interrupts usual activities of daily living, or significantly affects 
clinical status, or may  require intensive therapeutic intervention.
For non-commercial use only
Shire CONFIDENTIAL Page 51
Protocol SHP633 -304 08April 2016
Note that the severity  of AEs that constitute dose interruption criteria will also be evaluated 
using the National Cancer Institute’s (NCI) Common Termino logy Criteria for Adverse Events 
(CTCAE) grading criteria ( Table 8-1).
8.1.2 Relationship Categorization
A phy sician/investigator must make the assessment of relationship to investigational product for 
each AE. The investigator should decide whether, in his or h er medical judgment, there is a 
reasonable possibility  that the event may  have been caused b y the investigational product. If 
there is no valid reason for suggesting a relationship, then the AE should be classified as “not 
related”. Otherwise, if there is any valid reason, even if undetermined or untested, for suspecting 
a possible cause -and-effect relationship between the investigational product and the occurrence 
of the AE, then the AE should be considered “related”. The causality  assessment must be 
docum ented in the source document.
The following additional guidance may  be helpful:
Term Relationship Definition
RelatedThe temporal relationship between the event and the administration of 
the investigational product is compelling and/or follows a known or 
suspected response pattern to that product, and the event cannot be 
explained by [CONTACT_423]’s medical condition, other therapi[INVESTIGATOR_014], or 
accident.
Not RelatedThe event can be readily  explained by [CONTACT_11260]’s underly ing medical condition, concomitant therap y, or 
accident and no plausible temporal or biologic relationship exists 
between the investigational product and the event.
AEs that are related to study  drug that are not resolved at EOT will be followed until the event 
resol ves or stabilizes, as judged b y the investigator.
Laboratory  values, vital signs, and clinical findings at the scheduled ph ysical examinations must 
be reported as AEs if the investigator considers the finding to be a clinicall y significant change 
from the baseline. 
8.1.[ADDRESS_482950] be recorded during the course of the stud y in the eCRF. Outcomes are 
as follows:
Fatal
Not Recovered/Not Resolved
Recovered/Resolved
Recovered/Resolved with Sequelae
 Recovering/Resolving
 Unknown
For non-commercial use only
Shire CONFIDENTIAL Page 52
Protocol SHP633 -304 08April 2016
8.1.4 Symptoms of the Disease under Study
Symptoms of the disease under study  should not be classed as AEs as long as they  are within the 
normal day -to-day fluctuation or expected progression of the disease and are part of the efficacy  
data to be collected in th e study ; however, significant worsening of the s ymptoms should be 
recorded as an AE.
8.1.[ADDRESS_482951] be taken into consideration.
If, during the study , there are abnormal clinical laboratory  values or vital signs which were not 
present at the beginning of the study , further investigations should be performed until the values 
return to within the reference range or until a plausible explanation ( eg, concomitant disease) is 
found for the abnormal values.
The investigator should decide, based on the above criteria and the clinical condition of a 
subject, whether a change in a clinical laboratory  or vital sign is clinicall y significant and 
therefore repr esents an AE.
8.1.[ADDRESS_482952] be reported within 24 hours to the
Shire Global Pharmacovigilance and Risk Management Department using the Shire 
Investigational and Marketed Products Pregnancy  Report Form. A copy  of the Shire 
Investigational and Marketed Products Pregnancy  Report Form (and any  applicable follow -
up 
report s) must also be sent to the Shire Medical Monitor using the details specified in the 
emergency  contact [CONTACT_1739]. I n the event a subject becomes pregnant 
during the stud y, teduglutide administration must be discontinued immediatel y. 
Every  effort should be made to gather information regarding the pregnancy  outcome and 
condition of the infant. It is the responsibility  of the investigator to obtain this information within 
[ADDRESS_482953] partum.
Pregnancy  complications such as spontaneous abortion/miscarriage or congenital abnormality  
are considered SAEs and must be reported using the Shire Clinical Study  Adverse Event Form 
for Serious Adverse Events (SAEs) and N on-serious AEs as Required b y the Protocol. Note: An 
elective abortion is not considered an SAE.
In addition to the above, if the investigator determines that the pregnancy  meets serious criteria, 
it must be reported as an SAE using the Shire Clinical Stud y Adverse Event Form for SAEs and 
Non-serious AEs as Required by
 [CONTACT_319499]. The test date of the first positive serum/urine -HCG test or 
will determine the pregnancy  onset date.
For non-commercial use only
Shire CONFIDENTIAL Page 53
Protocol SHP633 -304 08April 2016
8.1.7 Abuse, Misuse, Overdose, and Medication Error
Abuse, misuse, overdose, or medication error (as defined below) must be reported to the sponsor 
according to the SAE reporting procedure whether or not they  result in an AE/SAE as described 
in Section 8.2. Note: The 24 -hour reporting requirement for SAEs does not apply  to reports of 
abuse, misuse, overdose, or medication errors unless these resu
lt in an SAE. 
The categories below are not mutually  exclusive; the event can meet more than 1 category .
 Abuse – Persistent or sporadic intentional intake of investigational product when used 
for a non -medical purpose ( eg, to alter one’s state of consciousness or get high) in a 
manner that may  be detrimental to the individual and/or society .
 Misuse – Intentional use of investigational product other than as directed or indicated 
at an y dose (Note: this includes a situation where the investigational product is not 
used as directed at the dose prescribed b y the protocol).
 Overdose 
– Administration of a dose greater than the allocated dose of the study  
medication or at a frequency  greater than the dosing interval specified by [CONTACT_760].
 Medication Error –An error made in prescribing, dispensing, administration, and/or 
use of an investigational product. For studies, m edication errors are reportable to the 
sponsor only  as defined below.
 Cases of subjects missing doses of the investigational product are not considered 
reportable as medication errors.
 Medication errors should be collected/reported for all products under 
investigation.
 The administration and/or use of an expi[INVESTIGATOR_319372] a reportable medication error. 
All investigational product provided to pediatric subjects should be supervised by  [CONTACT_31588]/legall y-authorized representative/caregiver.
8.[ADDRESS_482954] awareness of the event. Note: The 24- hour report ing requirement for SAEs does 
not apply  to reports of abuse, misuse, overdose, or medication errors (see Section 8.1.7) unless 
they result in an SAE.
All Adverse Events of Special Interest , as defined in Section 8.3, must be reported by [CONTACT_385957] [ADDRESS_482955] complete, sign, and date th e Shire Clinical Study  Adverse Event Form for 
SAEs and Non- serious AEs as Required b y Protocol, and verify the accuracy of the information 
recorded on the form with the corresponding source documents (Note: Source documents are not 
to be sent unless reques ted). Fax or e -mail the completed form to the Shire Global 
Pharmacovigilance and Risk Management Department. A copy  of the completed Shire Clinical 
Study  Adverse Event Form for Serious Adverse Events (SAEs) and Non -serious AEs as 
Required b y Protocol (and any  applicable follow -up reports) must also be sent to the Shire 
medical monitor or designee using the details specified in the emergency  contact [CONTACT_230514].
8.2.[ADDRESS_482956] medical occurrence (whether considered to be related to investigational 
product or not) that at any dose: 
Results in death
Is life -threatening. Note: The term 'life -threatening' in the definition of "serious" refers to 
an event in which t he subject was at risk of death at the time of the event; it does not refer 
to an event which h ypothetically might have caused death if it was more severe.
Requires inpatient hospi[INVESTIGATOR_1081]. Note: 
Hospi[INVESTIGATOR_48181], which are the result of elective or previousl y scheduled surgery for pre 
existing conditions, which have not worsened after initiation of treatment, should not be 
classified as SAEs. For example, an admission for a previousl y scheduled ventral hernia 
repair would not be classified as an SAE; however, complication(s) resulting from a 
hospi[INVESTIGATOR_10153] y scheduled surgery  that meet(s) serious 
criteria must be reported as SAE(s).
Results in persistent or significant disability /incapacity
Is a congenital abnormality /birth defect
Is an important medical event. Note: I mportant medical events that may not result in 
death, be life -threatening, or require hospi[INVESTIGATOR_12475], 
based upon appropriate medical judgm ent, they  may  jeopardize the subject and may  
require medical or surgical intervention to prevent 1 of the outcomes listed in this 
definition. Examples of such medical events include allergic bronchospasm requiring 
intensive treatment in an emergency  room or at home; blood dy scrasias or convulsions 
that do not result in inpatient hospi[INVESTIGATOR_059]; or the development of drug dependency  or 
drug abuse. 
8.2.4 Serious Adverse Event Collection Time Frame
All SAEs (regardless of relationship to study ) are collected from the time the subject signs the 
informed consent until the defined follow- up period stated in Section 7.1.4, and must be reported 
to the Shire Global Pharmacovigilance and Risk Management Depar
tment andthe Shire Medical 
Monitor within [ADDRESS_482957] awareness of the event. 
In addition, any SAE(s) considered “related” to the investigational product and discovered by  [CONTACT_10194] y interval after the study has completed must be reported to the Shire Global 
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_482958]’s dea th (ie, the SAE was noted as the primary  cause of death) 
must have fatal checked as an outcome with the date of death recorded as the resolution date. For 
all other events ongoing at the time of death that did not contribute to the subject’s death, the 
outcome should be considered not resolved, without a resolution date recorded.
For an y SAE that results in the subject’s death or any ongoing events at the time of death, unless 
another investigational product action was previously  taken ( eg, drug interrupted, reduced, 
withdrawn), the action taken with the investigational product should be recorded as “dose not 
changed” or “not applicable” (if the subject never received investigational product). The 
investigational product action of “withdrawn” should not be s elected solel y as a result of the 
subject’s death.
8.2.[ADDRESS_482959], Ethics Committee, and Site 
Reporting 
The Sponsor and/or Clinical Contract Research Organization ( CRO )is responsible for notify ing 
the relevant regulatory  authorities, and US central Institutional Review Boards ( IRBs)/EU central 
ethics committees ( ECs
),of related, unexpected SAEs.
In addition, the Clinical CRO is responsible for notify ing active sites of all related, unexpected 
SAEs occurring during all interventional studies across the SHP633 program.
The investigator is responsible for notifying the local IRB, local EC, or the relevant local 
regulatory  author ity of all SAEs that occur at his or her site as required.
8.[ADDRESS_482960] is an AE (serious or nonserious) of scientific and medical concern 
specific to the sponsor’s product or program and for which ongoing mo nitoring and immediate 
notification by  [CONTACT_230013].
The AEs of special interest that require expedited regulatory  reporting include the following:
 Growth of pre -existing poly ps of the colon
 Benign neoplasia of the GI tract including the hepatobiliary  system
 Tumor -promoting ability ( eg, benign and/or malignant neoplasia of any  kind, not 
limited to those of the GI or hepatobiliary  system)
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_482961] awarene ss as 
per the SAE notification instructions described in Section 8.2.2 even if the event does not fulfill 
the seriousness criteria.
8.4 Dose Interruption and Permanent Discontinuation
The investigator is responsible for contact[CONTACT_20610]/designee when the subject’s 
teduglutide dosing regimen is interrupted. Attempts should be made to contact [CONTACT_103]/designee prior to dose interruption. Reasons for dosage interruptions may  include but are 
not limited to hospi[INVESTIGATOR_059], incidents of certain AEs, SAEs co nsidered to be related to the 
study  drug, a lapse in investigational product delivery , etc.
Study  drug must be permanently  discontinued if any  of the following events occur:
 Pregnancy
 Severe h ypersensitivity , such as anaph ylaxis determined by  [CONTACT_385958] y drug. This does not include anti -teduglutide antibodies, mild injection 
site reactions or mild symptoms that according to the investigator do not pose a 
significant risk to the subject.
 An AE listed in ( Table 8-1) that is of NCI CTCAE severit y Grade 3 or 4 and 
considered to be related to study  drug administration
 Confirmed drug -induced liver injury  (DILI) related to teduglutide (See Section 8.4.2)
8.4.[ADDRESS_482962] has an AE listed in Table 8-1 that 
is of severit y ≥Grade 3 per the NCI CTCAE. All such AEs should be discussed with Shire’s 
medical monitor as soon as possible. Teduglutide administration must be permanentl y 
discontinued if the AE is considered related to the investigational product. The length of the dose 
interruption, and whether teduglutide administration resumes or is discontinued, depends on the 
clinical situation.
Investigators and the Data Monitoring Committee (DMC) should be guided by  [CONTACT_385959] 3 and 4 events, as they  relate to known and possible risks associated with the 
administration of teduglutide. 
For non-commercial use only
Shire CONFIDENTIAL Page 57
Protocol SHP633 -304 08April 2016
Table 8-1: CTCAE Criteria for Adverse Events that May Lead to Dose Interruption
Adverse Events Grade 3 Description Grade 4 Description
Gastrointestinal Disorders
Colorectal polyps Severe or medically significant but not 
immediately life threatening;
hospi[INVESTIGATOR_20578]; 
disabling; limiting self -care activities of 
daily livingLife-threatening consequences; urgent 
intervention indicated
Intestinal Obstruction Hospi[INVESTIGATOR_374]; elective 
operative intervention indicated; limiting 
self-care activities of daily living; 
disablingLife-threatening consequences; urgent 
operative intervention indicated
Gallbladder and Bile Duct Disease
Cholecystitis Severe symptoms; radiologic,
endoscopic or elective operative 
intervention indicatedLife-threatening consequences; urgent 
operative intervention indicated
Gallbladder perforation Not Applicable Life-threatening consequences; urgent 
intervention indicated
Gallbladder obstruction Symptomatic and s everely altered 
gastrointestinal function; tube feeding, 
total parenteral nutrition or 
hospi[INVESTIGATOR_374]; nonemergent 
operative intervention indicatedLife-threatening consequences; urgent 
operative intervention indicated
Gallbladder infection Intravenous antibiotic, antifungal, or 
antiviral intervention indicated; 
radiologic, endoscopic, or operative 
intervention indicatedLife-threatening consequences; urgent 
intervention indicated
Adverse Events Grade 3 Description Grade 4 Description
Alkaline Phosphatase 
increased>5.[ADDRESS_482963] >20.0x ULN
Blood bilirubin increased >3.[ADDRESS_482964] >10.0x ULN
Bile duct stenosis Severely altered gastrointestinal function; 
radiologic, endoscopic or elective 
operative intervention indicatedLife-threatening consequences; urgent 
operative intervention indicated
Pancreatic Disease
Pancreatitis Severe pain; vomiting; medical 
intervention indicated ( eg, analgesia, 
nutritional support)Life-threatening consequences; urgent 
intervention indicated
Pancreatic duct stenosis Severely altered gastrointestinal function; 
tube feeding or hospi[INVESTIGATOR_374]; 
elective operative intervention indicatedLife-threatening consequences; urgent 
operative intervention indicated
Pancreas infection Intravenous antibiotic, antifungal, or 
antiviral intervention indicated; 
radiologic or operative intervention 
indicatedLife-threatening consequences; urgent 
intervention indicated
Serum amylase increaseda>2.[ADDRESS_482965] >5.0x ULN
For non-commercial use only
Shire CONFIDENTIAL Page 58
Protocol SHP633 -304 08April 2016
Table 8-1: CTCAE Criteria for Adverse Events that May Lead to Dose Interruption
Lipase increaseda>2.0 to 5.0x UL N >5.0x ULN
Cardiovascular Disease
Heart failure Severe with symptoms at rest or with 
minimal activity or exertion; intervention 
indicatedLife-threatening consequences; urgent 
intervention indicated ( eg, continuous 
intravenous therapy or mechanical 
hemodynamic support)
Source: Common Terminology Criteria for Adverse Events, version 4.03, [ADDRESS_482966]=upper limit of normal
a In the setting of clinically acute and symptomatic pancreatitis 
8.4.[ADDRESS_482967] has 
clinical and laboratory  evidence of potential DILI, in the absence of an alternative explanation, 
as identified b y the following criteria:
 ALT or AST >8x ULN
 ALT or AST >5x ULN and >2x baseline value for more than 2 weeks
 (ALT or AST >3x ULN and >2x baseline value) and (total bilirubin >2x ULN or 
INR>1.5)
 ALT or AST >3x ULN and >2x baseline value with the appearance of fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia 
(>5%)
All laboratory  values suggestive of potentially  new DILI should be repeated and verified within 
[ADDRESS_482968] should be followed closely to determine the trajectory  of the 
laboratory  abnormalities and to evaluate the cause of liver injury . This evaluation may  include, 
as clinically  indicated, consideration of sepsis, acute viral hepatitis (eg, hepatitis A 
immunoglobulin [IgM], hepatitis B surface antigen, hepatitis C antibodies, cy tomegalovirus IgM, 
Epstein- Barr virus antibody panel), hepatobiliary  obstruction (ultrasound), autoimmune hepatitis 
(anti-nuclear, anti -smooth muscle, anti -actin, or anti -liver kidney  microsomal antibodies), 
intestinal failure associated liver disease, cardiovascular causes such as ischemic hepatitis, and 
concomitant hepatotoxic treatments.
Additional evaluations may  be performed at the discretion of the investigator in consultation 
with the 
Shire medical monitor.
Teduglutide administration must be permanentl y discontinued if DILI is confirmed and deem ed 
related to stud y drug.
For non-commercial use only
Shire CONFIDENTIAL Page 59
Protocol SHP633 -304 08April 2016
8.5 Early Termination of the Clinical Study
The DMC may  recommend stoppi[INVESTIGATOR_319373]:
 ≥2subjects being administered investigational product develop the same event listed 
in Table 8-1 of severit y CTCAE Grade 3 
or
 1subject develops an event listed in Table 8-[ADDRESS_482969] or is not reasonably  related to the underlying 
disease process.
For non-commercial use only
Shire CONFIDENTIAL Page 60
Protocol SHP633 -304 08April 2016
9DATA MANAGEMENT AND STATISTICAL METHODS
9.1 Data Collection
The investiga tors’ authorized site personnel must enter the information required by  [CONTACT_103365]. A study  monitor will visit each site in accordance with the monitoring plan and 
review the eCRF data against the source data for completeness and accuracy . Dis crepancies 
between source data and data entered in the eCRF will be addressed b y qualified site personnel. 
When a data discrepancy warrants correction, the correction will be made by [CONTACT_59752]. Data collection procedures will be discussed w ith the site at the site initiation visit 
and/or at the investigator’s meeting. Unscheduled safet y follow up assessments (conducted after 
EOS) are not required to be collected.
9.2 Clinical Data Management 
Data are to be entered into a clinical database as specified in the CRO’s data management 
process. Quality  control and data validation procedures are applied to ensure the validity  and 
accuracy  of the clinical database.
Data are to be reviewed and checked for omissions, errors, and values requiring further 
clarification using computerized and manual procedures. Data queries requiring clarification are 
to be communicated to the site for resolution. Only authorized personnel will make corrections to 
the clinical database, and all corrections are documented in a n auditable manner.
9.3 Statistical Analysis Process 
The study  will be anal yzed by  [CONTACT_10196]. All statistical anal yses will be performed 
using SAS®(SAS Institute, Cary , NC, [LOCATION_003]) version 9.3 or higher.
The statistical anal ysis plan (SAP) will provide the statistical methods and definitions for the 
analysis of the efficacy  and safet y data, as well as describe the approaches to be taken for 
summarizing other study  information such as subject disposition, d emographics and baseline 
characteristics, investigational product exposure, and prior and concomitant medications. 
9.[ADDRESS_482970] been collected. 
ADMC will be involved in the management of this study . The DMC members will review the 
data approximately every 3 months during the study  treatment period (date of the first subject’s 
first dose to date of the last subject’s last dose). The DMC review will include all cumulative 
safet y data ( ie, AEs, laboratory  assessments, ph ysical examinations, etc.) from study  assessments 
through each cutoff period. Further details regarding the DMC can be found in the DMC charter, 
which will be available prior to the ad ministration of investigational product. 
The DMC for this study  will be conducted in accordance with the FDA Guidance for Clinical 
Trial Sponsors: Establishment and Operation of Clinical Trial Data Monitoring Committees 
(March 2006).
The DMC will be an ex ternal, independent board comprised of ph ysicians with relevant training. 
The DMC will be restricted to individuals free of significant conflicts of interest, including, but 
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_482971] may not be 
study  investigators or be employ ed at the same institution as a study  investigator, individuals 
employ ed by [CONTACT_456], independent contractors hired by [CONTACT_456], or members of 
regulatory  agencies. The DMC may  make recommendations to the sponsor regarding stud y 
aspects including stoppi[INVESTIGATOR_007], modify ing or continuing the study ; however, the sponsor will have 
the final responsibility  to determine whether the study  should be modified or temporaril y or 
permanentl y stopped. 
9.5 Sample Size Calculation and Power Considerations 
The number of subjects in this study  is not based on statistical power considerations as this is an 
extension study  of the core study , TED -
C14- 006. The maximum number of subjects will be 
determined b y the enrollment in TED -C14-
006.
9.6 Study Population
The safet y population includes all enrolled subjects in the study . Safet y population will be used 
for both safet y and efficacy  anal yses.
9.7 Efficacy Analyses 
No claims of statistical significance will be made; however, 95% confidence intervals will be 
provided, if applicable. Continuous variables, including those assessed on a discrete scale, will 
be summarized using descriptive statistics including n umber of subjects, mean, median, standard 
deviation, maximum, and minimum. For categorical variables, statistical summaries will include 
number of subjects and percentages.
9.7.1 Efficacy Endpoints
The following efficacy /PD endpoints will be measured. For each e ndpoint, anal yses will be 
performed using the Baseline of this extension study  at the endof each teduglutide treatment 
period ( Week 24 or EOT) and each study  visit. I n addition, the efficacy /PD endpoints will be 
analyzed using the Baseline of the Core stu dy (TED -C14-006) and the Baseline of each 
treatment cy cle. The derivations of the weekl y PS volume and 3 baselines will be described in 
the study  SAP in detail. 
 Reduction in PS volume of at least 20%
• Absolute and relative change in PS volume
 Complete weaning off PS
 Change in day s per week of PS
9.8 Safety Analyses 
9.8.1 Safety Endpoints
The following safet y endpoints will be measured. For each endpoint, anal yses will be performed 
using the Baseline of this extension study . In addition, the safet y endpoints will be anal yzed 
using the Baseline of the Core study  (TED -C14-006). 
For non-commercial use only
Shire CONFIDENTIAL Page 62
Protocol SHP633 -304 08April 2016
 Adverse events , including those pertaining to GI sy mptoms
 Vital signs, including temperature, heart rate, blood pressure
 Body weight, height (or length), head circumference (up to 36 months o f age) trends 
on growth charts, BMI; z -scores will be calculated for height (or length), weight, head 
circumference and BMI
 Laboratory  safet y data ( ie, clinical chemistry , hematology , and urinaly sis)
 Urine output
 Stool output 
 Antibodies to teduglutide
 Gastrointestinal- specific testing (teduglutide treatment eligible subjects only ) 
including colonoscop y or sigmoidoscop y, abdominal ultrasound, and FOBT, upper GI 
series with small bowel follow through 
Adverse events will be coded using the Medical Dictionary for Regulatory  Activities 
(MedDRA). The number of events, incidence, and percentage of AEs will be calculated overall, 
by [CONTACT_1196] (SOC) and by  [CONTACT_11702]. SAEs will be further summarized by  
[CONTACT_11370] y and relationship to investigational produ ct. Adverse events related to investigational 
product, AEs leading to withdrawal, SAEs, and deaths will be similarly  summarized/listed.
Prior and concomitant medications will be coded using the World Health Organization- Drug 
Dictionary (WHO -DD) with regard to drug class and drug name. The number and percentage of 
subjects with specific prior m edications will be summarized. Medical history  (including 
surgical/procedural history ) will be coded using MedDRA. The number and percentage of 
subjects with specific 
histories will be summarized by  [CONTACT_6657]. 
For clinical laboratory  tests, vital signs, body  weight, and fluid balance variables, descriptive 
statistics (mean, median, standard deviation, minimum and maximum values, the number a nd 
percentage of subjects in specified categories) will be calculated to summarize the observed 
values and change from baseline at each scheduled visit.
The number and percentage of subjects classified as having positive specific or neutralizing 
antibodies to teduglutide will be used to summarize the presence of antibodies. 
Additional safet y parameters and measures will include change in bod y weight, height (or 
length) and head circumference (up to 36 months of age). Derived variables will include height 
z-score, weight z -score, BMI, and BMI z -score. Descriptive statistics (mean, median, standard 
deviation , minimum and maximum values, the number and percentage of subjects in specified 
categories) will be calculated to summarize the absolute values and chang e from baseline at each 
scheduled visit.
9.9 Other Analyses
9.9.1 Health -related Quality of Life Analyses 
The following HEOR endpoints will be measured. For each endpoint, analy ses will be performed 
using the Baseline of this extension study . In addition, the HEOR endpoints will be anal yzed 
For non-commercial use only
Shire CONFIDENTIAL Page 63
Protocol SHP633 -304 08April 2016
using the Baseline of each treatment cy cle at approximately  12 week intervals ( Weeks 12 and 24 
of each teduglutide treatment cy cle, and every  12 weeks for subjects not on teduglutide).
 Change in Pediatric Quality  of Life Invento ry (PedsQL) score
 Change in PedsQL Family  Impact Module score
 Change in PedsQL Gastrointestinal Sy mptoms Module Sub- Scales scores: 
Food and Drink L imits
Diarrhea 
For non-commercial use only
Shire CONFIDENTIAL Page 64
Protocol SHP633 -304 08April 2016
10SPONSOR’S AND INVEST IGATOR’S RESPONSIBIL ITIES
This study  is conducted in accordance with current applicable regulations, ICH, EU Directive 
2001/20/EC and its updates, and local ethical and legal requirements. 
The name [CONTACT_317368] y vendor ( eg, CRO) used in this study  will be maintained 
in the investigator’s and sponsor’s files, as appropriate.
10.1 Sponsor’s Responsibilities
10.1.[ADDRESS_482972] been delegated will undertake their assigned roles for this study  in compliance w ith all 
applicable industry  regulations, I CH Good Clinical Practice (GCP) Guideline E6 ( 1996), EU 
Directive 2001/20/EC, as well as all applicable national and local laws and regulations.
Visits to sites are conducted by  [CONTACT_10199]/or the company  
organizing/managing the research on behalf of the sponsor to inspect study  data, subjects’ 
medical records, and eCRFs in accordance with current GCP and the respective local and 
(inter)national government regulations and guidelines. Rec ords and data may  additionall y be 
reviewed b y auditors or by  [CONTACT_10200].
The sponsor ensures that local regulatory  authority requirements are met before the start of the 
study . The sponsor (or a nominated designee) is responsible for the prepar ation, submission, and 
confirmation of receipt of an y regulatory  authority  approvals required prior to release of 
investigational product for shipment to the site.
10.1.2 Indemnity/Liability and Insurance
The sponsor of this research adheres to the recommendations of the Association of British 
Pharmaceutical Industry  Guidelines. If appropriate, a cop y of the indemnity document is 
supplied to the investigator before study  initiation, per local country  guidelines.
The sponsor ensures that suitable clinical study  insurance coverage is in place prior to the start of 
the study . An insurance certificate is supplied to the CRO as necessary . 
10.1.3 Public Posting of Study Information
The sponsor is responsible for posting appro priate study  information on applicable websites. 
Information included in clinical study  registries may  include participating investigators’ names 
and contact [CONTACT_3031].
10.1.4 Submission of Summary of Clinical Study Report (CSR) to Competent 
Authorities of Mem ber States Concerned and Ethics Committees
The sponsor will provide a summary  of the clinical study  report to the competent authority  of the 
member state(s) concerned as required b y regulatory  requirement(s) and to comply  with the 
Community  guideline on GC P. This requirement will be fulfilled within 6 months of the end of 
the study  completion date for pediatric studies and within 1 y ear for non -pediatric studies as per 
guidance. The sponsor will provide the ECs with a copy  of the same summary .
For non-commercial use only
Shire CONFIDENTIAL Page 65
Protocol SHP633 -304 08April 2016
10.1.5 Study Suspension, Termination, and Completion
The sponsor may  suspend or terminate the study , or part of the study , at any  time for any  reason. 
If the stud y is suspended or terminated, the sponsor will ensure that applicable sites, regulatory 
agencies and IRBs/E Cs are notified as appropriate. Additionally , the discontinuation of a 
registered clinical study  which has been posted to a designated public website will be updated 
accordingl y.
The sponsor will make an EOS declaration to the relevant competent authority  as required b y 
Article 10 (c) of Directive 2001/20/EC .
10.2 Investigator’s Responsibilities
10.2.[ADDRESS_482973] undertake to perform the study  in accordance with ICH GCP Guideline E6 
(
1996), EU Directive 2001/20/EC, and appli cable regulatory  requirements and guidelines.
It is the investigator’s responsibility  to ensure that adequate time and appropriately  trained 
resources are available at the site prior to commitment to participate in this study . The 
investigator should also be able to estimate or demonstrate a potential for recruiting the required 
number of suitable subjects within the agreed recruitment period.
The investigator will maintain a list of appropriately  qualified persons to whom the investigator 
has delegated sig nificant study -
related tasks, and shall, upon request of the sponsor, provide 
documented evidence of any  licenses and certifications necessary  to demonstrate such 
qualification. Curriculum vitae for investigators and sub- investigators are provided to the s tudy 
sponsor (or designee) before starting the study .
If a potential research subject has a primary  care phy sician, the investigator should, with the 
subject’s consent, inform them of the subject’s participation in the study .
A coordinating principal inves
tigator is appointed to review the final CSR for multicenter 
studies. Agreement with the final CSR is documented by  [CONTACT_319426] (single -site study ) or coordinating principal investigator (multicenter 
study ),in compliance with Directive 2001/83/EC as amended b y Directive 2003/63/EC and I CH 
Guidance E3 ( 1995). 
10.2.[ADDRESS_482974] met 
protocol eligibility  criteria. Investigators are required to sign an investigator agreement to 
confirm acceptance and willingness to comply  with the study  protocol.
If the investigat or suspends or terminates the study  at their site, the investigator will promptly  
inform the sponsor and the I RB/EC and provide them with a detailed written explanation. The 
investigator will also return all investigational products, containers, and other study  materials to 
the sponsor. Upon study  completion, the investigator will provide the sponsor, I RB/EC, and 
regulatory  agency  with final reports and summaries as required by [CONTACT_59761].
Communication with local I RBs/ECs, to ensure accurate and timel y information is provided at 
all phases during the study , may  be done by  [CONTACT_456], applicable CRO, investigator, or for 
For non-commercial use only
Shire CONFIDENTIAL Page 66
Protocol SHP633 -304 08April 2016
multicenter studies, the coordinating principal investigator [INVESTIGATOR_49106].
10.2.3 Documentation and Retention of Records
[IP_ADDRESS] Case Report Forms
The investigator is responsible for maintaining adequate and accurate medical records from 
which accurate information is recorded into eCRFs, which have been designed to reco rd all 
observations and other data pertinent to the clinical investigation. Case report forms must be 
completed b y the investigator or designee as stated in the site delegation log.
All data will have separate source documentation; no data will be recorded directly  into the 
eCRF.
eCRFs should be approved by  [CONTACT_385960].
The clinical research associate (CRA)/study  monitor will verify  the contents against the source 
data per the monitoring plan. If the data are unclear or contradictory, queries are sent for 
corrections or verification of data.
[IP_ADDRESS] Recording, Access, and Retention of Source Data and Study Documents
Original source data to be reviewed during this study  will include, but are not limited to: 
subject’s medical file, subject diary  cards, original clinical laboratory  reports, and histology  and 
pathology  reports.
All key  data must be recorded in the subject’s medical records.
The investigator must permit authorized representatives of the spons or, the respective national, 
local, or foreign regulatory  authorities, the IRB/EC, and auditors to inspect facilities and to have 
direct access to original source records relevant to this study , regardless of media.
The CRA/study  monitor (and auditors, IRB /EC or regulatory  inspectors) may  check the eCRF 
entries against the source documents. The consent form includes a statement by  [CONTACT_10203]/auditor from the sponsor or its representatives, national or local 
regulatory  authoritie s, or the I RB/EC, having access to source data ( eg, subject’s medical file, 
appointment books, original laboratory reports, X -rays etc.). Non- study  site personnel will not 
disclose an y personal information or personal medical information.
These records must be made available within reasonable times for inspection and duplication, if 
required, b y a properly  authorized representative of any  regulatory  agency  (eg, the US FDA, 
EMA, [LOCATION_006] Medicines and Healthcare products Regulatory  Agency ) or an auditor.
Essent ial documents must be maintained according to ICH GCP requirements and may  not be 
destroy ed without written permission from the sponsor.
[IP_ADDRESS] Audit/Inspection
To ensure compliance with relevant regulations, data generated b y this study must be available 
for ins pection upon request by  [CONTACT_1779], for example, the US Food and Drug 
Administration (FDA) (as well as other US national and local regulatory  authorities), the 
European Medicines Agency (EMA), the Medicines and Healthcare products Regulatory  
For non-commercial use only
Shire CONFIDENTIAL Page 67
Protocol SHP633 -304 08April 2016
Agency , other regulatory authorities, the sponsor or its representatives, and the I RB/EC for each 
site.
[IP_ADDRESS] Financial Disclosure
The investigator is required to disclose an y financial arrangement during the study and for 1 year 
after, whereb y the outcome of the stud y could be influenced b y the value of the compensation for 
conducting the study , or other pay ments the investigator received from the sponsor. The 
following information is collected: an y significant payments from the sponsor or subsidiaries 
such as a grant to fund ongoing research, compensation in the form of equipment, retainer for 
ongoing consultation or honoraria; an y proprietary interest in investigational product; any 
significant equity  interest in the sponsor or subsidiaries as defined in 21 CFR 54 2( b) (1998).
10.[ADDRESS_482975]’s legall y-authorized representative, as 
applicable, is requested to sign and date the subject informed consent form or a certified 
translation if applicable, after the subject has received and read (or been read) the written subject 
information and received an explanation of what the study  involves, including but not limited to: 
the objectives, potential benefits and risk, inconvenienc es, and the subject’s rights and 
responsibilities. A copy  of the informed consent and assent documentation ( ie, a complete set of 
subject information sheets and fully  executed signature [CONTACT_1787]) must be given to the subject or the 
subject’s legall y-authorize d representative, as applicable. This document may require translation 
into the local language. Signed consent forms must remain in each subject’s study  file and must 
be available for verification at an y time.
Within the source documents, site personnel sh ould document instruction of and understanding 
by [CONTACT_7071]/legall y-authorized representative/caregiver of the safe, responsible storage and 
administration of investigational product to the study  subject.
The principal investigator [INVESTIGATOR_385938] a cop y of the consent form, and assent form 
where applicable, which was reviewed b y the IRB/EC and which received their favorable 
opi[INVESTIGATOR_1649]/approval. A copy  of the IRB/EC’s written favorable opi[INVESTIGATOR_1649]/approval of these 
documents must be provided to the spon sor, prior to the start of the study  unless it is agreed to 
and documented (abiding by  [CONTACT_319428]) prior to study  start 
that another party  (ie, sponsor or coordinating principal investigator) is responsible for this 
action. Additionally , if the I RB/EC requires modification of the sample subject information and 
consent document provided by  [CONTACT_456], the documentation supporting this requirement must 
be provided to the sponsor.
10.3.[ADDRESS_482976] or Ethics Committ ee
For sites outside the EU, it is the responsibility  of the investigator to submit this protocol, the 
informed consent document (approved b y the sponsor or their designee), relevant supporting 
information and all ty pes of subject recruitment information t o the I RB/EC for review, and all 
must be approved prior to site initiation .
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_482977] ing to national 
provisions.
Responsibility  for coordinating with IRBs/ECs is defined in the investigator agreement.
Prior to implementing changes in the study , the sponsor and the IRB/EC must approve any  
revisions of all informed consent documents and amen dments to the protocol unless there is a 
subject safet y issue.
Investigational product supplies will not be released until the Sponsor (or designee) has received 
written I RB/EC approval of and copi[INVESTIGATOR_10158].
For sites outside the EU, the inve stigator is responsible for keepi[INVESTIGATOR_1683]/EC apprised of the 
progress of the stud y and of an y changes made to the protocol, but in an y case at least once a 
year; for sites within the EU, this can be done by  [CONTACT_456], the investigator or for multicente r 
studies the coordinating principal investigator, according to national provisions. The investigator 
must also keep the local IRB/EC informed of an y serious and significant AEs.
10.[ADDRESS_482978] (HIPAA) of 
1996. A site that is not a covered entity  as defined by  [CONTACT_385961] (or designee).
The confidentialit y of records that may be able to identify subjects will be protected in 
accordance with applicable laws, regulations, and guidelines.
After subjects have consented to take part in the study , the sponsor and/or its representati ves 
review their medical records and data collected during the stud y. These records and data may, in 
addition, be reviewed b y others including the following: independent auditors who validate the 
data on behalf of the sponsor; third parties with whom the s ponsor may  develop, register, or 
market SHP633; national or local regulatory  authorities; and the I RBs/ECs which gave approval 
for the stud y to proceed. The sponsor and/or its representatives accessing the records and data 
will take all reasonable precauti ons in accordance with applicable laws, regulations, and 
guidelines to maintain the confidentialit y of subjects’ identities.
Subjects are assigned a unique identify ing number; however, their initials and date of birth may  
also be collected and used to assist the sponsor to verify  the accuracy  of the data ( eg, to confirm 
that laboratory  results have been assigned to the correct subject).
The results of studies –containing subjects’ unique identify ing number, relevant medical 
records, and possibly  initials and dates of birth –will be recorded. They  may  be transferred to, 
and used in, other countries which may  not afford the same level of protection that applies within 
the countries where this study  is conducted. The purpose of an y such transfer would includ e: to 
support regulatory  submissions, to conduct new data anal yses to publish or present the study  
results, or to answer questions asked by  [CONTACT_1775].
For non-commercial use only
Shire CONFIDENTIAL Page 69
Protocol SHP633 -304 08April 2016
10.5 Study Results / Publication Policy
Shire will endeavor to publish the results of a ll qualify ing, applicable, and covered studies 
according to external guidelines in a timely  manner regardless of whether the outcomes are 
perceived as positive, neutral, or negative. Additionally, Shire adheres to external guidelines ( eg, 
Good Publication Practices 2) when forming a publication steering committee, which is done for 
large, multicenter Phase [ADDRESS_482979] undergo appropriate technical and 
intellectual propert y review, with Shire agreement to publish prior to release of information. The 
review is aimed at protecting the sponsor’s proprietary  information existing either at the 
commencement of the study  or generated during the study . To the extent permitted by  [CONTACT_10206], the princip al investigator will own (or share with other authors) the 
copy right on his/her publications. To the extent that the principal investigator [INVESTIGATOR_10159], joint 
or shared rights, the principal investigator [INVESTIGATOR_10160] a perpetual, irrevocable, 
royalty-free license to make and distribute copi[INVESTIGATOR_10161].
The term “publication” refers to an y public disclosure including original research articles, review 
articles, oral presentations, abstracts and posters at medical congresses, journal suppl ements, 
letters to the editor, invited lectures, opi[INVESTIGATOR_10162], book chapters, electronic postings on 
medical/scientific websites, or other disclosure of the study  results, in printed, electronic, oral or 
other form.
Subject to the terms of the paragraph below, the investigator shall have the right to publish the 
study  results, and any  background information provided by  [CONTACT_10207] y publication of study results, or necessary for other scholars to verify such stud y 
results . Notwithstanding the foregoing, no publication that incorporates the sponsor’s 
confidential information shall be submitted for publication without the sponsor’s prior written 
agreement to publish, and shall be given to the sponsor for review at least [ADDRESS_482980] publication of the study  results shall be made 
by [CONTACT_10208]’s presentation of a joint, multicenter publication 
of the compi[INVESTIGATOR_10163]. If such a multicenter publi cation is not submitted to a 
journal for publication by  [CONTACT_10209] 18-month period after conclusion, abandonment, 
or termination of the study at all sites, or after the sponsor confirms there shall be no multicenter 
study  publication of the stud y results, an investigator may individually publish the study results 
from the specific site in accordance with this section. The investigator must, however, 
acknowledge in the publication the limitations of the single -site data being presented.
Unless otherwise required by  [CONTACT_10210], or the forum in which 
it is made, authorship will comply  with the International Committee of Medical Journal Editors 
current standards. Participation as an investigator does not confer an y rights to authorship of 
publications.
For non-commercial use only
Shire CONFIDENTIAL Page 70
Protocol SHP633 -304 08April 2016
11REFERENCES
Drucker, D. J. & Yusta, B. 2014. Physiology  and pharmacology  of the enteroendocrine hormone 
glucagon-like peptide-2. Annu Rev Physiol, 76,561- 83.
Khan, F. A., Squires, R. H., Litman, H. J., Balint, J., Carter, B. A., Fisher, J. G., Horslen, S. P., 
Jaksic, T., Kocoshis, S., Martinez, J. A., Mercer, D., Rhee, S., Rudolph, J. A., Soden, J., 
Sudan, D., Superina, R. A., Teitelbaum, D. H., Venick, R., Wales, P. W. & Duggan, C. 
2015. Predictors of Enteral Autonomy  in Children with Intestinal Failure: A Multicenter 
Cohort Study . J Pediatr, 167, 29-34.e1.
Mouksassi, M. S., Marier, J. F., Cyran, J. & Vinks, A. A. 2009. Clinical trial simulations in 
pediatric patients using realistic covariates: applicat ion to teduglutide, a glucagon- like 
peptide-2 analog in neonates and infants with short- bowel syndrome. Clin Pharmacol 
Ther, 86,667-71.
O'Keefe, S. J., Buchman, A. L., Fishbein, T. M., Jeejeebhoy , K. N., Jeppesen, P. B. & Shaffer, J. 
2006. Short bowel syndrome and intestinal failure: consensus definitions and overview. 
Clin Gastroenterol Hepatol, 4,6-10.
Squires, R. H., Duggan, C., Teitelbaum, D. H., Wales, P. W., Balint, J., Venick, R., Rhee, S., 
Sudan, D., Mercer, D., Martinez, J. A., Carter, B. A., Soden, J., Horslen, S., Rudolph, J. 
A., Kocoshis, S., Superina, R., Lawlor, S., Haller, T., Kurs -Lask y, M. & Belle, S. H. 
2012. Natural history  of pediatric intestinal failure: initial report from the Pediatric 
Intestinal Failure Consortium. J Pediatr, 161, 723-8.e2.
Tappenden, K. A., Edelman, J. & Joelsson, B. 2013. Teduglutide enhances structural adaptation 
of the small intestinal mucosa in patients with short bowel syndrome. J Clin 
Gastroenterol, 47,602-7.
Thymann, T., Stoll, B., Mecklenburg, L., Burrin, D. G., Vegge, A., Qvist, N., Eriksen, T., 
Jeppesen, P. B. & Sangild, P. T. 2014. Acute effects of the glucagon- like peptide 2 
analogue, teduglutide, on intestinal adaptation in short bowel syndrome. J Pediatr 
Gastroenterol Nutr, 58,694-702.
Varni, J. W., S herman, S. A., Burwinkle, T. M., Dickinson, P. E. & Dixon, P. 2004. The PedsQL 
Family  Impact Module: preliminary  reliability  and validity . Health Qual Life Outcomes,
2,55.
Wales, P. W., de Silva, N., Kim, J., Lecce, L., To, T. & Moore, A. 2004. Neonatal short bowel 
syndrome: population -based estimates of incidence and mortality  rates. J Pediatr Surg,
39,690-5.
For non-commercial use only
Shire CONFIDENTIAL Page 71
Protocol SHP633 -304 08April 2016
12APPENDICES
For non-commercial use only
Shire CONFIDENTIAL Page 72
Protocol SHP633 -304 08April 2016
APPENDIX 1 GUIDELINES FOR NUTRI TIONAL SUPPORT MANAG EMENT 
DURING THE STUDY
Nutritional support adjustment in volume and calories should be considered at all planned visits. 
Please consider the following clinical parameters identified as markers for adequate management 
of pediatric SBS. These parameters should also be considered for managing nutritional support 
(PS and/or oral/enteral feeding) in terms of volume and calories during the treatment period. 
Growth trajectory , including weight, height (or length), and head circumference (for pediatric 
subjects up to 36 months of age)
Other clinical evaluations
Normal serum electrol ytes
Stable blood urea nitrogen /creatinine levels
Decrease in stool frequency  or volume, including mixed output
Stool consistency  (ie, Bristol Stool Scale)
Urine specific gravit y
General consideration to possible clinical deterioration in SBS
Inability  to maintain weight and growth velocity
Diarrhea ( ≥10 bowel movements per day , ≥80 mL/kg/day  from an ostomy, or 
≥75mL/kg/day  mixed output)
Colic/vomiting frequency increased
Electrol yte changes or imbalance
Skin breakdown 
 Adjustments should be based on the actual nutritional support in volume and calories 
the subject infuses. Subjects should remain compliant with the nutritional support 
prescription in volume and calories during the study .
 Nutritional suppor t constituents may  be adjusted at the discretion of the investigator.
 During the 48 -hour Intake/Output measurement period prior to the subject’s scheduled 
visit, no further changes to the prescribed nutritional support should be made.
 If there is a change in EN or other food or fluid intake, the investigator should consider 
this when adjusting the PS/EN support in volume and calories.
For non-commercial use only
Shire CONFIDENTIAL Page 73
Protocol SHP633 -304 08April 2016
Figure A -1 Weaning Algorithm for Subjects Who are NOT Toilet Trained and in 
Diapers
For non-commercial use only
Shire CONFIDENTIAL Page 74
Protocol SHP633 -304 08April 2016
Figure A -2 Weaning Algorithm for Subjects Who are Toilet Trained and NOT in 
Diapers
For non-commercial use only
Shire CONFIDENTIAL Page 75
Protocol SHP633 -304 08April 2016
Figure A -3 Clinical Dehydration Assessment and PS/EN Adjustment
For non-commercial use only
PROTOCOL: SHP633 -304
TITLE: A Prospective, Open -label, Long-term Safet y and Efficacy  Study of 
Teduglutide in Pediatric Patients with Short Bowel Syndrome Who 
Completed TED -C14-006
DRUG: Teduglutide
IND: IND# [ADDRESS_482981] NO.: 2016-000849-30
SPONSOR: Shire Human Genetic Therapi[INVESTIGATOR_014], Inc.
[ADDRESS_482982] , Lexington, MA [ZIP_CODE] [LOCATION_003]
PROTOCOL 
HISTORY:Amendment 1: 22Nov 2016
Original Protocol: 08April [ADDRESS_482983] party without the express written 
consent of Shire.
For non-commercial use only
CONFIDENTIAL Page2 
Version 2 
PROTOCOL SIGNATURE [CONTACT_64783]'s (Shire) Approval 
Signature: 
, MD PhD 
 
Global Clinical Development 
Investigator's Acknowledgement 
I have read this protocol for Shire Study SHP633-304. Date: 
Title: A prospective, open label, long-term safety and efficacy study of teduglutide in pediatric 
patients with short bowel syndrome who completed TED-C14-[ADDRESS_482984] fully discussed the objective(s) of this study and the contents of this protocol with the 
sponsor's representative. 
I understand that the information in this protocol is confidential and should not be disclosed, 
other than to those directly involved in the execution or the scientific/ethical review of the study, 
without written authorization from the sponsor. It is, however, permissible to provide the 
information contained herein to a subject in order to obtain their consent to participate. 
I agree to conduct this study according to this protocol and to comply with its requirements, 
subject to ethical and safety considerations and guidelines, and to conduct the study in 
accordance with International Conference on Harmonization (ICH) guidelines on Good Clinical 
Practice (GCP) and with the applicable regulatory requirements. 
I understand that failure to comply with the requirements of the protocol may lead to the 
termination of my participation as an investigator for this study. 
I understand that the sponsor may decide to suspend or prematurely terminate the study at any 
time for whatever reason; such a decision will be communicated to me in writing. Conversely, 
should I decide to withdraw from execution of the study I will communicate my intention 
inrmediately in writing to the sponsor. 
Investigator Name [CONTACT_1781]: 
(please hand print or type) Shire CONFIDENTIAL Page 2
Protocol SHP633 -304 Version 2 / 22Nov 2016
Signature: [CONTACT_1782]:
For non-commercial use only
Shire CONFIDENTIAL Page 3
Protocol SHP633 -304 Version 2 / 22Nov 2016
SUMMAR Y OF CHANGES F ROM PREVIOUS VERSION
Protocol Am endments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 1 Amendment Date
22Nov 2016Global
Description of Change and Rationale Section(s) Affected by [CONTACT_385962].Protocol Signature [CONTACT_319504] [CONTACT_319431] -teduglutide treatment 
period, visits will take place approximately every 12 w eeks.Synopsis
Section s3.1, 7.1.2
Figure 3
-1
The study design flow chart has been edited for clarity. Synopsis
Figure 3 -1
The collection of all actual and prescribed enteral nutrition data has been 
removed to reduce the burden on the subjects and investigators. Enteral 
nutrition data are not required as the efficacy endpoints are limited to 
parenteral support parameters.Synopsis
Table 1-1, Table 1-2, Table 1 -3
Sections 7.1.2 ,[IP_ADDRESS] ,[IP_ADDRESS] , 
7.1.5 ,[IP_ADDRESS] , [IP_ADDRESS]
Exclusion criterion [ADDRESS_482985] been refined : 
exclusion/prohibition of treatment with growth hormone has been 
extended to [ADDRESS_482986] been clarified. Table 1-2, Table 1-3
Sections [IP_ADDRESS] , 7.1.[ADDRESS_482987] required at the pre- treatment visit should be performed at 
the local laboratory instead of the central laboratory. This will ensure 
timely results prior to starting treatment with teduglutide.Table 1-3
Section s [IP_ADDRESS] , 7.2.6
The requirement for urine specimen collection has been revised so that a
lack of urinalysis will not constitute a protocol deviation for any 
pediatric subjects (not only for subjects w earing diapers) .Table 1-1, Table 1-2, Table 1-[ADDRESS_482988] no -teduglutide treatment visit 
after the screening visit will occur within 2 to 12 w eeks of the screening 
(formerly within 12 weeks of screening).Synopsis
Table 1-[ADDRESS_482989] been clarified for visits during theno-teduglutide and 
teduglutide treatment periods.Table 1-2,Table 1-3
Section 7.1.2
For non-commercial use only
Shire CONFIDENTIAL Page 4
Protocol SHP633 -304 Version 2 / 22Nov 2016
Protocol Am endments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 1 Amendment Date
22Nov 2016Global
Description of Change and Rationale Section(s) Affected by [CONTACT_64737]
‘Specific’ has been deleted from ‘positive/specific anti-teduglutide 
antibodies’ to eliminate the redundancy. B y definition, positive samples 
must be specific (as assessed in the confirmatory assay), or otherwise
considered negative .Table 1-[ADDRESS_482990] been removed from 
medical history.Table 1-1 ( footnote b)
Section 7.2.1
For consistency within the protocol , sigmoidoscopy has been added as 
the alternate to colonoscopy throughout the protocol. Table 1-1, Table 1-2, Table 1-3
Section s 3.1,7.1.2 , [IP_ADDRESS]
Removal of former footnote i on fecal occult blood test for clarity. Table 1-3
Clarification has been made on circumstances when the CxW28 visit 
may be combined with the next pre-treatment or EOS/ET visit. Table 1-3
Section 7.1.4
The text on PS support requirements over time in pediatric subjects w ith 
SBS has been clarified, and text on intestinal adaptation has been refined.Section 1.1
Status of current teduglutide approvals for use has been updated. Section 1.2, 3.1
The term ‘re -challenge’ has been replaced w ith ‘additional teduglutide 
treatment’ for clarity and consistency with other studies .Section 3.[ADDRESS_482991]’s completion of the study has been corrected for 
consistency within the protocol.Section 3.[ADDRESS_482992] been clarified.Sections 4.8.1 , 4.8.2
Withdraw al by [CONTACT_7078]/guardian has been added as reason for 
discontinuation.Section 4.8.[ADDRESS_482993] met a follow -up period escape 
criterion .Section 7.2.5
Intake and output diaries (formerly in Section s7.2.11 and 7.2.12, 
respectively ) have been moved under a new Section 7.2.11 ‘Diaries’ for 
clarity, and are now Sections [IP_ADDRESS] and 7.2. 11.3, respectively. Sections 7.2.11 ,[IP_ADDRESS] ,  [IP_ADDRESS] , 
[IP_ADDRESS]
For non-commercial use only
Shire CONFIDENTIAL Page 5
Protocol SHP633 -304 Version 2 / 22Nov 2016
Protocol Am endments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 1 Amendment Date
22Nov 2016Global
Description of Change and Rationale Section(s) Affected by [CONTACT_385963] [IP_ADDRESS] . Clarification has been made that only available diary 
data w ill be reviewed at each clinic and telephone visit.
Performance of d ipstick specific gravity tests by [CONTACT_319433]. 
It is now at the discretion of the investigator for all subjects, not just 
those in diapers. This change is to align with standard medical practice.Section [IP_ADDRESS]
Clarifications have been made to the language on dose interruption. Sections 8.4, 8.4.1
Unscheduled safety follow  up assessments (including visits conducted 
after EOS) are not to be recorded. How ever, clarification has been made 
that they are to be collected where requested.Section 9.1
The protocol now  refers to the data monitoring committee (DMC) 
Charter for the schedule of DMC reviews.Section 9.[ADDRESS_482994] been made to the Health economics and outcomes research
endpoints to include the beginning of each treatment cycle (CxD1) as 
additional baseline. These changes ar e for clarity and consistency with 
other teduglutide studies.Synopsis
Section 9.9.[ADDRESS_482995] been made to the guidelines for nutritional 
support management during the study .Appendix 2
SeeAppendix 1 for protocol history , including all amendments.
For non-commercial use only
Shire CONFIDENTIAL Page 6
Protocol SHP633 -304 Version 2 / 22Nov [ADDRESS_482996] IN FORMA TION
In the event of a serious adverse event (SAE), the investigator must fax or e-mail the Shire 
Clinical Study  Adverse Event Form for Serious Adverse Events (SAEs) and Non-serious AEs as 
Required by [CONTACT_230478] 24 hours to the Shire Global Pharmacovigilance and Risk 
Management Department. Applicable fax numbers and e-mail address can be found on the form 
(sent under separate cover). A copy of this form must also be sent to the Shire Medical Monitor 
by [CONTACT_3719] e -mail using the details below.
, MD PhD
Email: 
Fax: 
For protocol -or safety- related issues during normal business hours ([ADDRESS_482997] Time) ,the investigator must contact [CONTACT_317344]:
, MD PhD, 
Phone: 
Mobile: 
Email: 
Fax: 
For protocol -or safety- related issues outside of normal business hours, the investigator 
must contact [CONTACT_319404]:
, MD, 
Phone:  (medical emergencies –US & Canada)
Phone:  (medical emergencies –global)
Email: 
For non-commercial use only
Shire CONFIDENTIAL Page 7
Protocol SHP633 -304 Version 2 / 22Nov [ADDRESS_482998] 
(marketed or investigational) does not meet expectations (eg, inadequate or faulty  closure, 
product contamination) or that the product did not meet the specifications defined in the 
application for the product (eg, wrong product such that the label and contents are different 
products) . For instructions on reporting AEs related to product complaints, see Section 8.
Please use the information below as applicable to report the Product Quality Complaint:
Origin of Product Quality Complaint E
-mail Address
North and South America
European Union and Rest of World
Telephone numbers (provided for reference): 
 Shire ([LOCATION_003]) 
For non-commercial use only
Shire CONFIDENTIAL Page 8
Protocol SHP633 -304 Version 2 / 22Nov [ADDRESS_482999] OF APPENDICES ................................................................................................................12
ABBREVIAT IONS .......................................................................................................................13
STUDY SYNOPSI S
......................................................................................................................15
STUDY SCHEDULE(S) ...............................................................................................................[ADDRESS_483000] Background .................................................................................................25
1.3 Clinical Studies with Teduglutide in Pediatric subjects ...........................................26
2STUDY OBJECTIVES AND PURPOSE ..............................................................................27
2.1 Rationale for the Study .............................................................................................27
2.2 Study  Objectives ......................................................................................................27
2.2.1 Primary  Objectives .................................................................................................27
2.2.2 Secondary  Objectives .............................................................................................27
3STUDY DESIGN ...................................................................................................................28
3.1 Study  Design and Flow Chart ..................................................................................28
3.2 Duration and Study  Completion Definition .............................................................30
4STUDY POPUL ATION.........................................................................................................31
4.1 Study  Inclusion Eligibility  Criteria ..........................................................................31
4.2 Study  Exclusion Eligibility  Criteria
.........................................................................31
4.3 Teduglutide Eligibility  Criteria ................................................................................31
4.4 Teduglutide Treatment Inclusion Criteria ................................................................31
4.5 Teduglutide Treatment Exclusion Criteria ...............................................................32
4.6 Follow -up Period Escape Criteria ................................ ................................ ............ 33
4.7 Reproductive Potential ................................ ................................ ............................. 33
4.7.1 Female Contraception ................................ ................................ ............................ 33
4.8 Discontinuation of Subjects .....................................................................................34
4.8.1
Teduglutide Discontinuation................................ ................................ .................. 34
4.8.2 Study  Withdrawal ................................ ................................ ................................ ..34
4.8.3 Reasons for Discontinuation ................................ ................................ .................. 34
[IP_ADDRESS] Subjects ‘L ost to Follow -up’ Prior to Last Scheduled Visit ..................35
For non-commercial use only
Shire CONFIDENTIAL Page 9
Protocol SHP633 -304 Version 2 / 22Nov [ADDRESS_483001](s) ...........................................................[ADDRESS_483002] Compliance ..................................................................................................40
7
STUDY PROCEDURES........................................................................................................41
7.1 Study  Schedule .........................................................................................................41
7.1.1 Screening ................................................................................................................41
7.1.2
Visits for Subjects Not Receiving Teduglutide .....................................................41
7.1.3
Visits for Subjects Receiving Teduglutide ............................................................42
[IP_ADDRESS] Pre-treatment Visit .................................................................................42
[IP_ADDRESS] Teduglutide Treatment Period (CxD1 -CxW24) .....................................43
7.1.4 Teduglutide Follow -up Period ...............................................................................45
7.1.5 Study  Completion/Earl y Termin
ation Visit (EOS/ET Visit) .................................45
7.2 Study  Evaluations and Procedures
...........................................................................46
7.2.1 Demographics, Medical History , and SBS History ................................ ............... 46
7.2.2 Physical Examination ................................ ................................ ............................. 46
7.2.3 Vital Signs, Bod y Weight, Height, Head Circumference and Bod y Mass 
Index (BMI) ...........................................................................................................46
7.2.4 Clinical L aboratory  Tests .......................................................................................47
7.2.5 Serum Sampling .....................................................................................................48
7.2.6 Pregnancy  Testing ................................ ................................ ................................ ..49
7.2.7 Antibody  Testing ................................ ................................ ................................ ...49
7.2.8 Volume of Blood ................................ ................................ ................................ ....49
7.2.9 Gastrointestinal -specific Testing ................................ ................................ ........... 50
For non-commercial use only
Shire CONFIDENTIAL Page 10
Protocol SHP633 -304 Version 2 / 22Nov 2016
[IP_ADDRESS] Fecal Occult Blood Testing ................................ ................................ ....50
[IP_ADDRESS] Colonoscopy  or Sigmoidoscopy .............................................................50
7.2.10 Nutritional Support ................................................................................................51
7.2.11 Diaries 51
[IP_ADDRESS] Study  Drug Administration Diary ..........................................................51
[IP_ADDRESS] Intake Diary ............................................................................................51
[IP_ADDRESS] Output Diary ...........................................................................................51
7.2.12 Health
-related Quality  ofLife Assessments ..........................................................52
[IP_ADDRESS] Pediatric Quality  of Life Generic Core Scale (PedsQL ™), Acute 
version ....................................................................................................52
[IP_ADDRESS] Pediatric Quality  of Life Family  Impact Module (PedsQL™), Acute 
version ....................................................................................................53
[IP_ADDRESS] PedsQL  Gastrointestinal Sy
mptoms Module (PedsQL ™), Acute 
version ....................................................................................................[ADDRESS_483003] ................................ ................................ ........... 60
8.4 Dose Interruption of Individual Subjects ................................ ................................ .60
8.4.1 Dose Interruption Criteria Based on Known or Possible Risks of 
Teduglutide ................................ ................................ ................................ ............ 61
8.4.2Dose Interruption Criteria Based on Drug -Induced L iver Injury .......................... 62
8.5 Early Termination of the Clinical Study ................................ ................................ ..63
For non-commercial use only
Shire CONFIDENTIAL Page 11
Protocol SHP633 -304 Version 2 / 22Nov 2016
9DATA MANAGEMENT AND STATISTICAL METHODS................................ ............... 64
9.1 Data Collection .........................................................................................................64
9.2 Clinical Data Management .......................................................................................64
9.3 Statistical Analy
sis Process ......................................................................................64
9.4 Planned Interim Anal ysis, and Data Monitoring Committee ...................................64
9.5
Sample Size Calculation and Power Considerations................................................65
9.6 Study  Population ......................................................................................................65
9.7 Efficacy  Anal yses.....................................................................................................65
9.7.1 Efficacy  Endpoints .................................................................................................65
9.8 Safety  Anal yses........................................................................................................65
9.8.1 Safety  Endpoints ....................................................................................................65
9.9 Other Anal yses.........................................................................................................67
9.9.1 Health
-related Quality  of L ife Anal yses................................................................67
10SPONSOR’S AND I NVEST IGATOR’S RESPONSIBIL
ITIES...........................................68
10.1
Sponsor’s Responsibilities .......................................................................................68
10.1.1 Good Clinical Practice Compliance .......................................................................68
10.1.2 Indemnity /Liability  and Insurance .........................................................................68
10.1.3 Public Posting of Study  Information ......................................................................68
10.1.4 Submission of Summary  of Clinical Study  Report (CSR) to Competent 
Authorities of Member States Concerned and Ethics Committees ........................68
10.1.5 Study  Suspension, Termination, and Completion
..................................................69
10.2 Investigator’s Responsibilities .................................................................................69
10.2.1 Good Clinical Practice Compliance .......................................................................69
10.2.2 Protocol Adherence and Investigator Agreement ..................................................69
10.2.3 Documentation and Retention of Records .............................................................70
[IP_ADDRESS] Case Report Forms .................................................................................70
[IP_ADDRESS] Recording, Access, and Retention of Source Data and Study  
Documents ................................ ................................ .............................. 70
[IP_ADDRESS] Audit/I nspection ................................ ................................ ..................... 71
[IP_ADDRESS] Financial Disclosure ................................ ................................ ............... [ADDRESS_483004] or Ethics Committee ..................................................72
10.4 Privacy  and Confidentiality ................................ ................................ ...................... 72
10.5 Study  Results / Publication Policy ................................ ................................ ........... 73
11REFERENCES ................................ ................................ ................................ ....................... 75
12APPENDI CES ................................ ................................ ................................ ........................ 76
For non-commercial use only
Shire CONFIDENTIAL Page 12
Protocol SHP633 -304 Version 2 / 22Nov [ADDRESS_483005]  OF TABLES
Table 1-1: Schedule of Events Required for All Subjects ..............................................20
Table 1
-2: Schedule of Events for Subjects Not Receiving Teduglutide .......................21
Table 1
-3: Schedule of Eve nts for Subjects While Receiving Teduglutide....................22
Table 5
-1: Prohibited Treatment .....................................................................................36
Table 7
-1: Approximate Volume of Blood to be Drawn from Each Subject 
Annually ........................................................................................................49
Table 7
-2: Developmentally Appropriate PedsQL™Generic Core Scales .....................53
Table 8
-1: CTCAE Criteria for Adverse Events that May  Lead to Dose 
Interruption ....................................................................................................[ADDRESS_483006]  OF FIGURES
Figure 3 -
1: Study  Design Flow Chart ..............................................................................[ADDRESS_483007]  OF APPENDICES
Appendix 1
Protocol History.............................................................................................77
Appendix 2 Guidelines for Nutritional Support Management During the Study ............. 78
For non-commercial use only
Shire CONFIDENTIAL Page 13
Protocol SHP633 -304 Version 2 / 22Nov [ADDRESS_483008] aspartate aminotransferase
-HCG beta-human chorionic gonadotropin
BMI body  mass index
CRA clinical research associate
CRO contract research organization
CSR clinical study  report
CTCAE common terminology  criteria for adverse events
DILI drug-induced livery  injury
DMC data monitoring committee
DPP-[ADDRESS_483009]
IV intravenous
For non-commercial use only
Shire CONFIDENTIAL Page 14
Protocol SHP633 -304 Version 2 / 22Nov 2016
IWRS interactive web -based response sy stem
MedDRA Medical Dictionary  for Regulatory  Activities
NCI National Cancer Institute
NDA new drug application
NTT no-teduglutide treatment
PDA patent ductus arteriosus
PedsQL Pediatric Quality  of Life inventory
PS parenteral support
PT/INR prothrombin time/international normalized ratio
QD once dail y
SAE serious adverse event
SAP statistical analy sis plan
SBS short bowel sy ndrome
SC subcutaneous
SOC standard of care
t1/[ADDRESS_483010] upper limit of normal
US [LOCATION_002]
WHO -DD World Health Organization
–Drug Dictionary
For non-commercial use only
Shire CONFIDENTIAL Page 15
Protocol SHP633 -304 Version 2 / 22Nov 2016
STUDY  SYNOPSIS
Protocol num ber: SHP633 -304 Drug: Teduglutide
Title of the study: A Prospective, Open -label, Long -term Safety and Efficacy Study of Teduglutide in Pediatric 
Patients with Short Bow el Syndrome (SBS) Who C ompleted TED -C14-006
Number of subjects (total and for each treatm ent arm):
Approximately 34subjects who completed the TED -C14-[ADDRESS_483011] of care 
treatment arm, are expected to enroll in this extension study. This study will enroll up to as many subjects as 
complete the TED -C14-006 study.
Investigator(s): Multicenter study
Site(s) and Region(s): 
Approximately 28 investigational sites in North America and Europe w ill participate in this extension study
Study period (planned):
October 2016 –September 2019Clinical phase: 3 Extension
Objectives:
Prim ary: To evaluate the long -term safety and tolerability of teduglutide treatment in pediatric subjects w ith SBS.
Secondary: To evaluate long -term efficacy of teduglutide treatment in pediatric subjects with SBS.
Rationale:
This is a Phase 3, prospective, open -label, long -term extension study to evaluate the safety and efficacy of 
teduglutide in pediatric subjects with short bow el syndrome (SBS) w ho completed the TED -C14-006 study (the 
core study). In addition to evaluating t he long -term safety and durability of efficacy after [ADDRESS_483012] of care (SOC) 
treatment arm in TED -C14-006. 
Investigational product, dose, and m ode of administration:
This study will allow repeat doses of teduglutide 0.05 mg/kg subcutaneous (SC) once daily (QD) injection for 
eligible p ediatric subjects. There is no active comparator or reference product.
Methodology:
This is a Phase 3, prospective, open -label, long-term extension study to evaluate the safety and efficacy of 
teduglutide in pediatric subjects who completed the TED -C14-006 study (core study).
Once the informed consent (and if applicable, informed assent) have been reviewed and signed , dem ographics, 
and updates to medical history and short bow el syndrome history will be obtained .Subjects not receiving 
teduglutide treatment (ie, in a no -teduglutide treatment 
[NTT] perio d), w ill be seen approximately every  12 weeks 
for safety, parenteral support (PS) requirements, and quality of life. The first NTT visit after the screening visit 
will occur within 2 to 12 w eeks of the screening visit . At any point after screening, including during a NTT 
period, subjects who meet ≥[ADDRESS_483013], and parent agree to proc eed with teduglutide therapy .
After the pre -treatment visit, subjects who meet ≥1 of the teduglutide treatment inclusion criteria, and meet none 
of the teduglutide treatment exclusion criteria, will start a 28 -week cycle, consisting of 24 weeks of teduglutide 
treatment at 0.05 mg/kg SC once daily, followed by a 4 -week follow -up period (during which no teduglutide is 
administered) (Figure 3 -1). During the 28 -week cycle, clinic visits will occur at weeks 1, 2, 4, 6, 9, 12, 16, 20, 24, 
and 28. Phone visits are required approximately 1 w eek after adjustments in PS during the teduglutide treatment 
period (betw een weeks 1 and 24), and w eekly during the teduglutide follow -up period (between weeks 24 and 
28).Safety and PS requirements will be evaluated at every visi t, and quality of life assessments will be m ade 
approximately every [ADDRESS_483014] has clinical deterioration and meets follow -up period escape criteria 
For non-commercial use only
Shire CONFIDENTIAL Page 16
Protocol SHP633 -304 Version 2 / 22Nov [ADDRESS_483015] may "escape" the follow -up period early and proceed imm ediately to 
another pre -treatment visit. Follow ing completion of the [ADDRESS_483016] w ill proceed to an
NTT visit within approximately 12 w eeks.
Atallsitevisits andtelephone contacts, safety willbemonitored andnutritional suppor twillbereviewed and
adjusted asneeded. Tomaintain consistency across centers, allattempts should bemade tofollow thenutritional
support adjustment guidelines (developed withSBS expert input andprovided intheprotocol) fordecisions
regarding PSsupport reduction andadvances inenteral feeds based onweightgain, urine andstool output, and
clinical stability. Departure from theguidelines, however, isnotconsidered aprotocol deviation. (Appendix 2).
Study Design Flow Chart 
Figure legend: Safety and efficacy data for subjects not receiving teduglutide treatment are captured approximately every 
12 weeks, but subjects may proceed to the pre -treatment visit at any time in order to assess eligibility for teduglutide 
therapy. Elig ible subjects will enter a 28 -week teduglutide cycle. During this cycle, subjects will return to the site for 
safety and efficacy assessments at weeks 1, 2, 4, 6, 9, 12, 16, 20, and 24 ( solid black lines ). Phone visits are required
approximately 1 week aft er adjustments in PS during the intervening weeks between weeks 2 and 24 ( dashed grey 
lines ). Subjects discontinue teduglutide at week 24 and enter a 4 -week follow -up (no-treatment) period, during which 
phone visits will be performed weekly ( solid grey lin es). If an escape criterion is met during the follow -up period, 
subjects may proceed directly to another pre -treatment visit.
Study Inclusion Criteria: 
The subject will be considered eligible for the study if they meet allof the study inclusion criteria. Teduglutide 
treatment eligibility does not impact study eligibility.
1.Subject provides w ritten informed consent (subject, parent or legal guardian and, as appropriate, 
informed assent) to participate in the study before com pleting any study -related procedures.
2.Subject completed the TED -C14-006 study (including subjects in the standard of care treatment arm).
3.Subject understands and is willing and able to fully adhere to study requirements as defined in this 
protocol. 
Study Exclusion Criteria: There are no exclusion criteria for this study.
Teduglutide Eligibility Criteria: Subjects are eligible for tedugluti de treatment if at least one ( ≥1) of the 
teduglutide treatment inclusion criteria, and none of the teduglutide treatment exclusion criteria, are met. In 
addition, the investigator and the subject (and/or parent or legal guardian, as appropriate) must agree to proceed 
with treatment.
Teduglutide Treatment Inclusion Criteria :
1.Subject is teduglutide -naïve, receiving P S, and unable to significantly reduce PS or advance enteral feeds 
(eg, 10% or less change in PS or advance in feeds) for at least 3 months prior to and during the 
For non-commercial use only
Shire CONFIDENTIAL Page 17
Protocol SHP633 -304 Version 2 / 22Nov 2016
teduglutide pre- treatment visit, as assessed by [CONTACT_093]. Transient instability for e vents such as 
interruption of central access or treatment for sepsis is allowed if the PS returns to within 10% of 
baseline prior to the event.
2.Subject w as previously treated w ith teduglutide and at least one of the following criteria is satisfied:
a.Increasing PS requirements follow ing teduglutide discontinuation.
b.Decreased PS requirement during prior teduglutide treatment, follow ed by  [CONTACT_319475].
c.Deteriorating nutritional status ( eg, weight loss or grow th failure) despi[INVESTIGATOR_319360].
d.Deteriorating fluid or electrolyte status despi[INVESTIGATOR_319361].
e.Severe diarrhea r elated to teduglutide discontinuation.
Teduglutide Treatment Exclusion Criteria:
1.Body  weight <10 kg at the pre- treatment visit.
2.Unresected gastrointestinal (GI) polyp, known polyposis condition, pre -malignant change, or 
malignancy, in the GI tract.
3.History of cancer in the previous 5 years except surgically curative skin cancers.
4.Serial transverse enteroplasty or other major intestinal surgery within 3 months preceding the teduglutide 
pre-treatment visit. Insertion of a feeding tube, anastomotic ulcer repai r, mi nor intestinal resections 
≤10cm, and endoscopic procedures are allow ed.
5.Intestinal or other major surgery planned or scheduled to occur during the 28 -week cycle.
6.Clinically significant intestinal stricture or obstruction.
7.Clinically significant, active or recurrent pancreatic or biliary disease.
8.Active, severe, or unstable, clinically significant hepatic impairment or injury, including the following 
laboratory values at the pre- treatm ent visit:
a.Total bilirubin ≥2× upper limit of normal (ULN)
b.Aspartate aminotransferase (AST) ≥7 × ULN
c.Alanine aminotransferase (ALT) ≥7 × ULN
9.Renal dysfunction shown by [CONTACT_319406] (eGFR) below 
50mL/min/1.[ADDRESS_483017] repair, or patent ductus arteriosus (PDA) ligation.
11.Participation in a clinical study using an experimental drug (other than glutamine , Om egaven , or 
Smoflipid) within 3 months or 5.5 half -lives of the experimental drug, whichever is longer, prior to the 
pre-treatment visit and for the duration of the 28 -
week cycle.
12.Treatment with analogs of glucagon -like peptide -1 (GLP -1), glucagon -like pe ptide -2 (GLP -2) (not 
including teduglutide), insulin -like growth factor -1 (IGF -1), or grow th hormone , within 3months
preceding the teduglutide pretreatment visit.
13.Treatment with octreotide or dipeptidyl peptidase 4 (DPP -4) inhibitors within [ADDRESS_483018], closely -related 
compounds, or any of the stated ingredients.
15.Known history of alcohol or other substance abuse within 1 year prior to the pre- treatment visit.
16.Pregnant or lactating female subjects.
For non-commercial use only
Shire CONFIDENTIAL Page 18
Protocol SHP633 -304 Version 2 / 22Nov 2016
17.Sexually active female subjects of child -bearing potential unwilling to use approved contraception 
during teduglutide treatment and for 30 days after the treatment period.
18.Any condition, disease, illne ss, or circumstance that in the investigator’s opi[INVESTIGATOR_319362], prevents completion of the study, or interferes with analysis of the study results.
Follow -up Period Escape Criteria: At the discretion of the investigator, the follow -up period may be interrupted 
and the subject may proceed directly to the pre -treatment visit, if ≥1 of the following criteria is met:
1.Increasing PS requirements follow ing teduglutide discontinuation
2.Deteriorating nutritional status ( eg, weight loss or growth failure) despi[INVESTIGATOR_319363].
3.Deteriorating fluid or electrolyte status despi[INVESTIGATOR_385939].
4.Severe diarrhea related to teduglutide discontinuation.
Maximum duration of subject involvem ent in the study:
A subject w ill be considered enrolled in the study once the subject has provided signed consent, and meets all of 
the Study Inclusion Criteria . Subjects may participate in multiple NTT periods and/or multiple [ADDRESS_483019] has access (as needed) to teduglutide. 
The subject’s maximum dur ation of participation is expected to be approximately [ADDRESS_483020] has not withdrawn early from the study for any reason 
prior to completing End of Study (EOS) visit.
Planned duration o fno-teduglutide treatm ent periods : variable, depending on disease course 
Planned duration of the teduglutide pre -treatm ent visit: 1 to 21 days
Planned cycle duration : 28 weeks. Each cycle consists of 24 w eeks of teduglutide treatment followed 
by a 4 -week follow -up period (no treatment)
Endpoints and statistical analysis: 
The safety population will consist of all enrolled subjects. The safety population will be used for both 
safety and efficacy analysis.
Efficacy Endpoints
Efficacy endpoints will be analyzed at the end of each teduglutide treatment period (Week 24 or end of treatment 
[EOT]), and at each study visit, relative to the baseline of the core study (TED -C14-006) and/or first exposure to 
teduglutide. The following efficacy endpoints will be a nalyzed:
Reduction in PS volume of at least 20%
Absolute and relative change in PS volume
Com plete weaning off PS
Change in days per w eek of PS
Health Econom ics and Outcom es Research Endpoints 
Health economics and outcomes research endpoints will be anal yzed at approximately 12 -week intervals 
(Weeks 12 and 24 of each teduglutide treatment cycle, and every 12 w eeks for subjects not on teduglutide), 
relative to the study baseline. The beginning of each treatment cycle (CxD1) will be an additional baseline.
Change in Pediatric Quality of Life Inventory (PedsQL) score
Change in PedsQL Family Impact Module score
Change in PedsQL Gastrointestinal Symptoms Module Sub -Scales scores: 
Food and Drink Limits
Diarrhea 
Safety Endpoints 
The follow ing safety endpoints will be analyzed:
For non-commercial use only
Shire CONFIDENTIAL Page 19
Protocol SHP633 -304 Version 2 / 22Nov 2016
Adverse events
Vital signs, including temperature, heart rate, blood pressure
Laboratory safety data ( ie, clinical chemistry, hematology, and urinalysis)
Urine output
Stool output
Antibodies to teduglutide
Gastrointestinal -specific testing , including fecal occult blood testing a nd colonoscopy or sigmoidoscopy
Z-scores for w eight, height (or length), head circumference (up to 36 months of age), and body mass index
Statistical Methodology for Efficacy Analysi s
No claims of statistical significance will be made; how ever, 95% confidence intervals will be provided, if 
applicable. Continuous variables, including those assessed on a discrete scale, will be summarized using 
descriptive statistics including number of subjects, mean, median, standard deviation , maximum, and minimum. 
For categorical variables, statistical summaries will include number of subjects and percentages.
Statistical Methodology for Safety Analysis 
Safety data, including laboratory tests and v ital signs assessments, will be summarized by [CONTACT_765]. AEs will also be 
collected and summarized. Descriptive statistics will be calculated for quantitative safety data as w ell as for the 
difference from baseline, if applicable. Frequency counts will be comp iled for classification of qualitative safety 
data.
Sample Size Justification 
As this is an extension study, the maximum number of subjects wasdetermined by [CONTACT_319435] -C14-006.
For non-commercial use only
Shire CONFIDENTIAL Page 20
Protocol SHP633 -304 Version 2 / 22Nov 2016
STUDY  SCHEDULE(S) 
Table 1-1: Schedule of Events Required for All Subjects 
PeriodScreening End of Study or Early Termination
Scr EOS/ET
Visit Type Site Site
Informed consent/assentaX
Study eligibility X
Demographics, Medical historyb, SBS historycX
Dispense intake and output diaries X
Evaluate teduglutide treatment inclusion criteriadX
Adverse events X X
Concomitant medications and GI procedureseX X
Physical examination and vital signs, including weight X
Height and head circumferencefX
Review intake and output diariesg X
Record PS prescription and adjust as neededhX
Safety laboratory testsiX
PedsQL Generic Core Scale/ PedsQL Family Impact Module/ 
PedsQL Gastrointestinal Symptoms Module Sub -ScalesX
Antibodies to teduglutidejX
Fecal occult blood testingk(X)
Colonoscopy or sigmoidoscopyl(X)
Pregnancy testingm(X)
FOBT = fecal occult blood testing ;FOCBP = female of child -bearing potential; EOS =end of study; ET=early termination; 
GI=gastrointestinal; NTx= no treatment; 
PedsQL= Pediatric Quality of Life Inventory; PS=parenteral support; SBS=Short Bowel Syndrome; Scr =Screening.
Note: (X) denotes conditional requirement for a given assessment if the subject meets certain conditions per protocol.
aInformed Consent (and informed assent, if applicable) must be obtained prior to performing any study -related procedures; consent (and 
informed assent, if applicable) may be obtained anytime during the Week 28 (or EOS) visit for the TED -C14-[ADDRESS_483021] has any changes to the SBS history that had been collected at the baseline of the TED -C14-006, then the updated SBS 
history will be collected.
dSubjects who meet ≥[ADDRESS_483022], and 
parent or legal guardian agrees to proceed with teduglutide therapy (Table 1 -3).
eConcom itant GI procedures include (but are not limited to) endoscopy, radiographic studies, GI and liver biopsies and associated 
pathology results.
fHead circumference will be measured in subjects [ADDRESS_483023] eted daily for a minimum of 2 weeks prior to the EOS/ET visit. The output diary should be completed 
daily over a 48 -hour period of nutritional stability before the EOS/ET visit .
hPS adjustments should be made after review of any available intake and outpu t diaries and the safety lab data according to the guidance 
for nutrition support adjustment provided in Appendix [ADDRESS_483024] of clinical chemistry, hematology, and urinalysis, with results pro cessed by a 
central laboratory. Urine specimen collection should be attempted as part of the safety labs, but lack of urinalysis w ill not constitute a 
protocol deviation.
jRequired for all teduglutide -exposed subjects
kFOBT should be performed on teduglutide -exposed subjects on an annual basis, approximately every 48 -60 weeks at a minimum.
lThe need for colonoscopy /sigmoidoscopy in response to a positive FOBT during a no -teduglutide treatment period is at the discretion of 
the investigator, but all teduglutide -exposed subjects will undergo colonoscopy /sigmoidoscopy after they have received the equivalent of 
2 treatment cycles (48 w eeks of study drug exposure), and subjects who continue to receive teduglutide will undergo 
colonoscopy /sigmoidoscopy at [ADDRESS_483025] 30 days after study drug 
discontinuation.
For non-commercial use only
Shire CONFIDENTIAL Page 21
Protocol SHP633 -304 Version 2 / 22Nov 2016
Table 1-2: Schedule of Events for Subjects Not Receiving Teduglutide 
Visit Number NTx
Visit Type Site
Visit FrequencyaEvery 12 weeks 
Window (days)b±[ADDRESS_483026] as neededgX
Safety laboratory testshX
PedsQL Generic Core Scale/PedsQL Family Impact Module/ 
PedsQL Gastrointestinal Symptoms Module Sub-ScalesX
Antibodies to teduglutidei(X)
Fecal occult blood testingjAnnually 
Colonoscopy or sigmoidoscopyk(X)
Serum samplelEvery 24 w eeks
FOBT = f ecal occult blood testing ; NTT = no -teduglutide treatment; PedsQL = Pediatric Quality of Life Inventory; 
PS= parenteral support ; TED = teduglutide .
Note: (X) denotes conditional requirement for a given assessment if the subject meets certain conditions per 
protocol.
aThe first NTx visit following the screening visit must occur w ithin [ADDRESS_483027] NTx visit in the current no -teduglutide treatment period.
cSubjects who meet ≥[ADDRESS_483028], and parent or guardian agree to proceed w ith teduglutide therapy ( Table 1 -3).
dConcomitant GI procedures include (but are not limited to) endoscopy, radiographic studies, GI and liver biopsies 
and associated pathology results.
eHead circumference will be measured in s ubjects [ADDRESS_483029] actual PS volume and hours per day, completed daily for a minimum of 2 w eeks prior to 
each study visit ( see Section [IP_ADDRESS] ). Urine and stool output should be recorded in the output diary over a 48 -hour 
period of nutritional stability before every clinic visit ( see Section [IP_ADDRESS] for more detail).
gPS adjustments should be made after review of the intake and output diaries and the safety lab data according to 
the guidance for nutrition support adjustment provided in Appendix [ADDRESS_483030] follow -up 
samples collected every 12 weeks during the study until a negative result is obtained.
jFOBT should be performed on teduglutide- exposed subjects on an annual basis, approximately every 48 -60 w eeks 
at a minimum.
kThe need for colonoscopy /sigmoidoscopy in response to a positive FOBT during a no -teduglutide treatment period 
is at the discretion of the investigator, but all teduglutide -exposed subjects w ill undergo colonoscopy /sigmoidoscopy
after they have received the equiv alent of 2 treatment cycles (48 w eeks of study drug exposure) and subjects who 
continue to receive teduglutide w ill undergo colonoscopy /sigmoidoscopy at 5 year intervals or more often as 
needed. See Section 7.2.9 for details.
lLack of collection of serum samples will not constitute a protocol deviation.
For non-commercial use only
Shire CONFIDENTIAL Page 22
Protocol SHP633 -304 Version 2/ 22Nov 2016
Table 1-3:Schedule of Events for Subjects While Receiving Teduglutide
PeriodPre-
treat mentTeduglutide Treat mentFollow -up
Visit Number PxCx
D1Cx
W1Cx
W2
Phone contact [CONTACT_319408] [ADDRESS_483031] is required approximately 1 week after PS adjustmentCxW24 
(EOT)CxW25 
CxW26 
CxW27CxW28b
Visit Type Site Site Site Site Site Site Site Site Site Site Site PhoneaSite
Cycle Day -21 to 0 1 8 15 29 43 64 85 113 141 169176
197 183
190
Window  (days)c-21 to 0 ±2 ±2 ±2 ±2 ±4 ±4 ±4 ±4 ±4 ±2 ±2
Evaluate teduglutide 
eligibility (inclusion 
and exclusion) criteriaX Xd
Dispense intake and 
output diariesX X X X X X X X X X X X
Adverse events X X X X X X X X X X X X X
Concomitant 
medications and GI
procedureseX X X X X X X X X X X X X
Physical examination 
and vital signs, 
including weightX X X X X X X X X X X X
Height and head 
circumferencef X X X X
Review intake and 
output diariesg X X X X X X X X X X X X X
Record PS Rx and 
adjust as neededh X X X X X X X X X X X X X
Safety laboratory testsiXiX X X X X X X X X X (X) X
PedsQL Generic Core 
Scale/ Family Impact 
Module/ GI 
Symptoms Module 
Sub-ScalesX X X
Antibodies to 
teduglutidej X X X X
Fecal occult blood 
testingX X X
Colonoscopy /
sigmoidoscopyk (X) (X) (X)
Pregnancy testinglX X X X X X X X X
For non-commercial use only
Shire CONFIDENTIAL Page 23
Protocol SHP633 -304 Version 2/ 22Nov 2016
Table 1-3:Schedule of Events for Subjects While Receiving Teduglutide
PeriodPre-
treat mentTeduglutide Treat mentFollow -up
Serum samplemX X
Evaluate escape 
criterian X X
Dispense study drugoX X X X X X X X X
EOS =end of stu dy; EOT = end of treatment; ET = early termination; FOBT = fecal occult blood test; FOCBP = female of child -bearing potential; FU= follow -up; GI = 
gastrointestinal; PedsQL = Pediatric Quality of Life Inventory; PS= parenteral support; SBS =Short Bowel Sy ndrome; SC = subcutaneous; Scr =Screening; TED = teduglutide; 
Tx = treatment.
Note: (X) denotes conditional requirement for a given assessment if the subject meets certain conditions per protocol.
aPhone visits are required approximately 1 week after adjustments in PS. The assessments to be performed at phone visits are the same as those described for CxW25-27 (except 
for evaluation of escape criteria). 
bThe investigator may combine the CxW28 visit with the next pre-treat ment visit if at least one escape criterion is met at the CxW28 visit, and the pre-treat ment assessments occur 
within [ADDRESS_483032] is completing the study at the CxW28 visit, the EOS/ET visit (Table 1-1) will take place in li eu of the CxW28 visit.
cVisit windows are relative to the CxD1 visit.
dEligibility will need to be re -confirmed prior to the first dose in the cycle. Negative urine pregnancy test is required prior to the first dose of teduglut ide, but results of other labs 
obtained at the CxD1 visit are not required to determine teduglutide treatment eligibility.
eConcomitant GI procedures include (but are not limited to) endoscopy, radiographic studies, GI and liver biopsies and associa ted pathology results.
fHead circumf erence will be measured in subjects [ADDRESS_483033] actual PS volume and hours per day. Intake d iaries should be completed daily for a minimum of 2 weeks immediately prior to each clinic visit (except 
atpre-treatment visit) , for [ADDRESS_483034] PT/INR at the pre -treatment 
visit. Additional collection will occur if a potential drug -induced liver injury signal is observed. Urine specimen collection should be attempted as part of the safety labs, but lack 
of urinalysis will not constitute a protocol deviation.
jSamples collected on CxD1 must be drawn prior to first administration of teduglutide. Samples collected while subjects are re ceiving teduglutide (CxW12 and CxW24) must be 
drawn at least 14 hours after dosing.
kThe teduglutide -naïve s ubjects age 12 and older will undergo colonoscopy /sigmoidoscopy at the pre -treatment visit if one has not been performed within 1 year. Subjects of any 
age with newly positive FOBT results at the pre -treatment visit for which a readily detectable cause can not be identified (eg, anal fissure) will undergo a 
colonoscopy /sigmoidoscopy prior to receiving teduglutide. If newly positive FOBT results (for which a readily detectable cause cannot be identified) ar e obtained at the end of a 
teduglutide treatment cycl e (CxW24/EOT), colonoscopy /sigmoidoscopy will be performed. The need for colonoscopy /sigmoidoscopy in response to positive FOBTs at CxW12 is 
at the discretion of the investigator. Teduglutide -exposed subjects who have received the equivalent of 2 treatment cycles (48 weeks of study drug exposure) will undergo 
colonoscopy /sigmoidoscopy. See Section 7.2.[ADDRESS_483035] is performed on all FOCBP at the teduglutide pre -treatment visit (when the pre -treatment and screening visits are combined, the serum pregnancy test 
For non-commercial use only
Shire CONFIDENTIAL Page 24
Protocol SHP633 -304 Version 2/ 22Nov 2016
Table 1-3:Schedule of Events for Subjects While Receiving Teduglutide
PeriodPre-
treat mentTeduglutide Treat mentFollow -up
should be performed at the local laboratory) . Urine pregnancy tests will be administ ered at all other visits according to the study schedules, or if pregnancy is suspected , or as 
specified per protocol upon withdrawal of the subject from the study .
mLack of collection of serum samples will not constitute a protocol deviation .
nIf escape criteria are met, the subject may proceed directly to another pre -treatment visit at t he discretion of the investigator.
oThe first SC injection of teduglutide in treatment -naïve subjects will be administered under the supervision of the investigator/designee after which the subject will be observ ed 
for hypersensitivity reactions for at le ast 4 hours. The site of administration (arm, thigh, abdomen) of the first teduglutide dose must be specified and recorded in the eCRF . See 
Section 6.2.3 for dose adjustment.
For non-commercial use only
Shire CONFIDENTIAL Page 25
Protocol SHP633 -304 Version 2 / 22Nov 2016
1BACKGROUND INFORMATI ON
1.1 Indication and Current Treatment Options 
Short bowel sy ndrome (SBS) is a rare disorder resulting from congenital abnormalities or severe 
intestinal diseases that result in major surgical resections of the small intestine. I t is estimated 
that, at most, there are a few hundred pediatric subjects 1 y ear and older with SBS (Khan et al. 
2015; Wales et al. 2004 ) .Unlike the adult population, the majority  of cases of SBS in pediatr ic 
subjects are due to congenital anomalies or catastrophic events that occur during infancy . 
Although the small intestine is capable of remarkable adaptation, excessive loss of absorptive 
surface area or specialized functions can lead to dependence on par enteral nutrition or 
intravenous (IV) fluids (parenteral support [PS]). Treatment of both pediatric and adult patients 
is focused on achieving adequate intestinal absorption to allow for minimization or 
discontinuation of PS. About 30% of infants with SBS become independent of PS requirements 
within12months of the initial insult , and an additional 10% wean off PS within 24 months. 
After this time, linear intestinal growth slows. About 60% of pediatric subjects with SBS are able 
to become independent of PS within 5 y ears of the initial diagnosis (Khan et al. 2015).
Nevertheless, despi[INVESTIGATOR_385940], many  pediatric subjects remain dependent 
on PS. Complications of long -term PS include liver disease, catheter -related blood stream 
infections, central line
-associated venous thrombosis and dwindling central venous access. 
Sepsis is the leading cau se of death in these patients and quality  of life is poor (Squires et al. 
2012 ).Accelerating the adaptive process and achieving enteral autonomy  is an urgent goal for all 
patients with SBS who are dependent on PS (Khan et al. 2015; Squires et al. 2012 ).
Intestinal adaptation is driven by [CONTACT_385964] (Drucker 
and Yusta 2014). Chief among these is hormones glucagon -like peptide 2 (GL P-2), which is 
secreted from L- type enteroendocrine cells that reside in the intestinal epi[INVESTIGATOR_319365]. Re section of these regions may  impair the adaptive r esponse b y limiting endogenous 
production of GLP -2. 
1.[ADDRESS_483036] Background 
Teduglutide is a novel, recombinant analog of naturally  occurring human GLP-2 that regulates 
the functional and structural integrit y of the cells lining the gastrointestinal (GI) tract. 
Teduglutide is a 33-amino acid peptide that differs from native GLP -2 in the substitution of 
glycine for alanine at the second position at the N -terminus. As a result, teduglutide demonstrates 
resistance to degradation by [CONTACT_20597] l peptidase -IV (DPP
-4) and therefore maintains a longer 
elimination half-life (t1/2) in adults of approximately  2 hours compared to the native peptide, 
which has a t1/2 of approximately  7 m inutes. Teduglutide has been shown in animal studies and 
previous human clinical trials to increase villus height and crypt depth in the intestinal 
epi[INVESTIGATOR_2130], thereby  [CONTACT_319463] (Tappenden et al. 
2013; Thymann et al. 2014). The European Commission granted a centralized marketing 
authorization valid throughout the European Union (EU) for teduglutide (Revestive™) on [ADDRESS_483037] 2012 and a New Drug Application (NDA) for teduglutide (Gattex®) was approved by [CONTACT_33104] (US) Food and Drug Administration (FDA) on 
21December 2012 for the 
treatment of adult patients with SBS who are dependent on PS. Teduglutide has also been 
approved for use in adult patients with SBS in Canada and Switzerland. On 29 Jun 2016, the 
For non-commercial use only
Shire CONFIDENTIAL Page 26
Protocol SHP633 -304 Version 2 / 22Nov 2016
European Commission granted an extension of the Market Authorization for teduglutide 
(REVESTIVE ™) for the treatment of patients a ged 1 year and above with SBS; patients should be 
stable following a period of intestinal adaptation.
1.3
Clinical Studies with Teduglutide in Pediatric subjects
One Phase 3 stud y, TED -C13-003, was completed in pediatric SBS subjects in the US and 
[LOCATION_008] ([LOCATION_006]). In this study , teduglutide was administered to 3 cohorts of pediatric 
subjects from age s 1-17. Thirty -seven pediatric subjects received teduglutide at doses of 0.0125, 
0.025, or 0.05 mg/kg/day for [ADDRESS_483038] of care (SOC) cohort. There were clear dose -dependent effects of 
teduglutide seen at the 0.025 and 0.05 mg/kg/day  doses compared to SOC and the 0.0125 
mg/kg/day  dose. In the 0.025 mg/kg/day  cohort there was a reduction in PS volume at Week 12 
of 37%, including complete independence from PS support in [ADDRESS_483039], and a reduction of 3.94 
hours per day  infusion time. I n the 0.05 mg/kg/day  cohort there was a reduction in PS vo lume at 
Week 12 of 39%, including complete independence from PS support in 3 subjects, and a 
reduction of 4.18 hours per day  infusion time. Teduglutide was generally  safe and well tolerated 
by [CONTACT_385953]. There were no deaths during the study  and no 
treatment -
emergent serious adverse events (TESAEs) related to teduglutide were reported. No 
discontinuations from study  were due to adverse events (AEs).
TED -C14-006 is an ongoing study  which includes 2 treatment arms: a teduglutide treatment arm 
and a standard of care treatment arm. Subjects in both arms participate in a [ADDRESS_483040] medical therap y for SBS; while 
those in the teduglutide treatment arm will receive daily  subcutaneous (SC) injections of 
teduglutide (stud
y drug) in addition to standard medical therap y. The subjects enrolling in the 
teduglutide treatment arm will be randomized 1:1 in a double- blinded manner into 2 parallel dose 
groups: 0.025 mg/kg/day or 0.05 mg/kg/day  of teduglutide administered subcutaneousl y for [ADDRESS_483041] version of the investigator’s brochure for the overall risk/benefit 
assessment and the most accurate and current information regarding the drug metabolism, 
pharmacokinetics, efficacy  and safet y of teduglutide (SHP633). 
For non-commercial use only
Shire CONFIDENTIAL Page 27
Protocol SHP633 -304 Version 2 / 22Nov [ADDRESS_483042]- time treatment of teduglutide -naïve subjects who participated in the 
SOC treatment arm in TED -C14-006.
2.2 Study Objectives
2.2.1 Primary Objectives
The primary  objective of the study  is to evaluate the long -term safet y and tolerability of 
teduglutide treatment in pediatric subjects with SBS who completed TED -C14-006.
2.2.2 Secondary Objectives
The secondary  objective of this study  is to evaluate the long -term efficacy  of teduglutide 
treatment in pediatric subjects with SBS who completed TED -C14-
006.
For non-commercial use only
Shire CONFIDENTIAL Page 28
Protocol SHP633 -304 Version 2 / 22Nov 2016
3STUDY DESIGN
3.1 Study Design and Flow Chart
This is a Phase 3, prospecti ve, open -label, long -term extension study  to evaluate the safet y and 
efficacy  of teduglutide in pediatric subjects who completed the TED -C14-006 study  (core stud y). 
At the time of entry  into the TED- C14-[ADDRESS_483043] 30% of their caloric or fluid needs, and had 
not been able to significantly  reduce PS for at least 3 months prior to enrollment. During the core 
study , pediatric subjects in the teduglutide treatmen t arm were randomized to 0.025 mg/kg or 
0.05 mg/kg once daily  (QD) dosing in a double -blinded manner. The TED -C14-[ADDRESS_483044] meet ≥1 of the teduglutide treatment inclusion 
criteria and none of the teduglutide treatment exclusion criteria.
Additional Teduglutide Treatment
Subjects not receiving teduglutide treatment ( ie, in a “no- teduglutide treatment period”), will be 
seen approximately  every 12 weeks for safety , parenteral support (PS) requirements, and qualit y 
of life. At an y point during a no -teduglutide treatment period, subjects who meet ≥[ADDRESS_483045], 
and parent agree to proceed with teduglutide therapy .
Rationale: Some pediatric subjects may have a durable beneficial effect after 24 weeks of 
teduglutide treatment and thus long -
term follow -up without additional teduglutide treatment may 
be appropriate. However, there may be some pediatric subjects who deteriorate or stop 
improving after discontinuation of teduglutide treatment. In these pediatric subjects, additional 
teduglutide t reatment may be beneficial. 
Dose Selection 
Analy sis suggested that pediatric patients, ages 1 to 17 y ears old, are likel y to require the same 
dose as used in adults, namely  0.05 mg/kg/day (Mouksassi et al. 2009 ).In this extension study  to 
TED -C14-006, repeat doses of teduglutide 0.05 mg/kg QD will be administered to eligible 
pediatric subjects who previously  received teduglutide 0.05 or 0.025 mg/kg in Study  TED -C14-
006.
Rationale: Teduglutide is approved for adult use in the US and E U, and for pediatric use in the 
EU,at a dose of 0.05 mg/kg SC once daily. The completed 12 -week pediatric study (TED- C13-
003) demonstrated that teduglutide dosing at 0.025 and 0.05 mg/kg/day was associated with a 
favorable benefit/risk profile. In addition, population pharmacokinetic modeling and simulations 
were conducted to determine the effective dose to be used in pediatric sub jects using data from 
8adult clinical studies including adult Phase 1 studies and Phases 2/3 studies as well as the 
For non-commercial use only
Shire CONFIDENTIAL Page 29
Protocol SHP633 -304 Version 2 / 22Nov 2016
pediatric study (TED -C13- 003) and suggested that the dose in pediatric subjects is likely to be 
same as the dose in adults (O'Keefe et al. 2006 ). 
Duration of Treatment
The duration of teduglutide treatment in this study mirrors that of the TED -C14-[ADDRESS_483046] may  be evaluated immediately  for 
additional teduglutide treatment. Subjects who clinically  deteriorate or stop improving at any  
time after the end of the follow- up period will also be assessed for additional treatment.
Rationale: During the teduglutide treatment cycle, visit frequency is similar to frequencies 
performed in TED- C13-[ADDRESS_483047] medical practices.
Measures and Parameters
Following the review and signing of the informed consent (and informed assent, if applicable), 
screening visit procedures will begin including demographics, and updates to medical history
and SBS history . Subjects who meet 
≥1 of the teduglutide treatment inclusion criteria may 
proceed to the pre -treatment visit.
Afterthe pre -treatment visit, subjects who still meet ≥1 of the teduglutide treatment inclusion 
criteria, and meet none of the teduglutide treatment exclusion criteria, will start a 28 -week cy cle, 
consisting of 24 weeks of teduglutide treatm ent at 0.05 mg/kg SC once daily , followed by  a 4-
week follow -up (no treatment) period ( Figure 3-1). During the 28 -week cycle, clinic visits will 
occur at weeks 1, 2, 4, 6, 9, 12, 16, 20, 24, and 28. Phone visits are required approximately  
1 week after adjustments in PS during the teduglutide treatment period ( between weeks 1-24), 
and weekl y during the teduglutide follow -up period (between weeks 24 and 28 ).
Safety  and PS requirements will be evaluated on a weekl y basis, and quality of life assessments 
will be made approximately  every  12 weeks. At all site visits and telephone contacts, safety  will 
be monitored and nutritional support will be reviewed and a djusted as needed. To maintain 
consistency  across centers, all attempts should be made to follow the nutritional support 
adjustment guidelines (developed with SBS expert input and provided in the protocol) for 
decisions regarding PS reduction and advances in enteral feeds based on weight gain, urine and 
stool output, and clinical stability . Departure from the guidelines, however, is not considered a 
protocol deviation ( Appendix 2 ).
Rationale: Measures of long term safety will include adverse events, growth parameters and 
anti-drug antibodies. Measure of long term efficacy will include durability of effect as measured 
by [CONTACT_319411] (PedsQL, PedsQL 
Family Impact Module). A reduction in PS volume of at least 20% at end of treatment ( EOT )was 
used as the primary endpoint in pi[INVESTIGATOR_30338] 3 adult clinical trials and the completed phase 3 
pediatric study (TED -C13-003), and will be used as an endpoint in this extension study. In 
previous clinical studies, a reduction of this magnitude was associated with a reduction in the 
For non-commercial use only
Shire CONFIDENTIAL Page 30
Protocol SHP633 -304 Version 2 / 22Nov [ADDRESS_483048] of teduglutide, GI -specific screening tests, 
including fecal occult blood testing and colonoscopy /sigmoidoscopy , which are commonl y part 
of the routine care of these subjects, will be performed to ensure safet y. This st udy captures long -
term safet y data on polyps and other colonic mucosal changes in teduglutide -exposed subjects 
using the surveillance strategy  proposed in Section 7.2.9 . 
Figure 3-1: Study Design Flow Chart
Figure legend: Safety and efficacy data for subjects not receiving teduglutide treatment are captured approximately every 
12weeks, but subjects may proceed to the pre -treatment visit at any time in order to assess eligibility for teduglutide therapy. 
Eligible subjects will enter a 28 -week teduglutide cycle. During this cycle, subjects will return to the site for safety and efficacy 
assessments at weeks 1, 2, 4, 6, 9, 12, 16, 20, and 24 ( solid black lines ). Phone visits are required approximately 1 week af ter 
adjustments in PS during the intervening weeks between weeks 2 and 24 ( dashed grey lines ). Subjects discontinue teduglutide at 
week 24 and enter a 4 -week follow-up (no -treatment) period, during which phone visits will be performed weekly ( solid grey 
lines). If an escape criterion is met during the follow -up period, subjects may proceed directly to another pre -treatment visit.
3.[ADDRESS_483049]’s maximum duration of participation is 
expected to be approximately  [ADDRESS_483050] has not withdrawn 
early from the stud y for any re ason prior to completing the End of Study  (EOS) visit.
The study  completion date is defined as the date the final subject, across all sites, completes their 
final protocol -defined assessment. Please note that this includes the follow -up visit or contact 
(last safet y contact), whichever is later. The stud y completion date will be used to ascertain 
timing for study  results posting and reporting.
For non-commercial use only
Shire CONFIDENTIAL Page 31
Protocol SHP633 -304 Version 2 / 22Nov [ADDRESS_483051] review and sign the informed consent (and informed assent, if applicable) 
before any stud y-related procedures specified in the protocol are performed. Teduglutide 
treatment eligibility  does not impact study  eligibility .
4.[ADDRESS_483052] will not be considered eligible for the study  without meeting all o f the criteria below:
1. Subject provides written informed consent (subject, parent or legal guardian and, as 
appropriate, subject informed assent) to participate in the study  before completing any  
study -related procedures. 
2. Subject completed the TED- C14-006 study  (including subjects in the standard of care 
treatment arm).
3.
Subject understands and is willing and able to fully  adhere to study  requirements as 
defined in this protocol.
4.[ADDRESS_483053] 1 ( ≥1) of the teduglutide treatment 
inclusion criteria, and none of the teduglutide treatment exclusion criteria aremet. In addition, 
the investigator and the subject (and/or parent or legal guardian, as appropriate) must agree to 
proceed with treatment.
4.[ADDRESS_483054] is teduglutide -naïve, receiving PS, and unable to significantl y red uce PS or 
advance enteral feeds ( eg, 10% or less change in PS or advance in feeds) for at least 
3months prior to and during the teduglutide pre -treatment visit, as assessed by  [CONTACT_1275]. Transient instability  for events such as interruption of cent ral access or 
treatment for sepsis is allowed if the PS returns to within 10% of baseline prior to the 
event.
2.Subject was previousl y treated with teduglutide and at least 1 of the following criteria is 
satisfied :
a.Increasing PS requirements following tedugl utide discontinuation.
b.Decreased PS requirement during prior teduglutide treatment, followed by  
[CONTACT_319412].
c.Deteriorating nutritional status eg, weight loss or growth failure) despi[INVESTIGATOR_385941] l nutrition following teduglutide discontinuation.
d.Deteriorating fluid or electroly te status despi[INVESTIGATOR_319367].
For non-commercial use only
Shire CONFIDENTIAL Page 32
Protocol SHP633 -304 Version 2 / 22Nov 2016
e.Severe diarrhea related to teduglutide discontinuation.
4.5 Tedug lutide Treatment Exclusion Criteria
1.Body weight <[ADDRESS_483055]
3.History  of cancer in the previous 5 y ears except surgically  curative ski n cancers
4.Serial transverse enteroplasty  or other major intestinal surgery  within 3 months 
preceding the teduglutide pre -treatment visit. I nsertion of a feeding tube, anastomotic 
ulcer repair, minor intestinal resections ≤10 cm, and endoscopic procedures a re allowed.
5.Intestinal or other major surgery planned or scheduled to occur during the 28 -week cy cle
6.Clinically  significant intestinal stricture or obstruction
7.Clinically  significant, active or recurrent pancreatic or biliary  disease
8.Active, severe, or unstable, clinically  significant hepatic impairment or injury , including 
the following laboratory  values at the pre -treatment visit:
a.Total bilirubin ≥2× upper limit of normal (ULN)
b.Aspartate aminotransferase (AST) ≥7 × ULN
c.Alanine aminotransferase (ALT) ≥7 × ULN
9.Renal dy sfunction shown by  [CONTACT_319406] (eGFR) 
below 50 mL /min/1.[ADDRESS_483056] repair, or patent ductus 
arteriosus (PDA) ligation
11.Participation in a clinical study  using an experimental drug (other than glutamine , 
Omegaven , or Smoflipid ) within 3 months or 5.5 half- lives of the experimenta l drug, 
whichever is longer, prior to the pre-treatment visit and for the duration of the 28-week 
cycle
12.Treatment with analogs of glucagon -like peptide -1 (GL P
-1), glucagon -like peptide -2 
(GLP-2) (not including teduglutide), insulin -like growth factor -1 (IG F-1), or growth 
hormone , within 3month s preceding the teduglutide pretreatment visit.
13.Treatment with octreotide or dipeptidy l peptidase 4 (DPP -4) inhibitors within [ADDRESS_483057], 
closely -related compounds, or any  of the stated ingredients
15.Known history  of alcohol or other substance abuse within 1year prior to the pre -
treatment visit
16. Pregnant or lactating female subjects 
17.Sexually  active female su bjects of child -bearing potential unwilling to use approved 
contraception during teduglutide treatment and for 30 day s after the treatment period 
For non-commercial use only
Shire CONFIDENTIAL Page 33
Protocol SHP633 -304 Version 2 / 22Nov 2016
18.Any condition, disease, illness, or circumstance that in the investigator’s opi[INVESTIGATOR_319368] y undue risk, prevents completion of the study , or interferes with 
analysis of the study  results.
4.[ADDRESS_483058] may  
proceed directl y to the pre -treatment visit, if ≥1of the following criteria is met:
1.Increasing PS requirements following teduglutide discontinuation .
2.Deteriorating nutritional status (eg, weight loss or growth failure) despi[INVESTIGATOR_319369] .
3.Deteriorating fluid or electrolyte status despi[INVESTIGATOR_319370] .
4. Severe diarrhea related to teduglutide discontinuation.
4.[ADDRESS_483059]. 
To be eligible for treatment with teduglutide, female pediatric subjects and adolescent subjects 
should be either:
Pre-menarchal and either Tanner Stage 1 or less than age 9 years, or
Females of child -bearing potential (FOCBP) with a negative serum beta- human chorionic 
gonadotropin ( -HCG) pregnancy  test at the teduglutide pre -treatment visit .Females of 
child- bearing potential must agree to abstain from sexual activity  that could result in 
pregnancy  or agree to use acceptable methods of contraception.
Acceptable methods of contraception are:
Abstinence
Intrauterine devices plus condoms
Double- barrier methods ( eg, condoms and diaphragms with spermicidal ge l or foam)
Hormonal contraceptives (oral, depot, patch, injectable, or vaginal ring), stabilized for at 
least 30 day s prior to the pre -treatment visit, plus condoms. Note: if subject becomes 
For non-commercial use only
Shire CONFIDENTIAL Page 34
Protocol SHP633 -304 Version 2 / 22Nov [ADDRESS_483060] wishes to remain in the study, the evaluations listed for the EOT visit are to be 
performed. A 4-week follow -up period will ensue, consisting of weekl y telephone visits 
(CxW25 -27) and the week 28 clinic visit (CxW28). The subject would 
then enter a 
no-teduglutide treatment ( NTT ) period and could be evaluated for subsequent teduglutide 
treatment eligibility  according to the study  schedules. Comments (spontaneous or elicited) or 
complaints made by  [CONTACT_1706]. The reason for 
permanent treatment discontinuation, dates of investigational product administered (including 
last date of treatment), and amount of investigational product taken must be recorded in the 
electronic case report form (eCR F) and source documents, as described in Section 4.8.3. The 
investigator is encouraged to discuss withdrawal of a subject f
rom investigational product with 
the medical monitor, when possible.
4.8.[ADDRESS_483061] will 
then be asked to return 4 weeks later for the earl y termination (ET) visit, and will be contact[CONTACT_319413] y by [CONTACT_385965] -up.
If a subject withdraws from the study  during a NTT period, the evaluations listed for the ET visit 
are to be performed as soon and completel y as possible. 
Subjects who withdraw from the study will not be replaced.
4.8.3 Reasons for Discontinuation
The reason(s) for permanent discontinuation of treatment and/or withdrawal from the study  must 
be determined b y the investigator, and recorded in the subject’s medical record and in the eCRF. 
If a subject is withdrawn for more tha n 1reason, each reason should be documented in the source 
document, and the most clinically  relevant reason should be entered in the eCRF.
Reasons for discontinuation include, but are not limited to:
Adverse event 
Protocol deviation
For non-commercial use only
Shire CONFIDENTIAL Page 35
Protocol SHP633 -304 Version 2 / 22Nov [ADDRESS_483062] 
Withdrawal by  [CONTACT_7078]/guardian
Lost to follow -up
Pregnancy  (Discontinuation of treatment onl y) 
Death 
Other 
[IP_ADDRESS] Subjects ‘Lost to Follow -up’ Prior to Last Scheduled Visit
A minimum of [ADDRESS_483063] (office visit or telephone contact). At least [ADDRESS_483064]’s last 
known address via courier or mail (with an acknowledgement of receipt request) asking that they  
return to the site for final safet y evaluations, and return an y unused investigational product.
For non-commercial use only
Shire CONFIDENTIAL Page 36
Protocol SHP633 -304 Version 2 / 22Nov [ADDRESS_483065] be recorded on the appropriate eCRF 
page. Concomitant treatments will be asses sed at each site visit, and include all non -study  
treatments (medications, herbal treatments, vitamins, invasive and diagnostic procedures). 
Concomitant GI  procedures include (but are not limited to) endoscopy , radiographic studies, GI 
and liver biopsies a nd associated pathology  results. Concomitant treatment information must be 
recorded on the appropriate eCRF page. Details of medication changes and/or dosages will be 
recorded on the eCRF.
The mechanism of action of teduglutide may  increase absorption of d rugs ( eg, motility  
medication including narcotics and opi[INVESTIGATOR_20574], warfarin, 
psychotropi[INVESTIGATOR_1102], metronidazole, and digoxin). Accordingl y, due consideration should be given to 
modify ing concomitant medication regimens. Down -titration of concomitant medications should 
be considered when drugs, especiall y those with a narrow therapeutic range, are prescribed at 
dosages that are higher than usual.
5.1.[ADDRESS_483066] medical therapy for SBS should be continued.
5.1.2 Prohibited Treatme nt
The mechanism of action of teduglutide may  increase enteral absorption of drugs ( eg, motility  
medication including narcotics and opi[INVESTIGATOR_20574], warfarin, 
psychotropi[INVESTIGATOR_1102], metronidazole, digoxin), so consideration should be given t o modify ing 
concomitant enteral medication regimens. Down -titration of concomitant enteral medications 
should be considered when drugs, especially  those with a narrow therapeutic range, are given at 
dosages that are higher than usual.
The following medications are prohibited during teduglutide treatment and within the provided 
timeframe prior to the pre -treatment visit:
Table 5-1: Prohibited Treatment
Prior Therapy Time Restriction Prior to 
the Pre -Treatment Visit
Native/synthetic glucagon -like peptide -2 (not -including teduglutide) Any
Glucagon-like peptide- 1 analog or human growth hormone 3month s
Octreotide or dipeptidyl peptidase 4 inhibitors 3 months
Biological therapy ( eg, antitumor necrosis factor) 6 months
For non-commercial use only
Shire CONFIDENTIAL Page 37
Protocol SHP633 -304 Version 2 / 22Nov [ADDRESS_483067] is teduglutide, which will be provided in sterile, single -use 3 mL  vials 
containing 5 mg or 1.25 mg teduglutide as a white ly ophilized powder to be reconstituted before
use with 0.5 mL  sterile water for injection. In addition to the active ingredient (teduglutide), each 
vial of teduglutide contains L -histidine, mannitol, monobasic sodium phosphate monohy drate, 
and dibasic sodium phosphate as excipi[INVESTIGATOR_840]. Additional information is provided in the current 
SHP633 i nvestigator’s brochure.
6.1.[ADDRESS_483068](s)
6.2.[ADDRESS_483069] Management
An interactive web -based response s ystem (IWRS) will be used for screening and enrolling 
subjects, recording subject visits, investigational product supply dispensation and management, 
inventory  management and supply  ordering, investigational product expi [INVESTIGATOR_49093], and return of investigational product. Please refer to the Study Manual for 
additional details regarding the IWRS. 
The I WRS will also be used for creating, tracking, and confirming investigational product 
shipments. A user manual with specific functions and instructions for the IWRS will be provided 
to the site, and site personnel will receive training.
6.2.[ADDRESS_483070], and/or parent/guardian agree 
to proceed with treatment, a formal evaluation of teduglutide in clusion and exclusion criteria will 
be performed at the pre -treatment visit ( Table 1-3 ). 
6.2.[ADDRESS_483071] will start a teduglutide tre atment period, consisting of 24 weeks of 
teduglutide treatment at 0.05 mg/kg SC once daily. The initial dose will be calculated based on 
body  weight measured at the teduglutide pre -treatment visit, and adjusted as needed, based on 
body  weight measured at W eek12 (CxW12). No other adjustments to dose will be made during 
the teduglutide treatment period, unless discussed with the sponsor’s medical monitor. 
Following reconstitution, teduglutide will be administered b y SC injection QD into 1 of the 
4quadrants of the abdomen (in subjects without a stoma) or into either the thigh or arm. For 
subjects with a stoma, the quadrant of the abdomen containing the stoma should not be used. 
For non-commercial use only
Shire CONFIDENTIAL Page 38
Protocol SHP633 -304 Version 2 / 22Nov [ADDRESS_483072] 
4 hours during their initial dosing visit. The site of ad ministration (arm, thigh, and abdomen) of 
the first teduglutide dose must be specified and recorded in the eCRF. 
Detailed instructions for reconstitution and injection of the investigational product can be found 
in the I nstructions for Use. 
Following eac h 24- week teduglutide treatment period, subjects will enter a [ADDRESS_483073] may  proceed 
directly  to another Pre -Treatment visit to assess treatment eligibility  for another cy cle 
(Section 4.6). Following the completion of the 4- week follow -up, the subject will continue in the 
study  off teduglutide. Additional [ADDRESS_483074](s) container. 
The study  drug will be packaged, labeled, and shipped to the study  site by  [CONTACT_98634]. Kits containing [ADDRESS_483075] is packaged in the following conditions:
Teduglutide will be provided in a sterile, single -use, glass vial as a l yophilized powder, t o be 
reconstituted with 0.5 mL sterile water for injection provided as the diluent in a prefilled s yringe.
For non-commercial use only
Shire CONFIDENTIAL Page 39
Protocol SHP633 -304 Version 2 / 22Nov [ADDRESS_483076] be kept in a locked area with access restricted to specific study  personnel. Study  
drug will be stored refrigerated at a temperature between 2 to 8°C (35.6 to 46.4°F) until 
dispensed to a subject. Once dispensed to a subject, the study  drug can be stored refrigerated or 
up to a controlled room temperature (acceptable range of 2 to 25°C, or 35.6 to 77°F). 
Parent/guardian will be instructed to keep the subject’s stud y drug and sterile water diluent at 
controlled room temperature. If there are c oncerns that the controlled room temperature cannot 
be maintained, the stud y drug may  be refrigerated. The study  drug is for single use only , and 
should be used within [ADDRESS_483077] is maintained within an established temperature range. The investigator is responsible 
for ensuring that the temperature is monitored throughout the duration of the study  and that 
records are maintained; the temperature should be monitored continuously  by [CONTACT_3570]-house sy stem, a mechanical recording device such as a calibrated chart recorder, or by  [CONTACT_10179], such that both minimum and maximum thermometric values over a specific time period 
can be recorded and retrieved as required. Such a device ( ie, certified min/max thermometer) 
would require manual resetting upon each recording. The sponsor must be notified i mmediately  
upon discovery  of any  excursion from the established range. Temperature excursions will require 
site investigation as to cause and remediation. The sponsor will determine the ultimate impact of 
excursions on the investigational product and will provide supportive documentation as 
necessary . Under no circumstances should the product be dispensed to subjects until the impact 
has been determined and the product is deemed appropriate for use b y the sponsor.
The sponsor should be notified immediately  if there are an y changes to the storage area of the 
investigational product that could affect the integrity  of the product(s), eg, fumigation of a 
storage room.
Investigational products are distributed b y the pharmacy or nominated member of the stud y 
team. The pharmacist/nominated team member will enter the unique subject identifier on the 
investigational product bottle/carton labels, as they are distributed. 
6.[ADDRESS_483078] will be made available to the sponsor’s site monitor for the purpose of accounting for 
For non-commercial use only
Shire CONFIDENTIAL Page 40
Protocol SHP633 -304 Version 2 / 22Nov [ADDRESS_483079] be accounted for and in no case will 
clinical supplies be used in any  unauthorized situation.
The investigator has overall responsibility  for administering/dispensing investigational product. 
Where permissible, tasks may  be delegated to a qualified designee ( eg, a pharmacist) who is 
adequatel y trained in the protocol and who works under the direct supervision of the investigator. 
This delegation must be documented in the applicable study  delegation of authority  form.
The investigator or his/her designee (as documented by  [CONTACT_49121] y form) will dispense the investigational product only to subjects eligible 
for teduglutide treatment following the procedures set out in t he study  protocol. All dispensed 
study  medication will be documented in the interactive response technology  system and/or other 
investigational product record ( eg, investigation product accountability  form). The investigator is 
responsible for assuring the retrieval of all stud y supplies from subjects.
All used and unused study  drug vials must be returned by  [CONTACT_20608]/or parent/guardian, 
and will be retained at the site. If deemed appropriate, the investigator or his/her designee may 
dispense the unu sed study  drug vials to the same subject. All original containers, whether empty  
or containing stud y drug will be returned to the pharmacy. Returned stud y drugs will NOT be 
relabeled or reassigned for use b y other subjects. Contents of the study drug conta iners will not 
be combined. All used and unused vials must be returned to the distribution center according to 
the sponsor’s instruction. No vial/kit may  be destroy ed on site without approval by  [CONTACT_456]. 
Please see the Pharmacy  Manual for additional information.
6.[ADDRESS_483080] and empty /used 
investigational product packaging to every  visit. Drug accountability  will be assessed at the 
container/packaging level for unused inv estigational product that is contained within the original 
tamper -evident sealed container ( eg, bottles, tray s, vials) or at the individual count level for 
opened containers/packaging. The pharmacist/nominated person will record details on the drug 
account ability  form.
Of those subjects eligible for teduglutide treatment, subjects who have received 80% of the 
planned doses administered will be assessed as being compliant with the study  protocol.
For non-commercial use only
Shire CONFIDENTIAL Page 41
Protocol SHP633 -304 Version 2 / 22Nov 2016
7STUDY PROCEDURES
7.1 Study Schedule
Detailed study  procedures and assessments to be performed for subjects throughout the stud y are 
outlined in the Schedule of Assessments ( Table 1 -1,Table 1 -2, and Table 1 -3) and must be 
referred to in conjunction with the instructions provided in th
is section. 
7.1.1 Screening 
Prior to per forming an y study-related procedures (including those related to screening), the 
investigator or his/her designee must obtain written informed consent (and assent, as applicable) 
from the subject. A subject will have up to [ADDRESS_483081] occur 
within 12 weeks of screening for a pre-treatment visit, and within 2 to 12 weeks of screening for 
an NTx visit.
The screening visit (Scr) assessments and procedures, beginning with informed consent, will be 
performed as outlined in Table 1-1, and as detailed below :
Informed consent, and informed assent (if applicable), is obtained
Study  eligibility  is determined. A screen failure is a subject who has given informed 
consent and failed to meet the Study  Inclusion Eligibility  Criteria. Subjects cannot be 
rescreened once they  have been designated as a screen failure. 
Demographics, upda tes to medical history  and SBS history
Intake and output diaries are dispensed
Evaluate teduglutide treatment inclusion criteria 
Adverse events , concomitant medications and concomitant GI  procedures
7.1.2 Visits for Subjects Not Receiving Teduglutide
While outside of the 28-week teduglutide -treatment cycle, subjects will be followed 
approximately  every  12weeks for safet y and efficacy  assessments. No-teduglutide treatment 
visits are numbered sequentially  (NT1, NT2, etc.), even if interrupted by [CONTACT_385956]. 
The visit window (±7days) is relative to the first NTx visit in the current NTT period.
Assessments will be performed as outlined in Table 1 -
2and described below .
Intake and output diaries are dispensed
Evaluate teduglutide treatment incl usion criteria
Adverse events , concomitant medications and concomitant GI  procedures
Physical examination and vital signs, including weight
For non-commercial use only
Shire CONFIDENTIAL Page 42
Protocol SHP633 -304 Version 2 / 22Nov [ADDRESS_483082] as needed
Safety  Laboratory  Tests ( ie, clinical chemistry , hematology , and urinaly sis)
PedsQL  Generic Core Scale/PedsQL Family  Impact Module/ PedsQL  Gastrointestinal 
Symptoms Module Sub- Scales
Antibodies to teduglutide, if and when required
Fecal occult blood testing , as indicated (Section [IP_ADDRESS] )
Colonoscopy /sigmoidoscopy , as indicated (see Section [IP_ADDRESS])
Serum sample , as indicated
Teduglutide treatment may  be considered at any  time during the NTT period. If the investigator 
and the subject (and parent or legal guardian, as appropriate) agrees to proceed with treatment if 
the subject is eligible, the subject may  proceed to the pre -treatment visit immediately  to 
determine eligibility .
7.1.3 Visits for Subjects Receiving Teduglutide
[IP_ADDRESS] Pre-treatment Visit
Subjects who meet at least [ADDRESS_483083] and parent agree to proceed with teduglutide therapy . Similarly , subjects 
who meet escape criteria during the teduglutide follow
-up period may  proceed to the 
pre-treatment visit immediately .
The pre -treatment visit may also be combined with screening visit, and if the pre -treatment 
visit assessments occur within 7 days of the T ED-C14-006 EOS visit (Week 28), both sets of 
assessments can be combined. A subject must have [ADDRESS_483084] dose administration (CxD1) during an y teduglutide treatment cy cle. In gene ral, pre -
treatment assessment s may  occur over a period of up to 21 day s. The teduglutide pre -treatment 
visit (Px) assessments and procedures will be performed asin Table 1-3 and as described below :
Evaluate teduglutide eligibility  (treatment inclusion/exclusion criteria) 
Dispense intake and output diaries
Adverse events , concomitant medications and concomitant GI  procedures
Fecal occult blood testing 
Gastrointestinal -specific testing, including colonoscopy  or sigmoidoscopy  as indicated
For non-commercial use only
Shire CONFIDENTIAL Page 43
Protocol SHP633 -304 Version 2 / 22Nov [ADDRESS_483085] as needed.
Safety  Laboratory  Tests 
(In addition to clinical chemistry , hematology , and urinaly sis, labs at this visit include 
prothrombin tim e [PT] international normalized ratio [I NR]. Subsequent prothrombin 
time/ international normalized ratio (PT/I NR) measurement is only  required to evaluate 
for suspected drug -induced liver injury  [DILI]). 
Serum pregnancy  testin g (when the pre- treatment and screening visits are combined, 
the serum pregnancy  test should be performed at the local laboratory )
Serum sample 
[IP_ADDRESS] Teduglutide Treatment Period (CxD1 -CxW24)
The open- label teduglutide treatment period will comprise [ADDRESS_483086] administration (Visit CxD1). 
VISIT CXD1
Assessments and procedures at this visit will be performed as outlined Table [ADDRESS_483087] as needed 
Safety  laboratory  tests
For non-commercial use only
Shire CONFIDENTIAL Page 44
Protocol SHP633 -304 Version 2 / 22Nov 2016
Quality  of life measurements 
Antibodies to teduglutide
Pregnancy  testing (urine)
Dispense study  drug
SITE V ISITS DURING TEDUGLUTIDE TREATMENT PERIOD
Subjects wi ll return for clinic visits on cy cle weeks 1, 2, 4, 6, 9, 12, 16, 20, and 24 /EOT . 
Assessments and procedures at these visits will be performed as outlined in Table 1-3 and as 
described below:
Dispense /review intake and output diaries (every  effort should be made to complete 
2weeks of intake diary  entries prior to each clinic visit and to complete 48 hours of 
output diary  entries during a period of nutritional stability prior to each clinic visit)
Physical examination and vital signs, including weight
Reco rd PS prescription and adjust as needed
Safety  laboratory tests 
Urine pregnancy  testing for FOCBP (CxW4, CxW9, CxW12, CxW16, CxW20, 
CxW24)
Study  drug dispensation (except for CxW24)
Adverse events , concomitant medications and concomitant GI  procedures
In addition, at CxW12 and CxW24 Visits ONLY , the following procedures will be performed:
Height and head circumference
Antibodies to teduglutide
Fecal occult blood testing (FOBT)
GI-specific testing, including colonoscop y or sigmoidoscopy  as indicated 
Quality of life measurements 
At CxW24 ONLY , a serum sample is collected and stored for future analysis. This sample will 
not be used for genetic testing and lack of collection will not constitute a protocol deviation.
PHONE VISITS 
Phone visits are required approximately  1 week after adjustments in PS during the teduglutide 
treatment period. Phone visit assessments and procedures are ou
tlined in Table 1 -3and described 
below:
For non-commercial use only
Shire CONFIDENTIAL Page 45
Protocol SHP633 -304 Version 2 / 22Nov 2016
Review intake and output diaries
Safety  laboratory  tests (clinical chemistry  and urinaly sis)
Record PS prescription and adjust as needed
Obtain AEs, concomitant medications, and concomitant GI  procedures   
Evaluate escape criteria
7.1.4 Teduglutide Follow -up Period
The safet y follow -up period for this protocol is 4 weeks (Weeks 25 – 28 of the cycle). Phone 
visits will occur on cycle weeks 25, 26, and [ADDRESS_483088] may  
proceed directl y to another pre -treatment visit at the investigator’s discretion. The investigator 
may combine the CxW28 vis it with the next pre-treatment visit if at least one escape criterion is 
met at the CxW28 visit, and the pre-treatment assessments occur within [ADDRESS_483089] is completing the stud y at the CxW28 visit, the EOS/ET visit (Section 7.1.5)
will take place in lieu of the CxW28 visit
.Otherwise, following completion of the [ADDRESS_483090] will proceed to an NTT visit within approximately  12 weeks.
At cy cle week 28 (CxW28), subjects will return to the study  site. In addition to the assessme nts 
performed at weeks 25 -27, the following procedures will be performed at CxW28 ONLY:
Dispense intake and output diaries 
Physical examination and vital signs, including weight
Antibodies to teduglutide
Pregnancy  testing (urine)
Evaluate escape criteria
7.1.5 Study Completion/Early Termination Visit (EOS/ET Visit) 
All subjects will return to the study  site for the end of study /early termination visit (EOS/ET). 
Assessments and procedures at this visit will be performed as outlined in Table 1-[ADDRESS_483091] discontinues the study prematurel y, the assessments for the EOS/ET 
Visit are to be performed as completel y as possible (see Section 4.8.2).
Adverse events , concomitant medications and concomitant GI  procedures   
Physical examination and vital signs, including weight
Height and head circumference
For non-commercial use only
Shire CONFIDENTIAL Page 46
Protocol SHP633 -304 Version 2 / 22Nov 2016
Review intake and output diaries (the intake diary should be completed daily  for a 
minimum of 2 weeks prior to the EOS/ET visit. The output diary  should be completed 
daily over a 48- hour period of nutritional stability  before the EOS/ET visit)
Record PS prescription and adjust as needed
Safety  laboratory tests 
Fecal occult blood testing, as indicated
Gastrointestinal -specific testing, including colonoscopy  or sigmoidoscopy as 
indicated. 
Quality  of life measurements 
Antibodies to teduglutide
Pregnancy  testing, as needed
7.[ADDRESS_483092] of the following:
Adverse events that were ongoing at the time of completion of TED -C14-[ADDRESS_483093] has an y changes to the SBS history  
collected at the baseline visit of the TED- C14-006 study , that information (updated SBS history ) 
will be collected.
7.2.2 Physical Examination
Physical examinations will be performed according to the study  schedules. Any  new clinicall y 
significant findings noted during ph ysical examinations should be recorded on the appropriate 
AE page of the eCRF. 
7.2.3 Vital Signs, Body Weight, Height, Head Circumference and Body Mass 
Index (BMI)
Vital signs will be measured according to the study  schedules. Measurements will include 
systolic and diastolic blood pressure (mmHg), pulse (b eats per minute), and body  temperature 
(°C/°F). Blood pressure should be determined b y cuff (using the same method, the same arm, 
and in the same position throughout the stud y).
For non-commercial use only
Shire CONFIDENTIAL Page 47
Protocol SHP633 -304 Version 2 / 22Nov 2016
Body weight will also be recorded in the eCRF; subjects should be weighed on t he same scale at 
each stud y visit. Height (or length) and head circumference (for subjects ≤36 months of age) will 
be measured at selected visits. A height z- score, weight z -score, BM I, and BMI z -score will be 
calculated b y the sponsor using the site -provi ded height and weight data collected at each site 
visit
New clinicall y significant vital sign abnormalities should be recorded on the appropriate AE 
page of the eCRF.
7.2.[ADDRESS_483094] of clinical chemistry , hematology , 
and urinal ysis and will be performed as outlined in the study  plan ( Table 1-1, Table 1-2, and 
Table 
1-3) Scheduled laboratory  testing will be processed by  a central lab. All laboratory  assay s 
will be performed according t o the central laboratory ’s normal procedures. Reference ranges are 
to be supplied by  [CONTACT_25699] . The investigator should assess out-of- range clinical laboratory  
values for clinical significance, indicating if the value(s) is/are not clinically  signific ant or 
clinically  significant. Abnormal clinical laboratory  values, which are unexpected or not 
explained by  [CONTACT_423]’s clinical condition, may , at the discretion of the investigator or sponsor, 
be repeated as soon as possible until confirmed, explained , or resolved. 
During the teduglutide treatment period, subjects will also have safet y labs within approximately  
5-[ADDRESS_483095] of clinical chemistry  and urina lysis and may  be processed by  [CONTACT_319438] a local laboratory. Local lab results are not required to be entered in the eCRFs; however, if 
the local lab results indicate an y new clinicall y significant changes, they must be reported as an 
advers e event (see Section 8.1). Urine specimen collection should be attempted as part of the 
safet y labs, but lack of urinalysis will not constitute a protocol deviation.
New clinicall y significant labs should be reported as AEs.
The following clinical laborato ry assessments will be performed according to the study  
schedules: 
For non-commercial use only
Shire CONFIDENTIAL Page 48
Protocol SHP633 -304 Version 2 / 22Nov [ADDRESS_483096] of Laboratory Tests 
Hematology :
Hematocrit 
Hemoglobin 
Platelet count
Red blood cell count 
Red blood cell morphology, if needed
White blood cell count with differential
Coagulation :
Prothrombin time/I nternational normalized ratio
Urinalysis : 
Blood
Glucose
Leuk ocytes
Microscopic analysis
pH 
Protein
Specific gravity
Pregnancy tests (females of childbearing potential):
oSerum β -HCG (screening)
oUrine β -HCG (all other visits)Biochemistry :
Albumin 
Alkaline phosphatase 
Alanine aminotransferase 
Amy lase
Aspartate aminotransferase 
Bicarbonate
Bilirubin (total and indirect)
Blood urea nitrogen 
Calcium (total)
Chloride
Cholesterol
C-reactive protein 
Creatinine
Estimated Glomerular Filtration Rate
(Schwartz formula)
Gamma -glutamyl transferase 
Glucose
Lipase
Magnesium
Phosphorus
Potassium 
Sodium 
Triglycerides
Uric acid
7.2.5 Serum Sampling
Serum samples will be collected and stored for future anal ysis at the following times: 
At the pre -treatment visit. If the subject met a follow -up period escape criterion, the 
serum sample will not be collected at the pre-treatment visit
At the CxW24 (EOT) visit
During NT T: Approximately  every  24 weeks
The serum sample will not be used for genetic testing. Lack of collection will not constitute a 
protocol deviation.
The sponsor, sponsor’s representatives, biorepositories, and an y specialty laboratories wil l be 
blinded to the subject’s identity . The sample and/or extracted material will otherwise be stored 
for up to [ADDRESS_483097] their 
For non-commercial use only
Shire CONFIDENTIAL Page 49
Protocol SHP633 -304 Version 2 / 22Nov 2016
sample and/or extracted material destro yed. An y results alread y generated from the samples will 
not be removed from an y anal yses that have already  been performed.
7.2.[ADDRESS_483098] is performed on all FOCBP at the teduglutide pre -treatment visit (when 
the pre -treatment and screening visits are combined, the serum pregnancy  test should be 
performed at the local laboratory ). Urine pregnancy  tests will be administered at all other visits 
according to the study  schedules, or if pregnancy  is suspected, or as specified per protocol upon 
withdrawal of the subject from the study .
7.2.7 Antibody Testing
Blood samples will be drawn for the anal ysis of antibodies to teduglutide according to the 
Schedule of Assessme nts (Table 1-1, Table 1 -2,and Table 1 -3). Blood samples for antibodies 
may be drawn from a central line or from peripheral access. The sample drawn on CxD1 must be 
drawn prior to administration of the first dose of teduglutide. Once the subject has started 
teduglutide treatment, samples must be drawn at least [ADDRESS_483099] annuall y are shown 
in Table 7-1.
Table 7-1: Approximate Volume of Blood to be Drawn from Each Subject Annually 
AssessmentSample 
Volume (mL)No. Sam ples per two 28 -week 
Teduglutide CyclesTotal 
Volume (mL)
Subjects Receiving Teduglutide Treatment 
Safety Biochemistry and -hCGa2.5 24 60
Hem atology 2 24 48
Coagulation Parameters 1 2 2
Antibodies 2 8 16
Serum storage samples 3 4 12
Total mL per 2, 28 -week Treatment Cycles (Approximate Annual Volume): 138
Subjects Not Receiving Teduglutide Treatmentb
AssessmentSample 
Volume (mL)No. Sam ples per 4 NTT VisitsTotal 
Volume (mL)
Safety Biochemistry 2.5 4 10
Hem atology 2 4 8
Serum storage samples 3 2 6
Total mL per 4 “No -Teduglutide Treatment” Visits 48 -week period: 24
For non-commercial use only
Shire CONFIDENTIAL Page 50
Protocol SHP633 -304 Version 2 / 22Nov 2016
Table 7-1: Approximate Volume of Blood to be Drawn from Each Subject Annually 
AssessmentSample 
Volume (mL)No. Sam ples per two 28 -week 
Teduglutide CyclesTotal 
Volume (mL)
Abbreviations: β-hCG=beta -human chorionic gonadotropin ; NTT=no -teduglutide treatment
a β-hCG testing will only be administered to females who are eligible for teduglutide treatment.
bSubjects not receiving teduglutide treatment, but who were exposed to it previously and tested positive for anti -teduglutide 
antibodies will require blood samples for antibody testing every [ADDRESS_483100] negative.
Note: The amount of blood to be drawn for each assessment is an estimate. The amount of blood 
to be drawn may  vary  according to the instructions provided by  [CONTACT_10190]. When more than 1 blood assessment is to be done at the time 
point/period, if they  require the same t ype of tube, the assessments should be combined. Bloo d 
volume estimates do not include safet y labs performed after PS adjustment, and anti -
teduglutide 
antibody  testing during no- teduglutide treatment.
7.2.9 Gastrointestinal- specific Testing
[IP_ADDRESS] Fecal Occult Blood Testing
Fecal occult blood testing must be performed on all subjects at the pre -treatment visit, week 12, 
and week [ADDRESS_483101] be performed on 
teduglutide -exposed subjects (subjects who have received teduglutide an y time in the past and 
are therefore not tedugluti de-naïve) on a roughl y annual basis (approximately every 48 -60 
weeks). Actions to be taken in response to a positive FOBT are described below.
[IP_ADDRESS] Colonoscopy or Sigmoidoscopy
Teduglutide -naïve subjects age 12 and older will undergo colonoscopy or sigmoidoscop yat the 
pre-treatment visit if one has not been performed within 1 y ear. 
Subjects of an y age with newly positive FOBT results at the pre -treatment visit for which a 
readil y detectable cause cannot be identified ( eg, anal fissure) will undergo a colonoscopy or 
sigmoidoscop yprior to receiving teduglutide. If newly  positive FOBT results (for which a 
readil y detectable cause cannot be identified) are obtained at the end of a teduglutide treatment 
cycle (CxW24/EOT), colonoscopy or sigmoidoscopy will be performed. The need for 
colonoscop yor sigmoidoscopy in response to positive FOBTs at any  other point during the 
study , or to re -evaluate persistently  positive FOBTs is at the discretion of the investigator. 
Teduglutide -exposed subjects who have received the equivalent of 2 treatment cy cles (48 weeks 
of study  drug exposure) will undergo colonoscopy or sigmoidoscopy . While receiving additional 
teduglutide treatment, subjects will undergo colonoscopy or sigmoidoscopy at 5 y ear intervals or 
more ofte n as needed. 
Upper endoscopy may be performed along with any  colonoscopy  or sigmoidoscopy  at the 
investigator’s discretion. If a pol yp is found, adherence to current pol yp follow -up guidelines is 
recommended. Subjects with unresected GI pol yps, poly posis conditions, pre
-malignant change 
or malignancy  in the GI tract will be excluded from teduglutide treatment.
For non-commercial use only
Shire CONFIDENTIAL Page 51
Protocol SHP633 -304 Version 2 / 22Nov 2016
7.2.10 Nutritional Support
Nutritional support includes PS, enteral nutrition , and other food and fluids. Advances in enteral 
nutrition and/or reductions t o PS will be based on clinical status, including weight, linear growth, 
hydration status, and safety  laboratory  results. Intake and output diaries will include data to be 
considered in the adjustment of each subject’s nutritional support. Guidelines for nu tritional 
support management and weaning algorithms are provided in Appendix 2 .
7.2.11 Diaries
[IP_ADDRESS] Study Drug Administration Diary
A study  drug administration diary  will record administration of teduglutide. This diary  should be 
completed by [CONTACT_423] (or parent/ legal guardian, as applicable) daily  during the teduglutide 
treatment period (between visits CxD1 and CxW24).
[IP_ADDRESS] Intake Diary
Intake diaries will be used to collect and evaluate each subject’s nutritional support. The 
subject/parent/guardian will complete the a ppropriate fields of the PS section of the intake diary  
2 weeks prior to ALL scheduled site visits (except at pre-treatment visit) . During the 24-week 
teduglutide treatment period, the intake diary  will also be completed for 1 week following PS 
adjustments. The intake diary  will also be completed daily  during the 4 -week follow -up period. 
The following data will be captured in the intake diaries:
Parenteral support volume and infusion duration
Site personnel will determine the actual PS daily calories based on diary  entries.
All available diary  data will be reviewed by [CONTACT_319479].
[IP_ADDRESS] Output Diary
Urine and stool output should be recorded in the output diary  over a 48-hour period of nutritional 
stability before every  clinic visit; in addition, output should be recorded for subjects that are in a 
teduglutide treatment cy cle within 1 week of implementing a change in the PS prescr iption, 
regardless of previous teduglutide exposure.
Urine data:
Toilet -trained subjects (who do not wear diapers)
Measure and record all urine output in mL  or cc
Nontoilet- trained subjects (who wear diapers)
Measure and record the weight of all urine -only diapers. Urine volume will be 
calculated using the following formula: 1 g (scale weight) = [ADDRESS_483102] void 
after the daily  PS infusion to measure specific gravity
For non-commercial use only
Shire CONFIDENTIAL Page 52
Protocol SHP633 -304 Version 2 / 22Nov 2016
Stool data (includes diapers with mixed urine and stool):
Toilet -trained subjects (who do not wear diapers)
Record the occurrence of each bowel movement and score the stool consistency  using 
the Bristol Stool Form Scale (see Output diary )
Nontoilet- trained subjects (who wear diapers)
Record the weight of diapers containing stool (including diapers with mixed urine and 
stool) as stool output and score the stool consistency  using the Bristol Stool Form 
Scale (see Output diary ). Stool volume will be calcul ated using the formula: 1 g (scale 
weight) = 1mLor [ADDRESS_483103] month, and parent -report of 
problems pursuing their normal work routine and conc entrating at work. The PedsQL Generic 
Core Scales are also responsive to clinical change, as demonstrated in field trials.
[IP_ADDRESS] Pediatric Quality of Life Generic Core Scale (PedsQL™), Acute version
The PedsQL Generic Core Scale is designed to measures health -related quality  of life (HRQoL) 
in pediatric subjects and adolescents (2 -18 years of age). The developmentally  appropriate 
PedsQL  Generic Core Scale will be completed by  [CONTACT_319416] 7 -2at the time po ints as outlined in Table 1-1, Table 1 -2,and Table 1 - 3.
For non-commercial use only
Shire CONFIDENTIAL Page 53
Protocol SHP633 -304 Version 2 / 22Nov 2016
Table 7-2:Developmentally Appropriate PedsQL™Generic Core Scales
Report Completed by
[CONTACT_319417] (ages 2 -4) Parent or Legal Guardian
Child Self Report and Parent Proxy -Report for Young Pediatric subjects 
(ages 5 -7)Subject and Parent or Legal Guardian
Child Self Report and Parent Proxy -Report for Pediatric subjects 
(ages 8 -12)Subject and Parent or Legal Guardian
Child Self Report and Parent Proxy -Report for Teens (ages 13 -18) Subject and Parent or Legal Guardian
Abbreviations: PedsQL=Pediatric Quality of Life Inventory
The Parent Report for Toddlers (ages 2 -4) of the PedsQL Gener ic Core Scale is composed of 
21 items comprising 4 dimensions as follows: 1) Physical Functioning (8 items), 2) Emotional 
Functioning (5 items), 3) Social Functioning (5 items), 4) School Functioning (3 items). 
The Child and Parent Reports of the PedsQL Generic Core Scale for Young Pediatric subjects 
(ages 5 -7), Pediatric subjects (ages 8- 12), and Teens (ages 13 -18) are composed of 23 items 
comprising 4 dimensions as follows: 1) Physical Functioning (8 items), 2) Emotional 
Functioning (5 items), 3) Social Functioning (5 items), 4) School Functioning (5 items).
[IP_ADDRESS] Pediatric Quality of Life Family Impact Module (PedsQL™), Acute version
The PedsQL Family  Impact Module is a parent -report multidimensional instrument that will be 
completed b y the parent or legal guardian, as outlined in Table 1-1, Table [ADDRESS_483104] of pediatric chronic health conditions on parents and the family (Varni et al. 2004 ). 
The 36- item PedsQL Family  Impact Module consists of 6 scales measuring parent self -reported 
functioning as follows: 1) Physical Functioning (6 items), 2) Emot ional Functioning (5 items), 
3) Social Functioning (4 items), 4) Cognitive Functioning (5 items; worries about treatment and 
disease), 5) Communication (3 items), 6) Worry  (5items). Two additional scales measure parent -
reported family  functioning as follows: 1) Dail y Activities (3 items), and 2) Family  Relationships 
(5 items). The PedsQL Family  Impact Module should take the parent or legal guardian 
approximately  5 to 10 minutes to complete.
[IP_ADDRESS] PedsQL Gastrointestinal Symptoms Module (PedsQL™), Acute version
ThePedsQL Gastrointestinal Sy mptom Module is a disease -specific 58- item module, comprised 
of 10 differe nt symptom scales that assess gastrointestinal sy mptom -related quality  of life: food 
and drink limits, trouble swallowing, heartburn and reflux, nausea and vomiting, gas and 
bloating, constipation, blood in poop, and diarrhea. The PedsQL Gastrointestinal Sy mptoms 
Module was designed t o allow the selection and scoring of individual scales from the Module. 
The scales of Food and Drink L imits (6 items) and Diarrhea (7 items) were identified as 
clinically  relevant and appropriate for the s ymptoms experienced in this pediatric study  
populat ion, and therefore, are the onl y scales used in this study . The scales will be completed by  
[CONTACT_319418] 7 -2at the time points 
outlined in Table 1-1
, Table 1 -2,and Table 1 - 3.
For non-commercial use only
Shire CONFIDENTIAL Page 54
Protocol SHP633 -304 Version 2 / 22Nov [ADDRESS_483105] a causal relationship with this 
treatment. An AE can therefore be an y unfavorable and unintended sign (including an abnormal 
laboratory  finding), s ymptom, or disease temporally  associated with the use of a medicinal 
(investigational) product, whether or not related to the medicinal (investigational) product (ICH 
Guidance E2A 1995). 
All AEs are collected from the time the informed consent is signed until the defined follow -up 
period stated in Section 7.1.[ADDRESS_483106] be followed to clo sure (the subject’s health has returned to his/her baseline status 
or all variables have returned to normal), regardless of whether the subject is still participating in 
the study . Closure indicates that an outcome is reached, stabilization achieved (the i nvestigator 
does not expect any  further improvement or worsening of the event), or the event is otherwise 
explained. When appropriate, medical tests and examinations are performed so that resolution of 
event(s) can be documented.
8.1.[ADDRESS_483107] be 
recorded as new AEs (for example, if a subject experiences mild intermittent dy spepsia prior to 
dosing of investigational product, but the dy spepsia becomes severe and more frequent after first 
dose of investigational product has been administered, a new AE of severe dy spepsia [with the 
appropriate date of onset] is recorded on the appropriate eCRF).
The medical assessment of severit y is determined by [INVESTIGATOR_1477]:
Mild: A type of AE that is usually  transient and may require only minimal treatment or 
therapeutic intervention. The event does not generall y interfere with usual 
activities of daily  living.
Moderate: A type of AE that is usually  alleviated with specific therapeutic intervention. The 
event interfer es with usual activities of daily  living, causing discomfort but poses 
no significant or permanent risk of harm to the research subject.
Severe: A type of AE that interrupts usual activities of daily  living, or significantly affects 
clinical status, or may require intensive therapeutic intervention.
For non-commercial use only
Shire CONFIDENTIAL Page 55
Protocol SHP633 -304 Version 2 / 22Nov 2016
Note that the severity  of AEs that constitute dose interruption criteria will also be evaluated 
using the National Cancer Institute’s (NCI) Common Terminology  Criteria for Adverse Events 
(CTCAE) grading criteria (Table 8-1).
8.1.2 Relationship Categorization
A phy sician/investigator must make the assessment of relationship to investigational product for 
each AE. The investigator should decide whether, in his or her medical judgment, there is a 
reasonable possibility  that the event may  have been caused b y the investigational product. If 
there is no valid reason for suggesting a relationship, then the AE should be classified as “not 
related”. Otherwise, if there is an y valid reason, even if undetermined or untested, for suspecting 
a possible cause -and-
effect relationship between the investigational product and the occurrence 
of the AE, then the AE should be considered “related”. The causality  assessment must be 
documented in the source document.
The following additional guidance may  be helpful:
Term Relationship Definition
RelatedThe temporal relationship between the event and the administration of 
the investigational product is compelling and/or follows a known or 
suspected response pattern to that product, and the event cannot be 
explained by [CONTACT_423]’s medical condition, other therapi[INVESTIGATOR_014], or 
accident.
Not RelatedThe event can be readily  explained by [CONTACT_11260]’s underly ing medical condition, concomitant therap y, or 
accident and no plausible temporal or biologic relationship exists 
between the investigational product and the event.
AEs that are related to study  drug that are not resolved at EOT will be followed until the event 
resolves or stabilizes, as judged b y the investigator.
Laboratory  values, vital signs, and clinical findings at the scheduled ph ysical examinations must 
be reported as AEs if the investigator considers the finding to be a clinicall y significant change 
from the baseline. 
8.1.[ADDRESS_483108] be recorded during the course of the study  in the eCRF. Outcomes are 
as follows:
Fatal
Not Recovered/Not Resolved
Recovered/Resolved
Recovered/Resolved with Sequelae
For non-commercial use only
Shire CONFIDENTIAL Page 56
Protocol SHP633 -304 Version 2 / 22Nov 2016
Recovering/Resolving
Unknown
8.1.4 Symptoms of the Disease under Study
Symptoms of the disease under study  should not be classed as AEs as long as they  are within the 
normal day -to-day fluctuation or expected progression of the disease and are part of the efficacy  
data to be collected in the study; however, significant worsening of the s ympt oms should be 
recorded as an AE.
8.1.[ADDRESS_483109] be taken into consideration.
If, during the stud y, there are abnormal clinical laboratory values or vital signs which were not 
present at the beginning of the study , further investigations should be performed until the values 
return to within the reference range or until a plausible explanation ( eg, concomitant disease) is 
found for the abnormal value s.
The investigator should decide, based on the above criteria and the clinical condition of a 
subject, whether a change in a clinical laboratory  or vital sign is clinicall y significant and 
therefore represents an AE.
8.1.[ADDRESS_483110] be reported within 24 hours to the 
Shire Global Pharmacovigilance and Risk Management Department using the Shire 
Investigational and Marketed Products Pregnancy  Report Form. A copy  of the Shire 
Investigational and Marketed Products Pregnancy  Report Form (and any  applicable follow -
up 
reports) must also be sent to the Shire Medical Monitor using the details specified in the 
emergency  contact [CONTACT_1739]. I n the event a subje ct becomes pregnant 
during the stud y, teduglutide administration must be discontinued immediately. 
Every  effort should be made to gather information regarding the pregnancy  outcome and 
condition of the infant. It is the responsibility  of the investigator to obtain this information within 
[ADDRESS_483111] partum.
Pregnancy  complications such as spontaneous abortion/miscarriage or congenital abnormality  
are considered SAEs and must be re ported using the Shire Clinical Study  Adverse Event Form 
For non-commercial use only
Shire CONFIDENTIAL Page 57
Protocol SHP633 -304 Version 2 / 22Nov 2016
for Serious Adverse Events (SAEs) and Non- serious AEs as Required b y the Protocol. Note: An 
elective abortion is not considered an SAE.
In addition to the above, if the investigator determines that the pregnancy  meets serious criteria, 
it must be reported as an SAE using the Shire Clinical Study  Adverse Event Form for SAEs and 
Non-serious AEs as Required by
 [CONTACT_319499]. The test date of the first positive serum/urine -HCG test or 
will determine the pregnancy  onset date.
8.1.7 Abuse, Misuse, Overdose, and Medication Error
Abuse, misuse, overdose, or medication error (as defined below) must be reported to the sponsor 
according t o the SAE reporting procedure whether or not they  result in an AE/SAE as described 
in Section 8.2. Note: The 24 -hour reporting requirement for SAEs does not apply  to reports of 
abuse, misuse, overdose, or medication errors unless these result in an SAE. 
The categories below are not mutually  exclusive; the event can meet more than 1 category .
Abuse –
Persistent or sporadic intentional intake of investigational product when used 
for a non -medical purpose ( eg, to alter one’s state of consciousness or get high ) in a 
manner that may  be detrimental to the individual and/or society .
Misuse –Intentional use of investigational product other than as directed or indicated 
at an y dose (Note: this includes a situation where the investigational product is not 
used as di rected at the dose prescribed b y the protocol).
Overdose –Administration of a dose greater than the allocated dose of the study  
medication or at a frequency  greater than the dosing interval specified by [CONTACT_760].
Medication Error – An error made in pr escribing, dispensing, administration, and/or 
use of an investigational product. For studies, m edication errors are reportable to the 
sponsor only  as defined below.
Cases of subjects missing doses of the investigational product are not considered 
reportab le as medication errors.
Medication errors should be collected/reported for all products under investigation.
The administration and/or use of an expi[INVESTIGATOR_319372] a reportable medication error. 
All investigational product provided to pediatric subjects should be supervised by  [CONTACT_31588]/legall y-authorized representative/caregiver.
For non-commercial use only
Shire CONFIDENTIAL Page 58
Protocol SHP633 -304 Version 2 / 22Nov [ADDRESS_483112] awareness of the event. Note: The 24-hour reporting requirement for SAEs does 
not apply  to reports of abuse, misuse, overdose, or medication errors (see Section 8.1.7) unless 
they result in an SAE.
All Adverse Events of Special Interest, as defined in Section 8.3, must be reported by [CONTACT_385957] [ADDRESS_483113] complete, sign, and date the Shire Clinical Study  Adverse Event Form for 
SAEs and Non
-serious AEs as Required b y Protocol, and verify the accuracy of the information 
recorded on the fo rm with the corresponding source documents (Note: Source documents are not 
to be sent unless requested). Fax or e -mail the completed form to the Shire Global 
Pharmacovigilance and Risk Management Department. A copy  of the completed Shire Clinical 
Study  Adv erse Event Form for Serious Adverse Events (SAEs) and Non- serious AEs as 
Required b y Protocol (and any applicable follow -
up reports) must also be sent to the Shire 
medical monitor or designee using the details specified in the emergency  contact [CONTACT_385966].
8.2.[ADDRESS_483114] medical occurrence (whether considered to be related to investigational 
product or not) that at any dose: 
Results in death
Is life -threatening. Note: The term 'life-threatening' in the definition of "serious" refers to 
an event in which the subject was at risk of death at the time of the event; it does not refer 
to an event which h ypothetically might have caused death if it was more severe.
Requires inpatient ho spi[INVESTIGATOR_1081]. Note: 
Hospi[INVESTIGATOR_602], which are the result of elective or previousl y scheduled surgery for pre 
existing conditions, which have not worsened after initiation of treatment, should not be 
classified as SAEs. For example, an admission for a previousl y scheduled ventral hernia 
repair would not be classified as an SAE; however, complication(s) resulting from a 
hospi[INVESTIGATOR_10153] y scheduled surgery  that meet(s) serious 
criteria must be reported as SAE(s).
For non-commercial use only
Shire CONFIDENTIAL Page 59
Protocol SHP633 -304 Version 2 / 22Nov 2016
Results in persistent or significant disability /incapacity
Is a congenital abnormality /birth defect
Is an important medical event. Note: I mportant medical events that may not result in 
death, be life -threatening, or require hosp italization may  be considered an SAE when, 
based upon appropriate medical judgment, they  may  jeopardize the subject and may  
require medical or surgical intervention to prevent 1 of the outcomes listed in this 
definition. Examples of such medical events inc lude allergic bronchospasm requiring 
intensive treatment in an emergency  room or at home; blood dy scrasias or convulsions 
that do not result in inpatient hospi[INVESTIGATOR_059]; or the development of drug dependency  or 
drug abuse. 
8.2.4 Serious Adverse Event Collection Time Frame
All SAEs (regardless of relationship to study ) are collected from the time the subject signs the 
informed consent until the defined follow- up period stated in Section 7.1.4, and must be reported 
to the Shire Global Pharmacovigilance and Risk M anagement Department andthe Shire Medical 
Monitor within [ADDRESS_483115] awareness of the event. 
In addition, any SAE(s) considered “related” to the investigational product and discovered by  [CONTACT_10194] y interval after the study has comp leted must be reported to the Shire Global 
Pharmacovigilance and Risk Management Department within [ADDRESS_483116]’s death ( ie, the SAE was noted as the primary  cause of death) 
must have fatal checked as an outcome with the date of death recorded as the resolution date. For 
all other events ongoi ng at the time of death that did not contribute to the subject’s death, the 
outcome should be considered not resolved, without a resolution date recorded.
For an y SAE that results in the subject’s death or any ongoing events at the time of death, unless 
another investigational product action was previously  taken ( eg, drug interrupted, reduced, 
withdrawn), the action taken with the investigational product should be recorded as “dose not 
changed” or “not applicable” (if the subject never received investigatio nal product). The 
investigational product action of “withdrawn” should not be selected solel y as a result of the 
subject’s death.
For non-commercial use only
Shire CONFIDENTIAL Page 60
Protocol SHP633 -304 Version 2 / 22Nov [ADDRESS_483117], Ethics Committee, and Site 
Reporting 
The Sponsor and/or Clinical Contract Research Organization ( CRO )is responsible for notify ing 
the relevant regulatory  authorities, and US central Institutional Review Boards ( IRBs)/EU central 
ethics committees ( ECs
),of related, unexpected SAEs.
In addition, the Clinical CRO is responsible fo r notify ing active sites of all related, unexpected 
SAEs occurring during all interventional studies across the SHP633 program.
The investigator is responsible for notifying the local IRB, local EC, or the relevant local 
regulatory  authorit y of all SAEs th at occur at his or her site as required.
8.[ADDRESS_483118] is an AE (serious or nonserious) of scientific and medical concern 
specific to the sponsor’s product or program and for which ongoing monitoring and immed iate 
notification by  [CONTACT_230013].
The AEs of special interest that require expedited regulatory  reporting include the following:
Growth of pre -existing poly ps of the colon
Benign neoplasia of the GI tract including the hepat obiliary  system
Tumor -promoting ability ( eg, benign and/or malignant neoplasia of any  kind, not limited 
to those of the GI or hepatobiliary  system)
For AEs of special interest, the sponsor must be informed within [ADDRESS_483119] awareness as 
per the SAE notification instructions described in Section 8.2.2 even if the event does not fulfill 
the seriousness criteria.
8.4 Dose Interruption of Individual Subjects
The investigator is responsible for contact[CONTACT_20610]/designee when the subject’s 
teduglutide do sing regimen is interrupted. Attempts should be made to contact [CONTACT_103]/designee prior to dose interruption. Reasons for dosage interruptions may  include but are 
not limited to hospi[INVESTIGATOR_059] ,AEs, a lapse in investigational product delivery , etc.
Study  drug must be discontinued if any  of the following events occur:
Pregnancy
Severe h ypersensitivity , such as anaph ylaxis determined by  [CONTACT_319447]. This does not include the presence of anti-teduglutide antibodies, mild
injection site reactions or mild sy mptoms that according to the investigator do not pose a 
significant risk to the subject.
For non-commercial use only
Shire CONFIDENTIAL Page 61
Protocol SHP633 -304 Version 2 / 22Nov 2016
An AE listed in ( Table 8-1) that is of NCI CTCAE severit y Grade 3 or 4 and considered 
to be related to stud y drug administration
Confirmed drug -induced liver injury  (DILI) related to teduglutide ( see Section 8.4.2)
8.4.[ADDRESS_483120] has an AE listed in Table 8-1 that 
is of severit y ≥Grade 3 per the NCI CTCAE. All such AEs should be discussed with Shire’s 
medical monitor or designee as soon as possible. Teduglutide administration must be 
discontinued if the AE is considered related to the investigational product. Thelength of the dose 
interruption, and whether teduglutide administration resumes or is permanently  discontinued, 
depends on the clinical situation.
Investigators and the Data Monitoring Committee (DMC) should be guided by  [CONTACT_385959] 3 and 4 events, as they  relate to known and possible risks associated with the 
administration of teduglutide. 
Table 8-1: CTCAE Criteria for Adverse Events that May Lead to Dose Interruption
Adverse Events Grade 3 De scription Grade 4 Description
Gastrointestinal Disorders
Colorectal polyps Severe or medically significant but not 
immediately life threatening; 
hospi[INVESTIGATOR_20578]; 
disabling; limiting self -care activities of 
daily livingLife-threatening consequences; urgent 
intervention indicated
Intestinal Obstruction Hospi[INVESTIGATOR_374]; elective 
operative intervention indicated; limiting 
self-care activities of daily living; 
disablingLife-threatening consequences; urgent 
operative intervention indicated
Gallbladder and Bile Duct Disease
Cholecystitis Severe symptoms; radiologic,
endoscopic or elective operative 
intervention indicatedLife-threatening consequences; urgent 
operative intervention indicated
Gallbladder perforation Not Applicable Life-threatening consequences; urgent 
intervention indicated
Gallbladder obstruction Symptomatic and severely altered 
gastrointestinal function; tube feeding, 
total parenteral nutrition or 
hospi[INVESTIGATOR_374]; nonemergent 
operative intervention indicatedLife-threatening consequences; urgent 
operative intervention indicated
Gallbladder infection Intravenous antibiotic, antifungal, or 
antiviral intervention indicated; 
radiologic, endoscopic, or operat ive 
intervention indicatedLife-threatening consequences; urgent 
intervention indicated
For non-commercial use only
Shire CONFIDENTIAL Page 62
Protocol SHP633 -304 Version 2 / 22Nov 2016
Table 8-1: CTCAE Criteria for Adverse Events that May Lead to Dose Interruption
Adverse Events Grade 3 Description Grade 4 Description
Alkaline Phosphatase 
increased>5.[ADDRESS_483121] >20.0x ULN
Blood bilirubin increased >3.[ADDRESS_483122] >10.0x ULN
Bile duct stenosis Severely altered gastrointestinal function; 
radiologic, endoscopic or elective 
operative intervention indicatedLife-threatening consequences; urgent 
operative intervention indicated
Pancreatic Disease
Pancreatitis Severe pain; vomiting; medical 
intervention indicated ( eg, analgesia, 
nutritional support)Life-threatening consequences; urgent 
intervention indicated
Pancreatic duct stenosis Severely altered gastrointestinal function; 
tube feeding or hospi[INVESTIGATOR_374]; 
elective operative intervention indicatedLife-threatening consequences; urgent 
operative intervention indicated
Pancreas infection Intravenous antibiotic, antifungal, or 
antiviral intervention indicated; 
radiologic or operative intervention 
indicatedLife-threatening consequences; urgent 
intervention indicated
Serum amylase increaseda>2.[ADDRESS_483123] >5.0x ULN
Lipase increaseda>2.[ADDRESS_483124] >5.0x ULN
Cardiovascular Disease
Heart failure Severe with symptoms at rest or with 
minimal activity or exertion; intervention 
indicatedLife-threatening consequences; urgent 
intervention indicated ( eg, continuous 
intravenous therapy or mechanical 
hemodynamic support)
Source: Common Terminology Criteria for Adverse Events, version 4.03, [ADDRESS_483125]=upper limit of normal
a In the setting of clinically acute and symptomatic pancreatitis 
8.4.[ADDRESS_483126] has 
clinical and laboratory  evidence of potential DILI, in the absence of an alternative explanation, 
as identified b y the following criteria:
ALT or AST >8x ULN
ALT or AST >5x ULN and >2x baseline value for more than 2 weeks
(ALT or AST >3x ULN and >2x baseline value ) and (total bilirubin >2x ULN or 
INR>1.5)
ALT or AST >3x ULN and >2x baseline value with the appearance of fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)
For non-commercial use only
Shire CONFIDENTIAL Page 63
Protocol SHP633 -304 Version 2 / 22Nov [ADDRESS_483127] should be followed closely to determine the trajectory  of the 
laboratory  abnormalities and to evaluate the cause of liver injury . This evaluation may  include, 
as clinically  indicated, consideration of sepsis, acute viral hepatitis (eg, hepatitis A 
immunoglobulin [IgM], hepatitis B surface antigen, hepatitis C antibodies, cy tomegalovirus IgM, 
Epstein- Barr virus antibody  panel), hepatobiliary  obstruction (ultrasound), autoimmune hepatitis 
(anti-nuclear, anti -smooth muscle, anti -actin
, or anti- liver kidney  microsomal antibodies), 
intestinal failure associated liver disease, cardiovascular causes such as ischemic hepatitis, and 
concomitant hepatotoxic treatments.
Additional evaluations may  be performed at the discretion of the investiga tor in consultation 
with the Shire medical monitor.
Teduglutide administration must be permanentl y discontinued if DILI is confirmed and deemed 
related to stud y drug.
8.5 Early Termination of the Clinical Study
The DMC may  recommend stoppi[INVESTIGATOR_319373]:
≥2subjects being administered investigational product develop the same event listed in 
Table 8-1 of severit y CTCAE Grade 3 
or
1subject develops an event listed in Table 8-[ADDRESS_483128] or is not reasonably  related to the underlying 
disease process.
For non-commercial use only
Shire CONFIDENTIAL Page 64
Protocol SHP633 -304 Version 2 / 22Nov 2016
9DATA MANAGEMENT AND STATISTICAL METHODS
9.1 Data Collection
The investigators’ authorized site personnel must enter the information required by  [CONTACT_103365]. A study  monitor will visit each sit e in accordance with the monitoring plan and 
review the eCRF data against the source data for completeness and accuracy . Discrepancies 
between source data and data entered in the eCRF will be addressed b y qualified site personnel. 
When a data discrepancy w arrants correction, the correction will be made by  [CONTACT_59752]. Data collection procedures will be discussed with the site at the site initiation visit 
and/or at the investigator’s meeting. Unscheduled safet y follow up assessments ( including visits 
conducted after EOS) are not to be collected unless requested .
9.2 Clinical Data Management 
Data are to be entered into a clinical database as specified in the CRO’s data management 
process. Quality  control and data validation procedures are applied to ensure the validity  and 
accuracy  of the clinical database.
Data are to be reviewed and checked for omissions, errors, and values requiring further 
clarification using computerized and manual procedures. Data queries requiring clarification are 
to be communicated to the site for resolution. Only authorized personnel will make corrections to 
the clinical database, and all corrections are documented in an auditable manner.
9.3 Statistical Analysis Process 
The study  will be anal yzed by  [CONTACT_385967].All statistical anal yses will be performed 
using SAS®(SAS Institute, Cary , NC, [LOCATION_003]) version 9.3 or higher.
The statistical anal ysis plan (SAP) will provide the statistical methods and definitions for the 
analysis of the efficacy  and safet y data, as we ll as describe the approaches to be taken for 
summarizing other study  information such as subject disposition, demographics and baseline 
characteristics, investigational product exposure, and prior and concomitant medications. 
9.[ADDRESS_483129] been collected. 
A DMC will be involved in the management of this study . The DMC members will review the 
data approximately  every 3 months according to the DMC Charter . The DMC review will 
include all cumulative safety  data ( ie, AEs, laboratory  assessments, phy sical examinations, etc.) 
from study  assessments through each cutoff period. Further details regarding the DMC can be 
found in the DMC charter, which will be available prior to the administration of investigational 
product. 
The DMC for this study  will be conducted in accordance with the FDA Guidance for Clinical 
Trial Sponsors: Establishment and Operation of Clinical Trial Data Monitoring Committees 
(March 20 06).
For non-commercial use only
Shire CONFIDENTIAL Page 65
Protocol SHP633 -304 Version 2 / 22Nov [ADDRESS_483130] may not be 
study  investigators or be employ ed at the same institution as a study  investigator, individuals 
employ ed by [CONTACT_456], indepe ndent contractors hired by  [CONTACT_456], or members of 
regulatory  agencies. The DMC may  make recommendations to the sponsor regarding stud y 
aspects including stoppi[INVESTIGATOR_007], modify ing or continuing the study ; however, the sponsor will have 
the final responsibilit y to determine whether the study  should be modified or temporaril y or 
permanentl y stopped. 
9.5 Sample Size Calculation and Power Considerations 
The number of subjects in this study  is not based on statistical power considerations as this is an 
extension stud y of the core study , TED -C14-006. The maximum number of subjects was
determined b y the enrollment in TED -C14-006.
9.6 Study Population
The safet y population includes all enrolled subjects in the study . Safet y population will be used 
for both safet y and efficac y analyses.
9.7 Efficacy Analyses 
No claims of statistical significance will be made; however, 95% confidence intervals will be 
provided, if applicable. Continuous variables, including those assessed on a discrete scale, will 
be summarized using descriptive s tatistics including number of subjects, mean, median, standard 
deviation, maximum, and minimum. For categorical variables, statistical summaries will include 
number of subjects and percentages.
9.7.1 Efficacy Endpoints
Efficacy  endpoints will be anal yzed at the end of each teduglutide treatment period (Week 24 or 
EOT), and at each stud y visit, relative to the baseline of the core study  (TED -C14-006) and/or 
first exposure to teduglutide. The following efficacy  endpoints will be analy zed:
Reduction in PS volume of at leas t 20%
Absolute and relative change in PS volume
Complete weaning off PS
Change in day s per week of PS
9.8 Safety Analyses 
9.8.1 Safety Endpoints
The following safet y endpoints will be analy zed:
For non-commercial use only
Shire CONFIDENTIAL Page 66
Protocol SHP633 -304 Version 2 / 22Nov 2016
Adverse events
Vital signs, including temperature, heart rate, and blood pressure
Laboratory  safet y data ( ie, clinical chemistry , hematology , and urinaly sis)
Urine output
Stool output 
Antibodies to teduglutide
Gastrointestinal -specific testing , including fecal occult blood testing and colonoscopy  or 
sigmoidoscop y
Z-scores for weight, height (or length), head circumference (up to 36 months of age), and 
body  mass index
Adverse events will be coded using the Medical Dictionary  for Regulatory  Activities 
(MedDRA). The number of events, incidence, and percentage of AEs will be calculated overall, 
by [CONTACT_1196] (SOC) and by  [CONTACT_11702]. SAEs will be further summarized by  
[CONTACT_11370] y and relationship to investigational product. Adverse events related to investigational 
product, AEs leading to withdrawal, SAEs, and deaths will be similarly  summarized/listed.
Prior and concomitant medications will be coded using the World Health Organization- Drug 
Dictionary (WHO -DD) with regard to drug class and drug name. The number and percentage of 
subjects with specific prior m edications will be summarized. Medical history  (including 
surgical/procedural history ) will be coded using MedDRA. The number and percentage of 
subjects with specific histories will be s ummarized by  [CONTACT_6657]. 
For clinical laboratory  tests, vital signs, body  weight, and fluid balance variables, descriptive 
statistics (mean, median, standard deviation, minimum and maximum values, the number and 
percentage of su bjects in specified categories) will be calculated to summarize the observed 
values and change from baseline at each scheduled visit.
The number and percentage of subjects classified as having positive or neutralizing antibodies to 
teduglutide will be used to summarize the presence of antibodies. 
Additional safet y parameters and measures will include change in bod y weight, height (or 
length) and head circumference (up to 36 months of age). Derived variables will include height 
z
-score, weight z -score, BMI, and BMI z -score. Descriptive statistics (mean, median, standard 
deviation , minimum and maximum values, the number and percentage of subjects in specified 
categories) will be calculated to summarize the absolute values and change from baseline at each 
scheduled visit.
For non-commercial use only
Shire CONFIDENTIAL Page 67
Protocol SHP633 -304 Version 2 / 22Nov 2016
9.9 Other Analyses
9.9.1 Health -related Quality of Life Analyses 
Health economics and outcomes research endpoints will be analy zed at approximately  12-week 
intervals (Weeks 12 and 24 of each teduglutide treatment cy cle, and every  12 weeks for subjects
not on teduglutide), relative to the study  baseline. The beginning of each treatment cy cle (CxD1) 
will be an additional baseline.
Change in Pediatric Quality  of Life Inventory  (PedsQL) score
Change in PedsQL Family  Impact Module score
Change in PedsQL Gas
trointestinal Sy mptoms Module Sub- Scales scores: 
Food and Drink L imits
Diarrhea 
For non-commercial use only
Shire CONFIDENTIAL Page 68
Protocol SHP633 -304 Version 2 / 22Nov 2016
10SPONSOR’S AND INVEST IGATOR’S RESPONSIBIL ITIES
This study  is conducted in accordance with current applicable regulations, ICH, EU Directive 
2001/20/EC and its updates, and local ethical and legal requirements. 
The name [CONTACT_317368] y vendor ( eg, CRO) used in this study  will be maintained 
in the investigator’s and sponsor’s files, as appropriate.
10.1 Sponsor’s Responsibilities
10.1.[ADDRESS_483131] been delegated will undertake their assigned roles for this study  in compliance with all 
applicable industry  regulations, I CH Good Clinical Practice (GCP) Guideline E6 ( 1996), EU 
Directive 2001/20/EC, as well as all applicable national and local laws and regulations.
Visits to sites are con ducted by  [CONTACT_10199]/or the company  
organizing/managing the research on behalf of the sponsor to inspect study  data, subjects’ 
medical records, and eCRFs in accordance with current GCP and the respective local and 
(inter)natio nal government regulations and guidelines. Records and data may  additionall y be 
reviewed b y auditors or by  [CONTACT_10200].
The sponsor ensures that local regulatory  authority requirements are met before the start of the 
study . The sponsor (or a nom inated designee) is responsible for the preparation, submission, and 
confirmation of receipt of an y regulatory  authority  approvals required prior to release of 
investigational product for shipment to the site.
10.1.2 Indemnity/Liability and Insurance
The sponsor 
of this research adheres to the recommendations of the Association of British 
Pharmaceutical Industry  Guidelines. If appropriate, a cop y of the indemnity document is 
supplied to the investigator before study  initiation, per local country  guidelines.
The sponsor ensures that suitable clinical study  insurance coverage is in place prior to the start of 
the study . An insurance certificate is supplied to the CRO as necessary . 
10.1.3 Public Posting of Study Information
The sponsor is responsible for posting appropriate study  information on applicable websites. 
Information included in clinical study  registries may  include participating investigators’ names 
and contact [CONTACT_3031].
10.1.4 Submission of Summary of Clinical Study Report (CSR) to Competent 
Authorities of Member St ates Concerned and Ethics Committees
The sponsor will provide a summary  of the clinical study  report to the competent authority  of the 
member state(s) concerned as required b y regulatory  requirement(s) and to comply  with the 
Community  guideline on GCP. Thi s requirement will be fulfilled within 6 months of the end of 
For non-commercial use only
Shire CONFIDENTIAL Page 69
Protocol SHP633 -304 Version 2 / 22Nov 2016
the study  completion date for pediatric studies and within 1 y ear for non -pediatric studies as per 
guidance. The sponsor will provide the ECs with a copy  of the same summary .
10.1.5 Study Suspension, T ermination, and Completion
The sponsor may  suspend or terminate the study , or part of the study , at any  time for any  reason. 
If the stud y is suspended or terminated, the sponsor will ensure that applicable sites, regulatory 
agencies and IRBs/ECs are notifi ed as appropriate. Additionally , the discontinuation of a 
registered clinical study  which has been posted to a designated public website will be updated 
accordingl y.
The sponsor will make an EOS declaration to the relevant competent authority  as required b y 
Article 10 (c) of Directive 2001/20/EC .
10.2 Investigator’s Responsibilities
10.2.[ADDRESS_483132] undertake to perform the study  in accordance with ICH GCP Guideline E6 
(1996), EU Directive 2001/20/EC, and applicable regulat ory requirements and guidelines.
It is the investigator’s responsibility  to ensure that adequate time and appropriately  trained 
resources are available at the site prior to commitment to participate in this study . The 
investigator should also be able to es timate or demonstrate a potential for recruiting the required 
number of suitable subjects within the agreed recruitment period.
The investigator will maintain a list of appropriately  qualified persons to whom the investigator 
has delegated significant stud y
-related tasks, and shall, upon request of the sponsor, provide 
documented evidence of any  licenses and certifications necessary  to demonstrate such 
qualification. Curriculum vitae for investigators and sub- investigators are provided to the study  
sponsor 
(or designee) before starting the study .
If a potential research subject has a primary  care phy sician, the investigator should, with the 
subject’s consent, inform them of the subject’s participation in the study .
A coordinating principal investigator [INVESTIGATOR_319387]. Agreement with the final CSR is documented by  [CONTACT_319426] (single -site study ) or coordinating principal inv estigator (multicenter 
study ), in compliance with Directive 2001/83/EC as amended b y Directive 2003/63/EC and I CH 
Guidance E3 ( 1995). 
10.2.[ADDRESS_483133] met 
protocol eligibility  criteria. Investigators 
arerequired to sign an investigator agreement to 
confirm acceptance and willingness to comply  with the stu dy protocol.
For non-commercial use only
Shire CONFIDENTIAL Page 70
Protocol SHP633 -304 Version 2 / 22Nov 2016
If the investigator suspends or terminates the study  at their site, the investigator will promptly  
inform the sponsor and the I RB/EC and provide them with a detailed written explanation. The 
investigator will also return all investigational pr oducts, containers, and other study  materials to 
the sponsor. Upon study  completion, the investigator will provide the sponsor, I RB/EC, and 
regulatory  agency  with final reports and summaries as required by [CONTACT_59761].
Communication with loca l IRBs/ECs, to ensure accurate and timel y information is provided at 
all phases during the study , may  be done by  [CONTACT_456], applicable CRO, investigator, or for 
multicenter studies, the coordinating principal investigator [INVESTIGATOR_49106].
10.2.3 Documentation and Retention of Records
[IP_ADDRESS] Case Report Forms
The investigator is responsible for maintaining adequate and accurate medical records from 
which accurate information is recorded into eCRFs, which have been designed to record all 
observations and other data pertinent to the clinical investigation. Case report forms must be 
completed b y the investigator or designee as stated in the site delegation log.
All data will have separate source documen tation; no data will be recorded directly  into the 
eCRF.
eCRFs should be approved by  [CONTACT_385960].
The clinical research associate (CRA)/study  monitor will verify  the contents against the sourc e 
data per the monitoring plan. If the data are unclear or contradictory , queries are sent for 
corrections or verification of data.
[IP_ADDRESS] Recording, Access, and Retention of Source Data and Study Documents
Original source data to be reviewed during this study  will include, but are not limited to: 
subject’s medical file, subject diary  cards, original clinical laboratory  reports, and histology  and 
pathology  reports.
All key  data must be recorded in the subject’s medical records.
The investigator must permit authori zed representatives of the sponsor, the respective national, 
local, or foreign regulatory  authorities, the IRB/EC, and auditors to inspect facilities and to have 
direct access to original source records relevant to this study , regardless of media.
The CRA/ study  monitor (and auditors, IRB/EC or regulatory  inspectors) may  check the eCRF 
entries against the source documents. The consent form includes a statement by  [CONTACT_10203]/auditor from the sponsor or its representatives, nationa l or local 
regulatory  authorities, or the I RB/EC, having access to source data ( eg, subject’s medical file, 
appointment books, original laboratory reports, X -rays etc.). Non- study  site personnel will not 
disclose an
y personal information or personal medica l information.
For non-commercial use only
Shire CONFIDENTIAL Page 71
Protocol SHP633 -304 Version 2 / 22Nov [ADDRESS_483134] be made available within reasonable times for inspection and duplication, if 
required, b y a properly  authorized representative of any  regulatory  agency  (eg, the US FDA, 
EMA, [LOCATION_006] Medicines and Healthcare products Regulatory  Agency ) or an auditor.
Essential documents must be maintained according to ICH GCP requirements and may  not be 
destroy ed without written permission from the sponsor.
[IP_ADDRESS] Audit/Inspection
To ensure compliance with relevant regulations, data generated b y this st udy must be available 
for inspection upon request by  [CONTACT_1779], for example, the US Food and Drug 
Administration (FDA) (as well as other US national and local regulatory  authorities), the 
European Medicines Agency (EMA), the Medicines and Healthca re products Regulatory  
Agency , other regulatory authorities, the sponsor or its representatives, and the I RB/EC for each 
site.
[IP_ADDRESS] Financial Disclosure
The investigator is required to disclose an y financial arrangement during the study and for 1 year 
after, wh ereby [CONTACT_385968] , or other pay ments the investigator received from the sponsor. The 
following information is collected: an y significant payments from the sponsor or subsidiaries 
such as a grant to fund ongoing research, compensation in the form of equipment, retainer for 
ongoing consultation or honoraria; an y proprietary interest in investigational product; any 
significant equity  interest in the sponsor or subsidiaries as defined in 21 CFR 54 2(b) (1998).
10.[ADDRESS_483135]’s legall y-authorized representative, as 
applicable, is requested to sign and date the subject informed consent form or a certified 
translation if applicable, after the subject has received and read (or been read) the written subject 
information and received an explanation of what the study  involves, including but not limited to: 
the objectives, potential be nefits and risk, inconveniences, and the subject’s rights and 
responsibilities. A copy  of the informed consent and assent documentation ( ie, a complete set of 
subject information sheets and fully  executed signature [CONTACT_1787]) must be given to the subject or the 
subject’s legall y-authorized representative, as applicable. This document may  require translation 
into the local language. Signed consent forms must remain in each subject’s study  file and must 
be available for verification at an y time.
Within the source documents, site personnel should document instruction of and understanding 
by [CONTACT_7071]/legall y-authorized representative/caregiver of the safe, responsible storage and 
administration of investigational product to the study  subject.
For non-commercial use only
Shire CONFIDENTIAL Page 72
Protocol SHP633 -304 Version 2 / 22Nov 2016
The principal investigator [INVESTIGATOR_1682] a copy  of the consent form, and assent form 
where applicable, which was reviewed b y the IRB/EC and which received their favorable 
opi[INVESTIGATOR_1649]/approval. A copy  of the IRB/EC’s written favorable opi[INVESTIGATOR_1649]/approval of these 
documents must be provided to the sponsor, prior to the start of the study  unless it is agreed to 
and documented (abiding by  [CONTACT_319428]) prior to study  start 
that another party  (ie, sponsor or coordinating principal investi gator) is responsible for this 
action. Additionally , if the I RB/EC requires modification of the sample subject information and 
consent document provided by  [CONTACT_456], the documentation supporting this requirement must 
be provided to the sponsor.
10.3.[ADDRESS_483136] or Ethics Committee
For sites outside the EU, it is the responsibility  of the investigator to submit this protocol, the 
informed consent document (approved b y the sponsor or their designee), relevant supporting 
information and all ty pes of subject recruitment information to the I RB/EC for review, and all 
must be approved 
prior to site initiation .
For sites within the EU, the applicant for an EC opi[INVESTIGATOR_319376], the investigator, or 
for multicenter studies the coordinating princ ipal investigator or sponsor, according to national 
provisions.
Responsibility  for coordinating with IRBs/ECs is defined in the investigator agreement.
Prior to implementing changes in the study , the sponsor and the IRB/EC must approve any  
revisions of all informed consent documents and amendments to the protocol unless there is a 
subject safet y issue.
Investigational product supplies will not be released until the Sponsor (or designee) has received 
written I RB/EC approval of and copi[INVESTIGATOR_10158] .
For sites outside the EU, the investigator is responsible for keepi[INVESTIGATOR_1683]/EC apprised of the 
progress of the stud y and of an y changes made to the protocol, but in an y case at least once a 
year; for sites within the EU, this can be done by  [CONTACT_456], the investigator or for multicenter 
studies the coordinating principal investigator, according to national provisions. The investigator 
must also keep the local IRB/EC informed of an y serious and significant AEs.
10.[ADDRESS_483137] (HIPAA) of 
1996. A site that is not a covered entity  as defined by  [CONTACT_385969] (or designee).
The confidentialit y of records that may be able to identify subjects will be protected in 
accordance with applicable laws, regulations, and guidelines.
After subjects have consented to take part in the study , the sponsor and/or its representatives 
review their medical records and data collected during the stud y. These records and data may, in 
For non-commercial use only
Shire CONFIDENTIAL Page 73
Protocol SHP633 -304 Version 2 / 22Nov 2016
addition, be reviewed b y others including the following: independent auditors who validate the 
data on behalf of the sponsor; third parties with whom the sponsor may  develop, register, or 
market SHP633; national or local regulatory  authorities; and the I RBs/ECs which gave approval 
for the stud y to proceed. The sponsor and/or its representatives accessing the records and data 
will take all reasonable precautions in accordance with applicable laws, regulations, and 
guidelines to maintain the confidentialit y of subjects’ identities.
Subjects are assigned a unique identify ing number; however, their initials and date of b irth may  
also be collected and used to assist the sponsor to verify  the accuracy  of the data ( eg, to confirm 
that laboratory  results have been assigned to the correct subject).
The results of studies –containing subjects’ unique identify ing number, releva nt medical 
records, and possibly  initials and dates of birth –will be recorded. They  may  be transferred to, 
and used in, other countries which may  not afford the same level of protection that applies within 
the countries where this study  is conducted. The purpose of an y such transfer would include: to 
support regulatory  submissions, to conduct new data anal yses to publish or present the study  
results, or to answer questions asked by  [CONTACT_1775].
10.5 Study Results / Publication Policy
Shire will endeavor to publish the results of all qualify ing, applicable, and covered studies 
according to external guidelines in a timely  manner regardless of whether the outcomes are 
perceived as positive, neutral, or negative. Additionally , Shire adheres to external guidelines ( eg, 
Good Publication Practices 2) when forming a publication steering committee, which is done for 
large, multicenter Phase [ADDRESS_483138] undergo appropriate technical and 
intellectual propert y review, with Shire agreement to publish prior to release of information. The 
review is aimed at protecting the sponsor’s proprietary  information existing either at the 
commencement of the study  or generated during the study . To the extent permitted by  [CONTACT_10206], the principal investigator [INVESTIGATOR_59702] (or share with other authors) the 
copy right on his/her publications. To the extent that the principal investigator [INVESTIGATOR_10159], joint 
or shared rights, the principal investigator [INVESTIGATOR_10160] a perpetual, irrevocable, 
royalty-free license to make and distribute copi[INVESTIGATOR_10161].
The term “publication” refers to an y public disclosure including original research articles, review 
articles, oral presentations, abstracts and post ers at medical congresses, journal supplements, 
letters to the editor, invited lectures, opi[INVESTIGATOR_10162], book chapters, electronic postings on 
medical/scientific websites, or other disclosure of the study  results, in printed, electronic, oral or 
other form .
Subject to the terms of the paragraph below, the investigator shall have the right to publish the 
study  results, and any  background information provided by  [CONTACT_64763], or necessary for oth er scholars to verify  such study  
results. Notwithstanding the foregoing, no publication that incorporates the sponsor’s 
For non-commercial use only
Shire CONFIDENTIAL Page 74
Protocol SHP633 -304 Version 2 / 22Nov 2016
confidential information shall be submitted for publication without the sponsor’s prior written 
agreement to publish, and shall be given to the sponsor for review at least [ADDRESS_483139] publication of the study results shall be made 
by [CONTACT_10208]’s presentation of a joint, multicenter publication 
of the compi[INVESTIGATOR_385942]. If such a multicenter publication is not submitted to a 
journal for publication by  [CONTACT_10209] 18-month period after conclusion, abandonment, 
or termination of the study  at all sites, or after the sponsor confirms there shall be no m ulticenter 
study  publication of the study  results, an investigator may individuall y publish the study results 
from the specific site in accordance with this section. The investigator must, however, 
acknowledge in the publication the limitations of the sing le-site data being presented.
Unless otherwise required by  [CONTACT_10210], or the forum in which 
it is made, authorship will comply  with the International Committee of Medical Journal Editors 
current standards. Participation as an investigator does not confer an y rights to authorship of 
publications.
For non-commercial use only
Shire CONFIDENTIAL Page 75
Protocol SHP633 -304 Version 2 / 22Nov 2016
11REFERENCES
Drucker, D. J. & Yusta, B. 2014. Phy siology  and pharmacology  of the enteroendocrine hormone 
glucagon-like peptide-2. Annu Rev Physiol, 76,561- 83.
Khan , F. A., Squires, R. H., L itman, H. J., Balint, J., Carter, B. A., Fisher, J. G., Horslen, S. P., 
Jaksic, T., Kocoshis, S., Martinez, J. A., Mercer, D., Rhee, S., Rudolph, J. A., Soden, J., Sudan, 
D., Superina, R. A., Teitelbaum, D. H., Venick, R., Wales, P. W. & Duggan, C. 2015. Predictors 
of Enteral Autonom y in Children with I ntestinal Failure: A Multicenter Cohort Study . J Pediatr,
167, 29-34.e1.
Mouksassi, M. S., Marier, J. F., Cy ran, J. & Vinks, A. A. 2009. Clinical trial simulations in 
pediatric patie nts using realistic covariates: application to teduglutide, a glucagon-like peptide-2 
analog in neonates and infants with short- bowel s yndrome. Clin Pharmacol Ther, 86,667-71.
O'Keefe, S. J., Buchman, A. L ., Fishbein, T. M., Jeejeebhoy , K. N., Jeppesen, P . B. & Shaffer, J. 
2006. Short bowel sy ndrome and intestinal failure: consensus definitions and overview. Clin 
Gastroenterol Hepatol, 4,6-10.
Squires, R. H., Duggan, C., Teitelbaum, D. H., Wales, P. W., Balint, J., Venick, R., Rhee, S., 
Sudan, D., Mercer, D., Martinez, J. A., Carter, B. A., Soden, J., Horslen, S., Rudolph, J. A., 
Kocoshis, S., Superina, R., L awlor, S., Haller, T., Kurs -Lask y, M. & Belle, S. H. 2012. Natural 
history  of pediatric intestinal failure: initial report from the Pediatric Intestinal Failure 
Consortium. J Pediatr, 161, 723-8.e2.
Tappenden, K. A., Edelman, J. & Joelsson, B. 2013. Teduglutide enhances structural adaptation 
of the small intestinal mucosa in patients with short bowel sy ndrome. J Clin Gastroenterol, 47,
602-7.
Thymann, T., Stoll, B., Mecklenburg, L., Burrin, D. G., Vegge, A., Qvist, N., Eriksen, T., 
Jeppesen, P. B. & Sangild, P. T. 2014. Acute effects of the glucagon -like peptide 2 analogue, 
teduglutide, on intestinal adaptation in short bowel sy ndrome. J Pediatr Gastroenterol Nutr, 58,
694-702.
Varni, J. W., Sherman, S. A., Burwinkle, T. M., Dickinson, P. E. & Dixon, P. 2004. The PedsQL  
Family  Impact Module: pr eliminary  reliability  and validity . Health Qual Life Outcomes, 2,55.
Wales, P. W., de Silva, N., Kim, J., L ecce, L., To, T. & Moore, A. 2004. Neonatal short bowel 
syndrome: population
-based estimates of incidence and mortality  rates. J Pediatr Surg, 39,690-
5.
For non-commercial use only
Shire CONFIDENTIAL Page 76
Protocol SHP633 -304 Version 2 / 22Nov 2016
12APPENDICES
For non-commercial use only
Shire CONFIDENTIAL Page 77
Protocol SHP633 -304 Version 2 / 22Nov 2016
APPENDIX 1 PROTOCOL HISTORY
Document Date Global/Country/Site Specific
Original Protocol 08 April 2016 Global
Amendment 1 22Nov 2016 Global
For non-commercial use only
Shire CONFIDENTIAL Page 78
Protocol SHP633 -304 Version 2 / 22Nov 2016
APPENDIX 2 GUIDELINES FOR NUTRI TIONAL SUPPORT MANAG EMENT 
DURING THE STUDY
Nutritional support adjustment in volume and calories should be considered at all planned visits. 
Please consider the following clinical parameters identified as markers for adequate management 
of pediatric SBS. These parameters should also be considered for managing nutritional support 
(PS and/or oral/enteral feeding) in terms of volume and calories during the treatment period. 
Growth trajectory , including weight, height (or length), and head circumference (for pediatric 
subjects up to 36 months of age)
Other clinical evaluations
Serum electrol ytes
Blood urea nitrogen /creatinine levels
Changes in stool frequency  orvolume, including mixed output
Stool consistency  (ie, Bristol Stool Scale)
Urine specific gravit y
General consideration to possible clinical deterioration in SBS
Inability  to maintain weight and growth velocity
Diarrhea ( ≥10 bowel movements per day , ≥80 mL/kg/day  from an ostomy, or 
≥75mL/kg/day  mixed output)
Colic/vomiting frequency increased
Electrol yte changes or imbalance
Skin breakdown 
Adjustments should be based on the actual nutritional support in volume and calories the 
subject infuses. Subjects should remain compliant with the nutritional support prescription in 
volume and calories during the stud y.
Nutritional support constituents may be adjusted at the discretion of the investigator.
During the [ADDRESS_483140]’s scheduled visit, no 
further changes to the prescribed nutritional support should be made.
If there is a change in enteral nutrition ( EN) or other food or fluid intake, the investigator 
should consider this when adjusting the PS/EN support in volume and calories.
For non-commercial use only
Shire CONFIDENTIAL Page 79
Protocol SHP633 -304 Version 2 / 22Nov 2016
Figure A -1 Weaning Algorithm for Subjects Who are NOT Toilet Trained and in 
Diapers
For non-commercial use only
Shire CONFIDENTIAL Page 80
Protocol SHP633 -304 Version 2 / 22Nov 2016
Figure A -2 Weaning Algorithm for Subjec ts Who are Toilet Trained and NOT in 
Diapers
For non-commercial use only
Shire CONFIDENTIAL Page 81
Protocol SHP633 -304 Version 2 / 22Nov 2016
Figure A -3 Clinical Dehydration Assessment and PS/EN Adjustment
For non-commercial use only
PROTOCOL: SHP633 -304
TITLE: A Prospective, Open -label, Long-term Safet y and Efficacy  Study of 
Teduglutide in Pediatric Patients with Short Bowel Syndrome Who 
Completed TED -C14-006
DRUG: Teduglutide
IND: IND# [ADDRESS_483141] NO.: 2016-000849-30
SPONSOR: Shire Human Genetic Therapi[INVESTIGATOR_014], Inc.
[ADDRESS_483142] , Lexington, MA [ZIP_CODE] [LOCATION_003]
PROTOCOL 
HISTORY:Amendment 2: 23Mar 2017
Amendment 1: 22Nov 2016
Original Protocol: 08April [ADDRESS_483143] party without the express written 
consent of Shire.
For non-commercial use only
Shire CONFIDENTIAL Page 2 
SHP633-304 Protocol Amendment 2 
Teduglutide  23 Mar 2017 
PROTOCOL SIGNATURE [CONTACT_64783]'s (Shire) Approval 
' ;' ' --, 
! Signature: 1 Date: 1 
I 1  : . 
1 , MD PhD 1 
i  1 
l_ Global Clinical Development I 
Investigator's Acknowledgement 
I have read this protocol for Shire Study SHP633-304. 
Title: A prospective, open label, long-term safety and efficacy study of teduglutide in pediatric 
patients with short bowel syndrome who completed TED-C14-[ADDRESS_483144] fully discussed the objective(s) of this study and the contents of this protocol with the 
sponsor's representative. 
I understand that the information in this protocol is confidential and should not be disclosed, 
other than to those directly involved in the execution or the scientific/ethical review of the study, 
without written authorization from the sponsor. It is, however, permissible to provide the 
information contained herein to a subject in order to obtain their consent to participate. 
I agree to conduct this study according to this protocol and to comply with its requirements, 
subject to ethical and safety considerations and guidelines, and to conduct the study in 
accordance with International Conference on Harmonization (ICH) guidelines on Good Clinical 
Practice (GCP) and with the applicable regulatory requirements. 
I understand that failure to comply with the requirements of the protocol may lead to the 
termination of my participation as an investigator for this study. 
I understand that the sponsor may decide to suspend or prematurely terminate the study at any 
time for whatever reason; such a decision will be communicated to me in writing. Conversely, 
should I decide to withdraw from execution of the study I will communicate my intention 
immediately in writing to the sponsor. 
Investigator Name [CONTACT_1781]: 
(please hand print or type) 
For non-commercial use only
Shire CONFIDENTIAL Page 3
SHP633 -304 Protocol Am endment 2
Teduglutide 23 Mar 2017
SUMMAR Y OF CHANGES F ROM PREVIOUS VERSION
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 2 Amendment Date
23Mar 2017Global
Description of Change and Rationale Section(s) Affected by [CONTACT_385970]; 
Section 8.1.6 ; Section 8.2.2 ; Section 
8.2.4
To allow  for approximately 7 days for subjects to transfer from Study 
TED -C14-006 to Study SHP633 -304 (instead of up to 7 days ).Table 1-1; Section 7.1.[ADDRESS_483145] pre -treatment visit (P1) follows the screening visit, it must occur 
within 12 w eeks of screening.Table 1-3
Revised the language on abstinence as a contraceptive method for
consisten cywith the Medicines and Healthcare Products Regulatory 
Agency (MHRA) Clinical Trial Facilitation Group's "Recommendations 
related to contraception and pregnancy testing in clinical trials."Section 4.7.1
Clarification that ancillary components, in addition to sterile w ater for 
injection syringes, will also be provided and labeled in accordance w ith 
the applicable regulatory requirements.Section 6.3.1
Afootnote was added in Table 7 -2to clarify that subjects older than 
18years of age will continue to use t he Child Self Report and Paren t 
Prox y-Report for Teens (ages 13 -18) when completing the Pediatric 
Quality o f Life Generic Core Scale (PEDSQL™) .Section [IP_ADDRESS] (Table 7-3)
Revised the text on severity categorization to specify that asevere 
treatment -emergent adverse event ( TEAE )that might lead to dose 
interruption (Section 8.4.1 ) or early te rmination of the study 
(Section 8.5)willalsobe graded according to the National Cancer 
Institute’s (NCI) Common Terminology Criteria for Adverse Events 
(CTCAE) severity grading criteria, in addition to the standard severity 
categorization. These events are no longer limited to only the events 
described in Table 8 -1, entitled “CTCAE Criteria for Adverse Events 
that May Lead to Dose Interruption (Prospective Period of Observation 
Only). ”There fore, Table 8 -1 has been deleted.Section 8.1.1 ; Section 8.4; Section 
8.4.1
Table 8 -1 (deleted)
Revised the criteria for early termination of the study: stoppi[INVESTIGATOR_385943] [ADDRESS_483146], and nolonger limited to the 
events described in Table 8 -1, entitled “CTCAE Criteria for Adverse 
Events that May Lead to Dose Interruption (Prospective Period of 
Observation Only). ”Section 8.[ADDRESS_483147] IN FORMA TION
In the event of a serious adverse event (SAE), the investigator must fax or e -mail the Shire 
Clinical Study  Adverse Event Form for Serious Adverse Events (SAEs) and Non -serious AEs as 
Required b y Protocol within 24 hours to the Shire Global Drug Safet yDepartment. Applicable 
fax numbers and e -mail address can be found on the form (sent under separate cover). A copy  of 
this form must also be sent to the Shire Medical Monitor by  [CONTACT_3719] e -mail using the details 
below.
, MD PhD
Email: 
Fax: 
For protocol -or safety- related issues ,the investigator must contact [CONTACT_319459] :
Primary contact [CONTACT_385971] (NA) and backup contact [CONTACT_385972] (EU)
, MD, 
Mobile: 
US Toll Free number: 
Phone:  (medical emergencies –NA)
Email: 
Primary contact [CONTACT_385973] b ackup contact [CONTACT_385974]
, MD, 
Mobile: 
Phone: 
Phone:  (medical emergencies –EU)
Email: 
In addition, the investigator may also contact [CONTACT_317344]:
, MD PhD, 
Phone: 
Mobile: 
Email: 
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_483148] 
(marketed or investigational) does not meet expectations ( eg, inadequate or faulty  closure, 
product contamination) or that the product did not meet the s pecifications defined in the 
application for the product ( eg, wrong product such that the label and contents are different 
products). For instructions on reporting AEs related to product complaints, see Section 8.
Please use the information below as applicable to report the Product Quality  Complaint:
Origin of Product Quality Complaint E
-mail Address
North and South America
European Union and Rest of World
Telephone numbers (provided for reference): 
 Shire ([LOCATION_003]) 
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_483149] OF APPENDICES ................................................................................................................10
ABBREVIAT IONS .......................................................................................................................11
STUDY SYNOPSI S
......................................................................................................................13
STUDY SCHEDULE(S) ...............................................................................................................[ADDRESS_483150] Background .................................................................................................23
1.3 Clinical Studies with Teduglutide in Pediatric Subjects ..........................................24
2STUDY OBJECTIVES AND PURPOSE ..............................................................................25
2.1 Rationale for the Study .............................................................................................25
2.2 Study  Objectives ......................................................................................................25
2.2.1 Primary  Objectives .................................................................................................25
2.2.2 Secondary  Objectives .............................................................................................25
3STUDY DESIGN ...................................................................................................................26
3.1 Study  Design and Flow Chart ..................................................................................26
3.2 Duration and Study  Completion Definition
.............................................................28
4STUDY POPUL ATION.........................................................................................................29
4.1 Study  Inclusion Eligibility  Criteria ..........................................................................29
4.2 Study  Exclusion Eligibility  Criteria
.........................................................................29
4.3 Teduglutide Eligibility  Criteria ................................................................................29
4.4 Teduglutide Treatment Inclusion Criteria ................................ ................................ 29
4.5 Teduglutide Treatment Exclusion Criteria................................ ............................... 30
4.6 Follow -up Period Escape Criteria ................................ ................................ ............ 31
4.7 Reproductive Potential ................................ ................................ ............................. 31
4.7.1 Female Contraception ............................................................................................31
4.8
Discontinuation of Subjects ................................ ................................ ..................... 32
4.8.1 Teduglutide Discontinuation................................ ................................ .................. 32
4.8.2 Study  Withdrawal ................................ ................................ ................................ ..32
4.8.3 Reasons for Discontinuation ................................ ................................ .................. 32
For non-commercial use only
Shire CONFIDENTIAL Page 7
SHP633 -304 Protocol Am endment 2
Teduglutide 23 Mar 2017
[IP_ADDRESS] Subjects ‘L ost to Follow -up’ Prior to Last Scheduled Vi sit..................[ADDRESS_483151](s) ...........................................................[ADDRESS_483152] Compliance ..................................................................................................38
7
STUDY PROCEDURES........................................................................................................39
7.1 Study  Schedule .........................................................................................................39
7.1.1 Screening ................................................................................................................39
7.1.2
Visits for Subjects Not Receiving Teduglutide .....................................................39
7.1.3
Visits for Subjects Receiving Teduglutide ............................................................40
[IP_ADDRESS] Pre-treatment Visit .................................................................................40
[IP_ADDRESS] Teduglutide Treatment Period (CxD1 -CxW24) .....................................41
7.1.4 Teduglutide Follow -up Period ...............................................................................43
7.1.5 Study  Completion/Earl y Termination Visit (EOS/ET Visit) .................................43
7.2 Study  Evaluations and Procedures
................................ ................................ ........... 44
7.2.1 Demographics, Medical History , and SBS History ................................ ............... 44
7.2.2 Physical Examination ................................ ................................ ............................. 44
7.2.3 Vital Signs, Bod y Weight, Height, Head Circumference and Bod y Mass 
Index (BMI) ...........................................................................................................45
7.2.4 Clinical L aboratory  Tests ................................ ................................ ....................... 45
7.2.5 Serum Sampling ................................ ................................ ................................ .....46
7.2.6 Pregnancy  Testing ................................ ................................ ................................ ..47
7.2.7 Antibody  Testing ................................ ................................ ................................ ...47
7.2.8 Volume of Blood ................................ ................................ ................................ ....47
For non-commercial use only
Shire CONFIDENTIAL Page 8
SHP633 -304 Protocol Am endment 2
Teduglutide 23 Mar 2017
7.2.9 Gastrointestinal -specific Testing ...........................................................................48
[IP_ADDRESS] Fecal Occult Blood Testing ....................................................................48
[IP_ADDRESS] Colonoscopy  or Sigmoidoscopy .............................................................48
7.2.10 Nutritional Support ................................................................................................48
7.2.11  Diaries.....................................................................................................................49
[IP_ADDRESS] Study  Drug Administration Diary ................................ .......................... 49
[IP_ADDRESS] Intake Diary ............................................................................................49
[IP_ADDRESS] Output Diary ...........................................................................................49
7.2.12 Health- related Quality  of L ife Assessments ................................ .......................... 50
[IP_ADDRESS] Pediatric Quality  of Life Generic Core Scale (PedsQL ™), Acute 
version ....................................................................................................50
[IP_ADDRESS] Pediatric Quality  of Life Family  Impact Module (PedsQL™), Acute 
version ....................................................................................................51
[IP_ADDRESS] PedsQL  Gastrointestinal Sy
mptoms Module (PedsQL ™), Acute 
version ....................................................................................................[ADDRESS_483153] .................................................................58
8.4.2 Dose Interruption Criteria Based on Drug -Induced Liver Injury .......................... 59
For non-commercial use only
Shire CONFIDENTIAL Page 9
SHP633 -304 Protocol Am endment 2
Teduglutide 23 Mar 2017
8.5 Early Termination of the Clinical Study ..................................................................59
9DATA MANAGEMENT AND STATISTICAL METHODS
...............................................60
9.1 Data Collection .........................................................................................................60
9.2 Clinical Data Management .......................................................................................60
9.3 Statistical Analy
sis Process ......................................................................................60
9.4 Planned Interim Anal ysis, and Data Monitoring Committee ...................................60
9.5
Sample Size Calculation and Power Considerations................................................61
9.6 Study  Population ......................................................................................................61
9.7 Efficacy  Anal yses.....................................................................................................61
9.7.1 Efficacy  Endpoints ................................ ................................ ................................ .61
9.8 Safety  Anal yses........................................................................................................61
9.8.1 Safety  Endpoints ....................................................................................................61
9.9 Other Anal yses.........................................................................................................62
9.9.1 Health
-related Quality  of L ife Anal yses................................................................62
10SPONSOR’S AND I NVEST IGATOR’S RESPONSIBIL
ITIES...........................................64
10.1
Sponsor’s Responsibilities .......................................................................................64
10.1.1 Good Clinical Practice Compliance .......................................................................64
10.1.2 Indemnity /Liability  and Insurance .........................................................................64
10.1.3 Public Posting of Study  Information ......................................................................64
10.1.4 Submission of Summary  of Clinical Study
 Report (CSR) to Competent 
Authorities of Member States Concerned and Ethics Committees ........................64
10.1.5 Study  Suspension, Termination, and Completion
..................................................65
10.2 Investigator’s Responsibilities .................................................................................65
10.2.1 Good Clinical Practice Compliance .......................................................................65
10.2.2 Protocol Adherence and Investigator Agreement ..................................................65
10.2.3 Documentation and Retention of Records .............................................................66
[IP_ADDRESS] Case Report Forms .................................................................................66
[IP_ADDRESS] Recording, Access, and Retention of Source Data and Study  
Documents ..............................................................................................66
[IP_ADDRESS] Audit/I nspection ................................ ................................ ..................... 66
[IP_ADDRESS] Financial Disclosure ................................ ................................ ............... [ADDRESS_483154] or Ethics Committee ................................ .................. 67
10.4 Privacy  and Confidentiality ................................ ................................ ...................... 68
10.5 Study  Results / Publication Policy ................................ ................................ ........... [ADDRESS_483155]  OF TABLES
Table 1-1: Schedule of Events Required for All Subjects ..............................................18
Table 1
-2: Schedule of Events for Subjects Not Receiving Teduglutide .......................19
Table 1
-3: Schedule of Events for Subjects While Receiving Teduglutide ....................20
Table 5
-1: Prohibited Treatment .....................................................................................34
Table 7
-1: List of Laboratory  Tests ................................................................................46
Table 7
-2: Approximate Volume of Blood to be Drawn from Each Subject 
Annually ........................................................................................................47
Table 7
-3: Developmentally Appropriate PedsQL™Generic Core Scales .....................[ADDRESS_483156]  OF FIGURES
Figure 3 -
1: Study  Design Flow Chart ..............................................................................[ADDRESS_483157] aspartate aminotransferase
-HCG beta-human chorionic gonadotropin
BMI body  mass index
CRA clinical research associate
CRO contract research organization
CSR clinical study  report
CTCAE Common Terminology  Criteria for Adverse Events
DILI drug-induced livery  injury
DMC data monitoring committee
DPP-[ADDRESS_483158]
IV intravenous
For non-commercial use only
Shire CONFIDENTIAL Page 12
SHP633 -304 Protocol Am endment 2
Teduglutide 23 Mar 2017
IWRS interactive web -based response sy stem
MedDRA Medical Dictionary  for Regulatory  Activities
NA North America
NCI National Cancer Institute
NDA new drug application
NTT no-teduglutide treatment
PDA patent ductus arteriosus
PedsQL Pediatric Quality  of Life inventory
PS parenteral support
PT/INR prothrombin time/international normalized ratio
QD once dail y
SAE serious adverse event
SAP statistical analy sis plan
SBS short bowel sy ndrome
SC subcutaneous
SOC standard of care
t1/[ADDRESS_483159] upper limit of normal
US [LOCATION_002]
WHO -DD World Health Organization
–Drug Dictionary
For non-commercial use only
Shire CONFIDENTIAL Page 13
SHP633 -304 Protocol Am endment 2
Teduglutide 23 Mar 2017
STUDY  SYNOPSIS
Protocol num ber: SHP633 -304 Drug: Teduglutide
Title of the study: A Prospective, Open -label, Long -term Safety and Efficacy Study of Teduglutide in Pediatric 
Patients with Short Bow el Syndrome (SBS) Who C ompleted TED -C14-006
Number of subjects (total and for each treatm ent arm):
Approximately 34subjects who completed the TED -C14-[ADDRESS_483160] of care 
treatment arm, are expected to enroll in this extension study. This study will enroll up to as many subjects as 
complete the TED -C14-006 study.
Investigator(s): Multicenter study
Site(s) and Region(s): 
Approximately 28 investigational sites in North America and Europe w ill participate in this extension study
Study period (planned):
October 2016 –September 2019Clinical phase: 3 Extension
Objectives:
Prim ary: To evaluate the long -term safety and tolerability of teduglutide treatment in pediatric subjects w ith SBS.
Secondary: To evaluate long -term efficacy of teduglutide treatment in pediatric subjects with SBS.
Rationale:
This is a Phase 3, prospective, open -label, long -term extension study to evaluate the safety and efficacy of 
teduglutide in pediatric subjects with short bow el syndrome (SBS) w ho completed the TED -C14-006 study (the 
core study). In addition to evaluating t he long -term safety and durability of efficacy after [ADDRESS_483161] of care (SOC) 
treatment arm in TED -C14-006. 
Investigational product, dose, and m ode of administration:
This study will allow repeat doses of teduglutide 0.05 mg/kg subcutaneous (SC) once daily (QD) injection for 
eligible p ediatric subjects. There is no active comparator or reference product.
Methodology:
This is a Phase 3, prospective, open -label, long-term extension study to evaluate the safety and efficacy of 
teduglutide in pediatric subjects who completed the TED -C14-006 study (core study).
Once the informed consent (and if applicable, informed assent) have been reviewed and signed , dem ographics, 
and updates to medical history and short bow el syndrome history will be obtained .Subjects not receiving 
teduglutide treatment ( ie, in a no -teduglutide treatment [NTT] perio d), w ill be seen approximately every  12 weeks 
for safety, parenteral support (PS) requirements, and quality of life. The first NTT visit after the screening visit 
will occur within 2 to 12 w eeks of the screening visit . At any point after screening, including during a NTT 
period, subjects who meet ≥[ADDRESS_483162], and parent agree to proc eed with teduglutide therapy .
After the pre -treatment visit, subjects who meet ≥1 of the teduglutide treatment inclusion criteria, and meet none 
of the teduglutide treatment exclusion criteria, will start a 28 -week cycle, consisting of 24 weeks of teduglutide 
treatment at 0.05 mg/kg SC once daily, followed by a 4 -week follow -up period (during which no teduglutide is 
administered) (Figure 3 -1). During the 28 -week cycle, clinic visits will occur at weeks 1, 2, 4, 6, 9, 12, 16 , 20, 24, 
and 28. Phone visits are required approximately 1 w eek after adjustments in PS during the teduglutide treatment 
period (betw een weeks 1 and 24), and w eekly during the teduglutide follow -up period (between weeks 24 and 
28).Safety and PS requireme nts will be evaluated at every visit, and quality of life assessments will be m ade 
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_483163] may "escape" the fol low-up period early and proceed immediately to 
another pre -treatment visit. Follow ing completion of the [ADDRESS_483164] w ill proceed to an
NTT visit within approximately 12 w eeks.
Atallsitevisits andtelephone contacts, safety willbemonitored andnutritional support willbereviewed and
adjusted asneeded. Tomaintain consistency across centers, allattempts should bemade tofollow thenutritional
support adjustment guidelines (developed withSBS expert input andprovided intheprotocol) fordecisions
regarding PSsupport reduction andadvances inenteral feeds based onweightgain, urine andstool output, and
clinical stability. Departure from theguidelines, however, isnotconsidered aprotocol deviation. (Appendix 2).
Study Design Flow Chart 
Figure legend: Safety and efficacy data for subjects not receiving teduglutide treatment are captured approximately every 
12 weeks, but subjects may proceed to the pre -treatment visit at any time in order to assess eligibility for teduglutide 
therapy. Eligible subjects will enter a 28 -week teduglutide cycle. During this cycle, subjects will return to the site for 
safety and efficacy assessments at weeks 1, 2, 4, 6, 9, 12, 16, 20, and 24 ( solid black lines ). Phone visits are requ ired
approximately 1 week after adjustments in PS during the intervening weeks between weeks 2 and 24 ( dashed grey 
lines ). Subjects discontinue teduglutide at week 24 and enter a 4 -week follow -up (no-treatment) period, during which 
phone visits will be per formed weekly ( solid grey lines ). If an escape criterion is met during the follow -up period, 
subjects may proceed directly to another pre -treatment visit.
Study Inclusion Criteria: 
The subject will be considered eligible for the study if they meet allof the study inclusion criteria. Teduglutide 
treatment eligibility does not impact study eligibility.
1.Subject provides w ritten informed consent (subject, parent or legal guardian and, as appropriate, 
informed assent) to participate in the study before com pleting any study -related procedures.
2.Subject completed the TED -C14-006 study (including subjects in the standard of care treatment arm).
3.Subject understands and is willing and able to fully adhere to study requirements as defined in this 
protocol. 
Study Exclusion Criteria: There are no exclusion criteria for this study.
Teduglutide Eligibility Criteria: Subjects are eligible for tedugluti de treatment if at least one ( ≥1) of the 
teduglutide treatment inclusion criteria, and none of the teduglutide treatmen t exclusion criteria, are met. In 
addition, the investigator and the subject (and/or parent or legal guardian, as appropriate) must agree to proceed 
with treatment.
Teduglutide Treatment Inclusion Criteria :
1.Subject is teduglutide -naïve, receiving PS, and u nable to significantly reduce PS or advance enteral feeds 
For non-commercial use only
Shire CONFIDENTIAL Page 15
SHP633 -304 Protocol Am endment 2
Teduglutide 23 Mar 2017
(eg, 10% or less change in PS or advance in feeds) for at least 3 months prior to and during the 
teduglutide pre- treatment visit, as assessed by [CONTACT_093]. Transient instability for events su ch as 
interruption of central access or treatment for sepsis is allowed if the PS returns to within 10% of 
baseline prior to the event.
2.Subject w as previously treated w ith teduglutide and at least one of the following criteria is satisfied:
a.Increasing PS requirements follow ing teduglutide discontinuation.
b.Decreased PS requirement during prior teduglutide treatment, follow ed by  [CONTACT_319475].
c.Deteriorating nutritional status ( eg, weight loss or growth failure) de spi[INVESTIGATOR_319360].
d.Deteriorating fluid or electrolyte status despi[INVESTIGATOR_319361].
e.Severe diarrhea related to tedu glutide discontinuation.
Teduglutide Treatment Exclusion Criteria:
1.Body  weight <10 kg at the pre- treatment visit.
2.Unresected gastrointestinal (GI) polyp, known polyposis condition, pre -malignant change, or 
malignancy, in the GI tract.
3.History of cancer in the previous 5 years except surgically curative skin cancers.
4.Serial transverse enteroplasty or other major intestinal surgery within 3 months preceding the teduglutide 
pre-treatment visit. Insertion of a feeding tube, anastomotic ulcer repair, mi nor intes tinal resections 
≤10cm, and endoscopic procedures are allow ed.
5.Intestinal or other major surgery planned or scheduled to occur during the 28 -week cycle.
6.Clinically significant intestinal stricture or obstruction.
7.Clinically significant, active or recurren t pancreatic or biliary disease.
8.Active, severe, or unstable, clinically significant hepatic impairment or injury, including the following 
laboratory values at the pre- treatm ent visit:
a.Total bilirubin ≥2× upper limit of normal (ULN)
b.Aspartate aminotransferase (AST) ≥ 7 × ULN
c.Alanine aminotransferase (ALT) ≥7 × ULN
9.Renal dysfunction shown by [CONTACT_319406] (eGFR) below 
50mL/min/1.[ADDRESS_483165] repair, or patent ductus arteriosus (PDA) ligation.
11.Participation in a clinical study using an experimental drug (other than glutamine , Om egaven , or 
Smoflipid) within 3 months or 5.5 half -lives of the experimental drug, whichever is longer, prior to the 
pre-treatment visit and for the duration of the 28 -week cycle.
12.Treatment with analogs of glucagon -like peptide -1 (GLP -1), glucagon -like peptide -2 (GLP-2) (not 
including teduglutide), insulin -like growth factor -1 (IGF -1), or grow th hormone , within 3months
preceding the teduglutide pretreatment visit.
13.Treatment with octreotide or dipeptidyl peptidase 4 (DPP -4) inhibitors within [ADDRESS_483166] cumstance that in the investigator’s opi[INVESTIGATOR_319362], prevents completion of the study, or interferes with analysis of the study results.
Follow -up Period Escape Criteria: At the discretion of the investigator, the follow -up period may be interrupted 
and the subject may proceed directly to the pre -treatment visit, if ≥1 of the following criteria is met:
1.Increasing PS requirements follow ing teduglutide discontinuation
2.Deteriorating nutritional status ( eg, weight loss or growth failure) despi[INVESTIGATOR_319363].
3.Deteriorating fluid or electrolyte status despi[INVESTIGATOR_385944].
4.Severe diarrhea related to teduglutide discontinuation.
Maximum duration of subject involvem ent in the study:
A subject w ill be considered enrolled in the study once the subject has provided signed consent, and meet s all of 
the Study Inclusion Criteria . Subjects may participate in multiple NTT periods and/or multiple [ADDRESS_483167] has access (as needed) to teduglutide. 
The subject’s maxim um duration of participation is expected to be approximately [ADDRESS_483168] has not withdrawn early from the study for any reason 
prior to completing End of Study (EOS) visit.
Planned dura tion of no-teduglutide treatm ent periods : variable, depending on disease course 
Planned duration of the teduglutide pre -treatm ent visit: 1 to 21 days
Planned cycle duration : 28 weeks. Each cycle consists of 24 w eeks of teduglutide treatment followed 
by a 4-week follow -up period (no treatment)
Endpoints and statistical analysis: 
The safety population will consist of all enrolled subjects. The safety population will be used for both 
safety and efficacy analysis.
Efficacy Endpoints
Efficacy endpoints will be analyzed at the end of each teduglutide treatment period (Week 24 or end of treatment 
[EOT]), and at each study visit, relative to the baseline of the core study (TED -C14-006) and/or first exposure to 
teduglutide. The following efficacy endpoints will b e analyzed:
Reduction in PS volume of at least 20%
Absolute and relative change in PS volume
Com plete weaning off PS
Change in days per w eek of PS
Health Econom ics and Outcom es Research Endpoints 
Health economics and outcomes research endpoints will be a nalyzed at approximately 12 -week intervals 
(Weeks 12 and 24 of each teduglutide treatment cycle, and every 12 w eeks for subjects not on teduglutide), 
relative to the study baseline. The beginning of each treatment cycle (CxD1) will be an additional baselin e.
Change in Pediatric Quality of Life Inventory (PedsQL) score
Change in PedsQL Family Impact Module score
Change in PedsQL Gastrointestinal Symptoms Module Sub -Scales scores: 
Food and Drink Limits
Diarrhea 
For non-commercial use only
Shire CONFIDENTIAL Page 17
SHP633 -304 Protocol Am endment 2
Teduglutide 23 Mar 2017
Safety Endpoints 
The follow ing safety endpoints will be analyzed:
Adverse events
Vital signs, including temperature, heart rate, blood pressure
Laboratory safety data ( ie, clinical chemistry, hematology, and urinalysis)
Urine output
Stool output
Antibodies to teduglutide
Gastrointestinal -specific testing , including fecal occult blood testing a nd colonoscopy or sigmoidoscopy
Z-scores for w eight, height (or length), head circumference (up to 36 months of age), and body mass index
Statistical Methodology for Efficacy Analysis
No claims of statistical significance will be made; how ever, 95% confidence intervals will be provided, if 
applicable. Continuous variables, including those assessed on a discrete scale, will be summarized using 
descriptive statistics including nu mber of subjects, mean, median, standard deviation , maximum, and minimum. 
For categorical variables, statistical summaries will include number of subjects and percentages.
Statistical Methodology for Safety Analysis 
Safety data, including laboratory test s and vital signs assessments, will be summarized by [CONTACT_765]. AEs will also be 
collected and summarized. Descriptive statistics will be calculated for quantitative safety data as w ell as for the 
difference from baseline, if applicable. Frequency counts will be compi[INVESTIGATOR_78415].
Sample Size Justification 
As this is an extension study, the maximum number of subjects wasdetermined by [CONTACT_319435] -C14-006.
For non-commercial use only
Shire CONFIDENTIAL Page 18
SHP633 -304 Protocol Am endment 2
Teduglutide 23 Mar 2017
STUDY  SCHEDULE(S) 
Table 1-1: Schedule of Events Required for All Subjects 
PeriodScreening End of Study or Early Termination
Scr EOS/ET
Visit Type Site Site
Informed consent/assentaX
Study eligibility X
Demographics, medical historyb, SBS historycX
Dispense intake and output diaries X
Evaluate teduglutide treatment inclusion criteriadX
Adverse events X X
Concomitant medications and GI procedureseX X
Physical examination and vital signs, including weight X
Height and head circumferencefX
Review intake and output diariesg X
Record PS prescription and adjust as neededhX
Safety laboratory testsiX
PedsQL Generic Core Scale/ PedsQL Family Impact Module/ 
PedsQL Gastrointestinal Symptoms Module Sub -ScalesX
Antibodies to teduglutidejX
Fecal occult blood testingk(X)
Colonoscopy or sigmoidoscopyl(X)
Pregnancy testingm(X)
FOBT = fecal occult blood testing ;FOCBP = female of child -bearing potential; EOS =end of study; ET=early termination; 
GI=gastrointestinal; NTx= no treatment; 
PedsQL= Pediatric Quality of Life Inventory; PS=parenteral support; SBS=Short Bowel Syndrome; Scr =Screening.
Note: (X) denotes conditional requirement for a given assessment if the subject meets certain conditions per protocol.
aInformed Consent (and informed assent, if applicable) must be obtained prior to performing any study -related procedures; consent (and 
informed assent, if applicable) may be obtained anytime during the Week 28 (or EOS) visit for the TED -C14-[ADDRESS_483169] has any changes to the SBS history that had been collected at the baseline of the TED -C14-006, then the updated SBS 
history will be collected.
dSubjects who meet ≥[ADDRESS_483170], and 
parent or legal guardian agrees to proceed with teduglutide therap y (Table 1 -3).
eConcomitant GI procedures include (but are not limited to) endoscopy, radiographic studies, GI and liver biopsies and associa ted 
pathology results.
fHead circumference will be measured in subjects 36 months of age and younger.
gThe intak e diary should be completed daily for a minimum of 2 weeks prior to the EOS/ET visit. The output diary should be completed 
daily over a 48 -hour period of nutritional stability before the EOS/ET visit .
hPS adjustments should be made after review of any ava ilable intake and output diaries and the safety lab data according to the guidance 
for nutrition support adjustment provided in Appendix [ADDRESS_483171] of clinical chemistry, hematology, and urinalysis, with results pro cessed by a 
central laboratory. Urine specimen collection should be attempted as part of the safety labs, but lack of urinalysis w ill not constitute a 
protocol deviation.
jRequired for all teduglutide -exposed subjects
kFOBT should be performed on teduglutide -exposed subjects on an annual basis, approximately every 48 -60 weeks at a minimum.
lThe need for colonoscopy /sigmoidoscopy in response to a positive FOBT during a no -teduglutide treatment period is at the discretion of 
the investigator, but all teduglutide -exposed subjects will undergo colonoscopy /sigmoidoscopy after they have received the equivalent of 
2 treatment cycles (48 w eeks of study drug exposure), and subjects who continue to receive teduglutide will undergo 
colonoscopy /sigmoidoscopy at [ADDRESS_483172] 30 days after study drug 
discontinuation.
For non-commercial use only
Shire CONFIDENTIAL Page 19
SHP633 -304 Protocol Am endment 2
Teduglutide 23 Mar 2017
Table 1-2: Schedule of Events for Subjects Not Receiving Teduglutide 
Visit Number NTx
Visit Type Site
Visit FrequencyaEvery 12 weeks 
Window (days)b±[ADDRESS_483173] as neededgX
Safety laboratory testshX
PedsQL Generic Core Scale/PedsQL Family Impact Module/ 
PedsQL Gastrointestinal Symptoms Module Sub-ScalesX
Antibodies to teduglutidei(X)
Fecal occult blood testingjAnnually 
Colonoscopy or sigmoidoscopyk(X)
Serum samplelEvery 24 w eeks
FOBT = f ecal occult blood testing ; NTT = no -teduglutide treatment; PedsQL = Pediatric Quality of Life Inventory; 
PS= parenteral support ; TED = teduglutide .
Note: (X) denotes conditional requirement for a given assessment if the subject meets certain conditions per 
protocol.
aThe first NTx visit following the screening visit must occur w ithin [ADDRESS_483174] NTx visit in the current no -teduglutide treatment period.
cSubjects who meet ≥[ADDRESS_483175], and parent or guardian agree to proceed w ith teduglutide therapy ( Table 1 -3).
dConcomitant GI procedures include (but are not limited to) endoscopy, radiographic studies, GI and liver biopsies 
and associated pathology results.
eHead circumference will be measured in s ubjects [ADDRESS_483176] actual PS volume and hours per day, completed daily for a minimum of 2 w eeks prior to 
each study visit ( see Section [IP_ADDRESS] ). Urine and stool output should be recorded in the output diary over a 48 -hour 
period of nutritional stability before every clinic visit ( see Section [IP_ADDRESS] for more detail).
gPS adjustments should be made after review of the intake and output diaries and the safety lab data according to 
the guidance for nutrition support adjustment provided in Appendix [ADDRESS_483177] follow -up 
samples collected every 12 weeks during the study until a negative result is obtained.
jFOBT should be performed on teduglutide- exposed subjects on an annual basis, approximately every 48 -60 w eeks 
at a minimum.
kThe need for colonoscopy /sigmoidoscopy in response to a positive FOBT during a no -teduglutide treatment period 
is at the discretion of the investigator, but all teduglutide -exposed subjects w ill undergo colonoscopy /sigmoidoscopy
after they have received the equiv alent of 2 treatment cycles (48 w eeks of study drug exposure) and subjects who 
continue to receive teduglutide w ill undergo colonoscopy /sigmoidoscopy at 5 year intervals or more often as 
needed. See Section 7.2.9 for details.
lLack of collection of serum samples will not constitute a protocol deviation.
For non-commercial use only
Shire CONFIDENTIAL Page 20
SHP633 -304 Protocol Am endment 2
Teduglutide 23 Mar 2017
Table 1-3: Schedule of Events for Subjects While Receiving Teduglutide
PeriodPre-
treat mentTeduglutide Treat mentFollow -
up
Visit Number Pxa Cx
D1Cx
W1Cx
W2
Phone contact [CONTACT_319408] [ADDRESS_483178] is required approximately 1 week after PS adjustmentCxW24 
(EOT)CxW25 
CxW26 
CxW27CxW28c
Visit Type Site Site Site Site Site Site Site Site Site Site Site PhonebSite
Cycle Day -21 to 0 1 8 15 29 43 64 85 113 141 169176
197 183
190
Window  (days)d-21 to 0 ±2 ±2 ±2 ±2 ±4 ±4 ±4 ±4 ±4 ±2 ±2
Evaluate teduglutide 
eligibility (inclusion 
and exclusion) criteriaX Xe
Dispense intake and 
output diariesX X X X X X X X X X X X
Adverse events X X X X X X X X X X X X X
Concomitant 
medications and GI
proceduresfX X X X X X X X X X X X X
Physical examination 
and vital signs, 
including weightX X X X X X X X X X X X
Height and head 
circumferenceg X X X X
Review intake and 
output diariesh X X X X X X X X X X X X X
Record PS Rx and 
adjust as neededi X X X X X X X X X X X X X
Safety laboratory testsjXjX X X X X X X X X X (X) X
PedsQL Generic Core 
Scale/ Family Impact 
Module/ GI 
Symptom s Module 
Sub-ScalesX X X
Antibodies to 
teduglutidek X X X X
Fecal occult blood 
testingX X X
Colonoscopy /
sigmoidoscopyl (X) (X) (X)
Pregnancy testingmX X X X X X X X X
For non-commercial use only
Shire CONFIDENTIAL Page 21
SHP633 -304 Protocol Am endment 2
Teduglutide 23 Mar 2017
Table 1-3: Schedule of Events for Subjects While Receiving Teduglutide
PeriodPre-
treat mentTeduglutide Treat mentFollow -
up
Serum samplenX X
Evaluate escape 
criteriao X X
Dispense study drugpX X X X X X X X X
EOS =end of stu dy; EOT = end of treatment; ET = early termination; FOBT = fecal occult blood test; FOCBP = female of child -bearing potential; FU= follow -up; GI = 
gastrointestinal; PedsQL = Pediatric Quality of Life Inventory; PS= parenteral support; SBS =Short Bowel Sy ndrome; SC = subcutaneous; Scr =Screening; TED = teduglutide; 
Tx = treatment.
Note: (X) denotes conditional requirement for a given assessment if the subject meets certain conditions per protocol.
aIf the first pre-treatment visit (P1) follows the screening visit, it must occur within 12 weeks of screening.
bPhone visits are required approximately 1 week after adjustments in PS. The assessments to be performed at phone visits are t he same as those described for CxW25 -27 (except 
for evaluation of es cape criteria). 
cThe investigator may combine the CxW28 visit with the next pre-treat ment visit if at least one escape criterion is met at the CxW28 visit, and the pre-treat ment assessments occur 
within [ADDRESS_483179] is completi ng the study at the CxW28 visit, the EOS/ET visit (Table 1-1) will take place in li eu of the CxW28 visit .
dVisit windows are relative to the CxD1 visit.
eEligibility will need to be re -confirmed prior to the first dose in the cycle. Negative urine pregnancy test is required prior to the first dose of teduglutide, but results of other labs 
obtained at the CxD1 visit are not required to determine teduglutide treatment eligibility.
fConcomitant GI procedures include (but are not limited to) endoscopy, radiographic studies, GI and liver biopsies and associated pathology results.
gHead circumference will be measured in subjects [ADDRESS_483180] actual PS volume and hours per day. Intake d iaries should be completed daily for a minimum of 2 weeks immediately prior to each clinic visit  (except 
at pre-treatment visit),  for [ADDRESS_483181] PT/INR a t the pre -treatment 
visit. Additional collection will occur if a potential drug -induced liver injury signal is observed. Urine specimen collection should be attempted as part of the safety labs, but lack 
of urinalysis will not constitute a protocol deviati on.
kSamples collected on CxD1 must be drawn prior to first administration of teduglutide. Samples collected while subjects are re ceiving teduglutide (CxW12 and CxW24) must be 
drawn at least 14 hours after dosing.
lThe teduglutide -
naïve subjects age 12 and older will undergo colonoscopy /sigmoidoscopy at the pre -treatment visit if one has not been performed within 1 year. Subjects of any 
age with newly positive FOBT results at the pre -treatment visit for which a readily detectable cause cannot be identifi ed (eg, anal fissure) will undergo a 
colonoscopy /sigmoidoscopy prior to receiving teduglutide. If newly positive FOBT results (for which a readily detectable cause cannot be identified) ar e obtained at the end of a 
teduglutide treatment cycle (CxW24/EOT), colonoscopy /sigmoidoscopy will be performed. The need for colonoscopy /sigmoidoscopy in response to positive FOBTs at CxW12 is 
at the discretion of the investigator. Teduglutide -exposed subjects who have received the equivalent of 2 treatment cycles (48 weeks of study drug exposure) will undergo 
For non-commercial use only
Shire CONFIDENTIAL Page 22
SHP633 -304 Protocol Am endment 2
Teduglutide 23 Mar 2017
Table 1-3: Schedule of Events for Subjects While Receiving Teduglutide
PeriodPre-
treat mentTeduglutide Treat mentFollow -
up
colonoscopy /sigmoidoscopy. See Section 7.2.[ADDRESS_483182] is performed on all FOCBP at the teduglutide pre -treatment visit (when the pre -treatment and screening visits are combined, the serum pregnancy test 
should be performed at the local laboratory) . Urine pregnancy tests will be administered at all other visits according to the study schedules, or if pregnancy is suspected, or as 
specified per protocol upon withdrawal of the subject from the study .
nLack of collection of serum samples will not constitute a protocol deviation .
oIf escape criteria are met, the subject may proceed directly to another pre -treatment visit at the discretion of the investigator.
pThe first SC injection of teduglutide in treatment-naïve subjects will be administered under the supervision of the investigator/designee after which the subject will be observ ed 
for hypersensitivity reactions for at least 4 hours. The site of administration (arm, thigh, abdomen) o f the first teduglutide dose must be specified and recorded in the eCRF . See 
Section 6.2.3 for dose adjustment.
For non-commercial use only
Shire CONFIDENTIAL Page 23
SHP633 -304 Protocol Am endment 2
Teduglutide 23 Mar 2017
1BACKGROUND INFORMATION
1.1 Indication and Current Treatment Options 
Short bowel sy ndrome (SBS) is a rare disorder resulting from congenital abnormalities or severe 
intestinal diseases that result in major surgical resections of the small intestine. I t is estimated 
that, at most, there are a few hundred pediatric subjects 1 y ear and older with SBS (Khan et al., 
2015; Wales et al., 2004 ) .Unlike the adult population, the majority  of cases of SBS in pediatric 
subjects are due to congenital anomalies or catastrophic events that occur during infancy . 
Although t he small intestine is capable of remarkable adaptation, excessive loss of absorptive 
surface area or specialized functions can lead to dependence on parenteral nutrition or 
intravenous (IV) fluids (parenteral support [PS]). Treatment of both pediatric and adult patients 
is focused on achieving adequate intestinal absorption to allow for minimization or 
discontinuation of PS. About 30% of infants with SBS become independent of PS requirements 
within12months of the initial insult , and an additional 10% wean off PS within 24 months. 
After this time, linear intestinal growth slows. About 60% of pediatric subjects with SBS are able 
to become independent of PS within 5 y ears of the initial diagnosis (Khan et al., 2015). 
Nevertheless, despi[INVESTIGATOR_385945] l management, many  pediatric subjects remain dependent 
on PS. Complications of long -term PS include liver disease, catheter -related blood stream 
infections, central line- associated venous thrombosis and dwindling central venous access. 
Sepsis is the leadin g cause of death in these patients and quality  of life is poor (Squires et al., 
2012). Accelerating the adaptive process and achieving enteral autonomy  is an urgent goal for all 
patients with SBS who are dependent on PS (Khan et al., 2015 ;Squires et al., 2012 ).
Intestinal adaptation is driven by  [CONTACT_319436] (Drucker 
and Yusta, 2014 ).Chief among these is hormones glucagon -like peptide 2 (GL P-2), which is 
secreted from L -type enteroendocrine cells that reside in the intestinal epi[INVESTIGATOR_319365]. Re section of these regions may  impair the adaptive response b y limiting endogenous 
production of GLP -2. 
1.[ADDRESS_483183] Background 
Teduglutide is a novel, re combinant analog of naturally occurring human GLP -2 that regulates 
the functional and structural integrity  of the cells lining the gastrointestinal (GI) tract. 
Teduglutide is a 33 -amino acid peptide that differs from native GLP- 2 in the substitution of 
glycine for alanine at the second position at the N -terminus. As a result, teduglutide demonstrates 
resistance to degradation by  [CONTACT_20597] l peptidase- IV (DPP -4) and therefore maintains a longer 
elimination half -life (t 1/2) in adults of approximately  2 hours c ompared to the native peptide, 
which has a t 1/2 of approximately  7 minutes. Teduglutide has been shown in animal studies and 
previous human clinical trials to increase villus height and cry pt depth in the intestinal 
epi[INVESTIGATOR_2130], thereb y increasing the absor ptive surface area of the intestines ( Tappenden et al., 
2013; Thymann et al., 2014 ). The European Commission granted a centralized marketing 
authorization valid throughout the European Union (EU) for teduglutide (Revestive™) on [ADDRESS_483184] 2012 and a New Drug Application (NDA) for teduglutide (Gattex®) was approved b y the 
[LOCATION_002] (US) Food and Drug Administration (FDA) on 21 Decem ber2012 for the 
treatment of adult patients with SBS who are dependent on PS. Teduglutide has also been 
approved for use in adult patients with SBS in Canada and Switzerland. On 29 Jun 2016, the 
For non-commercial use only
Shire CONFIDENTIAL Page 24
SHP633 -304 Protocol Am endment 2
Teduglutide 23 Mar 2017
European Commission granted an extension of the Market Autho rization for teduglutide 
(REVESTIVE ™) for the treatment of patients a ged 1 y ear and above with SBS; patients should be 
stable following a period of intestinal adaptation.
1.3 Clinical Studies with Teduglutide in Pediatric Subjects
One Phase 3 stud y, TED -C13-003, was completed in pediatric SBS subjects in the US and 
[LOCATION_008] ([LOCATION_006]). In this study , teduglutide was administered to 3 cohorts of pediatric 
subjects from age s 1-17. Thirty -seven pediatric subjects received teduglutide at doses of 0.0125, 
0.025, or 0.05 mg/kg/day for [ADDRESS_483185] of care (SOC) cohort. There were clear dose -dependent effects of 
teduglutide seen at the 0.025 and 0.05 mg/kg/day  doses compared to SOC and the 0.0125 
mg/kg/day  dose. In the 0.025 mg/kg/day  cohort there was a reduction in PS volume at Week 12 
of 37%, including complete independence from PS support in [ADDRESS_483186], and a reduction of 3.94 
hours per day  infusion time. I n the 0.05 mg/kg/day  cohort there was a reduction in PS volume at 
Week 12 of 39%, including complete independence from PS support in 3 subjects, and a 
reduction of 4.18 hours per day  infusion time. Teduglutide was generally  safe and well tolerated 
by [CONTACT_385953]. There were no deaths during the study  and no 
treatment -emergent serious adverse events (TESAEs) related to teduglutide were reported. No 
discontinuations from study  were due to adverse events (AEs).
TED -C14-006 is an ongoing study  which includes 2 treatment arms: a teduglutide treatment arm 
and a standard of care treatment arm. Subjects in both arms participate in a [ADDRESS_483187] medical therap y for SBS; while 
those in the teduglutide treatment arm will receive daily  subcutaneous (SC) injections of 
teduglut ide (stud y drug) in addition to standard medical therap y. The subjects enrolling in the 
teduglutide treatment arm will be randomized 1:1 in a double
-blinded manner into 2 parallel dose 
groups: 0.025 mg/kg/day or 0.05 mg/kg/day  of teduglutide administered subcutaneousl y for [ADDRESS_483188] version of the investigator’s brochure for the overall risk/benefit 
assessment and the most accurate and current information regarding the drug metabolism, 
pharmacokinetics, efficacy  and safet y of ted uglutide (SHP633). 
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_483189]- time treatment of teduglutide -naïve subjects who participated in the 
SOC treatment arm in TED -C14-006.
2.2 Study Objectives
2.2.1 Primary Objectives
The primary  objective of the study  is to evaluate the long -term safet y and tolerability of 
teduglutide treatment in pediatric subjects with SBS who completed TED -C14-006.
2.2.2 Secondary Objectives
The secondary  objective of this study  is to evaluate the long -term efficacy  of teduglutide 
treatment in pediatric subjects with SBS who completed TED -C14-006.
For non-commercial use only
Shire CONFIDENTIAL Page 26
SHP633 -304 Protocol Am endment 2
Teduglutide 23 Mar 2017
3STUDY DESIGN
3.1 Study Design and Flow Char t
This is a Phase 3, prospective, open -label, long -term extension study  to evaluate the safet y and 
efficacy  of teduglutide in pediatric subjects who completed the TED -C14-006 study  (core stud y). 
At the time of entry  into the TED- C14-[ADDRESS_483190] 30% of their caloric or fluid needs, and had 
not been able to significantly  reduce PS for at least 3 months prior to enrollment. During the core 
study , pediatric subjec ts in the teduglutide treatment arm were randomized to 0.025 mg/kg or 
0.05 mg/kg once daily  (QD) dosing in a double -blinded manner. The TED -C14-[ADDRESS_483191] meet ≥1 of the teduglutide treatment inclusion 
criteria and none of the teduglutide treatment exclusion criteria.
Additional Teduglutide Treatment
Subjects not receiving teduglutide treatment ( ie, in a “no -teduglutide treatment period”), will be 
seen approximately  every 12 weeks for safety , parenteral support (PS) requirements, and qualit y 
of life. At an y point during a no -teduglutide treatment period, subjects who meet ≥[ADDRESS_483192], 
and parent agree to proceed with teduglutide therapy .
Rationale: Some pediatric subjects may  have a durable beneficial effect after 24 weeks of 
teduglutide treatment and thus long-term follow -up without additional teduglutide treatment may  
be appropriate. However, there may  be some pediatric subjects who deteriorate or stop 
improving after discontinuation of teduglutide treatment. I n these pediatric subjects, additional 
teduglu tide treatment may  be beneficial. 
Dose Selection 
Analy sis suggested that pediatric patients, ages 1 to 17 y ears old, are likel y to require the same 
dose as used in adults, namely  0.05 mg/kg/day (Mouksassi et al., 2009 ).In this extension study  
to TED -C14-006, repeat doses of teduglutide 0.05 mg/kg QD will be administered to eligible 
pediatric subjects who previously  received teduglutide 0.05 or 0.025 mg/kg in Study  TED -C14-
006.
Rationale: Teduglutide is approved for adult use in the USand EU, and for pediatric use in the 
EU,at a dose of 0.05 mg/kg SC once daily . The completed 12 -week pediatric study  (TED -C13-
003) demonstrated that teduglutide dosing at 0.025 and 0.05 mg/kg/day  was associated with a 
favorable benefit/risk profile. In addition, population pharmacokinetic modeling and simulations 
were conducted to determine the effective dose to be used in pediatric sub jects using data from 
8adult clinical studies including adult Phase 1 studies and Phases 2/3 studies as well as the 
pediatric stud y (TED -C13-003) and suggested that the dose in pediatric subjects is likely  to be 
same as the dose in adults
(O'Keefe et al., 2006 ).
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_483193] may  be evaluated immediately  for 
additional teduglutide treatment. Subjects who clinically  deteriorate or stop improving at any  
time after the end of the follow- up period will also be assessed for additional treatment.
Rationale: During the teduglut ide treatment cy cle, visit frequency  is similar to frequencies 
performed in TED -C13-[ADDRESS_483194] medical practices.
Measures and Parameters
Following the review and signing of the informed consent (and informed assent, if applicable), 
screening visit procedures will begin including demographics, and updates to medical history
and SBS history . Subjects who meet 
≥1 of the teduglutide treatment inclusion criteria may 
proceed to the pre -treatment visit.
Afterthe pre -treatment visit, subjects who still meet ≥1 of the teduglutide treatment inclusion 
criteria, and meet none of the teduglutide treatment exclusion criteria, will start a 28 -week cy cle, 
consisting of 24 weeks of teduglutide treatm ent at 0.05 mg/kg SC once daily , followed by  a 4-
week follow -up (no treatment) period ( Figure 3-1). During the 28 -week cycle, clinic visits wi ll 
occur at weeks 1, 2, 4, 6, 9, 12, 16, 20, 24, and 28. Phone visits are required approximately  
1 week after adjustments in PS during the teduglutide treatment period ( between weeks 1-24), 
and weekl y during the teduglutide follow -up period (between weeks 24 and 28 ).
Safety  and PS requirements will be evaluated on a weekl y basis, and quality of life assessments 
will be made approximately  every  12 weeks. At all site visits and telephone contacts, safety  will 
be monitored and nutritional support will be reviewed and adjusted as needed. To maintain 
consistency  across centers, all attempts should be made to follow the nutritional support 
adjustment guidelines (developed with SBS expert input and provided in the protocol) for 
decisions regarding PS reduction and advances in enteral feeds based on weight gain, urine and 
stool output, and clinical stability . Departure from the guidelines, however, is not considered a 
protocol deviation ( Appendix 2 ).
Rationale: Measures of long term safet y will include adverse events , growth parameters and anti -
drug antibodies. Measure of long term efficacy  will include durability  of effect as measured b y 
reduction in PS and improvement in pediatric quality  of life measures (PedsQL , PedsQL Family  
Impact Module). A reduction in PS volu me of at least 20% at end of treatment ( EOT) was used 
as the primary  endpoint in pi[INVESTIGATOR_30338] 3 adult clinical trials and the completed phase 3 
pediatric stud y (TED -C13-003), and will be used as an endpoint in this extension study . In 
previous clinical studies, a reduction of this magnitude was associated with a reduction in the 
number of day s per week of PS, and increases in enteral intake. Reduction in volume and time of 
PS due to improved enteral absorption may  provide a pediatric subject with opportuni ties for 
more age -appropriate activities including oral rehabilitation. Quality  of life assessments will be 
performed in this study  to quantitate this effect.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_483195] of teduglutide, GI -specific screening tests, 
including fecal occult blood testing and colonoscopy /sigmoidoscopy , which are commonl y part 
of the routine care of these subjects, will be performed to ensure safet y. This study  captures long -
term safet y data on polyps and other colonic mucosal changes in teduglutide -exposed subjects 
using the surveillance strategy  proposed in Section 7.2.9 . 
Figure 3-1: Study Design Flow Chart
Figure legend: Safety and efficacy data for subjects not receiving teduglutide treatment are captured approximately every 
12weeks, but subjects may proceed to the pre -treatment visit at any time in order to assess eligibility for teduglutide therapy. 
Eligible subjects will enter a 28 -week teduglutide cycle. During this cycle, subjects will return to the site for safety and efficacy 
assessments at weeks 1, 2, 4, 6, 9, 12, 16, 20, and 24 ( solid black lines ). Phone visits are required approximate ly 1 week after 
adjustments in PS during the intervening weeks between weeks 2 and 24 ( dashed grey lines ). Subjects discontinue teduglutide at 
week 24 and enter a 4 -week follow-up (no -treatment) period, during which phone visits will be performed weekly ( solid grey 
lines ). If an escape criterion is met during the follow -up period, subjects may proceed directly to another pre -treatment visit.
3.[ADDRESS_483196]’s maximum duration of participation is 
expected to be approximately  [ADDRESS_483197] has not withdrawn 
early from the stud y for any re ason prior to completing the End of Study  (EOS) visit.
The study  completion date is defined as the date the final subject, across all sites, completes their 
final protocol -defined assessment. Please note that this includes the follow -up visit or contact 
(last safet y contact), whichever is later. The stud y completion date will be used to ascertain 
timing for study  results posting and reporting.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_483198] review and sign the informed consent (and informed assent, if applicable) 
before an y stud y-related procedures specified in the protocol are performed. Teduglutide 
treatment eligibility  does not impact study  eligibility .
4.[ADDRESS_483199] will not be considered eligible for the study  without meeting all of the criteria below:
1. Subject provides written informed consent (subject, parent or legal guardian and, as 
appropriate, subject informed assent) to participate in the study  before completing any  
study -related procedures. 
2. Subject completed the TED- C14-006 study  (including subjects in the standard of care 
treatment arm).
3. Subject understands and is willing and able to fully  adhere to study  requirements as 
defined in this protocol.
4.[ADDRESS_483200] 1 ( ≥1) of the teduglutide treatment 
inclusion criteria, and none of the teduglutide treatment exclusion criteria aremet. In addition, 
the investigator an d the subject (and/or parent or legal guardian, as appropriate) must agree to 
proceed with treatment.
4.[ADDRESS_483201] is teduglutide -naïve, receiving PS, and unable to significantl y reduce PS or 
advance enteral feeds ( eg, 10% or less change in PS or advance in feeds) for at least 
3months prior to and during the teduglutide pre -treatment visit, as assessed by  [CONTACT_1275]. Transient instability  for events such as interruption of central access or 
treatment for sepsis is 
allowed if the PS returns to within 10% of baseline prior to the 
event.
2.Subject was previousl y treated with teduglutide and at least 1 of the following criteria is 
satisfied :
a.Increasing PS requirements following teduglutide discontinuation.
b.Decreased PS requirement during prior teduglutide treatment, followed by  
[CONTACT_319412].
c.Deteriorating nutritional status eg, weight loss or growth failure) despi[INVESTIGATOR_385946].
d.Deteriorating fluid or electroly te status despi[INVESTIGATOR_319367].
e.Severe diarrhea related to teduglutide discontinuation.
For non-commercial use only
Shire CONFIDENTIAL Page 30
SHP633 -304 Protocol Am endment 2
Teduglutide 23 Mar 2017
4.5 Teduglutide Treatment Exclusion Criteria
1.Body weight <[ADDRESS_483202]
3.History  of cancer in the previous 5 y ears except surgically  curative skin cancers
4.Serial transverse enteroplasty  or other major intestinal surgery  within 3 months 
preceding the teduglutide pre -treatment visit. I nsertion of a feeding tube, anastomotic 
ulcer repair, minor intestinal resections ≤10 cm, and endoscopic procedures are allowed.
5.Intestinal or other majo r surgery  planned or scheduled to occur during the 28 -week cy cle
6.Clinically  significant intestinal stricture or obstruction
7.Clinically  significant, active or recurrent pancreatic or biliary  disease
8.Active, severe, or unstable, clinically  significant hepatic impairment or injury , including 
the following laboratory  values at the pre -treatment visit:
a.Total bilirubin ≥2× upper limit of normal (ULN)
b.Aspartate aminotransferase (AST) ≥7 × ULN
c.Alanine aminotransferase (ALT) ≥7 × ULN
9.Renal dy sfunction shown by  [CONTACT_385975] (eGFR) 
below 50 mL /min/1.[ADDRESS_483203] repair, or patent ductus 
arteriosus (PDA) ligation
11.Participation in a clinical study  using an experimental drug (other than glutamine , 
Omegaven , or Smoflipid ) within 3 months or 5.5 half- lives of the experimental drug, 
whichever is longer, prior to t he pre -treatment visit and for the duration of the 28-week 
cycle
12.Treatment with analogs of glucagon -like peptide -1 (GL P-1), glucagon -like peptide -2 
(GLP-2) (not including teduglutide), insulin -like growth factor -1 (IGF -1), or growth 
hormone , within 3month s preceding the teduglutide pretreatment visit.
13.Treatment with octreotide or dipeptidy l peptidase 4 (DPP -4) inhibitors within [ADDRESS_483204], 
closely-related compounds, or any  of the stated ingredients
15.Known history  of alcohol or other substance abuse within 1year prior to the pre -
treatment visit
16. Pregnant or lactating female subjects 
17.Sexually  active female subjects of child -bearing potential unwil ling to use approved 
contraception during teduglutide treatment and for 30 day s after the treatment period 
For non-commercial use only
Shire CONFIDENTIAL Page 31
SHP633 -304 Protocol Am endment 2
Teduglutide 23 Mar 2017
18.Any condition, disease, illness, or circumstance that in the investigator’s opi[INVESTIGATOR_319368] y undue risk, prevents completion of the s tudy, or interferes with 
analysis of the study  results.
4.[ADDRESS_483205] may  
proceed directl y to the pre -treatment visit, if ≥1of the following criteria is met:
1.Increasing PS requirements following teduglutide discontinuation .
2.Deteriorating nutritional status (eg, weight loss or growth failure) despi[INVESTIGATOR_319369] .
3.Deteriorating fluid or electroly te status despi[INVESTIGATOR_319370] .
4. Severe diarrhea related to teduglutide discontinuation.
4.[ADDRESS_483206]. 
To be eligible for treatment with teduglutide, female pediatric subjects and adolescent subjects 
should be either:
Pre-menarchal and either Tanner Stage 1 or less than age 9 years, or
Females of child -bearing potential (FOCBP) with a negative serum beta- human chorionic 
gonadotropin ( -HCG) pregnancy  test at the teduglutide pre -treatment visit .Females of 
child- bearing potential must agree to abstain from sexual activity that could resul t in 
pregnancy  or agree to use acceptable methods of contraception.
Acceptable methods of contraception are:
True abstinence : Abstention of sexual activity  that is in line with the preferred and usual 
lifesty le of the subject. (Periodic abstinence [eg, calendar, ovulation, sy mptothermal, 
post-ovulation methods] and withdrawal are not acceptable methods of contraception).
Intrauterine devices plus condoms
Double- barrier methods ( eg, condoms and diaphragms with spermicidal gel or foam)
For non-commercial use only
Shire CONFIDENTIAL Page 32
SHP633 -304 Protocol Am endment 2
Teduglutide 23 Mar 2017
Hormonal contraceptives (oral, depot, patch, injectable, or vaginal ring), stabilized for at 
least 30 day s prior to the pre -treatment visit, plus condoms. Note: if subject becomes 
sexually  active during the study , they  should use one of the other acceptable methods 
noted above in addition to the hormonal contraceptive until it has been stabilized for 
30days.
4.[ADDRESS_483207] w ishes to remain in the study , the evaluations listed for the EOT visit are to be 
performed. A 4-week follow -up period will ensue, consisting of weekl y telephone visits 
(CxW25 -27) and the week 28 clinic visit (CxW28). The subject would then enter a 
no-tedug lutide treatment ( NTT ) period and could be evaluated for subsequent teduglutide 
treatment eligibility  according to the study  schedules. Comments (spontaneous or elicited) or 
complaints made by  [CONTACT_1706]. The reaso n for 
permanent treatment discontinuation, dates of investigational product administered (including 
last date of treatment), and amount of investigational product taken must be recorded in the 
electronic case report form (eCRF) and source documents, as des cribed in Section 4.8.3. The 
investigator is encouraged to discuss withdrawal of a subject from investigational product with 
the medical monitor, when possible.
4.8.[ADDRESS_483208] will 
then be asked to return 4 weeks later for the earl y termination (ET) visit, and will be contact[CONTACT_319413] y by [CONTACT_385976] y follow -up.
If a subject withdraws from the study  during a NTT period, the evaluations listed for the ET visit 
are to be performed as soon and completel y as possible. 
Subjects who withdraw from the study will not be replaced.
4.8.3 Reasons for Discontinuation
The reason(s) for permanent discontinuation of treatment and/or withdrawal from the study  must 
be determined b y the investigator, and recorded in the subject’s medical record and in the eCRF. 
If a subject is withdrawn for more than [ADDRESS_483209] clinically  relevant reason should be entered in the eCRF.
Reasons for discontinuation include, but are not limited to:
Adverse event 
Protocol deviation
For non-commercial use only
Shire CONFIDENTIAL Page 33
SHP633 -304 Protocol Am endment 2
Teduglutide 23 Mar 2017
Lack of efficacy  
Physician decision 
Withdrawa l by [CONTACT_1130] 
Withdrawal by  [CONTACT_7078]/guardian
Lost to follow -up
Pregnancy  (Discontinuation of treatment onl y) 
Death 
Other 
[IP_ADDRESS] Subjects ‘Lost to Follow -up’ Prior to Last Scheduled Visit
A minimum of [ADDRESS_483210] (office visit or telephone contact). At least [ADDRESS_483211]’s last 
known address via courier or mail (with an acknowledgement of receipt request) asking that they  
return to the site for final safet y evaluations, and return an y unused investigational product.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_483212] be recorded on the appropriate eCRF 
page. Concomitant treatments will be asses sed at each site visit, and include all non -study  
treatments (medications, herbal treatments, vitamins, invasive and diagnostic procedures). 
Concomitant GI  procedures include (but are not limited to) endoscopy , radiographic studies, GI 
and liver biopsies a nd associated pathology  results. Concomitant treatment information must be 
recorded on the appropriate eCRF page. Details of medication changes and/or dosages will be 
recorded on the eCRF.
The mechanism of action of teduglutide may  increase absorption of d rugs ( eg, motility  
medication including narcotics and opi[INVESTIGATOR_20574], warfarin, 
psychotropi[INVESTIGATOR_1102], metronidazole, and digoxin). Accordingl y, due consideration should be given to 
modify ing concomitant medication regimens. Down -titration of concomitant medications should 
be considered when drugs, especiall y those with a narrow therapeutic range, are prescribed at 
dosages that are higher than usual.
5.1.[ADDRESS_483213] medical therapy for SBS should be continued.
5.1.2 Prohibited Treatment
The mechanism of action of teduglutide may  increase enteral absorption of drugs ( eg, motility  
medication including narcotics and opi[INVESTIGATOR_20574], warfarin, 
psychotropi[INVESTIGATOR_1102], metronidazole, digoxin), so consideration should be given to modify ing 
concomitant enteral medication regimens. Down -titration of concomitant enteral medications 
should be considered when drugs, especially  those with a narrow therapeutic range, are given at 
dosages that are higher than usual.
The following medications are prohibited during teduglutide treatment and within the provided 
timeframe prior to the pre -treatment visit:
Table 5-1: Prohibited Treatment
Prior Therapy Time Restriction Prior to 
the Pre -Treatment Visit
Native/synthetic glucagon -like peptide -2 (not -including teduglutide) Any
Glucagon-like peptide- 1 analog or human growth hormone 3month s
Octreotide or dipeptidyl peptidase 4 inhibitors 3 months
Biological therapy ( eg, antitumor necrosis factor) [ADDRESS_483214] is teduglutide, which will be provided in sterile, single -use 3 mL  vials 
containing 5 mg or 1.25 mg teduglutide as a white lyophilized powder to be reconstitut ed before 
use with 0.5 mL  sterile water for injection. In addition to the active ingredient (teduglutide), each 
vial of teduglutide contains L -histidine, mannitol, monobasic sodium phosphate monohy drate, 
and dibasic sodium phosphate as excipi[INVESTIGATOR_840]. Addition al information is provided in the current 
SHP633 i nvestigator’s brochure.
6.1.[ADDRESS_483215](s)
6.2.[ADDRESS_483216] M anagement
An interactive web -based response s ystem (IWRS) will be used for screening and enrolling 
subjects, recording subject visits, investigational product supply dispensation and management, 
inventory  management and supply  ordering, investigational product expir ation tracking and 
management, and return of investigational product. Please refer to the Study Manual for 
additional details regarding the IWRS. 
The I WRS will also be used for creating, tracking, and confirming investigational product 
shipments. A user m anual with specific functions and instructions for the IWRS will be provided 
to the site, and site personnel will receive training.
6.2.[ADDRESS_483217], and/or parent/guardian agree 
to proceed with treatment, a formal evaluation of teduglutide inc lusion and exclusion criteria will 
be performed at the pre -treatment visit ( Table 1-3 ). 
6.2.[ADDRESS_483218] will start a teduglutide treatment period, consisting of 24 weeks of 
teduglutide treatment at 0.05 mg/kg SC once daily. The initial dose will be calculated based on 
body  weight measured at the teduglutide pre -treatment visit, and adjusted as needed, based on 
body  weight measured at Week 12 (CxW12). No other adjustments to dose will be made during 
the teduglutide treatment period, unless discussed with the sponsor’s medical monitor. 
Following reconstitution, teduglutide will be administ ered b y SC injection QD into 1 of the 
4 quadrants of the abdomen (in subjects without a stoma) or into either the thigh or arm. For 
subjects with a stoma, the quadrant of the abdomen containing the stoma should not be used. 
Teduglutide should be used as so on as possible after reconstitution, but no more than [ADDRESS_483219] 
4 hours during their initial dosing visit. The site of administrati on (arm, thigh, and abdomen) of 
the first teduglutide dose must be specified and recorded in the eCRF. 
Detailed instructions for reconstitution and injection of the investigational product can be found 
in the I nstructions for Use. 
Following each [ADDRESS_483220] may  proceed 
directly  to another Pre -Treatment visit to assess treatment eligibility  for another cy cle 
(Section 4.6). Following the completion of the 4- week follow -up, the subject will continue in the 
study  off teduglutide. Additional [ADDRESS_483221](s) container. 
The study  drug will be packaged, labeled, and shipped to the study  site by  [CONTACT_98634]. Kits containing [ADDRESS_483222] is packaged in the following conditions:
Teduglutide will be provided in a sterile, single -use, glass vial as a ly ophilized powder, to be 
reconstituted with 0.[ADDRESS_483223] be kept in a locked area with access restricted to specific study  personnel. Study  
drug will be stored refrigerated at a temperature between 2 to 8°C (35.6 to 46.4°F) until 
dispensed to a subject. Once dispensed to a subject, the study  drug can be stored refrigerated or 
up to a controlled room temperature (acceptable range of 2 to 25°C, or 35.6 to 77°F). 
Parent/guardian will be instructed to keep the subject’s stud y drug and sterile water diluent at 
controlled room temperature. If there are concerns that the controlled room temperature cannot 
be maintained, the stud y drug may  be refrigerated. The study  drug is for single use only , and 
should be used within [ADDRESS_483224] is maintained within an established temperature range. The investigator is responsible 
for ensuring that th e temperature is monitored throughout the duration of the study  and that 
records are maintained; the temperature should be monitored continuously  by [CONTACT_3570]-house sy stem, a mechanical recording device such as a calibrated chart recorder, or by  [CONTACT_10179], such that both minimum and maximum thermometric values over a specific time period 
can be recorded and retrieved as required. Such a device ( ie, certified min/max thermometer) 
would require manual resetting upon each recording. The sponsor mus t be notified immediately  
upon discovery  of any  excursion from the established range. Temperature excursions will require 
site investigation as to cause and remediation. The sponsor will determine the ultimate impact of 
excursions on the investigational pr oduct and will provide supportive documentation as 
necessary . Under no circumstances should the product be dispensed to subjects until the impact 
has been determined and the product is deemed appropriate for use b y the sponsor.
The sponsor should be notifi ed immediately  if there are an y changes to the storage area of the 
investigational product that could affect the integrity  of the product(s), eg, fumigation of a 
storage room.
Investigational products are distributed b y the pharmacy or nominated member of the study  
team. The pharmacist/nominated team member will enter the unique subject identifier on the 
investigational product bottle/carton labels, as they are distributed. 
6.[ADDRESS_483225] will be made available to the sponsor’s site monitor for the purpose of accounting for 
all clinical supplies. Any  discrepancy  or deficiency  will be recorded and will include an 
explanation. All supplies sent to the investigator must be accounted for and in no case will 
clinical supplies be used in any  unauthorized situation.
The investigator has overall responsibility  for administering/dispensing investigational product. 
Where perm issible, tasks may  be delegated to a qualified designee ( eg, a pharmacist) who is 
adequatel y trained in the protocol and who works under the direct supervision of the investigator. 
This delegation must be documented in the applicable study  delegation of authority  form.
The investigator or his/her designee (as documented by  [CONTACT_49121] y form) will dispense the investigational product only to subjects eligible 
For non-commercial use only
Shire CONFIDENTIAL Page 38
SHP633 -304 Protocol Am endment 2
Teduglutide 23 Mar 2017
for teduglutide treatment following the procedur es set out in the study  protocol. All dispensed 
study  medication will be documented in the interactive response technology  system and/or other 
investigational product record ( eg, investigation product accountability  form). The investigator is 
responsible for assuring the retrieval of all stud y supplies from subjects.
All used and unused study  drug vials must be returned by  [CONTACT_20608]/or parent/guardian, 
and will be retained at the site. If deemed appropriate, the investigator or his/her designee may 
dispense the unused study  drug vials to the same subject. All original containers, whether empty  
or containing stud y drug will be returned to the pharmacy. Returned stud y drugs will NOT be 
relabeled or reassigned for use b y other subjects. Contents of the study  drug containers will not 
be combined. All used and unused vials must be returned to the distribution center according to 
the sponsor’s instruction. No vial/kit may  be destroy ed on site without approval by  [CONTACT_456]. 
Please see the Pharmacy  Manual for additional information.
6.[ADDRESS_483226] and empty /used 
investigational product packaging to every  visit. Drug accountability  will be assessed at the 
container/packaging level for unused investigational product that is contained within the original 
tamper -evident sealed container ( eg, bottles, tray s, vials) or at the individual count level for 
opened containers/packaging. The pharmacist/nominated person will record details on th e drug 
accountability  form.
Of those subjects eligible for teduglutide treatment, subjects who have received 80% of the 
planned doses administered will be assessed as being compliant with the study  protocol.
For non-commercial use only
Shire CONFIDENTIAL Page 39
SHP633 -304 Protocol Am endment 2
Teduglutide 23 Mar 2017
7STUDY PROCEDURES
7.1 Study Schedule
Detailed study  procedures and assessments to be performed for subjects throughout the study  are 
outlined in the Schedule of Assessments ( Table 1 -1,Table 1-2, and Table 1 -3) and must be 
referred to in conjunction with the instructions provided in this section. 
7.1.1 Screening
Prior to performing an y study-related procedures (including those related to screening), the 
investigator or his/her designee must obtain written informed consent (and assent, as applicable) 
from the subject. A subject will have approximately [ADDRESS_483227] occur within 12 weeks of screening for a pre-treatment visit, and within 2 to 12 weeks of 
screening for an NTx visit.
The screening visit (Scr) assessments and procedures, beginning with informed consent, will be 
performed as outlined in Table 1-1, and as detailed below :
Informed consent, and informed assent (if applicable), is obtained
Study  eligibility  is determined. A screen failure is a subject who has given informed 
consent and failed to meet the Study  Inclusion Eligibility  Criteria. Subjects cannot be 
rescreened once they  have been designated as a screen failure. 
Demographics, updates to medical history  and SBS hist ory
Intake and output diaries are dispensed
Evaluate teduglutide treatment inclusion criteria 
Adverse events , concomitant medications and concomitant GI  procedures
7.1.2 Visits for Subjects Not Receiving Teduglutide
While outside of the 28- week teduglutide -treatment cy cle, subjects will be followed 
approximately  every  12weeks for safety  and efficacy  assessments. No -teduglutide treatment 
visits are numbered sequentially  (NT1, NT2, etc.), even if interrupted by  [CONTACT_319415]. 
The visit window (±7 days) is relative to the first NTx visit in the current NTT period.
Assessments will be performed as outlined in Table 1 -2and described below .
Intake and output diaries are dispensed
Evaluate teduglutide treatment inclusion criteria
Adverse events , concomitant medications and concomitant GI  procedures
Physical examination and vital signs, including weight
For non-commercial use only
Shire CONFIDENTIAL Page 40
SHP633 -304 Protocol Am endment 2
Teduglutide 23 Mar 2017
Height and head circumference
Review intake and output diaries
Record PS prescription and adjust as needed
Safety  Laboratory  Tests ( ie, clinical chemistry , hematology , and urinaly sis)
PedsQL  Generic Core Scale/PedsQL Family  Impact Module/ PedsQL  Gastrointestinal 
Symptoms Module Sub- Scales
Antibodies to teduglutide, if and when required
Fecal occult blood testing , as indicated (Section [IP_ADDRESS])
Colonoscopy /sigmoi doscopy , as indicated (see Section [IP_ADDRESS])
Serum sample , as indicated
Teduglutide treatment may  be considered at any  time during the NTT period. If the investigator 
and the subject (and parent or legal 
guardian, as appropriate) agrees to proceed with trea tment if 
the subject is eligible, the subject may  proceed to the pre -treatment visit immediately  to 
determine eligibility .
7.1.3 Visits for Subjects Receiving Teduglutide
[IP_ADDRESS] Pre-treatment Visit
Subjects who meet at least [ADDRESS_483228] and parent agree to proceed with teduglutide th erapy. Similarly , subjects 
who meet escape criteria during the teduglutide follow- up period may  proceed to the 
pre-treatment visit immediately .
The pre -treatment visit may also be combined with screening visit, and if the pre -treatment 
visit assessments occur within 7 days of the TED- C14-006 EOS visit (Week 28), both sets of 
assessments can be combined. A subject must have [ADDRESS_483229] dose administration (CxD1) during an y teduglutide treatment cy cle. In gene ral, pre -
treatment assessments may  occur over a period of up to 21 day s. The teduglutide pre -treatment 
visit (Px) assessments and procedures will be performed asin Table 1-3 and as described below :
Evaluate teduglutide eligibility (treatment inclusion/exclu sion criteria) 
Dispense intake and output diaries
Adverse events , concomitant medications and concomitant GI  procedures
Fecal occult blood testing 
For non-commercial use only
Shire CONFIDENTIAL Page 41
SHP633 -304 Protocol Am endment 2
Teduglutide 23 Mar 2017
Gastrointestinal -specific testing, including colonoscopy  or sigmoidoscopy  as indicated
Physical examination and vital signs, including weight
Height and head circumference
Review intake and output diaries
Record PS prescription and adjust as needed.
Safety  Laboratory  Tests 
(In addition to clinical chemistry , hematology , and urinaly sis, labs at this visit inclu de 
prothrombin time [PT] international normalized ratio [I NR]. Subsequent prothrombin 
time/international normalized ratio (PT/I NR) measurement is only  required to evaluate 
for suspected drug -induced liver injury  [DILI]). 
Serum p
regnancy  testing ( when the pre -treatment and screening visits are combined, the 
serum pregnancy  test should be performed at the local laboratory )
Serum sample 
[IP_ADDRESS] Teduglutide Treatment Period (CxD1 -CxW24)
The open- label teduglutide treatment period will comprise [ADDRESS_483230] administration (Visit CxD1). 
Visit CxD1
Assessments and procedures at this visit will be performed as outlined Table 1 -3and as 
described below. 
Two weeks of intake diary data are required befo re drug is administered at CxD1.
Confirm teduglutide treatment eligibility
Dispense intake and output diaries
Adverse events , concomitant medications and concomitant GI  procedures
Physical examination and vital signs, including weight 
Height and head circ umference
Review intake and output diaries
Record PS prescription and adjust as needed 
For non-commercial use only
Shire CONFIDENTIAL Page 42
SHP633 -304 Protocol Am endment 2
Teduglutide 23 Mar 2017
Safety  laboratory  tests
Quality  of life measurements 
Antibodies to teduglutide
Pregnancy  testing (urine)
Dispense study  drug
Site Visits during Teduglutide Treatment Period
Subjects will return for clinic visits on cy cle weeks 1, 2, 4, 6, 9, 12, 16, 20, and 24 /EOT . 
Assessments and procedures at these visits will be performed as outlined in Table 1-3 and as 
described below:
Dispense /review intake and output diaries (every  effort should be made to complete 
2weeks of intake diary  entries prior to each clinic visit and to complete 48 hours of 
output diary  entries during a period of nutritional stability prior to each clinic visit)
Physical examination and vital signs, including weight
Record PS prescription and adjust as needed
Safety  laboratory tests 
Urine pregnancy  testing for FOCBP (CxW4, CxW9, CxW12, CxW16, CxW20, CxW24)
Study  drug dispensation (except for CxW24)
Adverse events , concomitant medications and concomi tant GI  procedures
In addition, at CxW12 and CxW24 Visits ONLY , the following procedures will be performed:
Height and head circumference
Antibodies to teduglutide
Fecal occult blood testing (FOBT)
GI-specific testing, including colonoscop y or sigmoidoscopy  as indicated 
Quality  of life measurements 
At CxW24 ONLY , a serum sample is collected and stored for future analysis. This sample will 
not be used for genetic testing and lack of collection will not constitute a protocol deviation.
For non-commercial use only
Shire CONFIDENTIAL Page 43
SHP633 -304 Protocol Am endment 2
Teduglutide 23 Mar 2017
PHONE VISITS 
Phone visits are required approximately  1 week after adjustments in PS during the teduglutide 
treatment period. Phone visit assessments and procedures are outlined in Table 1 -3and described 
below:
Review intake and output diaries
Safety  laboratory  tests (clinical chemistry  and urinaly sis)
Record PS prescription and adjust as needed
Obtain AEs, concomitant medications, and concomitant GI  procedures  
Evaluate escape criteria
7.1.4 Teduglutide Follow -up Period
Thesafet y follow -up period for this protocol is 4 weeks (Weeks 25 – 28 of the cy cle). Phone 
visits will occur on cycle weeks 25, 26, and [ADDRESS_483231] may  
proceed directl y to another pre -treatment visit at the investigator’s discretion. The investigator 
may combine the CxW28 visit with the next pre-treatment visit if at least one escape criterion is 
met at the CxW28 visit, and the pre-treatment assessments occur within [ADDRESS_483232] is completing the study  at the CxW28 visit, the EOS/ET visit (Section 7.1.5)
will take place in lieu of the CxW28 visit. Otherwise, following completion of the [ADDRESS_483233] will proceed to an NTT visit within approximately  12 weeks.
At cy cle week 28 (CxW28), subjects will return to the study  site. In addition to the assessme nts 
performed at weeks 25 -27, the following procedures will be performed at CxW28 ONLY:
Dispense intake and output diaries 
Physical examination and vital signs, including weight
Antibodies to teduglutide
Pregnancy  testing (urine)
Evaluate escape criteria
7.1.5 Study Completion/Early Termination Visit (EOS/ET Visit) 
All subjects will return to the study  site for the end of study /early termination visit (EOS/ET). 
Assessments and procedures at this visit will be performed as outlined in Table 1-[ADDRESS_483234] discontinues the study prematurel y, the assessments for the EOS/ET 
Visit are to be performed as completel y as possible (see Section 4.8.2).
For non-commercial use only
Shire CONFIDENTIAL Page 44
SHP633 -304 Protocol Am endment 2
Teduglutide 23 Mar 2017
Adverse events , concomitant medications and concomitant GI  procedures  
Physical examination and vital signs, including weight
Height and head circumference
Review intake and output diaries (the intake diary should be completed daily  for a 
minimum of 2 weeks prior to the EOS/ET visit. The output diary  should be completed 
daily  over a 48- hour period of nutritional stability  before the EOS/ET visit)
Record PS prescription and adjust as needed
Safety  laboratory tests 
Fecal occult blood testing, as indicated
Gastrointestinal -specific testing, including colonoscopy  or sigmoidoscopy  as indicated. 
Quality  of life measurements 
Antibodies to teduglutide
Pregnancy  testing, as needed
7.[ADDRESS_483235] of the following:
Adverse events that were ongoing at the time of completion of TED -C14-006
Events that occurred during the period between completion of TED -C14-[ADDRESS_483236] has an y changes to the SBS history  
collected at the baseline visit of the TED- C14-006 study , that information (updated SBS history ) 
will be collected.
7.2.2 Physical Examination
Physical examinations will be performed according to the stud y schedules. Any new clinicall y 
significant findings noted during ph ysical examinations should be recorded on the appropriate 
AE page of the eCRF. 
For non-commercial use only
Shire CONFIDENTIAL Page 45
SHP633 -304 Protocol Am endment 2
Teduglutide 23 Mar 2017
7.2.3 Vital Signs, Body Weight, Height, Head Circumference and Body Mass 
Index (BMI)
Vital signs will be measured according to the study  schedules. Measurements will include 
systolic and diastolic blood pressure (mmHg), pulse (beats per minute), and body  temperature 
(°C/°F). Blood pressure should be determined b y cuff (using the same method, the same arm, 
and in the same position throughout the stud y).
Body weight will also be recorded in the eCRF; subjects should be weighed on the same scale at 
each stud y visit. Height (or length) and head circumference (for subjects ≤36 months of age) will 
be measured at selected visits. A height z- score, weight z -score, BM I, and BMI z -score will be 
calculated b y the sponsor using the site -provided height and weight data collected at each site 
visit
New clinicall y significant vital sign abnormalities should be recorded on the appropriate AE 
page of the eCRF.
7.2.[ADDRESS_483237] of clinical chemistry , hematology , 
and urinal ysis and will be performed as outlined in the study  plan ( Table 1-1, Table 1-2, and 
Table 1-3) Scheduled laboratory  testing will be processed by  a central lab. All laboratory  assay s 
will be performed according to the central laboratory ’s normal procedures. Reference ranges are 
to be supplied by  [CONTACT_25699] . The investigator should assess out -of
-range clinical laboratory  
values for clinical significance, indicating if the value(s) is/are not clinically  significant or 
clinically  significant. Abnormal clinical laboratory  values, which are unexpected or not 
explained b y the subject’s clinical condition, may, at the discretion of the investigator or sponsor, 
be repeated as soon as possible until confirmed, explained, or resolved. 
During the teduglutide treatment period, subjects will also have safet y labs within approxi mately  
5-[ADDRESS_483238] of clinical chemistry  and urinal ysis and may  be processed by  [CONTACT_319438] a local laboratory. Local lab results are not requi red to be entered in the eCRFs; however, if 
the local lab results indicate an y new clinicall y significant changes, they must be reported as an 
adverse event (see Section 8.1). Urine specimen collection should be attempted as part of the 
safet y labs, but la ck of urinaly sis will not constitute a protocol deviation.
New clinicall y significant labs should be reported as AEs.
The following clinical laboratory
 assessments will be performed according to the study  
schedules: 
For non-commercial use only
Shire CONFIDENTIAL Page 46
SHP633 -304 Protocol Am endment 2
Teduglutide 23 Mar 2017
Table 7-1: List of Laboratory Tests 
Hematology :
Hematocrit 
Hemoglobin 
Platelet count
Red blood cell count 
Red blood cell morphology, if needed
White blood cell count with differential
Coagulation :
Prothrombin time/I nternational nor malized ratio
Urinalysis : 
Blood
Glucose
Leuk ocytes
Microscopic analysis
pH 
Protein
Specific gravity
Pregnancy tests (females of childbearing potential):
oSerum β -HCG (screening)
oUrine β -HCG (all other visits)Biochemistry :
Albumin 
Alkaline phosphatase 
Alanine aminotransferase 
Amy lase
Aspartate aminotransferase 
Bicarbonate
Bilirubin (total and indirect)
Blood urea nitrogen 
Calcium (total)
Chloride
Cholesterol
C-reactive protein 
Creatinine
Estimated Glomerular Filtration Rate
(Schwartz formula)
Gamma -glutamyl transferase 
Glucose
Lipase
Magnesium
Phosphorus
Potassium 
Sodium 
Triglycerides
Uric acid
7.2.5 Serum Sampling
Serum samples will be collected and stored for future anal ysis at the following times: 
At the pre -treatment visit. If the subject met a follow -up period escape criterion, the 
serum sample will not be collected at the pre-treatment visit
At the CxW24 (EOT) visit
During NT T: Approximately  every  24 weeks
The serum sample will not be used for genetic testing. Lack of collection will not constitute a 
protocol deviation.
The sponsor, sponsor’s representatives, biorepositories, and an y specialt y laboratories will be 
blinded to the subject’s identity . The sample and/or extracted material will otherwise be stored 
for up to [ADDRESS_483239] their 
For non-commercial use only
Shire CONFIDENTIAL Page 47
SHP633 -304 Protocol Am endment 2
Teduglutide 23 Mar 2017
sample and/or extracted material destro yed. An y results alread y generated from the samples will 
not be removed from an y anal yses that have already  been performed.
7.2.[ADDRESS_483240] is performed on all FOCBP at the teduglutide pre -treatment visit (when 
the pre -treatment and screening visits are combined, the serum pregnancy  test should be 
performed at the local laboratory ). Urine pregnancy  tests will be administered at all other visits 
according to the stud y schedules, or if pregnancy is suspected , or as specified per protocol upon 
withdrawal of the subject from the study .
7.2.7 Antibody Testing
Blood samples will be drawn for the anal ysis of antibodies to teduglutide according to the 
Schedule of Assessments ( Table 1-1, Table 1 -2,and Table 1-3). Blood samples for antibodies 
may be drawn from a central line or from peripheral access. The sample drawn on CxD1 must be 
drawn prior to administration of the first dose of teduglutide. Once the subject has started 
teduglutide treatment, samples must be drawn at least [ADDRESS_483241] annuall y are shown 
in Table 7-2.
Table 7-2: Approximate Volume of Bl ood to be Drawn from Each Subject Annually 
AssessmentSample 
Volume (mL)No. Sam ples per two 28 -week 
Teduglutide CyclesTotal 
Volume (mL)
Subjects Receiving Teduglutide Treatment 
Safety Biochemistry and -hCGa2.5 24 60
Hem atology 2 24 48
Coagulation Parameters 1 2 2
Antibodies 2 8 16
Serum storage samples 3 4 12
Total mL per 2, 28 -week Treatment Cycles (Approximate Annual Volume): 138
Subjects Not Receiving Teduglutide Treatmentb
AssessmentSample 
Volume (mL)No. Sam ples per 4 NTT VisitsTotal 
Volume (mL)
Safety Biochemistry 2.5 4 10
Hem atology 2 4 8
Serum storage samples 3 2 6
Total mL per 4 “No -Teduglutide Treatment” Visits 48 -week period: 24
Abbreviations: β -hCG=beta -human chorionic gonadotropin ; NTT=no -teduglutide treatment
a β-hCG testing will only be administered to females who are eligible for teduglutide treatment.
For non-commercial use only
Shire CONFIDENTIAL Page 48
SHP633 -304 Protocol Am endment 2
Teduglutide 23 Mar 2017
Table 7-2: Approximate Volume of Bl ood to be Drawn from Each Subject Annually 
AssessmentSample 
Volume (mL)No. Sam ples per two 28 -week 
Teduglutide CyclesTotal 
Volume (mL)
bSubjects not receiving teduglutide treatment, but who were exposed to it previously and tested positive for anti -teduglutide 
antibodies will require blood samples for antibody testing every [ADDRESS_483242] negative.
Note: The amount of blood to be drawn for each assessment is an estimate. The amount of blood 
to be drawn may  vary  according to the instructions provided by  [CONTACT_10190]. When more than 1 blood assessment is to be done at the time 
point/period, if they  require the same t ype of tube, the assessments should be combined. Blood 
volume estimates do not include safet y labs performed after PS adjustment, and anti -teduglutide 
antibody  testing during no- teduglutide treatment.
7.2.9 Gastrointestinal- specific Testing
[IP_ADDRESS] Fecal Occult Blood Testing
Fecal occult blood testing must be performed on all subjects at the pre-treatment visit, week 12, 
and week [ADDRESS_483243] be performed on 
teduglutide -exposed subjects (subjects who have received teduglutide an y time in the past and 
are therefore not teduglutide -naïve) on a roughl y annual basis (approxima tely every  48-60 
weeks). Actions to be taken in response to a positive FOBT are described below.
[IP_ADDRESS] Colonoscopy or Sigmoidoscopy
Teduglutide -naïve subjects age 12 and older will undergo colonoscopy or sigmoidoscopy at the 
pre-treatment visit if one has not be en performed within 1 y ear. 
Subjects of an y age with newly positive FOBT results at the pre -treatment visit for which a 
readil y detectable cause cannot be identified ( eg, anal fissure) will undergo a colonoscopy or 
sigmoidoscop y prior to receiving teduglu tide. If newly  positive FOBT results (for which a 
readil y detectable cause cannot be identified) are obtained at the end of a teduglutide treatment 
cycle (CxW24/EOT), colonoscopy or sigmoidoscopy will be performed. The need for 
colonoscop yor sigmoidoscopy in response to positive FOBTs at any  other point during the 
study , or to re -evaluate persistently  positive FOBTs is at the discretion of the investigator. 
Teduglutide -exposed subjects who have received the equivalent of 2 treatment cy cles (48 weeks 
of study drug exposure) will undergo colonoscopy or sigmoidoscopy . While receiving additional 
teduglutide treatment, subjects will undergo colonoscopy or sigmoidoscopy at 5 y ear intervals or 
more often as needed. 
Upper endoscopy may be performed along with any colonoscopy  or sigmoidoscopy  at the 
investigator’s discretion. If a pol yp is found, adherence to current pol yp follow -up guidelines is 
recommended. Subjects with unresected GI pol yps, poly posis conditions, pre -
malignant change 
or malignancy  in the GI trac t will be excluded from teduglutide treatment.
7.2.10 Nutritional Support
Nutritional support includes PS, enteral nutrition , and other food and fluids. Advances in enteral 
nutrition and/or reductions to PS will be based on clinical status, including weight, linear growth, 
hydration status, and safety  laboratory  results. Intake and output diaries will include data to be 
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_483244]’s nutritional support . Guidelines for nutritional 
support management and weaning algorithms are provided in Appendix 2 .
7.2.11 Diaries
[IP_ADDRESS] Study Drug Administration Diary
A study  drug administration diary  will record administration of teduglutide. This diary  should be 
completed b y the su bject (or parent/ legal guardian , as applicable) dail y during the teduglutide 
treatment period (between visits CxD1 and CxW24).
[IP_ADDRESS] Intake Diary
Intake diaries will be used to collect and evaluate each subject’s nutritional support. The 
subject/parent/guardian will complete the appropriate fields of the PS section of the intake diary  
2 weeks prior to ALL scheduled site visits (except at pre-treatment visit) . During the 24-week 
teduglutide treatment period, the intake diary  will also be completed for 1 week follo wing PS 
adjustments. The intake diary  will also be completed daily  during the 4 -week follow -up period. 
The following data will be captured in the intake diaries:
Parenteral support volume and infusion duration
Site personnel will determine the actual PS da ily calories based on diary  entries.
All available diary  data will be reviewed by [CONTACT_319479].
[IP_ADDRESS] Output Diary
Urine and stool output should be recorded in the output diary  over a 48-hour period of nutritional 
stability before every  clinic visit; in addition, output should be recorded for subjects that are in a 
teduglutide treatment cy cle within 1 week of implementing a chan ge in the PS prescription, 
regardless of previous teduglutide exposure.
Urine data:
Toilet -trained subjects (who do not wear diapers)
Measure and record all urine output in mL  or cc
Nontoilet- trained subjects (who wear diapers)
Measure and record the weight of all urine -only diapers. Urine volume will be calculated 
using the following formula: 1 g (scale weight) = 1 mL  or 1 cc
At the discretion of the investigator, the parent may be asked to collect the first void after 
the daily  PS infusion to measure specific gravity
Stool data (includes diapers with mixed urine and stool):
Toilet -trained subjects (who do not wear diapers)
Record the occurrence of each bowel movement and score the stool consistency  using the 
Bristol Stool Form Scale (see Output diary )
For non-commercial use only
Shire CONFIDENTIAL Page 50
SHP633 -304 Protocol Am endment 2
Teduglutide 23 Mar 2017
Nontoilet- trained subjects (who wear diapers)
Record the weight of diapers containing stool (including diapers with mixed urine and 
stool) as stool output and score the stool consistency  using the Bristol Stool Form Scale 
(see Output diary ). Stool volume will be calculated using the formula: 1 g (scale weight)
= 1mLor [ADDRESS_483245] month, and parent -report of 
problems pursuing their normal work routine and concentrating at work. The PedsQL Generic 
Core Scales are al so responsive to clinical change, as demonstrated in field trials.
[IP_ADDRESS] Pediatric Quality of Life Generic Core Scale (PedsQL™), Acute version
The PedsQL Generic Core Scale is designed to measures health -related quality  of life (HRQoL) 
in pediatric subjects and adolescents (2 -18 years of age). The developmentally  appropriate 
PedsQL  Generic Core Scale will be completed by  [CONTACT_319416] 7 -3at the time points as outlined inTable 1-1, Table 1 -2,and Table 1 -3.
Table 7-3: Developmentally Appropriate PedsQL™Generic Core Scales
Report Completed by
[CONTACT_319417] (ages 2 -4) Parent or Legal Guardian
Child Self Report and Parent Proxy -Report for Young Pediatric subjects 
(ages 5 -7)Subject and Parent or Legal Guardian
For non-commercial use only
Shire CONFIDENTIAL Page 51
SHP633 -304 Protocol Am endment 2
Teduglutide 23 Mar 2017
Table 7-3: Developmentally Appropriate PedsQL™Generic Core Scales
Report Completed by
[CONTACT_385977] -Report for Pediatric subjects 
(ages 8 -12)Subject and Parent or Legal Guardian
Child Self Report and Parent Proxy -Report for Teens (ages 13 -18)aSubject and Parent or Legal Guardian
Abbreviations: PedsQL=Pediatric Quality of Life Inventory
a The Child Self Report and Parent Proxy -Report for Teens (ages 13 -18)will also be completed for subjects older 
than 18 years of age
The Parent Report for Toddlers (ages 2 -4) of the PedsQL Gener ic Core Scale is composed of 
21 items comprising 4 dimensions as follows: 1) Physical Functioning (8 items), 2) Emotional 
Functioning (5 items), 3) Social Functioning (5 items), 4) School Functioning (3 items). 
The Child and Parent Reports of the PedsQL Generic Core Scale for Young Pediatric subjects 
(ages 5 -7), Pediatric subjects (ages 8- 12), and Teens (ages 13 -18) are composed of 23 items 
comprising 4 dimensions as follows: 1) Physical Functioning (8 items), 2) Emo tional 
Functioning (5 items), 3) Social Functioning (5 items), 4) School Functioning (5 items).
[IP_ADDRESS] Pediatric Quality of Life Family Impact Module (PedsQL™), Acute 
version
The PedsQL Family  Impact Module is a parent -report multidimensional instrument that will be 
completed b y the parent or legal guardian, as outlined in Table 1-1, Table [ADDRESS_483246] of pediatric chronic health conditions on parents and the family (Varni et al., 2004 ). 
The 36- item PedsQL Family  Impact Module consists of 6 scales measuring parent self -reported 
functioning as follows: 1) Physical Functioning (6 items), 2) Emot ional Functioning (5 items), 
3)Social Functioning (4 items), 4) Cognitive Functioning (5 items; worries about treatment and 
disease), 5) Communication (3 items), 6) Worry  (5items). Two additional scales measure parent -
reported family  functioning as follows: 1) Dail y Activities (3 items), and 2) Family  Relationships 
(5 items). The PedsQL Family  Impact Module should take the parent or legal guardian 
approximately  5 to 10 minutes to complete.
[IP_ADDRESS] PedsQL Gastrointestinal Symptoms Module (PedsQL™), Acute version
The PedsQL Gastrointestinal Sy mptom Module is a disease -specific 58- item module, comprised 
of 10 differe ntsymptom scales that assess gastrointestinal sy mptom -related quality  of life: food 
and drink limits, trouble swallowing, heartburn and reflux, nausea and vomiting, gas and 
bloating, constipation, blood in poop, and diarrhea. The PedsQL Gastrointestinal Sy mptoms 
Module was designed t o allow the selection and scoring of individual scales from the Module. 
The scales of Food and Drink L imits (6 items) and Diarrhea (7 items) were identified as 
clinically  relevant and appropriate for the s ymptoms experienced in this pediatric study  
populat ion, and therefore, are the onl y scales used in this study . The scales will be completed by  
[CONTACT_319418] [ADDRESS_483247] a causal relationship with this 
treatment. An AE can therefore be an y unfavorable and unintended sign (including an abnormal 
laboratory  finding), s ymptom, or disease temporally  associated with the use of a medicinal 
(investigational) product, whether or not related to the medicinal (investigational) product (ICH 
Guidance E2A 1995). 
All AEs are collected from the time the informed consent is signed until the defined follow -up 
period stated in Section 7.1.[ADDRESS_483248] be followed to clo sure (the subject’s health has returned to his/her baseline status 
or all variables have returned to normal), regardless of whether the subject is still participating in 
the study . Closure indicates that an outcome is reached, stabilization achieved (the i nvestigator 
does not expect any  further improvement or worsening of the event), or the event is otherwise 
explained. When appropriate, medical tests and examinations are performed so that resolution of 
event(s) can be documented.
8.1.[ADDRESS_483249] be 
recorded as new AEs (for example, if a subject experiences mild intermittent dy spepsia prior to 
dosing of investigational product, but the dy spepsia becomes severe and more frequent after first 
dose of investigational product has been administered, a new AE of severe dy spepsia [with the 
appropriate date of onset] is recorded on the appropriate eCRF).
The medical assessment of severit y is determined by [INVESTIGATOR_1477]:
Mild: A type of AE that is usually  transient and may  require only  minimal treatment or 
therapeutic intervention. The event does not generally  interfere with usual 
activities of daily  living.
Moderate: A type of AE that is usually  alleviated with specific therapeutic intervention. The 
event interfer es with usual activities of daily  living, causing discomfort but poses 
no significant or permanent risk of harm to the research subject.
Severe: A type of AE that interrupts usual activities of daily  living, or significantl y affects 
clinical status, or may require intensive therapeutic intervention.
For non-commercial use only
Shire CONFIDENTIAL Page 53
SHP633 -304 Protocol Am endment 2
Teduglutide 23 Mar 2017
In consideration of whether a treatment -emergent adverse event (TEAE) might lead to dose 
interruption (Section 8.4.1) or early  termination of the study  (Section 8.5), severe TEAEs will 
also be graded according to the National Cancer Institute’s (NCI) Common Terminology  Criteria 
for Adverse Events (CTCAE) severit y grading criteria (US Department of Health and Human 
Services et al., 2010 ).
8.1.2 Relationship Cate gorization
A phy sician/investigator must make the assessment of relationship to investigational product for 
each AE. The investigator should decide whether, in his or her medical judgment, there is a 
reasonable possibility  that the event may  have been caus ed by [CONTACT_7198]. If 
there is no valid reason for suggesting a relationship, then the AE should be classified as “not 
related”. Otherwise, if there is an y valid reason, even if undetermined or untested, for suspecting 
a possible cause -and-
effect relationship between the investigational product and the occurrence 
of the AE, then the AE should be considered “related”. The causality  assessment must be 
documented in the source document.
The following additional guidance may  be helpful:
Term Relationship Definition
RelatedThe temporal relationship between the event and the administration of 
the investigational product is compelling and/or follows a known or 
suspected response pattern to that product, and the event cannot be 
explained by  [CONTACT_423]’s medical condition, other therapi[INVESTIGATOR_014], or 
accident.
Not RelatedThe event can be readil y explained by  [CONTACT_11260]’s underl ying medical condition, concomitant therapy , or 
accident and no plausible temporal or biologic relations hip exists 
between the investigational product and the event.
AEs that are related to study  drug that are not resolved at EOT will be followed until the event 
resolves or stabilizes, as judged b y the investigator.
Laboratory  values, vital signs, and clinical findings at the scheduled ph ysical examinations must 
be reported as AEs if the investigator considers the finding to be a clinicall y significant change 
from the baseline. 
8.1.[ADDRESS_483250] be recorded during the cours e of the stud y in the eCRF. Outcomes are 
as follows:
Fatal
Not Recovered/Not Resolved
Recovered/Resolved
Recovered/Resolved with Sequelae 
For non-commercial use only
Shire CONFIDENTIAL Page 54
SHP633 -304 Protocol Am endment 2
Teduglutide 23 Mar 2017
Recovering/Resolving
Unknown
8.1.4 Symptoms of the Disease under Study
Symptoms of the disease under study  should not be classed as AEs as long as they  are within the 
normal day -to-day fluctuation or expected progression of the disease and are part of the efficacy  
data to be collected in the study; however, significant worsening of the s ymptoms should be 
recorded as an AE.
8.1.[ADDRESS_483251] be taken into consideration.
If, during the study, there are abnormal clinical laboratory values or vital signs which were not 
present at the beginning of the study , further investigations should be performed until the values 
return to within the reference range or until a plausible explanation ( eg, concomitant disease) is 
found for the abnormal values.
The investigator should decide, based on the above criteria and the clinical condition of a 
subject, whether a change in a clinical laboratory  or vital sign is clinicall y significant and 
therefore represents an AE.
8.1.[ADDRESS_483252] be reported within 24 hours to the 
Shire Global 
Drug Safet y Department using the Shire Investigational and Marketed Products 
Pregnancy  Report Form. A copy  of the Shire Investigational and Marketed Products Pregnancy 
Report Form (and an y applicable follow -up reports) must also be sent to the Shire Medical 
Monitor using the details specified in the emergency  contact [CONTACT_1739]. 
In the event a subject becomes pregnant during the study , teduglutide administration must be 
discontinued immediately. 
Every  effort should be made to gather informat ion regarding the pregnancy  outcome and 
condition of the infant. It is the responsibility  of the investigator to obtain this information within 
[ADDRESS_483253] ications such as spontaneous abortion/miscarriage or congenital abnormality  
are considered SAEs and must be reported using the Shire Clinical Study  Adverse Event Form 
for Serious Adverse Events (SAEs) and Non- serious AEs as Required b y the Protocol. Note: An 
elective abortion is not considered an SAE.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_483254] positive serum/urine -HCG test or 
will determine the pregnancy  onset date.
8.1.7 Abuse, Misuse, Overdose, and Medication Error
Abuse, misuse, overdose, or medication error (as defined below) must be reported to the sponsor 
according to the SAE reporting procedure whether or not they  result in an AE/SAE as described 
in Section 8.2. Note: The 24 -hour reporting requirement for SAE s does not apply  to reports of 
abuse, misuse, overdose, or medication errors unless these result in an SAE. 
The categories below are not mutually  exclusive; the event can meet more than 1 category .
Abuse –
Persistent or sporadic intentional intake of inve stigational product when used for 
a non -medical purpose ( eg, to alter one’s state of consciousness or get high) in a manner 
that may  be detrimental to the individual and/or society .
Misuse –Intentional use of investigational product other than as directed or indicated at 
any dose (Note: this includes a situation where the investigational product is not used as 
directed at the dose prescribed by  [CONTACT_760]).
Overdose –Administration of a dose greater than the allocated dose of the study  
medication or at a frequency  greater than the dosing interval specified by [CONTACT_760].
Medication Error –An error made in prescribing, dispensing, administration, and/or use 
of an investigational product. For studies, medication errors are reportable to the sponsor 
only as defined below.
Cases of subjects missing doses of the investigational product are not considered reportable as 
medication errors.
Medication errors should be collected/reported for all products under investigation.
The administration and/or use of an expi[INVESTIGATOR_10151] a 
reportable medication error. 
All investigational product provided to pediatric subjects should be supervised by [CONTACT_31588]/legall y-authorized representative/caregiver.
8.[ADDRESS_483255] awareness of 
For non-commercial use only
Shire CONFIDENTIAL Page 56
SHP633 -304 Protocol Am endment 2
Teduglutide 23 Mar 2017
the event. Note: The 24 -hour reporting requirement for SAEs does not apply  to reports of abuse, 
misuse, overdose, or medication errors (see Section 8.1.7) unless they  result in an SAE.
All Adverse Events of Special Interest , as defined in Section 8.3, must be reported by [CONTACT_385978] y Department and the Shire Medical Monitor within 
[ADDRESS_483256] complete, sign, and date the Shire Clinica l Study  Adverse Event Form for 
SAEs and Non- serious AEs as Required b y Protocol, and verify the accuracy of the information 
recorded on the form with the corresponding source documents (Note: Source documents are not 
to be sent unless requested). Fax or e -mail the completed form to the Shire Global Drug Safet y 
Department. A cop y of the completed Shire Clinical Study Adverse Event Form for Serious 
Adverse Events (SAEs) and Non -serious AEs as Required b y Protocol (and any applicable 
follow -up reports) must al so be sent to the Shire medical monitor or designee using the details 
specified in the emergency  contact [CONTACT_1739].
8.2.[ADDRESS_483257] medical occurrence (whether considered to be related to inv estigational 
product or not) that at any dose: 
Results in death
Is life -threatening. Note: The term 'life -threatening' in the definition of "serious" refers to 
an event in which the subject was at risk of death at the time of the event; it does not refer 
to an event which h ypothetically might have caused death if it was more severe.
Requires inpatient hospi[INVESTIGATOR_1081]. Note: 
Hospi[INVESTIGATOR_602], which are the result of elective or previousl y scheduled surgery for pre
existing conditions, which have not worsened after initiation of treatment, should not be 
classified as SAEs. For example, an admission for a previousl y scheduled ventral hernia 
repair would not be classified as an SAE; however, complication(s) resulting from a 
hospi[INVESTIGATOR_10153] y scheduled surgery  that meet(s) serious 
criteria must be reported as SAE(s).
Results in persistent or significant disability /incapacity
Is a congenital abnormality /birth defect
Is an important medical eve nt. Note: I mportant medical events that may not result in 
death, be life -threatening, or require hospi[INVESTIGATOR_12475], 
based upon appropriate medical judgment, they  may  jeopardize the subject and may  
require medical or surgical intervention to prevent 1 of the outcomes listed in this 
definition. Examples of such medical events include allergic bronchospasm requiring 
intensive treatment in an emergency  room or at home; blood dy scrasias or convulsions 
that do not result in inpatient h ospi[INVESTIGATOR_059]; or the development of drug dependency  or 
drug abuse. 
For non-commercial use only
Shire CONFIDENTIAL Page 57
SHP633 -304 Protocol Am endment 2
Teduglutide 23 Mar 2017
8.2.4 Serious Adverse Event Collection Time Frame
All SAEs (regardless of relationship to study ) are collected from the time the subject signs the 
informed consent until the defined follow-up period stated in Section 7.1.4, and must be reported 
to the Shire Global Drug Safety  Department andthe Shire Medical Monitor within [ADDRESS_483258] awareness of the event. 
In addition, any  SAE(s) considered “related” to the investigational product and discovered b y the 
investigator at an y interval after the study has completed must be reported to the Shire Global 
Drug Safet y Department within [ADDRESS_483259]’s death ( ie, the SAE was noted as the primary  cause of death) 
must have fatal checked as an outcome with the date of death recorded a s the resolution date. For 
all other events ongoing at the time of death that did not contribute to the subject’s death, the 
outcome should be considered not resolved, without a resolution date recorded.
For an y SAE that results in the subject’s death or a ny ongoing events at the time of death, unless 
another investigational product action was previously  taken ( eg, drug interrupted, reduced, 
withdrawn), the action taken with the investigational product should be recorded as “dose not 
changed” or “not applic able” (if the subject never received investigational product). The 
investigational product action of “withdrawn” should not be selected solel y as a result of the 
subject’s death.
8.2.[ADDRESS_483260], Ethics Committee, and Site 
Reporting 
The Sponsor and/or Clinical Contract Research Organization ( CRO )is responsible for notify ing 
the relevant regulatory  authorities, and US central Institutional Review Boards ( IRBs)/EU central 
ethics committees ( ECs), of related, unexpected SAEs.
In addition, the Clinical CRO is responsible for notify ing active sites of all related, unexpected 
SAEs occurring during all interventional studies across the SHP633 program.
The investigator is responsible for notifying the local IRB, local EC, or the rel evant local 
regulatory  authorit y of all SAEs that occur at his or her site as required.
8.[ADDRESS_483261] is an AE (serious or nonserious) of scientific and medical concern 
specific to the sponsor’s product or pro gram and for which ongoing monitoring and immediate 
notification by  [CONTACT_230013].
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_483262] that require expedited regulatory  reporting include the following:
Growth of pre -existing poly ps of the colon
Benig n neoplasia of the GI tract including the hepatobiliary  system
Tumor -promoting ability ( eg, benign and/or malignant neoplasia of any  kind, not limited 
to those of the GI or hepatobiliary  system)
For AEs of special interest, the sponsor must be informed wit hin [ADDRESS_483263] awareness as 
per the SAE notification instructions described in Section 8.2.2 even if the event does not fulfill 
the seriousness criteria.
8.4 Dose Interruption of Individual Subjects
The investigator is responsible for contact[CONTACT_20610]/designee when the subject’s 
teduglutide dosing regimen is interrupted. Attempts should be made to contact [CONTACT_103]/designee prior to dose interruption. Reasons for dosage interruptions may  include but are 
not limited to hospi[INVESTIGATOR_059] ,AEs, a lapse in investigational product delivery , etc.
Study  drug must be discontinued if any  of the following events occur:
Pregnancy
Severe h ypersensitivity , such as anaph ylaxis determined by  [CONTACT_319447]. This does not include the presence of anti -teduglutide antibodies, mild 
injection site reactions or mild sy mptoms that according to the investigator do not pose a 
significant risk to the subject.
An AE that is of NCI CTCAE severit y Grade 3 or 4 and considered to be related to stu dy 
drug administration
Confirmed drug -induced liver injury  (DILI) related to teduglutide ( see Section 8.4.2)
8.4.[ADDRESS_483264] experienced an AE that is of 
severit y ≥Grade [ADDRESS_483265] . 
In consideration of whether a TEAE might lead to dose interruption, severe TEAEs will also be 
graded ac cording to the NCI  CTCAE severit y grading criteria (US Department of Health and 
Human Services et al., 2010 )
.All such TEAEs s hould be discussed with the Shire M edical 
Monitor or designee as soon as possible. The length of the dose interruption, and whether 
teduglutide administration resumes or is permanently  discontinued, depends on the clinical 
situation.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_483266] has 
clinical and laboratory  evidence of potential DILI, in the absence of an alternative explanation, 
as identified b y the following criteria:
ALT or AST >8x ULN
ALT or AST >5x ULN and >2x baseline value for more than 2 weeks
(ALT or AST >3x ULN and >2x baseline value) and (total bilirubin >2x ULN or 
INR>1.5)
ALT or AST >3x ULN and >2x baseline value with the appearance of fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)
All laboratory  values suggestive of potentially  new DILI should be repeated and verified within 
[ADDRESS_483267] should be followed closely to determine the trajectory  of the 
laboratory  abnorm alities and to evaluate the cause of liver injury . This evaluation may  include, 
as clinically  indicated, consideration of sepsis, acute viral hepatitis (eg, hepatitis A 
immunoglobulin [IgM], hepatitis B surface antigen, hepatitis C antibodies, cy tomegalovi rus IgM, 
Epstein- Barr virus antibody  panel), hepatobiliary  obstruction (ultrasound), autoimmune hepatitis 
(anti-nuclear, anti -smooth muscle, anti -actin, or anti -liver kidney  microsomal antibodies), 
intestinal failure associated liver disease, cardiovascula r causes such as ischemic hepatitis, and 
concomitant hepatotoxic treatments.
Additional evaluations may  be performed at the discretion of the investigator in consultation 
with the 
Shire medical monitor.
Teduglutide administration must be permanentl y discontinued if DILI is confirmed and deemed 
related to stud y drug.
8.5 Early Termination of the Clinical Study
The DMC may  recommend stoppi[INVESTIGATOR_319390] :
≥2subjects develop the same event of CTCAE severity  Grade [ADDRESS_483268]
or
[ADDRESS_483269].
For non-commercial use only
Shire CONFIDENTIAL Page 60
SHP633 -304 Protocol Am endment 2
Teduglutide 23 Mar 2017
9DATA MANAGEMENT AND STATISTICAL METHODS
9.1 Data Collection
The investigators’ authorized site personnel must enter the information required by  [CONTACT_103365]. A study  monitor will visit each site in accordance with the monitoring plan and 
review the eCRF data against the source data for completeness and accuracy . Discrepancies 
betwee n source data and data entered in the eCRF will be addressed b y qualified site personnel. 
When a data discrepancy warrants correction, the correction will be made by [CONTACT_59752]. Data collection procedures will be discussed with the site at t he site initiation visit 
and/or at the investigator’s meeting. Unscheduled safet y follow up assessments ( including visits 
conducted after EOS) are not to be collected unless requested .
9.2
Clinical Data Management 
Data are to be entered into a clinical database as specified in the CRO’s data management 
process. Quality  control and data validation procedures are applied to ensure the validity  and 
accuracy  of the clinical database.
Data are to be reviewed and checked for omissions, errors, and values requiring f urther 
clarification using computerized and manual procedures. Data queries requiring clarification are 
to be communicated to the site for resolution. Only authorized personnel will make corrections to 
the clinical database, and all corrections are documen ted in an auditable manner.
9.3 Statistical Analysis Process 
The study  will be anal yzed by  [CONTACT_10196]. All statistical anal yses will be performed 
using SAS®(SAS Institute, Cary , NC, [LOCATION_003]) version 9.3 or higher.
The statistical anal ysis plan (SAP ) will provide the statistical methods and definitions for the 
analysis of the efficacy  and safet y data, as well as describe the approaches to be taken for 
summarizing other study  information such as subject disposition, demographics and baseline 
character istics, investigational product exposure, and prior and concomitant medications. 
9.[ADDRESS_483270] been collected. 
A DMC will be involved in the manag ement of this study . The DMC members will review the 
data approximately  every 3 months according to the DMC Charter . The DMC review will 
include all cumulative safety  data ( ie, AEs, laboratory  assessments, phy sical examinations, etc.) 
from study  assessment s through each cutoff period. Further details regarding the DMC can be 
found in the DMC charter, which will be available prior to the administration of investigational 
product. 
The DMC for this study  will be conducted in accordance with the FDA Guidance f or Clinical 
Trial Sponsors: Establishment and Operation of Clinical Trial Data Monitoring Committees 
(March 2006).
The DMC will be an external, independent board comprised of ph ysicians with relevant training. 
The DMC will be restricted to individuals free of significant conflicts of interest, including, but 
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_483271] may not be 
study  investigators or be employed at the same institution as a study  investigator, individuals 
employ ed by [CONTACT_456], independent contractors hired by  [CONTACT_456], or members of 
regulatory  agencies. The DMC may  make recommendations to the sponsor regarding stud y 
aspects including stoppi[INVESTIGATOR_007], modify ing or continuing the study ; however, the sponsor will have 
the final responsibility  to determine whether the study  should be modified or temporaril y or 
permanentl y stopped. 
9.5 Sample Size Calculation and Power Considerations 
The number of subjects in this study  is not based on statistical power considerations as this is an 
extension study  of the core study , TED -C14-006. The maximum number of subjects was
determined b y the enrollment in TED -C14-006.
9.6 Study Population
The safet y population includes all enrolled subjects in the study . Safet y population will be used 
for both safet y and efficacy  anal yses.
9.7 Efficacy Analyses 
No claims of statistical significance will be made; however, 95% confidence intervals will be 
provided, if appl icable. Continuous variables, including those assessed on a discrete scale, will 
be summarized using descriptive statistics including number of subjects, mean, median, standard 
deviation, maximum, and minimum. For categorical variables, statistical summari es will include 
number of subjects and percentages.
9.7.1 Efficacy Endpoints
Efficacy  endpoints will be anal yzed at the end of each teduglutide treatment period (Week 24 or 
EOT), and at each stud y visit, relative to the baseline of the core study  (TED -C14-006) a nd/or 
first exposure to teduglutide. The following efficacy  endpoints will be analy zed:
Reduction in PS volume of at leas t 20%
Absolute and relative change in PS volume
Complete weaning off PS
Change in day s per week of PS
9.8 Safety Analyses 
9.8.1 Safety Endpoint s
The following safet y endpoints will be analy zed:
Adverse events
Vital signs, including temperature, heart rate, and blood pressure
For non-commercial use only
Shire CONFIDENTIAL Page 62
SHP633 -304 Protocol Am endment 2
Teduglutide 23 Mar 2017
Laboratory  safet y data ( ie, clinical chemistry , hematology , and urinaly sis)
Urine output
Stool output 
Antibodies to teduglutide
Gastrointestinal -specific testing , including fecal occult blood testing and colonoscopy  or 
sigmoidoscop y
Z-scores for weight, height (or length), head circumference (up to 36 months of age), and 
body  mass index
Adverse events will be coded us ing the Medical Dictionary  for Regulatory  Activities 
(MedDRA). The number of events, incidence, and percentage of AEs will be calculated overall, 
by [CONTACT_1196] (SOC) and by  [CONTACT_11702]. SAEs will be further summarized by  
[CONTACT_11370] y and relationshi p to investigational product. Adverse events related to investigational 
product, AEs leading to withdrawal, SAEs, and deaths will be similarly  summarized/listed.
Prior and concomitant medications will be coded using the World Health Organization- Drug 
Dicti onary (WHO -DD) with regard to drug class and drug name. The number and percentage of 
subjects with specific prior m edications will be summarized. Medical history  (including 
surgical/procedural history ) will be coded using MedDRA. The number and percentage of 
subjects with specific histories will be summarized by  [CONTACT_6657]. 
For clinical laboratory  tests, vital signs, body weight, and fluid balance variables, descriptive 
statistics (mean, median, standard deviation, minimum and maximum values, the number and 
percentage of subjects in specified categories) will be calculated to summarize the observed 
values and change from b aseline at each scheduled visit.
The number and percentage of subjects classified as having positive or neutralizing antibodies to 
teduglutide will be used to summarize the presence of antibodies. 
Additional safet y parameters and measures will include cha nge in body  weight, height (or 
length) and head circumference (up to 36 months of age). Derived variables will include height 
z
-score, weight z -score, BMI, and BMI z -score. Descriptive statistics (mean, median, standard 
deviation , minimum and maximum value s, the number and percentage of subjects in specified 
categories) will be calculated to summarize the absolute values and change from baseline at each 
scheduled visit.
9.9 Other Analyses
9.9.1 Health -related Quality of Life Analyses 
Health economics and outcomes r esearch endpoints will be analy zed at approximately  12-week 
intervals (Weeks 12 and 24 of each teduglutide treatment cy cle, and every  12 weeks for subjects 
not on teduglutide), relative to the study  baseline. The beginning of each treatment cy cle (CxD1) 
will be an additional baseline.
Change in Pediatric Quality  of Life Inventory  (PedsQL) score
For non-commercial use only
Shire CONFIDENTIAL Page 63
SHP633 -304 Protocol Am endment 2
Teduglutide 23 Mar 2017
Change in PedsQL Family  Impact Module score
Change in PedsQL Gastrointestinal Sy mptoms Module Sub- Scales scores: 
Food and Drink L imits
Diarrhea 
For non-commercial use only
Shire CONFIDENTIAL Page 64
SHP633 -304 Protocol Am endment 2
Teduglutide 23 Mar 2017
10SPONSOR’S AND INVES TIGATOR’S RESPONSIBI LITIES
This study  is conducted in accordance with current applicable regulations, ICH, EU Directive 
2001/20/EC and its updates, and local ethical and legal requirements. 
The name [CONTACT_317368] y vendor ( eg, CRO) used in this study  will be maintained 
in the investigator’s and sponsor’s files, as appropriate.
10.1 Sponsor’s Responsibilities
10.1.[ADDRESS_483272] been delegated will undertake their assigned roles for this study in compliance with all 
applicable industry  regulations, I CH Good Clinical Practice (GCP) Guideline E6 ( 1996), EU 
Directive 2001/20/EC, as well as all applicable national and local laws and regula tions.
Visits to sites are conducted by  [CONTACT_10199]/or the company  
organizing/managing the research on behalf of the sponsor to inspect study  data, subjects’ 
medical records, and eCRFs in accordance with current GCP and the res pective local and 
(inter)national government regulations and guidelines. Records and data may additionall y be 
reviewed b y auditors or by  [CONTACT_10200].
The sponsor ensures that local regulatory  authority requirements are met before the start of th e 
study . The sponsor (or a nominated designee) is responsible for the preparation, submission, and 
confirmation of receipt of an y regulatory  authority  approvals required prior to release of 
investigational product for shipment to the site.
10.1.2 Indemnity/Liabil ity and Insurance
The sponsor of this research adheres to the recommendations of the Association of British 
Pharmaceutical Industry  Guidelines. If appropriate, a cop y of the indemnity document is 
supplied to the investigator before study  initiation, per lo cal country  guidelines.
The sponsor ensures that suitable clinical study  insurance coverage is in place prior to the start of 
the study . An insurance certificate is supplied to the CRO as necessary . 
10.1.3 Public Posting of Study Information
The sponsor is responsible for posting appropriate study  information on applicable websites. 
Information included in clinical study  registries may  include participating investigators’ names 
and contact [CONTACT_3031].
10.1.4
Submission of Summary of Clinical Study Report (CSR) to Competent 
Authorities of Member States Concerned and Ethics Committees
The sponsor will provide a summary  of the clinical study  report to the competent authority  of the 
member state(s) concerned as required b y regulatory  requirement(s) and to comply  with the 
Community  guideline on GCP. This requirement will be fulfilled within 6 months of the end of 
the study  completion date for pediatric studies and within 1 y ear for non -pediatric studies as per 
guidance. The sponsor will provide the ECs with a copy  of the same summary .
For non-commercial use only
Shire CONFIDENTIAL Page 65
SHP633 -304 Protocol Am endment 2
Teduglutide 23 Mar 2017
10.1.5 Study Suspension, Termination, and Completion
The sponsor may  suspend or terminate the study , or part of the study , at any  time for any  reason. 
If the stud y is suspended or terminated, the sponsor will ensure that applicable sites, regulato ry 
agencies and IRBs/ECs are notified as appropriate. Additionally , the discontinuation of a 
registered clinical study  which has been posted to a designated public website will be updated 
accordingl y.
The sponsor will make an EOS declaration to the relevan t competent authority  as required b y 
Article 10 (c) of Directive 2001/20/EC .
10.2 Investigator’s Responsibilities
10.2.[ADDRESS_483273] undertake to perform the study  in accordance with ICH GCP Guideline E6 
(1996), EU Directive 2001/20/EC, and applicable regulatory  requirements and guidelines.
It is the investigator’s responsibility  to ensure that adequate time and appropriately  trained 
resources are available at the site prior to commitment to participate in this study . The 
investigator should also be able to estimate or demonstrate a potential for recruiting the required 
number of suitable subjects within the agreed recruitment period.
The investigator will maintain a list of appropriately  qualified persons to whom the investig ator 
has delegated significant study -
related tasks, and shall, upon request of the sponsor, provide 
documented evidence of any  licenses and certifications necessary  to demonstrate such 
qualification. Curriculum vitae for investigators and sub- investigators are provided to the study  
sponsor (or designee) before starting the study .
If a potential research subject has a primary  care phy sician, the investigator should, with the 
subject’s consent, inform them of the subject’s participation in the study .
A coordi nating principal investigator [INVESTIGATOR_319387]. Agreement with the final CSR is documented by  [CONTACT_319426] (single -site study ) or coordinating principal investigato r (multicenter 
study ), in compliance with Directive 2001/83/EC as amended b y Directive 2003/63/EC and I CH 
Guidance E3 ( 1995). 
10.2.[ADDRESS_483274] met 
protocol eligibility  criteria. Investigators are required to sign an investigator agreement to 
confirm acceptance and willingness to comply  with the study  protocol.
If the investigator suspends or terminates the study  at their site, the investigator will promptly  
inform the sponsor and the I RB/EC and provide them with a detailed written explanation. The 
investigator will also return all investigational products, containers, and other study  materials to 
the sponsor. Upon study  completion, the investigator will provide the sponsor, I RB/EC, and 
regulatory  agency  with final reports and summaries as required by [CONTACT_59761].
Communication with local I RBs/E Cs, to ensure accurate and timel y information is provided at 
all phases during the study , may  be done by  [CONTACT_456], applicable CRO, investigator, or for 
For non-commercial use only
Shire CONFIDENTIAL Page 66
SHP633 -304 Protocol Am endment 2
Teduglutide 23 Mar 2017
multicenter studies, the coordinating principal investigator [INVESTIGATOR_49106].
10.2.3 Documentation and Retention of Records
[IP_ADDRESS] Case Report Forms
The investigator is responsible for maintaining adequate and accurate medical records from 
which accurate information is recorded into eCRFs, which have been designed to record all 
observations and other data pertinent to the clinical investigation. Case report forms must be 
completed b y the investigator or designee as stated in the site delegation log.
All data will have separate source documentation; no data will be recorded directly  into the 
eCRF.
eCRFs should be approved by  [CONTACT_385960].
The clinical research associate (CRA)/study  monitor will verify  the contents against the source 
data per the monitoring plan. If the data are unclear or contradictory , queries are sent for 
corrections or verification of data.
[IP_ADDRESS] Recording, Access, and Retention of Source Data and Study Documents
Original source data to be reviewed during this study  will include , but are not limited to: 
subject’s medical file, subject diary  cards, original clinical laboratory  reports, and histology  and 
pathology  reports.
All key  data must be recorded in the subject’s medical records.
The investigator must permit authorized repres entatives of the sponsor, the respective national, 
local, or foreign regulatory  authorities, the IRB/EC, and auditors to inspect facilities and to have 
direct access to original source records relevant to this study , regardless of media.
The CRA/study  moni tor (and auditors, IRB/EC or regulatory  inspectors) may  check the eCRF 
entries against the source documents. The consent form includes a statement by  [CONTACT_10203]/auditor from the sponsor or its representatives, national or local
regulatory  authorities, or the I RB/EC, having access to source data ( eg, subject’s medical file, 
appointment books, original laboratory reports, X -rays etc.). Non- study  site personnel will not 
disclose an y personal information or personal medical informat ion.
These records must be made available within reasonable times for inspection and duplication, if 
required, b y a properly  authorized representative of any  regulatory  agency  (eg, the US FDA, 
EMA, [LOCATION_006] Medicines and Healthcare products Regulatory  Agency ) oran auditor.
Essential documents must be maintained according to ICH GCP requirements and may  not be 
destroy ed without written permission from the sponsor.
[IP_ADDRESS] Audit/Inspection
To ensure compliance with relevant regulations, data generated b y this study must b
e available 
for inspection upon request by  [CONTACT_1779], for example, the US Food and Drug 
Administration (FDA) (as well as other US national and local regulatory  authorities), the 
European Medicines Agency (EMA), the Medicines and Healthcare product s Regulatory  
For non-commercial use only
Shire CONFIDENTIAL Page 67
SHP633 -304 Protocol Am endment 2
Teduglutide 23 Mar 2017
Agency , other regulatory authorities, the sponsor or its representatives, and the I RB/EC for each 
site.
[IP_ADDRESS] Financial Disclosure
The investigator is required to disclose an y financial arrangement during the study and for 1 year 
after, whereb y the outcome of the study  could be influenced by  [CONTACT_10204] , or other pay ments the investigator received from the sponsor. The 
following information is collected: an y significant payments from the sponsor or subsidiar ies 
such as a grant to fund ongoing research, compensation in the form of equipment, retainer for 
ongoing consultation or honoraria; an y proprietary interest in investigational product; any 
significant equity  interest in the sponsor or subsidiaries as defi ned in 21 CFR 54 2(b) ( 1998).
10.[ADDRESS_483275]’s legall y-authorized representative, as 
applicable, is requested to sign and date the subject informed consent fo rm or a certified 
translation if applicable, after the subject has received and read (or been read) the written subject 
information and received an explanation of what the study  involves, including but not limited to: 
the objectives, potential benefits and risk, inconveniences, and the subject’s rights and 
responsibilities. A copy  of the informed consent and assent documentation ( ie, a complete set of 
subject information sheets and fully  executed signature [CONTACT_1787]) must be given to the subject or the 
subject’s legall y-authorized representative, as applicable. This document may  require translation 
into the local language. Signed consent forms must remain in each subject’s study  file and must 
be available for verification at an y time.
Within the source documents , site personnel should document instruction of and understanding 
by [CONTACT_7071]/legall y-authorized representative/caregiver of the safe, responsible storage and 
administration of investigational product to the study  subject.
The principal investigator [INVESTIGATOR_385947] a copy  of the consent form, and assent form 
where applicable, which was reviewed b y the IRB/EC and which received their favorable 
opi[INVESTIGATOR_1649]/approval. A copy  of the IRB/EC’s written favorable opi[INVESTIGATOR_1649]/approval of these 
documents must be p rovided to the sponsor, prior to the start of the study  unless it is agreed to 
and documented (abiding by  [CONTACT_319428]) prior to study  start 
that another party  (ie, sponsor or coordinating principal investigator) is respons ible for this 
action. Additionally , if the I RB/EC requires modification of the sample subject information and 
consent document provided by  [CONTACT_456], the documentation supporting this requirement must 
be provided to the sponsor.
10.3.2 Institutional Review Boar d or Ethics Committee
For sites outside the EU, it is the responsibility  of the investigator to submit this protocol, the 
informed consent document (approved b y the sponsor or their designee), relevant supporting 
information and all types of subject recrui tment information to the I RB/EC for review, and all 
must be approved prior to site initiation .
For non-commercial use only
Shire CONFIDENTIAL Page 68
SHP633 -304 Protocol Am endment 2
Teduglutide 23 Mar 2017
For sites within the EU, the applicant for an EC opi[INVESTIGATOR_319376], the investigator, or 
for multicenter studies the coordinating principal investigator [INVESTIGATOR_10157], according to national 
provisions.
Responsibility  for coordinating with IRBs/ECs is defined in the investigator agreement.
Prior to implementing changes in the study , the sponsor and the IRB/EC must approve any  
revisions of all informed consent documents and amendments to the protocol unless there is a 
subject safet y issue.
Investigational product supplies will not be released until the Sponsor (or designee) has received 
written I RB/EC approval of and copi[INVESTIGATOR_10158].
For sites outside the EU, the investigator is responsible for keepi[INVESTIGATOR_100025] I RB/EC apprised of the 
progress of the stud y and of an y changes made to the protocol, but in an y case at least once a 
year; for sites within the EU, this can be done by  [CONTACT_456], the investigator or for multicenter 
studies the coordinating principal investigator, according to national provisions. The investigator 
must also keep the local IRB/EC informed of an y serious and significant AEs.
10.[ADDRESS_483276] (HIPAA) of 
1996. A site that is not a covered entity  as defined by  [CONTACT_385979] (or designee).
The confidentialit y of records that may be able to identify subjects will be protected in 
accordance with applicable laws, regulations, and guidelines.
After subjects have consented to take part in the study , the sponsor and/or its representatives 
review their medical records and data collected during the stud y. These records and data may, in 
addition, be reviewed b y others including the following: independent auditors who validate the 
data on behalf of the sponsor; third parties with whom the sponsor may  develop, register, or 
market SHP633; national or local regulatory  authorities; and the I RBs/ECs which gave approval 
for the stud y to proceed. The sponsor and/or its representatives accessing the records and data 
will take all reasonable precautions in accordance with applicable laws, regulations, and 
guidelines to maintain the confidentialit y of subjects’ identities.
Subjects are assigned a unique identify ing number; however, their initials and date of birth may  
also be collected and used to assist the sponsor to verify  the accuracy  of the data ( eg, to confirm 
that laboratory  results have been assigned to the correct subject).
The results of studies –containing subjects’ unique identify ing number, relevant medical 
records, and possibly  initials and dates of birth –will be recorded. They  may  be transferred to, 
and used in, other countries which may  not afford the same level of protection that applies within 
the countries where this study  is conducted. The purpose of an y suc h transfer would include: to 
support regulatory  submissions, to conduct new data anal yses to publish or present the study  
results, or to answer questions asked by  [CONTACT_1775].
For non-commercial use only
Shire CONFIDENTIAL Page 69
SHP633 -304 Protocol Am endment 2
Teduglutide 23 Mar 2017
10.5 Study Results / Publication Policy
Shire will endeavor to p ublish the results of all qualify ing, applicable, and covered studies 
according to external guidelines in a timely  manner regardless of whether the outcomes are 
perceived as positive, neutral, or negative. Additionally , Shire adheres to external guidelines (eg, 
Good Publication Practices 2) when forming a publication steering committee, which is done for 
large, multicenter Phase [ADDRESS_483277] undergo appropriate technical and 
intellectual propert y review, with Shire agreement to publish prior to release of information. The 
review is aimed at protecting the sponsor’s proprietary  information existing either at the 
commencement of the study  or generated during the study . To the extent permitted by  [CONTACT_10206], the principal investigator [INVESTIGATOR_59702] (or share with other authors) the 
copy right on his/her publications. To the extent that the principal investigator [INVESTIGATOR_10159], joint 
or shared rights, the principal investigator [INVESTIGATOR_10160] a perpetua l, irrevocable, 
royalty-free license to make and distribute copi[INVESTIGATOR_10161].
The term “publication” refers to an y public disclosure including original research articles, review 
articles, oral presentations, abstracts and posters at medical cong resses, journal supplements, 
letters to the editor, invited lectures, opi[INVESTIGATOR_10162], book chapters, electronic postings on 
medical/scientific websites, or other disclosure of the study  results, in printed, electronic, oral or 
other form.
Subject to the te rms of the paragraph below, the investigator shall have the right to publish the 
study  results, and any  background information provided by  [CONTACT_10207] y publication of study results, or necessary for other scholars to veri fy such study  
results. Notwithstanding the foregoing, no publication that incorporates the sponsor’s 
confidential information shall be submitted for publication without the sponsor’s prior written 
agreement to publish, and shall be given to the sponsor for review at least [ADDRESS_483278] publication of the study results shall be made 
by [CONTACT_10208]’s presentation of a joint, multicenter publication 
of the compi[INVESTIGATOR_10163]. If suc h a multicenter publication is not submitted to a 
journal for publication by  [CONTACT_10209] 18-month period after conclusion, abandonment, 
or termination of the study at all sites, or after the sponsor confirms there shall be no multicenter 
study  publication of the study  results, an investigator may  individuall y publish the study results 
from the specific site in accordance with this section. The investigator must, however, 
acknowledge in the publication the limitations of the single -site data being presented.
Unless otherwise required by  [CONTACT_10210], or the forum in which 
it is made, authorship will comply  with the International Committee of Medical Journal Editors 
current standards. Participation as an investigator d oes not confer an y rights to authorship of 
publications.
For non-commercial use only
Shire CONFIDENTIAL Page 70
SHP633 -304 Protocol Am endment 2
Teduglutide 23 Mar 2017
11REFERENCES
Drucker, D. J. & Yusta, B. 2014. Phy siology  and pharmacology  of the enteroendocrine hormone 
glucagon-like peptide-2. Annu Rev Physiol, 76,561-83.
Khan, F. A., Squires, R . H., L itman, H. J., Balint, J., Carter, B. A., Fisher, J. G., Horslen, S. P., 
Jaksic, T., Kocoshis, S., Martinez, J. A., Mercer, D., Rhee, S., Rudolph, J. A., Soden, J., Sudan, 
D., Superina, R. A., Teitelbaum, D. H., Venick, R., Wales, P. W. & Duggan, C. 2015. Predictors 
of Enteral Autonom y in Children with I ntestinal Failure: A Multicenter Cohort Study . J Pediatr,
167, 29-34.e1.
Mouksassi, M. S., Marier, J. F., Cy ran, J. & Vinks, A. A. 2009. Clinical trial simulations in 
pediatric patients using realistic covariates: application to teduglutide, a glucagon-like peptide-2 
analog in neonates and infants with short- bowel s yndrome. Clin Pharmacol Ther, 86,667-71.
O'Keefe, S. J., Buchman, A. L ., Fishbein, T. M., Jeejeebhoy , K. N., Jeppesen, P. B. & Shaffer, J. 
2006. Short bowel sy ndrome and intestinal failure: consensus definitions and overview. Clin 
Gastroenterol Hepatol, 4,6-10.
Squires, R. H., Duggan, C., Teitelbaum, D. H., Wales, P. W., Balint, J., Venick, R., Rhee, S., 
Sudan, D., Mercer, D., Martinez, J. A ., Carter, B. A., Soden, J., Horslen, S., Rudolph, J. A., 
Kocoshis, S., Superina, R., L awlor, S., Haller, T., Kurs -Lask y, M. & Belle, S. H. 2012. Natural 
history  of pediatric intestinal failure: initial report from the Pediatric Intestinal Failure 
Consorti um. J Pediatr, 161, 723-8.e2.
Tappenden, K. A., Edelman, J. & Joelsson, B. 2013. Teduglutide enhances structural adaptation 
of the small intestinal mucosa in patients with short bowel sy ndrome. J Clin Gastroenterol, 47,
602-7.
Thymann, T., Stoll, B., Meckl enburg, L., Burrin, D. G., Vegge, A., Qvist, N., Eriksen, T., 
Jeppesen, P. B. & Sangild, P. T. 2014. Acute effects of the glucagon -like peptide 2 analogue, 
teduglutide, on intestinal adaptation in short bowel sy ndrome. J Pediatr Gastroenterol Nutr, 58,
694-702.
US Department of Health and Human Services, National Institutes of Health & National Cancer 
Institute 2010. Common Terminology
 Criteria for Adverse Events (CTCAE).
Varni, J. W., Sherman, S. A., Burwinkle, T. M., Dickinson, P. E. & Dixon, P. 2004. The PedsQL  
Family  Impact Module: preliminary  reliability  and validity . Health Qual Life Outcomes, 2,55.
Wales, P. W., de Silva, N., Kim, J., L ecce, L., To, T. & Moore, A. 2004. Neonatal short bowel 
syndrome: population
-based estimates of incidence and mortal ity rates. J Pediatr Surg, 39,690-
5.
For non-commercial use only
Shire CONFIDENTIAL Page 71
SHP633 -304 Protocol Am endment 2
Teduglutide 23 Mar 2017
12APPENDICES
For non-commercial use only
Shire CONFIDENTIAL Page 72
SHP633 -304 Protocol Am endment 2
Teduglutide 23 Mar 2017
APPENDIX 1 PROTOCOL HISTORY
Document Date Global/Country/Site Specific
Original Protocol 08 April 2016 Global
Amendment 1 22Nov 2016 Global
Amendment 2 23Mar 2017 Global
Protocol Am endments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 1 Amendment Date
22 Nov 2016Global
Description of Change and Rationale Section(s) Affected by [CONTACT_385962].Protocol Signature [CONTACT_319504] [CONTACT_319431] -teduglutide treatment 
period, visits will take place approximately every 12 w eeks.Synopsis
Sections 3.1, 7.1.2
Figure 3 -1
The study design flow chart has been edited for clarity. Synopsis
Figure 3 -1
The collection of all actual and prescribed enteral nutrition data has been 
removed to reduce the burden on the subjects and investigators. Enteral 
nutrition data are not required as the efficacy endpoints are limited to 
parenteral support parameters.Synopsis
Table 1 -1, Table 1 -2, Table 1 -3
Sections 7.1.2 ,[IP_ADDRESS] ,[IP_ADDRESS] , 7.1.5 ,
[IP_ADDRESS], [IP_ADDRESS]
Exclusion criterion [ADDRESS_483279] been refined : 
exclusion/prohibition of treatment with growth hormone has been 
extended to [ADDRESS_483280] been clarified. Table 1 -2, Table 1 -3
Sections [IP_ADDRESS], 7.1.[ADDRESS_483281] required at the pre- treatment visit should be performed at 
the local laboratory instead of the central laboratory. This will ensure 
timely results prior to starting treatment with teduglutide.Table 1 -3
Sections [IP_ADDRESS], 7.2.6
The requirement for urine specimen collection has been revised so that a
lack of urinalysis will not constitute a protocol deviatio nfor any pediatric Table 1 -1, Table 1 -2, Table 1 -3
Section 7.2.4
For non-commercial use only
Shire CONFIDENTIAL Page 73
SHP633 -304 Protocol Am endment 2
Teduglutide 23 Mar 2017
Protocol Am endments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 1 Amendment Date
22 Nov 2016Global
Description of Change and Rationale Section(s) Affected by [CONTACT_64778] (not only for subjects wearing diapers) .
Clarification has been made that the first no -teduglutide treatment visit 
after the screening visit will occur within 2 to 12 w eeks of the screening 
(formerly within 12 weeks of screening).Synopsis
Table [ADDRESS_483282] been clarified for visits during the no -teduglutide and 
teduglutide treatment periods.Table 1 -2,Table 1 -3
Section 7.1.2
‘Specific’ has been deleted from ‘positive/specific anti-teduglutide 
antibodies’ to eliminate the redundancy. B y definition, positive samples 
must be specific (as assessed in the confirmatory assay), or otherwise
considered negative .Table [ADDRESS_483283] been removed from 
medical history.Table 1 -1 (footnote b)
Section 7.2.1
For consistency within the protocol , sigmoidoscopy has been added as the 
alternate to colonoscopy throughout the protocol. Table 1 -1, Table 1 -2, Table 1 -3
Sections 3.1, 7.1.2 , [IP_ADDRESS]
Removal of former footnote i on fecal occult blood test for clarity. Table 1 -3
Clarification has been made on circumstances when the CxW28 visit may 
be combined with the next pre-treatment or EOS/ET visit. Table 1 -3
Section 7.1.4
The text on PS support requirements over time in pediatric subjects w ith 
SBS has been clarified, and text on intestinal adaptation has been refined.Section 1.1
Status of current teduglutide approvals for use has been updated. Section 1.2, 3.1
The term ‘re -challenge’ has been replaced w ith ‘additional teduglutide 
treatment’ for clarity and consistency with other studies .Section 3.[ADDRESS_483284]’s completion of the study has been corrected for 
consistency within the protocol.Section 3.[ADDRESS_483285] been clarified.Sections 4.8.1, 4.8.2
Withdraw al by [CONTACT_7078]/guardian has been added as reason for 
discontinuation.Section 4.8.[ADDRESS_483286] if deemed appropriate to ensure sufficient 
supplies between visits.Also, documentation of all dispensed study 
medication has been clarified.Section 6.4
Clarification has been made that local laboratory results are not required to 
be entered in the eCRFs.Section 7.2.4
Collection of urine sodium and urine osmolality has been removed. Section 7.2.4
For non-commercial use only
Shire CONFIDENTIAL Page 74
SHP633 -304 Protocol Am endment 2
Teduglutide 23 Mar 2017
Protocol Am endments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 1 Amendment Date
22 Nov 2016Global
Description of Change and Rationale Section(s) Affected by [CONTACT_385980]-treatment visit if the subject met a follow -up period escape 
criterion .Section 7.2.5
Intake and output diaries (formerly in Section s7.2.11 and 7.2.12, 
respectively ) have been moved under a new Section 7.2.11 ‘Diaries’ for 
clarity, and are now Sections [IP_ADDRESS] and 7.2. 11.3, respectively. 
Information on study drug administration diary has been added in Section
[IP_ADDRESS] . Clarification has been made that only available diary data will be 
reviewed at each clinic and telephone visit.Sections 7.2.11 , [IP_ADDRESS] ,  [IP_ADDRESS], 
[IP_ADDRESS] 
Performance of d ipstick specific gravity tests by [CONTACT_385981]. It is 
now at the discretion of the investigator for all subjects, not just those in 
diapers. This change is to align with standard medical practice.Section [IP_ADDRESS]
Clarifications have been made to the language on dose interruption. Sections 8.4, 8.4.1
Unscheduled safety follow  up assessments (including visits conducted 
after EOS) are not to be recorded. How ever, clarification has been made 
that they are to be collected where requested.Section 9.1
The protocol now  refers to the data monitoring com mittee (DMC) Charter 
for the schedule of DMC reviews.Section 9.[ADDRESS_483287] been made to the Health economics and outcomes research
endpoints to include the beginning of each treatment cycle ( CxD1) as 
additional baseline. These changes are for clarity and consistency with 
other teduglutide studies.Synopsis
Section 9.9.[ADDRESS_483288] been made to the guidelines for nutritional support 
management during the study .Appendix 2
For non-commercial use only
Shire CONFIDENTIAL Page 75
SHP633 -304 Protocol Am endment 2
Teduglutide 23 Mar 2017
APPENDIX 2 GUIDELINES FOR NUTRITIONAL SUPPORT MANAGEMENT 
DURING THE STUDY
Nutritional support adjustment in volume and calories should be considered at all planned visits. 
Please consider the following clinical parameters identified as markers for adequate management 
of pediatric SBS. These parameters should also be considered for managing nutritional support 
(PS and/or oral/enteral feeding) in terms of volume and calories during the treatment period. 
Growth trajectory , including weight, height (or length), and head circumference (for pediatric 
subjec ts up to 36 months of age)
Other clinical evaluations
Serum electrol ytes
Blood urea nitrogen /creatinine levels
Changes in stool frequency  orvolume, including mixed output
Stool consistency  (ie, Bristol Stool Scale)
Urine specific gravit y
General 
consideration to possible clinical deterioration in SBS
Inability  to maintain weight and growth velocity
Diarrhea ( ≥10 bowel movements per day , ≥80 mL/kg/day  from an ostomy, or 
≥75mL/kg/day  mixed output)
Colic/vomiting frequency increased
Electrol yte chan ges or imbalance
Skin breakdown 
Adjustments should be based on the actual nutritional support in volume and calories the 
subject infuses. Subjects should remain compliant with the nutritional support prescription in 
volume and calories during the stud y.
Nutritional support constituents may  be adjusted at the discretion of the investigator.
During the [ADDRESS_483289]’s scheduled visit, no 
further changes to the prescribed nutritional support should be made.
If there is a change in enteral nutrition ( EN)
or other food or fluid intake, the investigator 
should consider this when adjusting the PS/EN support in volume and calories.
For non-commercial use only
Shire CONFIDENTIAL Page 76
SHP633 -304 Protocol Am endment 2
Teduglutide 23 Mar 2017
Figure A -1 Weaning Algorithm for Subjects Who are NOT Toilet Trained and in 
Diapers
For non-commercial use only
Shire CONFIDENTIAL Page 77
SHP633 -304 Protocol Am endment 2
Teduglutide 23 Mar 2017
Figu re A-2 Weaning Algorithm for Subjects Who are Toilet Trained and NOT in 
Diapers
For non-commercial use only
Shire CONFIDENTIAL Page 78
SHP633 -304 Protocol Am endment 2
Teduglutide 23 Mar 2017
Figure A -3 Clinical Dehydration Assessment and PS/EN Adjustment
For non-commercial use only
PROTOCOL: SHP633 -304
TITLE: A Prospective, Open -label, Long-term Safet y and Efficacy  Study of 
Teduglutide in Pediatric Patients with Short Bowel Syndrome Who 
Completed TED- C14-006 or SHP633-301
DRUG: Teduglutide
IND: IND# [ADDRESS_483290] NO.: 2016-000849-30
SPONSOR: Shire Human Genetic Therapi[INVESTIGATOR_014], Inc.
[ADDRESS_483291] , Lexington, MA [ZIP_CODE] [LOCATION_003]
PROTOCOL 
HISTORY:Amendment 3: 16 May  2018
Amendment 2: 23 Mar 2017
Amendment 1: 22 Nov 2016
Original Protocol: [ADDRESS_483292] party without the express written 
consent of Shire.
For non-commercial use only
Shire CONFIDENTIAL Page2 
SHP633-304 Protocol Amendment 3 
Teduglutide 16May2018 
PROTOCOL SIGNATURE [CONTACT_64783]'s (Shire) Approval 
Signature: i Date: -
I 
, MD PhD 
 
Global Clinical Development 
Investigator's Acknowledgement 
I have read this protocol for Shire Study SHP633-304. 
Title: A prospective, open label, long-term safety and efficacy study ofteduglutide in pediatric 
patients with short bowel syndrome who completed TED-C14-[ADDRESS_483293] fully discussed the objective(s) of this study and the contents of this protocol with the 
sponsor's representative. 
I understand that the information in this protocol is confidential and should not be disclosed, 
other than to those directly involved in the execution or the scientific/ethical review ofthe study, 
without written authorization from the sponsor. It is, however, permissible to provide the 
information contained herein to a subject in order to obtain their consent to participate. 
I agree to conduct this study according to this protocol and to comply with its requirements, 
subject to ethical and safety considerations and guidelines, and to conduct the study in 
accordance with International Conference on Harmonization (ICH) guidelines on Good Clinical 
Practice (GCP) and with the applicable regulatory requirements. 
I understand that failure to comply with the requirements of the protocol may lead to the 
termination of my participation as an investigator for this study. 
I understand that the sponsor may decide to suspend or prematurely terminate the study at any 
time for whatever reason; such a decision will be communicated to me in writing. Conversely, 
should I decide to withdraw from execution of the study I will communicate my intention 
immediately in writing to the sponsor. 
Investigator Name [CONTACT_1781]: 
(please hand print or type) 
For non-commercial use only
Shire CONFIDENTIAL Page 3
SHP633 -304 Protocol Am endment 3
Teduglutide 16 May 2018
SUMMAR Y OF CHANGES F ROM PREVIOUS VERSION
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 3 Amendment Date
16 May 2018Global
Description of Change and Rationale Section(s) Affected by [CONTACT_319472] 
.Emergency Contact [CONTACT_385982]633 -[ADDRESS_483294] been modified to accommodate 
younger chi ldren completing SHP633 -301. 
SHP633 -304 w ill evaluate long -term safety and efficacy in subjects who 
completed SHP633 -301 and will provide a mechanism for subjects who 
complete SHP633 -301 to receive additional teduglutide treatment if 
clinically indicated.  Synopsis ; Table 1-1; Section 2; 
Section 3.1; Section 4.1; 
Section 4.5; Section 6.2.2 ; 
Section 7.1.1 ; Section [IP_ADDRESS] ; 
Section 7.2.1 ; Section 9.5; 
Section 9.7.1
To minimize risk to subjects, a new escape criterion was added, allow ing 
those who had escaped during the follow -up period of a previous 
teduglutide treatment to omit the follow -up period during subsequent 
teduglutide treatment cycles. 
For subjects who p reviously escaped the follow -up period, CxW24 
assessments ca n be combined with the next pretreatment visit assessments.Synopsis ; Table 1-3;  Figure 3-1; 
Section 3.1; Section 4.6; 
Section 6.2.3 ; Section [IP_ADDRESS] ; 
Section [IP_ADDRESS] ; Section 7.1.4 ; 
Section 7.2.[ADDRESS_483295] gastrointestinal procedures .Table 1-1; Table 1-2 ; Table 1-3, 
Section 5.1; Section 7.1.1 ; Section 
7.1.2 ; Section [IP_ADDRESS] ; 
Section [IP_ADDRESS] ; Section 7.1.5
Updated the information on the clinical studies with teduglutide in pediatric 
subjects to include the results of TED -C14-006 and a description of the 
additional core study, SHP633 -301. Section 1.3
Added new PK simulation data to further support dosing. Section 3.1
Deleted text that was duplicated in other sentences of sections. Section 5.1
Deleted biological therapy (eg, antitumor necrosis factor) from the table of 
prohibited treatments as it was included in error.Table 5-[ADDRESS_483296] of laboratory tests. Table 7-1
Specified that blood pressure should be collected in the same extremity 
rather than in the same arm as blood pressure is not collected using the arm 
in small children.Section 7.2.3
Specified that s aved serum samples should be omitted for subjects 
weighing less than 10 kg and whenever local blood volume limitations are 
exceeded.Section 7.2.8
Clarified that if a child is under 2 years of age or unable to complete a 
quality of life questionnaire (due to developmental delay or other illness) it 
will not constitute a protocol deviation.Section 7.2.[ADDRESS_483297] been collected for subjects entering from TED -C14-006. Additional 
interim analyses may be conducted as needed.Section 9.4
Minor editorial changes and corrections to typographical errors (w hich do 
not modify content and/or intent of the original document ) were made.Throughout protocol
See Appendix [ADDRESS_483298] IN FORMA TION
In the event of a serious adverse event (SAE), the investigator must fax or e -mail the Shire 
Clinical Study  Adverse Event Form for Serious Adverse Events (SAEs) and Non -serious AEs as 
Required b y Protocol within 24 hours to the Shire Global Drug Safet y Department. Applicable 
fax numbers and e -mail address can be found on the form (sent under separate cover). A copy  of 
this form must also be sent to the Shire Medical Monitor by  [CONTACT_3719] e -mail using the details 
below.
, MD PhD
Email: 
Fax: 
For protocol -or safety- related issues ,the investigator must contact [CONTACT_319459]:
Primary contact [CONTACT_385971] (NA) and backup contact [CONTACT_385972] (EU)
, MD, 
Mobile: 
US Toll Free number: 
Phone:  (medical emergencies –NA)
Email: 
Primary contact [CONTACT_385983]
, MD, 
Mobile: 
Phone: 
Phone:  (medical emergencies –EU)
Email: 
In addition, the investigator may also contact [CONTACT_317344]:
, MD PhD, 
Phone: 
Mobile: 
Email: 
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_483299] 
(marketed or investigational) does not meet expectations (eg, inadequate or faulty  closure, 
product contamination) or that the product did not meet the specifications defined in the 
application for the product (eg, wrong product such that the label and contents are different 
products). For instructions on reporting AEs related to product complaints, see Section 8.
Please use the information below as applicable to report the Product Quality Complaint:
Origin of Product Quality Complaint E
-mail Address
North and South America
European Union and Rest of World
Telephone numbers (provided for reference): 
 Shire ([LOCATION_003]) 
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_483300] OF APPENDICES ................................................................................................................11
ABBREVIAT IONS .......................................................................................................................12
STUDY SYNOPSI S
......................................................................................................................14
STUDY SCHEDULE(S) ...............................................................................................................[ADDRESS_483301] Background .................................................................................................24
1.3 Clinical Studies with Teduglutide in Pediatric Subjects ..........................................25
2STUDY OBJECTIVES AND PURPOSE ..............................................................................27
2.1 Rationale for the Study .............................................................................................27
2.2 Study  Objectives ......................................................................................................27
2.2.1 Primary  Objectives .................................................................................................27
2.2.2 Secondary  Objectives .............................................................................................27
3STUDY DESIGN ...................................................................................................................28
3.1 Study  Design and Flow Chart ..................................................................................28
3.2 Duration and Study  Completion Definition .............................................................31
4STUDY POPUL ATION.........................................................................................................32
4.1 Study  Inclusion Eligibility  Criteria ..........................................................................32
4.2 Study  Exclusion Eligibility  Criteria
.........................................................................32
4.3 Teduglutide Eligibility  Criteria ................................................................................32
4.4 Teduglutide Treatment Inclusion Criteria ................................ ................................ 32
4.5 Teduglutide Treatment Exclusion Criteria ...............................................................33
4.6 Follow -up Period Escape Criteria ............................................................................34
4.7 Reproductive Potential ................................ ................................ ............................. 34
4.7.1 Female Contraception ............................................................................................34
4.8
Discontinuation of Subjects ................................ ................................ ..................... 35
4.8.1 Teduglutide Discontinuation................................ ................................ .................. 35
4.8.2 Study  Withdrawal ................................ ................................ ................................ ..35
4.8.3 Reasons for Discontinuation ................................ ................................ .................. 35
For non-commercial use only
Shire CONFIDENTIAL Page 8
SHP633 -304 Protocol Am endment 3
Teduglutide 16 May 2018
[IP_ADDRESS] Subjects ‘L ost to Follow -up’ Prior to Last Scheduled Visit ..................[ADDRESS_483302](s) ...........................................................[ADDRESS_483303] Compliance ..................................................................................................41
7
STUDY PROCEDURES........................................................................................................42
7.1 Study  Schedule .........................................................................................................42
7.1.1 Screening ................................................................................................................42
7.1.2
Visits for Subjects Not Receiving Teduglutide .....................................................42
7.1.3
Visits for Subjects Receiving Teduglutide ............................................................43
[IP_ADDRESS] Pre-treatment Visit .................................................................................43
[IP_ADDRESS] Teduglutide 
Treatment Period (CxD1 -CxW24) .....................................44
7.1.4 Teduglutide Follow -up Period ...............................................................................46
7.1.5 Study  Completion/Earl y Termination Visit (EOS/ET Visit) .................................47
7.2 Study  Evaluations and Procedures ...........................................................................47
7.2.1 Demographics, Medical History , and SBS History ................................ ............... 47
7.2.2 Physical Examination ................................ ................................ ............................. 48
7.2.3 Vital Signs, Bod y Weight, Height, Head Circumf erence and Body  Mass 
Index ......................................................................................................................48
7.2.4 Clinical L aboratory  Tests ................................ ................................ ....................... 48
7.2.5 Serum Sampling ................................ ................................ ................................ .....49
7.2.6 Pregnancy  Testing ................................ ................................ ................................ ..50
7.2.7 Antibody  Testing ................................ ................................ ................................ ...50
7.2.8 Volume of Blood ................................ ................................ ................................ ....50
For non-commercial use only
Shire CONFIDENTIAL Page 9
SHP633 -304 Protocol Am endment 3
Teduglutide 16 May 2018
7.2.9 Gastrointestinal -specific Testing ...........................................................................51
[IP_ADDRESS] Fecal Occult Blood Testing ....................................................................51
[IP_ADDRESS] Colonoscopy  or Sigmoidoscopy .............................................................51
7.2.10 Nutritional Support ................................................................................................51
7.2.11 Diaries ................................................................................................................52
[IP_ADDRESS] Study  Drug Administration Di ary
..........................................................52
[IP_ADDRESS] Intake Diary ............................................................................................52
[IP_ADDRESS] Output Diary ...........................................................................................52
7.2.12 Health
-related Quality  of L ife Assessments ..........................................................53
[IP_ADDRESS] Pediatric Quality  of Life Generic Core Scale (PedsQL ™), Acute 
version ....................................................................................................53
[IP_ADDRESS] Pediatric Quality  of Life Family  Impact Module (PedsQL™), Acute 
version ....................................................................................................54
[IP_ADDRESS] PedsQL  Gastrointestinal Symptoms Module (PedsQL ™), Acute 
version ....................................................................................................[ADDRESS_483304] .................................................................61
8.4.2 Dose Interruption Criteria Based on Drug
-Induced L iver Injury .......................... 62
For non-commercial use only
Shire CONFIDENTIAL Page 10
SHP633 -304 Protocol Am endment 3
Teduglutide 16 May 2018
8.5 Early Termination of the Clinical Study ................................ ................................ ..62
9DATA MANAGEMENT AND STATISTICAL METHODS...............................................63
9.1 Data Collection .........................................................................................................63
9.2 Clinical Data Management .......................................................................................63
9.3 Statistical Analy
sis Process ......................................................................................63
9.4 Planned Interim Anal ysis, and Data Monitoring Committee ...................................63
9.5
Sample Size Calculation and Power Considerations................................................64
9.6 Study  Population ......................................................................................................64
9.7 Efficacy  Anal yses.....................................................................................................64
9.7.1 Efficacy  Endpoints ................................ ................................ ................................ .64
9.8 Safety  Anal yses........................................................................................................64
9.8.1 Safety  Endpoints ....................................................................................................64
9.9 Other Anal yses.........................................................................................................66
9.9.1 Health
-related Quality  of L ife Anal yses................................................................66
10SPONSOR’S AND I NVEST IGATOR’S RESPONSIBIL
ITIES...........................................67
10.1
Sponsor’s Responsibilities .......................................................................................67
10.1.1 Good Clinical Practice Compliance .......................................................................67
10.1.2 Indemnity /Liability  and Insurance .........................................................................67
10.1.3 Public Posting of Study  Information ......................................................................67
10.1.4 Submission of Summary  of Clinical Study  Report to Competent Authorities 
of Member States Concerned and Ethics Committees ...........................................67
10.1.5 Study  Suspension, Termination, and Completion
..................................................68
10.2 Investigator’s Responsibilities .................................................................................68
10.2.1 Good Clinical Practice Compliance .......................................................................68
10.2.2 Protocol Adherence and Investigator Agreement ..................................................68
10.2.3 Documentation and Retention of Records .............................................................69
[IP_ADDRESS] Case Report Forms .................................................................................69
[IP_ADDRESS] Recording, Access, and Retention of Source Data and Study  
Documents ..............................................................................................69
[IP_ADDRESS] Audit/I nspection ................................ ................................ ..................... 69
[IP_ADDRESS] Financial Disclosure ................................ ................................ ............... [ADDRESS_483305] or Ethics Committee ................................ .................. 70
10.4 Privacy  and Confidentiality ................................ ................................ ...................... 71
10.5 Study  Results / Publication Policy ................................ ................................ ........... [ADDRESS_483306]  OF TABLES
Table 1-1: Schedule of Events Required for All Subjects ..............................................19
Table 1
-2: Schedule of Events for Subjects Not Receiving Teduglutide .......................20
Table 1
-3: Schedule of Events for Subjects While Receiving Teduglutide ....................21
Table 5
-1: Prohibited Treatment .....................................................................................37
Table 7
-1: List of Laboratory  Tests ................................................................................49
Table 7
-2: Approximate Volume of Blood to be Drawn from Each Subject 
Annually ........................................................................................................50
Table 7
-3: Developmentally Appropriate PedsQL™Generic Core Scales .....................[ADDRESS_483307]  OF FIGURES
Figure 3 -
1: Study  Design Flow Chart ..............................................................................[ADDRESS_483308] aspartate aminotransferase
-HCG beta-human chorionic gonadotropin
BMI body  mass index
CRA clinical research associate
CRO contract research organization
CSR clinical study  report
CTCAE Common Terminology  Criteria for Adverse Events
DILI drug-induced livery  injury
DMC data monitoring committee
DPP-[ADDRESS_483309]
IV intravenous
IWRS interactive web -based response sy stem
For non-commercial use only
Shire CONFIDENTIAL Page 13
SHP633 -304 Protocol Am endment 3
Teduglutide 16 May 2018
MedDRA Medical Dictionary  for Regulatory  Activities
NA North America
NCI National Cancer Institute
NDA new drug application
NTT no-teduglutide treatment
PedsQL Pediatric Quality  of Life inventory
PS parenteral support
PT/INR prothrombin time/international normalized ratio
QD once dail y
SAE serious 
adverse event
SAP statistical analy sis plan
SBS short bowel sy ndrome
SC subcutaneous
SOC standard of care
t1/[ADDRESS_483310] upper limit of normal
US [LOCATION_002]
WHO -DD World Health Organization – Drug Dictionary
For non-commercial use only
Shire CONFIDENTIAL Page 14
SHP633 -304 Protocol Am endment 3
Teduglutide 16 May 2018
STUDY  SYNOPSIS
Protocol num ber: SHP633 -304 Drug: Teduglutide
Title of the study: A Prospective, Open -label, Long -term Safety and Efficacy Study of Teduglutide in Pediatric 
Patients with Short Bowel Syndrome (SBS) Who Completed TED -C14-006 or SHP633 -301
Number of subjects (total and for each treatm ent arm):
Approximately [ADDRESS_483311] of care treatment arms, are expected to enroll in this extension study. This study will enroll up to as 
many subjects as complete the TED -C14-006 and SHP633 -301 studies.
Investigator(s): Multicenter study
Site(s) and Region(s): 
Approximately 28 investigational sites in North America and Europe w ill participate in this extension study
Study period (planned):
October 2016 –September 2019Clinical phase: 3 Extension
Objectives:
Prim ary: To evaluate the long -term safety and tolerability of teduglutide treatment in pediatric subjects w ith SBS.
Secondary: To evaluate long -term efficacy of teduglutide treatment in pediatric subjects with SBS.
Rationale:
This is a Phase 3, prospective, open -label, long -term extension study to evaluate the safety and efficacy of 
teduglutide in pediatric subjects with short bow el syndrome (SBS) w ho completed either the TED -C14-006 or 
SHP633 -301 studies (the core studies). In addition to evaluating the long -term safety and durability of efficacy 
after [ADDRESS_483312] of care (SOC) treatment arms in TED -C14-[ADDRESS_483313], dose, and m ode of administration:
This study will allow repeat doses of teduglutide 0.05 mg/kg subcutaneous (SC) once daily (QD) injection for 
eligible pediatric subjects. There is no active comparator or reference product.
Methodology:
This is a Phase 3, prospective, open -label, long-term extension study to evaluate the safety and efficacy of 
teduglutide in pediatric subjects who completed the TED -C14-006 or SHP633 -301 studies (core studies).
Once the informed consent (and if applicable, informed assent) have been reviewed and signed, demographics, 
and updates to medical history and short bow el syndrome histo ry will be obtained .Subjects not receiving 
teduglutide treatment (ie, in a no -teduglutide treatment [NTT] period), w ill be seen approximately every 12 weeks 
for safety, parenteral support (PS) requirements, and quality of life. The first NTT visit after the screening visit 
will occur within 2 to 12 w eeks of the screening visit . At any point after screening, including during a NTT 
period, subjects who meet ≥[ADDRESS_483314], and parent agree to proceed w ith teduglutide therapy .
After the pre treatment visit, subjects who meet ≥1 of the teduglutide treatment inclusion criteria, and meet none 
of the teduglutide treatment exclusion criteria, will start a 2 8-week cycle, consisting of 24 weeks of teduglutide 
treatment at 0.05 mg/kg SC once daily, followed by a 4 -week follow -up period (during which no teduglutide is 
administered) (Figure 3 -1). During the 28 -week cycle, clinic visits will occur at weeks 1, 2, 4 , 6, 9, 12, 16, 20, 24, 
and 28. Phone visits are required approximately 1 w eek after adjustments in PS during the teduglutide treatment 
period (betw een weeks 1 and 24), and w eekly during the teduglutide follow -up period (between weeks 24 and 
28). Safety an d PS requirements will be evaluated at every visit, and quality of life assessments will be made 
approximately every [ADDRESS_483315] may "escape" the follow -upperiod early and proceed immediately to another pretreatment 
visit.  Follow ing completion of the [ADDRESS_483316] w ill proceed to an NTT visit or another 
pretreatment visit within approximately 12 w eeks.
Atallsitevisits andtelephon econtacts, safety willbemonitored andnutritional support willbereviewed and
adjusted asneeded. Tomaintain consistency across centers, allattempts should bemade tofollow thenutritional
support adjustment guidelines (developed withSBS expert inputandprovided intheprotocol) fordecisions
regarding PSsupport reduction andadvances inenteral feeds based onweightgain, urine andstool output, and
clinical stability. Departure from theguidelines, however, isnotconsidered aprotocol deviation .(Appendix 2).
Study Design Flow Chart 
Figure legend: Safety and efficacy data for subjects not receiving teduglutide treatment are captured approximately every 
12 weeks, but subjects may proceed to the pre treatment visit at any time in order to assess eligibility for teduglutide 
therapy. Eligible subjects will enter a 28 -week teduglutide cycle. During this cycle, subjects will return to the site for 
safety and efficacy assessments at weeks 1, 2, 4, 6, 9, 12, 16, 20, and 24 ( solid black lines ). Ph one visits are required 
approximately 1 week after adjustments in PS during the intervening weeks between weeks 2 and 24 ( dashed grey 
lines ). Subjects discontinue teduglutide at week 24 and enter a 4 -week follow -up (no-treatment) period, during which 
phone visits will be performed weekly ( solid grey lines ). If an escape criterion is met at week 24 or during the follow -up 
period, subjects may proceed directly to another pretreatment visit.
Study Inclusion Criteria: 
The subject will be considered eligible f or the study if they meet allof the study inclusion criteria. Teduglutide 
treatment eligibility does not impact study eligibility.
1.Subject provides w ritten informed consent (subject, parent or legal guardian and, as appropriate, 
informed assent) to participate in the study before completing any study -related procedures.
2.Subject completed the TED -C14-006 or SHP633 -301 studies (including subjects in the standard of care 
treatment arms). Subjects are considered to have completed SHP633 -[ADDRESS_483317] understands and is willing and able to fully adhere to study requirements as defined in this 
protocol. 
Study Exclusion Criteria: There are no exclusion criteria for this study.
Teduglutide Eligibility Criteria: Subjects are eligible for teduglutide treatment if at least one ( ≥1) of the 
teduglutide treatment inclusion criteria, and none of the teduglutide treatment exclusion criteria, are met. In 
addition, the investigator and the subject (and/or parent or legal guardian, as appropriate) must agree to proceed 
with treatment.
Teduglutide Treatment Inclusion Criteria :
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_483318] is teduglutide -naïve, receiving PS, and unable to significantly reduce PS or advance enteral feeds 
(eg, 10% or less change in PS or a dvance in feeds) for at least 3 months prior to and during the 
teduglutide pretreatment visit, as assessed by [CONTACT_093]. Transient instability for events such as 
interruption of central access or treatment for sepsis is allowed if the PS returns to within 10% of 
baseline prior to the event.
2.Subject w as previously treated w ith teduglutide and at least one of the following criteria is satisfied:
a.Increasing PS requirements follow ing teduglutide discontinuation.
b.Decreased PS requirement during prior teduglutide treatment, follow ed by  [CONTACT_319475].
c.Deteriorating nutritional status (eg, weight loss or growth failure) despi[INVESTIGATOR_319391] (EN) following teduglutide discontinuation.
d.Dete riorating fluid or electrolyte status despi[INVESTIGATOR_319361].
e.Severe diarrhea related to teduglutide discontinuation.
Teduglutide Treatment Exclusion Criteria:
1.Body  weight <5 kg at the pretreatment visit.
2.Unresected gastrointestinal (GI) polyp, known polyposis condition, prema lignant change, or malignancy, 
in the GI tract.
3.History of cancer in the previous [ADDRESS_483319] asty or other major intestinal surgery within 3 months preceding the teduglutide 
pretreatment visit. Insertion of a feeding tube, anastomotic ulcer repair, minor intestinal resections 
≤10cm, and endoscopic procedures are allow ed.
5.Intestinal or other major surgery planned or scheduled to occur during the 28 -week cycle.
6.Clinically significant intestinal stricture or obstruction.
7.Clinically significant, active or recurrent pancreatic or biliary disease.
8.Active, severe, or unstable, clinically significant hepa tic impairment or injury, including the followi ng 
laboratory values at the pretreatment visit:
a.Total bilirubin ≥2× upper limit of normal (ULN)
b.Aspartate aminotransferase (AST) ≥7 × ULN
c.Alanine aminotransferase (ALT) ≥7 × ULN
9.Renal dysfunction shown by [CONTACT_385984]  50mL/min/1.[ADDRESS_483320] repair, or patent ductus arteriosus ligation.
11.Participation in a clinical study using an experimental drug (other than glutamine, Omegaven, or 
Smoflipid) w ithin 3 months or 5.5 half -lives of the experimental drug, whiche ver is longer, prior to the 
pretreatment visit and for the duration of the 28 -week cycle.
12.Treatment with analogs of glucagon -like peptide -1 (GLP -1), glucagon -like peptide -2 (GLP -2) (not 
including teduglutide), insulin -like growth factor -1 (IGF -1), or grow th hormone, within 3 months 
preceding the teduglutide pretreatment visit.
13.Treatment with octreotide or dipeptidyl peptidase 4 (DPP -4) inhibitors w ithin [ADDRESS_483321], closely -related 
compounds, or any of the stated ingredients.
15.Known history of alcohol or other substance abuse within 1 year prior to the pre treatment visit.
For non-commercial use only
Shire CONFIDENTIAL Page 17
SHP633 -304 Protocol Am endment 3
Teduglutide 16 May 2018
16.Pregnant or lactating female subjects.
17.Sexually active female subjects of child -bearing potential unwilling to use approved contraception 
during teduglutide treatment and for 30 days after the treatment period.
18.Any condition, disease, illness, or circumstance that in the investigator’s opi[INVESTIGATOR_319362], prevents completion of the study, or interferes with analysis of the study results.
Follow -up Period Escape Criteria: At the discretion of the investigator, the follow -up period may be interrupted 
or omitted and the subject ma y proceed directly to the pre treatment visit, if ≥1 of the foll owing criteria is met:
1.Increasing PS requirements follow ing teduglutide discontinuation
2.Deteriorating nutritional status (eg, weight loss or growth failure) despi[INVESTIGATOR_319392].
3.Deteriorating fluid or electrol yte status despi[INVESTIGATOR_319364].
4.Severe diarrhea related to teduglutide discontinuation.
5.The subject escaped during the follow -up period of SHP633 -[ADDRESS_483322] involvem ent in the study:
A subject w ill be considered enrolled in the study once the subject has provided signed consent, and meets all of 
the Study Inclusion Criteria. Subjects may participate in multiple NTT periods and/or multiple [ADDRESS_483323] has access (as needed) to teduglutide. 
The subject’s maximum duration of participation is expected to be approximately [ADDRESS_483324] has not withdrawn early from the study for any reason 
prior to completing End of Study (EOS) visit.
Planned duration of no-teduglutide treatm ent periods : variable, depending on disease course 
Planned duratio n of the teduglutide pre treatm ent visit: 1 to 21 days
Planned cycle duration : 28 weeks. Each cycle consists of 24 w eeks of teduglutide treatment followed 
by a 4 -week follow -up period (no treatment)
Endpoints and statistical analysis: 
The safety population will consist of all enrolled subjects. The safety population will be used for both 
safety and efficacy analysis.
Efficacy Endpoints
Efficacy endpoints will be analyzed at the end of eac hteduglutide treatment period (w eek 24 or end of treatment 
[EOT]), and at each study visit, relative to the baseline of the core study (TED -C14-006 or SHP633 -301) and/or 
first exposure to teduglutide. The follow ing efficacy endpoints will be analyzed: 
Reduction in PS volume of at least 20%
Absolute and relative change in PS volume
Com plete weaning off PS
Change in days per w eek of PS
For non-commercial use only
Shire CONFIDENTIAL Page 18
SHP633 -304 Protocol Am endment 3
Teduglutide 16 May 2018
Health Econom ics and Outcom es Research Endpoints 
Health economics and outcomes research endpoints will be analyzed at approximately 12 -week intervals 
(weeks 12 and 24 of each teduglutide treatment cycle, and every 12 w eeks for subjects not on teduglutide), 
relative to the study baseline. The beginning of each treatment cycle (CxD1) will be an additional baseline.
Change in Pediatric Quality of Life Inventory (PedsQL) score
Change in PedsQL Family Impact Module score
Change in PedsQL Gastrointestinal Symptoms Module Sub -Scales scores: 
Food and Drink Limits
Diarrhea 
Safety Endpoints 
The follow ing safety endpoints will be analyzed:
Adverse events
Vital signs, including temperature, heart rate, blood pressure
Laboratory safety data (ie, clinical chemistry, hematology, and urinalysis)
Urine output
Stool output
Antibodies to teduglutide
Gastrointestinal -specific testin g, including fecal occult blood testing and colonoscopy or sigmoidoscopy
Z-scores for w eight, height (or length), head circumference (up to 36 months of age), and body mass index 
Statistical Methodology for Efficacy Analysis
No claims of statistical signi ficance will be made; how ever, 95% confidence intervals will be provided, if 
applicable. Continuous variables, including those assessed on a discrete scale, will be summarized using 
descriptive statistics including number of subjects, mean, median, standar d deviation , maximum, and minimum. 
For categorical variables, statistical summaries will include number of subjects and percentages.
Statistical Methodology for Safety Analysis 
Safety data, including laboratory tests and vital signs assessments, will be summarized by [CONTACT_765]. AEs will also be 
collected and summarized. Descriptive statistics will be calculated for quantitative safety data as w ell as for the 
difference from baseline, if applicable. Frequency counts will be compi[INVESTIGATOR_385948].
Sample Size Justification 
As this is an extension study, the maximum number of subjects was determined by [CONTACT_385985] -C14-006 
and SHP633 -301.
For non-commercial use only
Shire CONFIDENTIAL Page 19
SHP633 -304 Protocol Am endment 3
Teduglutide 16 May 2018
STUDY  SCHEDULE(S) 
Table 1-1: Schedule of Events Required for All Subjects 
PeriodScreening End of Study or Early Termination
Scr EOS/ET
Visit Type Site Site
Informed consent/assentaX
Study eligibility X
Demographics, medical historyb, SBS historycX
Dispense intake and output diaries X
Evaluate teduglutide treatment inclusion criteriadX
Adverse events X X
Concomitant medications and procedures X X
Physical examination and vital signs, including weight X
Height and head circumferenceeX
Review intake and output diariesfX
Record PS prescription and adjust as neededgX X
Safety laboratory testshX
PedsQL Generic Core Scale/ PedsQL Family Impact Module/ 
PedsQL Gastrointestinal Symptoms Module Sub -ScalesX
Antibodies to teduglutideiX
Fecal occult blood testingj(X)
Colonoscopy or sigmoidoscopyk(X)
Pregnancy testingl(X)
FOBT = fecal occult blood testing; FOCBP = female of child-bearing potential; EOS =end of study; ET=early termination; 
GI=gastrointestinal; NTx=no treatment; PedsQL=Pediatric Quality of Life Inventory; PS=parenteral support; SBS=Short Bowel 
Syndrome; Scr =Screening.
aInformed Consent (and informed assent, if applicable) must be ob tained prior to performing any study-related procedures; 
consent (and informed assent, if applicable) may be obtained anytime during the EOS visit for the TED -C14 -[ADDRESS_483325] has any changes to the SBS history that had been collected at the baseline of the TED -C14 -006 or SHP633- 301, 
then the updated SBS history will be collected.
dSubjects who meet ≥[ADDRESS_483326], 
and parent or legal guardian agrees to proceed with teduglutide therapy ( Table 1 -3).
eHead circumference will be measured in subjects 36 months of age and younger.
fThe intake d iary should be completed daily for a minimum of 2 weeks prior to the EOS/ET visit. The output diary should be 
completed daily over a 48 -hour period of nutritional stability before the EOS/ET visit.
gPS adjustments should be made after review of any availa ble intake and output diaries and the safety lab data according to the 
guidance for nutrition support adjustment provided in Appendix [ADDRESS_483327] of clinical chemistry, hematology, and urinalysis, with re sults processed 
by a central laboratory. Urine specimen collection should be attempted as part of the safety labs, but lack of urinalysis wil l not 
constitute a protocol deviation.
iRequired for all teduglutide -exposed subjects
jFOBT should be performed o n teduglutide -exposed subjects on an annual basis, approximately every 48-60 weeks at a 
minimum.
kThe need for colonoscopy/sigmoidoscopy in response to a positive FOBT during a no -teduglutide treatment period is at the 
discretion of the investigator, but all teduglutide -exposed subjects will undergo colonoscopy/sigmoidoscopy after they have 
received the equivalent of 2 treatment cycles (48 weeks of study drug exposure), and subjects who continue to receive teduglu tide 
will undergo colonoscopy/sigmoidoscopy at [ADDRESS_483328] 30 days after study 
drug discontinuation.
Note: (X) denotes conditional requirement for a given assessment if the subject meets certain conditions per protocol.
For non-commercial use only
Shire CONFIDENTIAL Page 20
SHP633 -304 Protocol Am endment 3
Teduglutide 16 May 2018
Table 1-2: Schedule of Events for Subjects Not Receiving Teduglutide 
Visit Number NTx
Visit Type Site
Visit FrequencyaEvery 12 weeks 
Window (days)b±[ADDRESS_483329] as neededfX
Safety laboratory testsgX
PedsQL Generic Core Scale/PedsQL Family Impact Module/ 
PedsQL Gastrointestinal Symptoms Module Sub-ScalesX
Antibodies to teduglutideh(X)
Fecal occult blood testingiAnnually 
Colonoscopy or sigmoidoscopyj(X)
Serum samplekEvery 24 w eeks
FOBT = fecal occult blood testing; NTT = no-teduglutide treatment; PedsQL = Pediatric Quality of Life Inventory; PS= 
parenteral support; TED = teduglutide.
aThe first NTx visit following the screening visit must occur within [ADDRESS_483330] NTx visit in the current no- teduglutide treatment period.
cSubjects w ho meet ≥[ADDRESS_483331], 
and parent or guardian agree to proceed with teduglutide therapy ( Table 1 -3).
dHead circumference will be measured in subjects [ADDRESS_483332] actual PS volume and hours per day, completed daily for a minimum of 2 weeks prior to each study 
visit (see Section [IP_ADDRESS] ). Urine and stool output should be recorded in the output diary over a 48 -hour period of nutritional 
stability before every clinic visit (see Section [IP_ADDRESS] for more detail).
fPS adjustments should be made after review of the intake and output diaries and the safety lab data according to the guidance
for nutrition support adjustment provided in Appendix [ADDRESS_483333] follow -up samples collected 
every 12 weeks during the study until a negative result is obtained.
iFOBT should be performed on teduglutide -exposed subjects on an annual basis, approxi mately every 48 -60 weeks at a 
minimum.
jThe need for colonoscopy/sigmoidoscopy in response to a positive FOBT during a no -teduglutide treatment period is at the 
discretion of the investigator, but all teduglutide -exposed subjects will undergo colonoscopy/ sigmoidoscopy after they have 
received the equivalent of 2 treatment cycles (48 weeks of study drug exposure) and subjects who continue to receive teduglutide 
will undergo colonoscopy/sigmoidoscopy at 5 year intervals or more often as needed. See Section 7.2.9 for details.
kLack of collection of serum samples will not constitute a protocol deviation.
Note: (X) denotes conditional requirement for a given assessment if the subject meets certain conditions per protocol.
For non-commercial use only
Shire CONFIDENTIAL Page 21
SHP633 -304 Protocol Am endment 3
Teduglutide 16 May 2018
Table 1-3: Schedule of Events for Subjects While Receiving Teduglutide
PeriodPre-
treat mentTeduglutide Treat mentFollow -
up
Visit Number Pxa Cx
D1Cx
W1Cx
W2
Phone contact [CONTACT_319408] [ADDRESS_483334] is required approximately 1 week after PS adjustmentCxW24 
(EOT)CxW25 
CxW26 
CxW27CxW28c
Visit Type Site Site Site Site Site Site Site Site Site Site Site PhonebSite
Cycle Day -21 to 0 1 8 15 29 43 64 85 113 141 169176
197 183
190
Window  (days)d-21 to 0 ±2 ±2 ±2 ±2 ±4 ±4 ±4 ±4 ±4 ±2 ±2
Evaluate teduglutide 
eligibility (inclusion 
and exclusion) criteriaX Xe
Dispense intake and 
output diariesX X X X X X X X X X X X
Adverse events X X X X X X X X X X X X X
Concomitant 
medications and 
proceduresX X X X X X X X X X X X X
Physical examination 
and vital signs, 
including weightX X X X X X X X X X X X
Height and head 
circumferencef X X X X
Review intake and 
output diariesg X X X X X X X X X X X X X
Record PS Rx and 
adjust as neededh X X X X X X X X X X X X X
Safety laboratory 
testsiXiX X X X X X X X X X (X) X
PedsQL Generic Core 
Scale/ Family Impact 
Module/ GI 
Symptoms Module 
Sub-ScalesX X X
Antibodies to 
teduglutidej X X X X
Fecal occult blood 
testingX X X
Colonoscopy /
sigmoidoscopyk (X) (X) (X)
For non-commercial use only
Shire CONFIDENTIAL Page 22
SHP633 -304 Protocol Am endment 3
Teduglutide 16 May 2018
Table 1-3: Schedule of Events for Subjects While Receiving Teduglutide
PeriodPre-
treat mentTeduglutide Treat mentFollow -
up
Pregnancy testinglX X X X X X X X X
Serum samplemX X
Evaluate escape 
criterian XpX X
Dispense study drugoX X X X X X X X X
EOS =end of study; EOT = end of treatment; ET = early termination; FOBT = fecal occult blood test; FOCBP = female of child -bearing potential; FU = follow -up; 
GI=gastrointestinal; PedsQL = Pediatric Quality of Life Inventory; PS= parenteral support; SBS =Short Bowel Syndrome; SC = subcutaneous; Scr =Screening; 
TED =teduglutide; Tx = treatment.
aIf the first pre treatment visit (P1) follows the screening visit, it must occur within 12 weeks of screening.
bPhone visits are required approximately 1 week after adjustments i n PS. The assessments to be performed at phone visits are the same as those described for CxW25 -27 (except 
for evaluation of escape criteria). 
cThe investigator may combine the CxW28 visit with the next pretreatment visit if at least one escape criterion is met at the CxW28 visit, and the pretreatment assessments occur 
within [ADDRESS_483335] is completing the study at the CxW28 visit, the EOS/ET visit ( Table 1 -1) will take place in lieu of the CxW28 visit.
dVisit windows are relative to the CxD1 visit.
eEligibility will need to be re -confirmed prior to the first dose in the cycle. Negative urine pregnancy test is required prior to the first dose of teduglut ide, but results of other labs 
obtained at the CxD1 visit are not required to determine teduglutide treatment eligibility.
fHead circumference will be measured in subjects [ADDRESS_483336] actual PS volume and hours per day. Intake diaries should be completed daily for a minimum of 2 w eeks immediately prior to each clinic visit (except 
at pretreatment visit), for [ADDRESS_483337] PT/INR at the pretreatment 
visit. Additional collection will occ ur if a potential drug -induced liver injury signal is observed. Urine specimen collection should be attempted as part of the safety labs, but lack 
of urinalysis will not constitute a protocol deviation.
jSamples collected on CxD1 must be drawn prior to fi rst administration of teduglutide. Samples collected while subjects are receiving teduglutide (CxW12 and CxW24) must be 
drawn at least 14 hours after dosing.
kThe teduglutide -naïve subjects age 12 and older will undergo colonoscopy /sigmoidoscopy at the pr etreatment visit if one has not been performed within 1 year. Subjects of any 
age with newly positive FOBT results at the pretreatment visit for which a readily detectable cause cannot be identified (eg, anal fissure) will undergo a 
colonoscopy /sigmoidosco pyprior to receiving teduglutide. If newly positive FOBT results (for which a readily detectable cause cannot be identified) ar e obtained at the end of a 
teduglutide treatment cycle (CxW24/EOT), colonoscopy /sigmoidoscopy will be performed. The need for co lonoscopy /sigmoidoscopy in response to positive FOBTs at CxW12 is 
at the discretion of the investigator. Teduglutide -exposed subjects who have received the equivalent of 2 treatment cycles (48 weeks of study drug exposure) will undergo 
colonoscopy /sigmoido scopy . See Section 7.2.[ADDRESS_483338] is performed on all FOCBP at the teduglutide pretreatment visit (when the pretreatment and screening v isits are combined, the serum pregnancy test 
should be performed at the local laboratory). Urine pregnancy tests will be administered at all other visits according to the study schedules, or if pregnancy is suspected , or as 
specified per protocol upon withdrawal of the subject from the study.
mLack of collection of serum samples will not consti tute a protocol deviation.
For non-commercial use only
Shire CONFIDENTIAL Page 23
SHP633 -304 Protocol Am endment 3
Teduglutide 16 May 2018
Table 1-3: Schedule of Events for Subjects While Receiving Teduglutide
PeriodPre-
treat mentTeduglutide Treat mentFollow -
up
nIf escape criteria are met, the subject may proceed directly to another pretreatment visit at the discretion of the investiga tor.
oThe first SC injection of teduglutide in treatment -naïve subjects will be administered under the supervision of the investigator/designee after which the subject will be observ ed 
for hypersensitivity reactions for at least 4 hours. The site of administrat ion (arm, thigh, abdomen) of the first teduglutide dose must be specified and recorded in the eCRF. See 
Section 6.2.[ADDRESS_483339] occur 
within 7 days of the CxW 24 visit. 
Note: (X) denotes conditional requirement for a given assessment if the subject meets certain conditions per protocol.
For non-commercial use only
Shire CONFIDENTIAL Page 24
SHP633 -304 Protocol Amendment 3
Teduglutide 16 May 2018
1 BACKGROUND INFORMATI ON
1.1 Indication and Current Treatment Options 
Short bowel sy ndrome (SBS) is a rare disorder resulting from congenital abnormalities or severe 
intestinal diseases that result in major surgical resections of the small intestine. I t is estimated 
that, at most, there are a few hundred pediatric subjects 1 y ear and older with SBS ( Khan et al., 
2015; Wales et al., 2004 ).Unlike the adult population, the majority  of cases of SBS in pediatric 
subjects are due to congenital anomalies or catastrophic events
 that occur during infancy . 
Although the small intestine is capable of remarkable adaptation, excessive loss of absorptive 
surface area or specialized functions can lead to dependence on parenteral nutrition or 
intravenous (IV) fluids (parenteral support [PS]). Treatment of both pedi atric and adult patients 
is focused on achieving adequate intestinal absorption to allow for minimization or 
discontinuation of PS. About 30% of infants with SBS become independent of PS requirements 
within 12 months of the initial insult, and an additiona l 10% wean off PS within 24 months. 
After this time, linear intestinal growth slows. About 60% of pediatric subjects with SBS are able 
to become independent of PS within 5 y ears of the initial diagnosis ( Khan et al., 2015 ). 
Nevertheless, despi[INVESTIGATOR_3062], many  pediatric subjects remain dependent 
on PS. Complications of long -term PS include liver disease, catheter -related blood stream 
infections, central line- associated venous thrombosis and dwindling central venous access. 
Sepsis is the leading cause of death in these patients and quality  of life is poor ( Squires et al., 
2012). Accelerating the adaptive process and achieving enteral autonomy  is an urgent goal for all 
patients with SBS who are dependent on PS ( Khan et al., 2015; Squires et al., 2012 ).
Intestinal adaptation is driven by  [CONTACT_319436] ( Drucker 
and Yusta, 2014 ).Chief among these is hormones glucagon -like peptide 2 (GL P
-2), which is 
secreted from L -type enteroendocrine cells that reside in the intestinal epi[INVESTIGATOR_319365]. Resection of these regions may  impair the adaptive response by  [CONTACT_319410] -2. 
1.[ADDRESS_483340] Background 
Teduglutide is a novel, re combinant analog of naturally occurring human GLP -2 that regulates 
the functional and structural integrity  of the cells lining the gastrointestinal (GI) tract. 
Teduglutide is a 33 -amino acid peptide that differs from native GLP- 2 in the substitution of 
glycine for alanine at the second position at the N -
terminus. As a result, teduglutide demonstrates 
resistance to degradation by  [CONTACT_20597] l peptidase- IV (DPP -4) and therefore maintains a longer 
elimination half -life (t 1/2) in adults of approximately  2 hours c ompared to the native peptide, 
which has a t 1/2 of approximately  7 minutes. Teduglutide has been shown in animal studies and 
previous human clinical trials to increase villus height and cry pt depth in the intestinal 
epi[INVESTIGATOR_2130], thereb y increasing the absor ptive surface area of the intestines ( Tappenden et al., 
2013; Thymann et al., 2014 ). The European Commission granted a centralized marketing 
authorization valid throughout the European Union (EU) for teduglutide (Revestive™) on [ADDRESS_483341] 2012 and a New Drug Application (NDA) for teduglutide (Gattex®) was approved b y the 
[LOCATION_002] (US) Food and Drug Administration (FDA) on 21 Decem ber2012 for the 
treatment of adult patients with SBS who are dependent on PS. Teduglutide has also been 
approved for use in adult patients with SBS in Canada and Switzerland. On 29 Jun 2016, the 
For non-commercial use only
Shire CONFIDENTIAL Page 25
SHP633 -304 Protocol Amendment 3
Teduglutide 16 May 2018
European Commission granted an extension of the Market Autho rization for teduglutide 
(REVESTIVE ™) for the treatment of patients aged 1 year and above with SBS; patients should be 
stable following a period of intestinal adaptation.
1.3 Clinical Studies with Teduglutide in Pediatric Subjects
One Phase 3 stud y, TED -C13-003, was completed in pediatric SBS subjects in the US and 
[LOCATION_008] ([LOCATION_006]). In this study , teduglutide was administered to 3 cohorts of pediatric 
subjects from ages 1 -17. Thirty -
seven pediatric subjects received teduglutide at doses of 0.0125, 
0.025, or 0.05 mg/kg/day for [ADDRESS_483342] of care (SOC) cohort. There were clear dose -dependent effects of 
teduglutide seen at the 0.025 and 0.05 mg/kg/day  doses compared to SOC and the 0.0125 
mg/kg/day  dose. In the 0.025 mg/kg/day  cohort there was a reduction in PS volume at w eek 12 
of 37%, including complete independence from PS support in [ADDRESS_483343], and a reduction of 
3.94 hours per day  infusion time. I n the 0.05 mg/kg/day  cohort there w as a reduction in PS 
volume at w eek 12 of 39%, including complete independence from PS support in 3 subjects, and 
a reduction of 4.18 hours per day  infusion time. Teduglutide was generall y safe and well 
tolerated b y pediatric subjects in all dosing cohorts. There were no deaths during the stud y and 
no treatment -emergent serious adverse events (TESAEs) related to teduglutide were reported. No 
discontinuations from study  were due to adverse events (AEs).
TED -C14-006 is a recently  completed study  of pediatric sub jects through 17 y ears which 
included 2 treatment arms: a teduglutide treatment arm and a SOC treatment arm. Subjects in 
both arms participated in a [ADDRESS_483344] 
medical therap y for SBS; while those in the teduglutide treatment arm received daily  
subcutaneous (SC) injection s of teduglutide (study drug) in addition to standard medical therap y. 
The subjects enrolling in the teduglutide treatment arm were randomized 1:1 in a double -blinded 
manner into 2 parallel dose groups: 0.025 mg/kg/day  or 0.05 mg/kg/day  of teduglutide 
admi nistered subcutaneously  for 24 weeks.  Compared to the SOC , treatment of pediatric 
subjects with SBS with teduglutide resulted in clinically  meaningful reductions in PN/I V 
volume, calories, day s per week, and hours per day .  A total 10% of subjects who rec eived 
teduglutide achieved enteral autonomy  within 24 weeks despi[INVESTIGATOR_319393]/IV for 
several years.  Teduglutide treatment also resulted in increases in EN volume and caloric intake 
as well as plasma citrulline.  Although the differences in ef ficacy  between the 0.025 and 0.05 
mg/kg dose groups were small, a consistently  greater effect was seen in the 0.05 mg/kg dose in 
all efficacy  parameters.  The PK properties were well characterized in this population and were 
consistent with the prior [ADDRESS_483345] medic al therap y for SBS; while those in the teduglutide treatment arm 
will receive daily  SC injections of 0.05 mg/kg teduglutide in addition to standard medical 
therap y. Similar to the treatment cycles in SHP633 -304, subjects in SHP633- [ADDRESS_483346] version of the investigator’s brochure for the overall risk/benefit 
assessment and the most accurate and current information regarding the drug metabolism, 
pharmacokinetics, efficacy  and safet y of teduglutide (SHP633). 
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_483347]- time treatment of te duglutide -naïve 
subjects who participated in the SOC treatment arms in TED- C14-006 or SHP633 -301.
2.2 Study Objectives
2.2.1 Primary Objectives
The primary  objective of the study  is to evaluate the long -term safet y and tolerability of 
teduglutide treatment in pediat ric subjects with SBS who completed TED -C14-006 or SHP633 -
301. 
2.2.2 Secondary Objectives
The secondary  objective of this study  is to evaluate the long -term efficacy  of teduglutide 
treatment in pediatric subjects with SBS who completed TED -C14-006 or SHP633-301.
For non-commercial use only
Shire CONFIDENTIAL Page 28
SHP633 -304 Protocol Amendment 3
Teduglutide 16 May 2018
3 STUDY DESIGN
3.1 Study Design and Flow Chart
This is a Phase 3, prospective, open -label, long -term extension study  to evaluate the safet y and 
efficacy  of teduglutide in pediatric subjects who completed the TED -C14-006 or SHP633-301 
studies (the "core studies"). At the time of entry  into TED -C14-006, subjects were less than 
18years of age, were dependent on parenteral nutrition to provide at least 30% of their caloric or 
fluid needs, and had not been able to significantly reduce PS for at least [ADDRESS_483348] of care instead of 
teduglutide treatment. Subjects who elected to receive teduglutide were randomized to 
0.025 mg/kg or 0.05 mg/kg once dail y (QD) dosing in a double -blind ed manner. 
At the time of entry  into SHP633- 304, subjects were [ADDRESS_483349] 35% of their caloric or fluid needs, and 
had not been able to significantly  reduce PS for a t least [ADDRESS_483350] of care or teduglutide 0.05 mg/kg SC 
QD. 
Approximately  [ADDRESS_483351] meet ≥1 of the teduglutide treatment inclusion criter ia and 
none of the teduglutide treatment exclusion criteria.  
Additional Teduglutide Treatment
Subjects not receiving teduglutide treatment (ie, in a “no- teduglutide treatment period”), will be 
seen approximately  every  12 weeks for safety , parenteral support (PS) requirements, and qualit y 
of life. At an y point during a no -teduglutide treatment perio d, subjects who meet ≥[ADDRESS_483352], and 
parent agree to proceed with teduglutide therapy .
Rationale: Some pediatric subjects may  have a durable beneficial effe ct after 24 weeks of 
teduglutide treatment and thus long -term follow -up without additional teduglutide treatment may  
be appropriate. However, there may  be some pediatric subjects who deteriorate or stop 
improving after discontinuation of teduglutide treatm ent. I n these pediatric subjects, additional 
teduglutide treatment may  be beneficial. 
Dose Selection 
Analy sis suggested that pediatric patients, ages 1 to 17 y ears old, are likel y to require the same 
dose as used in adults, namely  0.05 mg/kg/day  (Mouksassi et al., 2009 ).In this extension study , 
all subjects who enter a teduglutide treatment cy cle will receive 0.05 mg/kg SC QD.
Rationale: Teduglutide is approved for adult use in the US and EU, and for pediatric use in the 
EU, at a dose of 0.05 mg/kg SC once daily . The completed pediatric studies (TED -C13-003 and 
TED -C14-006) demonstrated that teduglutide dosing at 0.025 and 0.05 mg/kg/day  was 
associated with a favorable benefit/risk profile. In addition, population pharmacokinetic 
modeling and simulations were conducted to determine the effective dose to be used in pediatric 
subjects using data from 8 adult clinical studies including adult Phase 1 studies and Phases 2/3 
For non-commercial use only
Shire CONFIDENTIAL Page 29
SHP633 -304 Protocol Amendment 3
Teduglutide 16 May 2018
studies as wel l as the pediatric study  (TED -C13-003) and suggested that the dose in pediatric 
subjects is likely  to be same as the dose in adults ( O'Keefe et al., 2006 ). 
Further PK simulation was conducted based on the population PK model previously  established 
and a virtual population of 1000 pediatric patients created based on Centers for Disease Control 
(CDC) growth charts in the target age group (4 to 12 months) and taking into consideration bod y 
weights of pediatric patients with SBS enrolled in study  TED -C13-003 (approximately  15% 
lower than healthy subjects in the same age group). Monte Carlo simulations for all age groups 
were performed according to the SC dosing regimens of 0.0125, 0.025 and 0.05 mg/kg every  
24hours. Rich concentration- time profiles were simulated with the customized population P K 
model to derive the exposure metrics area under the concentration curve at steady  state (AUC ss) 
and maximum concentration at steady  state (C max,ss). Following 0.05 mg/kg daily  SC 
administration, the median C max,ss of teduglutide in infants (24.9 ng/mL ) was within 20% of that 
observed in the 2 to 4 and 4 to 6 y ears age groups (26.9 and 29.4 ng/mL , respectively ); and 
approximately  ~28% lower than that in adult patients with SBS. The clinical package in 
conjunction with C maxwas considered to support teduglu tide dose of 0.05 mg/kg since AUC ss
was previousl y shown not to correlate with efficacy. Thus, the 0.05 mg/kg dose is proposed for 
testing in all age groups.
Duration of Treatment
The duration of teduglutide treatment in this study mirrors that of the TED -C14-[ADDRESS_483353] may  be 
evaluated immediatel y for additional teduglutide treatment. Subjects who clinically deteriorate or 
stop improving at an y time after the end of the follow
-up period will also be assessed for 
additional treatment.
Rationale: During the teduglutide treatment cy cle, visit frequency  is similar to frequencies 
performed in TED -C13-003, TED -C14-006, and SHP633 -[ADDRESS_483354] deteriorated quickly  after treatment interruption (ie, escaped from a prior follow-up 
period) may  be evaluated immediately  for eligibility  for additi onal treatment when they  reach the 
week 24 visit. 
Measures and Parameters
Following the review and signing of the informed consent (and informed assent, if applicable), 
screening visit procedures will begin including demographics, and updates to medical h istory  
and SBS history . Subjects who meet ≥1 of the teduglutide treatment inclusion criteria may  
proceed to the pretreatment visit.
After the pretreatment visit, subjects who still meet ≥1 of the teduglutide treatment inclusion 
criteria, and meet none of the teduglutide treatment exclusion criteria, will start a 28- week cy cle, 
consisting of 24 weeks of teduglutide treatment at 0.05 mg/kg SC once daily , followed by  a 4-
week follow -up (no treatment) period ( Figure 3-1). During the 28 -week cycle, clinic visits will 
occur at weeks 1, 2, 4, 6, 9, 12, 16, 20, 24, and 28. Phone visits are required approximately  
For non-commercial use only
Shire CONFIDENTIAL Page 30
SHP633 -304 Protocol Amendment 3
Teduglutide 16 May 2018
1 week after adjustments in PS during the teduglutide treatment period (between weeks 1- 24), 
and weekl y during the teduglutide follow -up period (between wee ks 24 and 28).
Safety  and PS requirements will be evaluated on a weekl y basis, and quality of life assessments 
will be made approximately  every  12 weeks. At all site visits and telephone contacts, safety  will 
be monitored and nutritional support will be re viewed and adjusted as needed. To maintain 
consistency  across centers, all attempts should be made to follow the nutritional support 
adjustment guidelines (developed with SBS expert input and provided in the protocol) for 
decisions regarding PS reduction and advances in enteral feeds based on weight gain, urine and 
stool output, and clinical stability . Departure from the guidelines, however, is not considered a 
protocol deviation ( Appendix 2 ).
Rationale: Measures of long term safet y will include adverse eve nts, growth parameters and anti-
drug antibodies. Measure of long term efficacy  will include durability  of effect as measured b y 
reduction in PS and improvement in pediatric quality  of life measures (PedsQL , PedsQL Family  
Impact Module). A reduction in PS v olume of at least 20% at end of treatment (EOT) was used 
as the primary  endpoint in pi[INVESTIGATOR_30338] 3 adult clinical trials and the completed phase 3 
pediatric stud y (TED -C13-003), and will be used as an endpoint in this extension study . In 
previous clinical studies, a reduction of this magnitude was associated with a reduction in the 
number of day s per week of PS, and increases in enteral intake. Reduction in volume and time of 
PS due to improved enteral absorption may  provide a pediatric subject with opport unities for 
more age -appropriate activities including oral rehabilitation. Quality  of life assessments will be 
performed in this study  to quantitate this effect.
Teduglutide has been found to have a targeted intestinotrophic effect. Taking into account the
patient population and the pharmacologic effect of teduglutide, GI -specific screening tests, 
including fecal occult blood testing and colonoscopy /sigmoidoscopy , which are commonl y part 
of the routine care of these subjects, will be performed to ensure saf ety. This study  captures long -
term safet y data on polyps and other colonic mucosal changes in teduglutide -exposed subjects 
using the surveillance strategy  proposed in Section 7.2.9. 
For non-commercial use only
Shire CONFIDENTIAL Page 31
SHP633 -304 Protocol Amendment 3
Teduglutide 16 May 2018
Figure 3-1: Study Design Flow Chart
Figure legend: Safety and efficacy data for subjects not receiving teduglutide treatment are captured approximately every 
12weeks, but subjects may proceed to the pretreatment visit at any time in order to assess eligibility for teduglutide therapy. 
Eligible subjects will enter a 28 -week teduglutide cycle. During this cycle, subjects will return to the site for safety and efficacy 
assessments at weeks 1, 2, 4, 6, 9, 12, 16, 20, and 24 ( solid black lines ). Phone visits are required approximate ly 1 week after 
adjustments in PS during the intervening weeks between weeks 2 and 24 ( dashed grey lines ). Subjects discontinue teduglutide at 
week 24 and enter a 4 -week follow-up (no -treatment) period, during which phone visits will be performed weekly ( solid grey 
lines ). Ifan escape criterion is met at w eek [ADDRESS_483355]’s maximum duration of participation is 
expected to be approxima tely [ADDRESS_483356] has not withdrawn 
early from the stud y for any reason prior to completing the End of Study (EOS) visit.
The stud y completion date is defined as the date the final subject, across all sites, completes their 
final protocol -defined assessment. Please note that this includes the follow -up visit or contact 
(last safet y contact), whichever is later. The stud y completion d ate will be used to ascertain 
timing for study  results posting and reporting.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_483357] review and sign the informed consent (and informed assent, if applicable) 
before an y stud y-related procedures specified in the protocol are performed. Teduglutide 
treatment eligibility  does not impact study  eligibility .
4.[ADDRESS_483358] will not be considered eligible for the study  without meeting all of the criteria below:
1.Subject provides written informed cons ent (subject, parent or legal guardian and, as 
appropriate, subject informed assent) to participate in the study  before completing any  
study -related procedures. 
2. Subject completed the TED- C14-006 or SHP633 -301 studies (including subjects in the 
standard of care treatment arms).   Subjects are considered to have completed SHP633-
[ADDRESS_483359] 1 (≥1) of the teduglutide treatment 
inclusion criteria, and none of the teduglutide treatment exclusion criteria are met. In addition, 
the investigator and the subject (and/or parent or legal guardian, as appropriate) must agree to 
proceed with treatment.
4.[ADDRESS_483360] is teduglutide -naïve, receiving PS, and una ble to significantl y reduce PS or 
advance enteral feeds (eg, 10% or less change in PS or advance in feeds) for at least 
3months prior to and during the teduglutide pretreatment visit, as assessed by  [CONTACT_1275]. Transient instability  for events such as interruption of central access or 
treatment for sepsis is allowed if the PS returns to within 10% of baseline prior to the 
event.
2.Subject was previousl y treated with teduglutide and at least 1 of the following criteria is 
satisfied:
a.Increasing PS requir ements following teduglutide discontinuation.
b.Decreased PS requirement during prior teduglutide treatment, followed by  
[CONTACT_319412].
c.Deteriorating nutritional status eg, weight loss or growth failure) despi[INVESTIGATOR_319394] (EN) following teduglutide discontinuation.
d.Deteriorating fluid or electroly te status despi[INVESTIGATOR_319367].
For non-commercial use only
Shire CONFIDENTIAL Page 33
SHP633 -304 Protocol Amendment 3
Teduglutide 16 May 2018
e.Severe diarrhea related to teduglutide discontinuation.
4.5 Teduglutide Treatment Exclusion Criteria
1.Body weight <[ADDRESS_483361]
3.History  of cancer in the previous 5 y ears except surgically  curative skin cancers
4.Serial transverse enteroplasty  or other major intestinal surgery  within 3 months 
preceding the teduglutide pretreatment visit. I nsertion of a feeding tube, anastomotic 
ulcer repair, minor intestinal resections ≤10 cm , and endoscopic procedures are allowed.
5.Intestinal or other major surgery planned or scheduled to occur during the 28 -week cy cle
6.Clinically  significant intestinal stricture or obstruction
7.Clinically  significant, active or recurrent pancreatic or biliary  disease
8.Active, severe, or unstable, clinically  significant hepatic impairment or injury , including 
the followi ng laboratory  values at the pre treatment visit:
a.Total bilirubin ≥2× upper limit of normal (ULN)
b.Aspartate aminotransferase (AST) ≥7 × ULN
c.Alanine aminotransferase (ALT) ≥7 × ULN
9.Renal dy sfunction shown by  [CONTACT_319476] 
50mL/min/1.[ADDRESS_483362] repair, or patent ductus 
arteriosus ligation
11.Participation in a clinical study  using an experimental drug (other than glutamine, 
Omegaven, or Smoflipid) within 3 months or 5.5 half -lives of the experimental drug, 
whichever is longer, prior to the pretreatment visit and for the duration of the 28 -
week 
cycle
12.Treatment with analogs of glucagon -like peptide -1 (GL P-1), glucagon -like peptide -2 
(GLP-2) (not including teduglutide), insulin -like growth fa ctor-1 (IGF -1), or growth 
hormone, within 3 months preceding the teduglutide pretreatment visit.
13.Treatment with octreotide or dipeptidy l peptidase 4 (DPP -4) inhibitors within [ADDRESS_483363], 
closely -related compounds, or any  of the stated ingredients
15.Known history  of alcohol or other substance abuse within 1 y ear prior to the 
pretreatment visit
16. Pregnant or lactating female subjects 
17.Sexually  active female subjects of child -bearing potential unwilling to use approved 
contraception during teduglutide treatment and for 30 day s after the treatment period 
For non-commercial use only
Shire CONFIDENTIAL Page 34
SHP633 -304 Protocol Amendment 3
Teduglutide 16 May 2018
18.Any condition, disease, illness, or circumstance that in the investigator’s opi[INVESTIGATOR_319368] y undue risk, prevents completion of the study, or interferes with 
analysis of the study  results.
4.[ADDRESS_483364] may proceed di rectly  to the pretreatment visit, if ≥1 of the following criteria is met:
1.Increasing PS requirements following teduglutide discontinuation.
2.Deteriorating nutritional status (eg, weight loss or growth failure) despi[INVESTIGATOR_319395].
3.Deteriorating fluid or electrolyte status despi[INVESTIGATOR_319370].
4. Severe diarrhea related to teduglutide discontinuation.
5.The subject escaped during the follow -up period of SHP633- [ADDRESS_483365]. 
Tobe eligible for treatment with teduglutide, female pediatric subjects and adolescent subjects 
should be either:
Pre-menarchal and either Tanner Stage 1 or less than age 9 years, or
Females of child -bearing potential (FOCBP) with a negative serum beta- huma n chorionic 
gonadotropin ( -HCG) pregnancy  test at the teduglutide pretreatment visit .Females of 
child- bearing potential must agree to abstain from sexual activity  that could result in 
pregnancy  or agree to use acceptable methods of contraception.
Acceptable methods of contraception are:
True abstinence: Abstention of sexual activity  that is in line with the preferred and usual 
lifesty le of the subject. (Periodic abstinence [eg, calendar, ovulation, sy mptothermal, 
post-ovulation methods] and withdra wal are not acceptable methods of contraception).
Intrauterine devices plus condoms
For non-commercial use only
Shire CONFIDENTIAL Page 35
SHP633 -304 Protocol Amendment 3
Teduglutide 16 May 2018
Double-barrier methods (eg, condoms and diaphragms with spermicidal gel or foam)
Hormonal contraceptives (oral, depot, patch, injectable, or vaginal ring), stabilized for a t 
least 30 day s prior to the pretreatment visit, plus condoms. Note: if subject becomes 
sexually  active during the study , they  should use one of the other acceptable methods 
noted above in addition to the hormonal contraceptive until it has been stabilized for 
30days.
4.[ADDRESS_483366] wishes to remain in the study , the evaluations listed for the EOT visit a re to be 
performed. A 4- week follow -up period will ensue, consisting of weekl y telephone visits 
(CxW25 -27) and the week 28 clinic visit (CxW28). The subject would then enter a 
no-teduglutide treatment (NTT) period and could be evaluated for subsequent tedu glutide 
treatment eligibility  according to the study  schedules. Comments (spontaneous or elicited) or 
complaints made by  [CONTACT_1706]. The reason for 
permanent treatment discontinuation, dates of investigational prod uct administered (including 
last date of treatment), and amount of investigational product taken must be recorded in the 
electronic case report form (eCRF) and source documents, as des
cribed in Section 4.8.3. The 
investigator is encouraged to discuss withd
rawal of a subject from investigational product with 
the medical monitor, when possible.
4.8.[ADDRESS_483367] will 
then be asked to return 4 weeks later for the earl y termination (ET) visit, and will be contact[CONTACT_319413] y by [CONTACT_319445] -up.
If a subject withdraws from the study  during a NTT period, the e valuations listed for the ET visit 
are to be performed as soon and completel y as possible. 
Subjects who withdraw from the study will not be replaced.
4.8.3 Reasons for Discontinuation
The reason(s) for permanent discontinuation of treatment and/or withdrawal from the study  must 
be determined b y the investigator, and recorded in the subject’s medical record and in the eCRF. 
If a subject is withdrawn for more than [ADDRESS_483368] clinically  relevant r eason should be entered in the eCRF.
Reasons for discontinuation include, but are not limited to:
For non-commercial use only
Shire CONFIDENTIAL Page 36
SHP633 -304 Protocol Amendment 3
Teduglutide 16 May 2018
Adverse event 
Protocol deviation
Lack of efficacy  
Physician decision 
Withdrawal by  [CONTACT_1130] 
Withdrawal by  [CONTACT_7078]/guardian
Lost to follow -up
Pregnancy  (Discontinuation of treatment onl y) 
Death 
Other 
[IP_ADDRESS] Subjects ‘Lost to Follow -up’ Prior to Last Scheduled Visit
A minimum of [ADDRESS_483369] (office visit or telephone contact). At least [ADDRESS_483370]’s last 
known address via courier or mail (with an acknowledgement of receipt request) asking that they  
return to th e site for final safet y evaluations, and return an y unused investigational product.
For non-commercial use only
Shire CONFIDENTIAL Page 37
SHP633 -304 Protocol Amendment 3
Teduglutide 16 May 2018
5 CONCOMITANT TREATMENT
5.1 Concomitant Medications and Procedures
Concomitant treatment refers to all treatment taken between the dates of informed consent and 
EOS, inclusive. Concomitant medications and procedures will be assessed at each site visit, and 
include all non -study  treatments (medications, herbal treatments, vitamins, invasive and 
diagnostic procedures). Concomitant treatment information must be recorded on the appro priate 
eCRF page. Details of medication changes and/or dosages will be recorded on the eCRF.  
5.1.[ADDRESS_483371] medical therap
y for SBS should be continued.
5.1.2 Prohibited Treatment
The mechanism of action of teduglutide may  increase enteral absorption of drugs (eg, motility  
medication including narcotics and opi[INVESTIGATOR_20574], warfarin, 
psychotropi[INVESTIGATOR_1102], metronidazole, digoxin), so consideration should be given to modify ing 
concomitant enteral medication regimens. Down -titration of concomitant enteral medications 
should be considered when drugs, especially  those with a narrow therapeutic range, are given at 
dosages that are higher than usual.
The following medications are prohibited during teduglutide treatment and within the provided 
timeframe prior to the pretreatment visit:
Table 5-1: Prohibited Treatment
Prior Therapy Time Restriction Prior to 
the Pre treatment Visit
Native/synthetic glucagon -like peptide -2 (not -including teduglutide) Any
Glucagon-like peptide- [ADDRESS_483372] is teduglutide, which will be provided in sterile, single- use 3 mL  vials 
containing 5 mg or 1.25 mg teduglutide as a white ly ophilized powder to be reconstituted before 
use with 0.5 mL  sterile water for injection. In addition to the active ingredient (teduglutide), each 
vial of teduglu tide contains L -histidine, mannitol, monobasic sodium phosphate monohy drate, 
and dibasic sodium phosphate as excipi[INVESTIGATOR_840]. Additional information is provided in the current 
SHP633 investigator’s brochure.
6.1.[ADDRESS_483373](s)
6.2.[ADDRESS_483374] Management
An interactive web -based response s ystem (IWRS) will be used for screening and enrolling 
subjects, recording subject visits, investigational product supply  dispensation and management, 
inventory  management and supply  ordering, investigational product expi[INVESTIGATOR_49093], and return of investigational product. Please refer to the Study Manual for 
additional details regarding the IWRS. 
The I WRS will also be used for creating, tracking, and confirming investigational product 
shipments. A user manual with specific functions and instructions for the IWRS will be provided 
to the site, and site personnel will receive training.
6.2.[ADDRESS_483375], and/or 
parent/guardian agree to proceed with treatment, a formal evaluation of teduglutide inclusion and 
exclusion criteria will be performed at the pretreatment visit ( Table 1-3). 
6.2.[ADDRESS_483376] will start a teduglutide treatment period, consisting of 24 weeks of 
teduglutide treatment at 0.05 mg/kg SC once daily . The initial dose will be calculated based on 
body  weight measured at the teduglutide pretreatment visit, and adjusted as needed, ba sed on 
body  weight measured at w eek12 (CxW12). No other adjustments to dose will be made during 
the teduglutide treatment period, unless discussed with the sponsor’s medical monitor. 
Following reconstitution, teduglutide will be administered b y SC injection QD into 1 of the 
4quadrants of the abdomen (in subjects without a stoma) or into either the thigh or arm. For 
subjects with a stoma, the quadrant of the abdomen containing the stoma should not be used. 
Teduglutide should be used as soon as possible after reconstitution, but no more than [ADDRESS_483377] 
4 hours during their initial dosing visit. The site of administration (arm, thigh, and abdomen) of 
the first teduglutide dose must be specified and recorded in the eCRF. 
Detailed instructions for reconstitution and injection of the investigational product can be found 
in the I nstructions for Use. 
At the end of each [ADDRESS_483378] may  proceed d irectly  to another Pre -Treatment visit to assess 
treatment eligibility  for another cy cle (Section 4.6). Following the completion of the 4-week 
follow -up, the subject will continue in the study  off teduglutide until teduglutide treatment 
eligibility  criteri a are again met. Additional [ADDRESS_483379](s) container. 
The study  drug will be packaged, labeled, and shipped to the study  site by  [CONTACT_98634]. Kits containing [ADDRESS_483380] is packaged in the following conditions:
Teduglutide wil l be provided in a sterile, single -use, glass vial as a l yophilized powder, to be 
reconstituted with 0.[ADDRESS_483381] be kept in a locked area with access restricted to specific study  personnel. Study  
drug will be stored refrigerated at a temperature between 2 to 8°C (35.6 to 46.4°F) unt il 
dispensed to a subject. Once dispensed to a subject, the study  drug can be stored refrigerated or 
up to a controlled room temperature (acceptable range of 2 to 25°C, or 35.6 to 77°F). 
Parent/guardian will be instructed to keep the subject’s stud y drug a nd sterile water diluent at 
controlled room temperature. If there are concerns that the controlled room temperature cannot 
be maintained, the stud y drug may be refrigerated. The study  drug is for single use only , and 
should be used within [ADDRESS_483382] is maintained within an established temperature ran ge. The investigator is responsible 
for ensuring that the temperature is monitored throughout the duration of the study and that 
records are maintained; the temperature should be monitored continuously  by [CONTACT_3570]-house sy stem, a mechanical recor ding device such as a calibrated chart recorder, or by  [CONTACT_10179], such that both minimum and maximum thermometric values over a specific time period 
can be recorded and retrieved as required. Such a device (ie, certified min/max thermometer) 
would requi re manual resetting upon each recording. The sponsor must be notified immediately  
upon discovery  of any  excursion from the established range. Temperature excursions will require 
site investigation as to cause and remediation. The sponsor will determine the ultimate impact of 
excursions on the investigational product and will provide supportive documentation as 
necessary . Under no circumstances should the product be dispensed to subjects until the impact 
has been determined and the product is deemed appropri ate for use b y the sponsor.
The sponsor should be notified immediately  if there are an y changes to the storage area of the 
investigational product that could affect the integrity  of the product(s), eg, fumigation of a 
storage room.
Investigational products are distributed b y the pharmacy or nominated member of the stud y 
team. The pharmacist/nominated team member will enter the unique subject identifier on the 
investigational product bottle/carton labels, as they are distributed. 
6.[ADDRESS_483383] will be made available to the sponsor’s site monitor for the purpose of accounting for 
all clinical supplies. Any  discrepancy  or deficiency  will be recorded and will include an 
explanation. All supplies sent to the investigator must be accounted for and in no case will 
clinical supplies be used in any  unauthorized situation.
For non-commercial use only
Shire CONFIDENTIAL Page 41
SHP633 -304 Protocol Amendment 3
Teduglutide 16 May 2018
The investigator has overall responsibility  for administering/dispensing investigational product. 
Where permissible, tasks may  be delegated to a qualified designee (eg, a pharmacist) who is 
adequatel y trained in the protocol and who works under the direct supervision of the investigator. 
This delegati on must be documented in the applicable study  delegation of authority  form.
The investigator or his/her designee (as documented by  [CONTACT_49121] y form) will dispense the investigational product only to subjects eligible 
for teduglutide treatment following the procedures set out in the study  protocol. All dispensed 
study  medication will be documented in the interactive response technology  system and/or other 
investigational product record (eg, investigation p roduct accountability  form). The investigator is 
responsible for assuring the retrieval of all stud y supplies from subjects.
All used and unused study  drug vials must be returned by  [CONTACT_20608]/or parent/guardian, 
and will be retained at the site. If deemed appropriate, the investigator or his/her designee may  
dispense the unused study  drug vials to the same subject. All original containers, whether empty  
or containing stud y drug will be returned to the pharmacy. Returned stud y drugs will NOT be 
relabe led or reassigned for use by  [CONTACT_23837]. Contents of the study  drug containers will not 
be combined. All used and unused vials must be returned to the distribution center according to 
the sponsor’s instruction. No vial/kit may  be destroy ed on site with out approval by  [CONTACT_456]. 
Please see the Pharmacy  Manual for additional information.
6.[ADDRESS_483384] and empty /used 
investigational product packaging to every  visit. Drug accountability  will be assessed at the 
container/packaging level for unused investigational product that is contained within the original 
tamper -evident sealed container (eg, bottles, tray s, vials) or at the individual count level for 
opened containers/packagi
ng. The pharmacist/nominated person will record details on the drug 
accountability  form.
Compliance with study  drug is calculated from subject diaries. Of those subjects eligible for 
teduglutide treatment, subjects who have received 80% of the planned dose s administered will be 
assessed as being compliant with the study  protocol.
For non-commercial use only
Shire CONFIDENTIAL Page 42
SHP633 -304 Protocol Amendment 3
Teduglutide 16 May 2018
7 STUDY PROCEDURES
7.1 Study Schedule
Detailed study  procedures and assessments to be performed for subjects throughout the study  are 
outlined in the Schedule of Assessments ( Table 1 -1,Table 1 -2, and Table 1 -3) and must be 
referred to in conjunction with the instructions provided in th
is section. 
7.1.1 Screening 
Prior to performing an y study-related procedures (including those related to screening), the 
investigator or his/her designee must obtain written informed consent (and assent, as applicable) 
from the subject. A subject will have approximately [ADDRESS_483385] occur within 12 weeks of screening for a pretreatment visit, 
and within 2 to 12 weeks of screening for an NTx visit.
The screening visit (Scr) assessments and procedures, beginning with informed consent, will be 
performed as outline d in Table 1-1, and as detailed below :
Informed consent, and informed assent (if applicable), is obtained
Study  eligibility  is determined. A screen failure is a subject who has given informed 
consent and failed to meet the Study  Inclusion Eligibility  Crite ria. Subjects cannot be 
rescreened once they  have been designated as a screen failure. 
Demographics, updates to medical history  and SBS history
Intake and output diaries are dispensed
Evaluate teduglutide treatment inclusion criteria 
Adverse events, concomitant medications and concomitant procedures
7.1.2 Visits for Subjects Not Receiving Teduglutide
While outside of the 28- week teduglutide -treatment cy cle, subjects will be followed 
approximately  every  12weeks for safety  and efficacy  assessments. No -teduglutid e treatment 
visits are numbered sequentially  (NT1, NT2, etc.), even if interrupted by  [CONTACT_319415]. 
The visit window (±7 days) is relative to the first NTx visit in the current NTT period. 
Assessments will be performed as outlined in Table 1 -2and described below .
Intake and output diaries are dispensed
Evaluate teduglutide treatment inclusion criteria
Adverse events, concomitant medications and concomitant procedures
Physical examination and vital signs, including weight
For non-commercial use only
Shire CONFIDENTIAL Page 43
SHP633 -304 Protocol Amendment 3
Teduglutide 16 May 2018
Height and head circumfere nce
Review intake and output diaries
Record PS prescription and adjust as needed
Safety  Laboratory  Tests (ie, clinical chemistry , hematology , and urinaly sis)
PedsQL  Generic Core Scale/PedsQL Family  Impact Module/ PedsQL  Gastrointestinal 
Symptoms Module Sub -Scales
Antibodies to teduglutide, if and when required
Fecal occult blood testing, as indicated (Section [IP_ADDRESS])
Colonoscopy /sigmoidoscopy , as indicated (see Section [IP_ADDRESS])
Serum sample, as indicated
Teduglutide treatment may  be considered at any  time during the NTT period. If the investigator 
and the subject (and parent or legal guardian, as appropriate) agrees to proceed with treatment if 
the subject is eligible, the subject may  proceed to the pretre atment visit immediately  to determine 
eligibility . 
7.1.3 Visits for Subjects Receiving Teduglutide
[IP_ADDRESS] Pre-treatment Visit
Subjects who meet at least [ADDRESS_483386] dose administration (CxD1) during an y teduglutide treatment cy cle. I n general, 
pretreatment assessments may  occur over a period of up to 21 day s. The teduglutide pretreatment 
visit (Px) assessments and procedures will be performed as in Table 1-3 and as described below:
Evaluate teduglutide eligibility  (treatment inclusion/exclusion criteria) 
Dispense intake and output diaries
Adverse events, concomitant medications and concomitant procedures
Fecal occult blood testing 
For non-commercial use only
Shire CONFIDENTIAL Page 44
SHP633 -304 Protocol Amendment 3
Teduglutide 16 May 2018
Gastrointestinal -specific testing, including colonoscopy  or sigmoidoscopy  as indicated
Physical examination and vital signs, including weight
Height and head circumference
Review intake and output diaries
Record PS prescription and adjust as needed.
Safety  Laboratory  Tests 
(In addition to clinical chemistry , hematology , and urinaly sis, labs at this visit include 
prothrombin time [PT] international normalized ratio [I NR]. Subsequent prothrombin 
time/ international normalized ratio [PT/I NR]measurement is only  required to evaluate 
for suspected drug -induced liver injury  [DILI]). 
Serum pregnancy  testing, if applicable (when the pretreatment and screening visits are 
combined, the serum pregnancy  test should be performed at the local laboratory )
Serum sample 
[IP_ADDRESS] Teduglutide Treatment Period (CxD1 -CxW24)
The open
-label teduglutide treatment period will comprise [ADDRESS_483387] administration (Visit CxD1). 
Visit CxD1
Assessments and procedures at this visit will be performed as outlined Table 1 -3and as 
described below. 
Two weeks of intake diary data are required before drug is administered at CxD1.
Confirm teduglutide treatment eligibility
Dispense intake and output diaries
Adverse events, concomitant medications and concomitant procedures
Physical examination and vital signs, including weight 
Height and head circumference
Review intake and output diaries
Record PS prescription and adjust as needed 
For non-commercial use only
Shire CONFIDENTIAL Page 45
SHP633 -304 Protocol Amendment 3
Teduglutide 16 May 2018
Safety  laboratory tests
Quality  of life measurements 
Antibodies to teduglutide
Pregnancy  testing (urine), if applicable
Dispense study  drug
Site Visits during Teduglutide Treatment Period
Subjects will return for clinic visits on cy cle weeks 1, 2, 4, 6, 9, 12, 16, 20, and 24/EOT. 
Assessments and procedures at these visits will be performed as outlined in Table 1-3 and as 
described below:
Dispense/review intake and output diaries (every effort should be made to complete 
2weeks of intake diary  entries prior to each clinic visit and to complete 48 hours of 
output diary  entries during a period of nutritional stability  prior to each clinic visit)
Physical examination and vital signs, including weight
Record PS prescription and adjust as needed
Safety  laboratory tests 
Urine pre gnancy  testing for FOCBP (CxW4, CxW9, CxW12, CxW16, CxW20, CxW24)
Study  drug dispensation (except for CxW24)
Adverse events, concomitant medications and concomitant procedures
In addition, at CxW12 and CxW24 Visits ONLY , the following procedures will be performed:
Height and head circumference
Antibodies to teduglutide
Fecal occult blood testing (FOBT)
GI-specific testing, including colonoscop y or sigmoidoscopy  as indicated 
Quality  of life measurements 
At CxW24 ONLY , a serum sample is collected and stored for future analysis. This sample will 
not be used for genetic testing and lack of collection will not constitute a protocol deviation.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_483388] 1 escape criterion is met at the 
CxW24 visit and the pretreatment assessments occur within 7 day s of the CxW24 visit.
Phone Visits 
Phone visits are required approximately  1 week after adjustments in PS during the te duglutide 
treatment period. Phone visit assessments and procedures are outlined in Table 1 -3and described 
below:
Review intake and output diaries
Safety  laboratory  tests (clinical chemistry  and urinaly sis)
Record PS prescription and adjust as needed
Obtain AEs, concomitant medications, and concomitant procedures  
Evaluate escape criteria
7.1.4 Teduglutide Follow -up Period
The safet y follow -up period for this protocol is 4 weeks (w eeks 25 – 28 of the cy cle). Phone 
visits will occur on cy cle weeks 25, 26, and [ADDRESS_483389] may  
proceed directl y to another pretreatment visit at the investigator’s discretion. The investigator 
may combine the CxW24 or CxW28 visits with the next pretreatment visit if at least 1escape 
criterion is met at the CxW24 or CxW28 visits, and the pretreatment assessments occur within 
7days of the CxW24 or CxW28 visit. I f a subject is completing the study  at the CxW28 visit, the 
EOS/ET visit (Section 7.1.5 ) will take place in lieu of t he CxW28 visit. Otherwise, following 
completion of the [ADDRESS_483390] will proceed to an NTT visit within 
approximately  12 weeks.
At cy cle week 28 (CxW28), subjects will return to the study  site. In addition to the assessments 
perform ed at weeks 25-27, the following procedures will be performed at CxW28 ONLY:
Dispense intake and output diaries 
Physical examination and vital signs, including weight
Antibodies to teduglutide
Pregnancy  testing (urine), if applicable
Evaluate escape crite ria
For non-commercial use only
Shire CONFIDENTIAL Page 47
SHP633 -304 Protocol Amendment 3
Teduglutide 16 May 2018
7.1.5 Study Completion/Early Termination Visit (EOS/ET Visit) 
All subjects will return to the study  site for the end of study /early termination visit (EOS/ET). 
Assessments and procedures at this visit will be performed as outlined in Table 1-[ADDRESS_483391] discontinues the study prematurel y, the assessments for the EOS/ET 
Visit are to be performed as completel y as possible (see Section 4.8.2).
Adverse events, concomitant medications and concomitant procedures  
Physical examination and vital signs, including weight
Height and head circumference
Review intake and output diaries (the intake diary should be completed daily  for a 
minimum of 2 weeks prior to the EOS/ET visit. The output diary  should be completed 
daily  over a 48
-hour period o f nutritional stability  before the EOS/ET visit)
Record PS prescription and adjust as needed
Safety  laboratory tests 
Fecal occult blood testing, as indicated
Gastrointestinal -specific testing, including colonoscopy  or sigmoidoscopy  as indicated. 
Quality  of life measurements 
Antibodies to teduglutide
Pregnancy  testing, as needed
7.[ADDRESS_483392] of the following:
Adverse events that were ongoing at the time of completion of TED- C14-006 or 
SHP633 -
301
Events that occurred during the period between completion of TED -C14-[ADDRESS_483393] has an y changes to the 
SBS history  collected at the baseli ne visit of the TED -C14-006 or SHP633 -301 studies, that 
information (updated SBS history ) will be collected.
For non-commercial use only
Shire CONFIDENTIAL Page 48
SHP633 -304 Protocol Amendment 3
Teduglutide 16 May 2018
7.2.2 Physical Examination
Physical examinations will be performed according to the study  schedules. Any  new clinicall y 
significant findings noted during physical examinations should be recorded on the appropriate 
AE page of the eCRF. 
7.2.3 Vital Signs, Body Weight, Height, Head Circumference and Body Mass 
Index
Vital signs will be measured according to the study  schedules. Measurements will include 
systolic an d diastolic blood pressure (mmHg), pulse (beats per minute), and body  temperature 
(°C/°F). Blood pressure should be determined b y cuff (using the same method, the same 
extremity , and in the same position throughout the study , whenever possible).
Body weigh t will also be recorded in the eCRF; subjects should be weighed on the same scale at 
each stud y visit. Height (or length) and head circumference (for subjects ≤36 months of age) will 
be measured at selected visits. A height z- score, weight z -score, BM I, and BMI z -score will be 
calculated b y the sponsor using the site -provided height and weight data collected at each site 
visit
New clinicall y significant vital sign abnormalities should be recorded on the appropriate AE 
page of the eCRF.
7.2.[ADDRESS_483394] of clinical chemistry , hematology , 
and urinal ysis and will be performed as outlined in the study  plan ( Table 1-1, Table 1-2, and 
Table 1-3) Scheduled laboratory  testing will be processed b y a central lab. All laboratory  assay s 
will be performed according to the central laboratory ’s normal procedures. Reference ranges are 
to be supplied by  [CONTACT_25699] . The investigator should assess out-of
-range clinical laboratory  
values for clinical sig nificance, indicating if the value(s) is/are not clinically  significant or 
clinically  significant. Abnormal clinical laboratory  values, which are unexpected or not 
explained by  [CONTACT_423]’s clinical condition, may , at the discretion of the investigator or sponsor, 
be repeated as soon as possible until confirmed, explained, or resolved. 
During the teduglutide treatment period, subjects will also have safet y labs within approximately  
5-[ADDRESS_483395] of clinical chemistry  and urinal ysis and may  be processed by  [CONTACT_319438] a local laboratory . Local lab results are not required to be entered in the eCRFs; however, if 
the local lab results indicate an y new clinicall y significant changes, they must be reported as an 
adverse event (see Section 8.1). Urine specimen collection should be attempted as part of the 
safet y labs, but lack of urinalysis will not constitute a protocol deviation.
New clinicall y signifi cant labs should be reported as AEs.
The following clinical laboratory
 assessments will be performed according to the study  
schedules: 
For non-commercial use only
Shire CONFIDENTIAL Page 49
SHP633 -304 Protocol Amendment 3
Teduglutide 16 May 2018
Table 7-1: List of Laboratory Tests 
Hematology :
Hematocrit 
Hemoglobin 
Platelet count
Red blood cell count 
Red blood cell morphology, if needed
White blood cell count with differential
Coagulation :
Prothrombin time/I nternational normalized ratio 
Urinalysis : 
Blood
Glucose
Leukocytes
Microscopic analysis
pH 
Protein
Specific gravity
Pregnancy tests (females of childbearing potential):
oSerum β -HCG (screening)
oUrine β -HCG (all other visits)Biochemistry :
Albumin 
Alkaline phosphatase 
Alanine aminotransferase 
Amy lase
Aspartate aminotransferase 
Bicarbonate
Bilirubin (total, direct, and indirect)
Blood urea nitrogen 
Calcium (total)
Chloride
Cholesterol
C-reactive protein 
Creatinine
Estimated Glomerular Filtration Rate 
(Schwartz formula)
Gamma -glutamyl transferase 
Glucose
Lipase
Magnesium
Phosphorus
Potassium 
Sodiu m 
Triglycerides
Uric acid
7.2.5 Serum Sampling
Serum samples will be collected and stored for future anal ysis at the following times: 
At the pre treatment visit.  If the subject arrived at the pre treatment visit by  [CONTACT_319478], the serum sample will not be repeated at the pre treatment visit, because 
it will have been collected recentl y at the CxW24 visit.
At the CxW24 (EOT) visit
During NTT: Approximately  every  24 weeks 
The serum s ample will not be used for genetic testing. Lack of collection will not constitute a 
protocol deviation.
The sponsor, sponsor’s representatives, biorepositories, and an y specialt y laboratories will be 
blinded to the subject’s identity . The sample and/or ex tracted material will otherwise be stored 
for up to [ADDRESS_483396] their 
For non-commercial use only
Shire CONFIDENTIAL Page 50
SHP633 -304 Protocol Amendment 3
Teduglutide 16 May 2018
sample and/or extracted material destro yed. An y results alread y generated from the samples will 
not be removed from an y anal yses that have already  been performed.
7.2.[ADDRESS_483397] is performed on all FOCBP at the teduglutide pretreatment visit (when 
the pretreatment and screening visits are combined, the serum pregnancy  test should be 
performed at the local laboratory ). Urine pregnancy  tests will be administered at all other visits 
according to the study schedules, or if pregnancy is suspected, or as specified per protocol upon 
withdrawal of the subject from the study . 
7.2.7 Antibody Testing
Blood samples will be drawn for the anal ysis of antibodies to teduglutide according to the 
Schedule of Assessments ( Table 1-1, Table 1 -2, and Table 1 -3). Blood samples for antibodies 
may be drawn from a central line or from peripheral access. The sample drawn on CxD1 must be 
drawn prior to administration of the first dose of teduglutide. Once the subject has started 
teduglutide treatment, samples must be drawn at least [ADDRESS_483398] annuall y are shown 
in Table 7-2.
Table 7-2: Approximate Volume of Blood to be Drawn from Each Subject Annually 
AssessmentSample 
Volume (mL)No. Sam ples per two 28 -week 
Teduglutide CyclesTotal 
Volume (mL)
Subjects Receiving Teduglutide Treatment 
Safety Biochemistry and -hCGa2.5 24 60
Hem atology 2 24 48
Coagulation Param eters 1 2 2
Antibodies 2 8 16
Serum storage samples 3 4 12
Total mL per 2, 28 -week Treatment Cycles (Approximate Annual Volume): 138
Subjects Not Receiving Teduglutide Treatmentb
AssessmentSample 
Volume (mL)No. Sam ples per 4 NTT VisitsTotal 
Volume (mL)
Safety Biochemistry 2.5 4 10
Hem atology 2 4 8
Serum storage samples 3 2 6
Total mL per 4 “No -Teduglutide Treatment” Visits 48 -week period: 24
Abbreviations: β -hCG=beta -human chorionic gonadotropin; NTT=no -teduglutide treatment
a β-hCG testing will only be administered to females who are eligible for teduglutide treatment.
bSubjects not receiving teduglutide treatment, but who were exposed to it previously and tested positive for anti -teduglutide 
antibodies will require blood samples for antibody testing every [ADDRESS_483399] negative.
For non-commercial use only
Shire CONFIDENTIAL Page 51
SHP633 -304 Protocol Amendment 3
Teduglutide 16 May 2018
Note: The amount of blood to be drawn for each assessment is an estimate. The amount of blood 
to be drawn may  vary  according to the instructions provided by  [CONTACT_10190]. When more than 1 blood assessment is to be done at the time 
point/p eriod, if they  require the same t ype of tube, the assessments should be combined. Blood 
volume estimates do not include safet y labs performed after PS adjustment, and anti -teduglutide 
antibody  testing during no- teduglutide treatment.  Saved serum samples s hould be omitted for 
subjects weighing less than 10 kg and whenever local blood volume limitations are exceeded.
7.2.9 Gastrointestinal- specific Testing
[IP_ADDRESS] Fecal Occult Blood Testing
Fecal occult blood testing must be perfo rmed on all subjects at the pre treatment visit, week 12, 
and week [ADDRESS_483400] be performed on 
teduglutide -exposed subjects (subjects who have received teduglutide an y time in the past and 
are therefore not teduglutide -naïve) on a roughl y annual basis (approximately  every  48-60 
weeks). Actions to be taken in response to a positive FOBT are described below.
[IP_ADDRESS]
Colonoscopy or Sigmoidoscopy
Teduglutide -naïve subjects age 12 and older will undergo colonosc opy or sigmoidoscopy  at the 
pretreatment visit if one has not been performed within 1 y ear. 
Subjects of an y age with newly positive FOBT res ults at the pretreatment visit for which a 
readil y detectable cause cannot be identified (eg, anal fissure) will undergo a colonoscop y or 
sigmoidoscop y prior to receivin g teduglutide. If newly positive FOBT results (for which a 
readil y detectable cause cannot be identified) are obtained at the end of a teduglutide treatment 
cycle (CxW24/EOT), colonoscopy  or sigmoidoscopy  will be performed. The need for 
colonoscop y or sigm oidoscopy  in response to positive FOBTs at any  other point during the 
study , or to re -evaluate persistently  positive FOBTs is at the discretion of the investigator. 
Teduglutide -exposed subjects who have received the equivalent of 2 treatment cy cles (48 weeks 
of study  drug exposure) will undergo colonoscopy  or sigmoidoscopy . While receiving additional 
teduglutide treatment, subjects will undergo colonoscopy  or sigmoidoscopy at 5 y ear intervals or 
more often as needed. 
Upper endoscop y ma y be performed along with any  colonoscopy  or sigmoidoscopy  at the 
investigator’s discretion. If a pol yp is found, adherence to current pol yp follow -up guidelines is 
recommended. Subjects with unresected GI po lyps, poly posis conditions, pre malignant change 
or malignancy  in the GI tract will be excluded from teduglutide treatment.
7.2.10 Nutritional Support
Nutritional support includes PS, EN , and other food and fluids. Advances in ENand/or 
reductions to PS will be based on clinical status, including weight, linear growth, hy dration 
status, and safet y laboratory  results. Intake and output diaries will include data to be considered 
in the adjustment of each subject’s nutritional support. Guidelines for nutritional support 
management and weaning algorithms are provided in Appendix 2 .
For non-commercial use only
Shire CONFIDENTIAL Page 52
SHP633 -304 Protocol Amendment 3
Teduglutide 16 May 2018
7.2.11 Diaries
[IP_ADDRESS] Study Drug Administration Diary
A study  drug administration diary  will record administration of teduglutide. This diary  should be 
completed b y the subject (or parent/legal guardian, as applicable) dail y during the teduglutide 
treatment periods (betwee
n visits CxD1 and CxW24).
[IP_ADDRESS] Intake Diary
Intake diaries will be used to collect and evaluate each subject’s nutritional support. The 
subject/parent/guardian will complete the appropriate fields of the PS section of the intake diary  
2 weeks prior to ALL sched uled site visits (except a t pretreatment visit). During the 24 -week 
teduglutide treatment period, the intake diary  will also be completed for 1 week following PS 
adjustments. The intake diary  will also be completed daily  during the 4 -week follow -up period.
The following data will be captured in the intake diaries:
Parenteral support volume and infusion duration
Site personnel will determine the actual PS daily  calories based on diary  entries.
All available diary  data will be reviewed by  [CONTACT_319479].
[IP_ADDRESS] Output Diary
Urine and stool output should be recorded in the output diary  over a 48- hour period of nutritional 
stability  before every  clinic visit; in addition, output should be recorded for subjects that are in a 
teduglutide treatment cy cle within 1 week of implementing a change in the PS prescription, 
regardless of previous teduglutide exposure.
Urine data:
Toilet -trained sub jects (who do not wear diapers)
Measure and record all urine output in mL  or cc 
Nontoilet- trained subjects (who wear diapers)
Measure and record the weight of all urine -only diapers. Urine volume will be calculated 
using the following formula: 1 g (scale weight) = 1 mL  or 1 cc
At the discretion of the investigator, the parent may be asked to collect the first void after 
the daily  PS infusion to measure specific gravity
Stool data (includes diapers with mixed urine and stool):
Toilet -trained subjects (who do not wear diapers)
Record the occurrence of each bowel movement and score the stool consistency  using the 
Bristol Stool Form Scale (see Output diary )
Nontoilet- trained subjects (who wear diapers)
Record the weight of diapers containing stool (including d iapers with mixed urine and 
stool) as stool output and score the stool consistency  using the Bristol Stool Form Scale 
For non-commercial use only
Shire CONFIDENTIAL Page 53
SHP633 -304 Protocol Amendment 3
Teduglutide 16 May 2018
(see Output diary ). Stool volume will be calculated using the formula: 1 g (scale weight) 
= 1mLor 1 cc
All ostomy  output volume should be recorded. Ostomy  output will not be scored using the 
Bristol scale.
All available diary  data will be reviewed by  [CONTACT_319479].
7.2.12 Health -related Quality of Life Assessments
Throughout the stud y, health -related quality  of life assessments will be performed using the 
PedsQL  Generic Core Scales. Each PedsQL age- appropriate form takes less than 4 minutes to 
complete.  The scales include self -reports for pediatric subjects and adolescents aged 5 to 
18years and prox y-reports from parents of pediatric subjects aged 2 to 18 years.  The PedsQL 
Generic Core Scales will not be performed for subjects y ounger than 2 y ears of age.  If a child is 
unable to complete the age -appropriate questionnaire (eg, due to developmental delay or other 
illness) it will not constitute a protocol deviation, but the parent should continue to complete the 
appropriate parent -specific forms.
Field trials hav e shown that the internal consistency  reliability  of the PedsQL  was excellent, with 
alphas for the generic core scales in both self -and proxy -report greater than the 0.[ADDRESS_483401] month, and parent -report of 
problems pursuing their normal work routine and concentrating at work. The PedsQL Generic 
Core Scales are also responsive to clinical change, as demonstrated in field trials.
[IP_ADDRESS] Pediatric Quality of Life Generic Core Scale (PedsQL™), Acute version
The PedsQL Generic Core Scale is designed to measures health -related quality  of life (HRQoL) 
in pediatric subjects and adolescents (2 -18 years of age). The developmentally  appropriate 
PedsQL  Generic Core Scale will be completed by  [CONTACT_319416] 7 -3at the time points as outlined in Table 1-1, Table 1 -2, and Table 1 - 3.
For non-commercial use only
Shire CONFIDENTIAL Page 54
SHP633 -304 Protocol Amendment 3
Teduglutide 16 May 2018
Table 7-3: Developmentally Appropriate PedsQL™Generic Core Scales
Report Completed by
[CONTACT_319417] (ages 2 -4) Parent or Legal Guardian
Child Self Report and Parent Proxy -Report for Young Pediatric subjects 
(ages 5 -7)Subject and Parent or Legal Guardian
Child Self Report and Parent Proxy -Report for Pediatric subjects 
(ages 8 -12)Subject and Parent or Legal Guardian
Child Self Report and Parent Proxy -Report for Teens (ages 13 -18)aSubject and Parent or Legal Guardian
Abbreviations: PedsQL=Pediatric Quality of Life Inventory
a The Child Self Report and Parent Proxy -Report for Teens (ages 13 -18) w ill also be completed for subjects older 
than 18 years of age
The Parent Report for Toddlers (ages 2 -4) of the PedsQL Generic Core Scale is composed of 
21 items comprising 4 dimensions as follows: 1) Physical Functioning (8 items), 2) Emotional 
Functioning (5 items), 3) Social Functioning (5 items), 4) School Functio ning (3 items). 
The Child and Parent Reports of the PedsQL Generic Core Scale for Young Pediatric subjects 
(ages 5 -7), Pediatric subjects (ages 8- 12), and Teens (ages 13 -18) are composed of 23 items 
comprising 4 dimensions as follows: 1) Physical Function ing (8 items), 2) Emotional 
Functioning (5 items), 3) Social Functioning (5 items), 4) School Functioning (5 items).
[IP_ADDRESS] Pediatric Quality of Life Family Impact Module (PedsQL™), Acute version
The PedsQL Family  Impact Module is a parent -report multidimensional instrument that will be 
completed b y the parent or legal guardian, as outlined in Table 1-1, Table [ADDRESS_483402] of pediatric chronic health condit ions on parents and the family  (Varni et al., 2004 ). 
The [ADDRESS_483403] Module consists of 6 scales measuring pare nt self -reported 
functioning as follows: 1) Physical Functioning (6 items), 2) Emotional Functioning (5 items), 
3) Social Functioning (4 items), 4) Cognitive Functioning (5 items; worries about treatment and 
disease), 5) Communication (3 items), 6) Worry  (5items). Two additional scales measure parent -
reported family  functioning as follows: 1) Dail y Activities (3 items), and 2) Family  Relationships 
(5 items). The PedsQL Family  Impact Module should take the parent or legal guardian 
approximately  5 to 10 minu tes to complete.
[IP_ADDRESS] PedsQL Gastrointestinal Symptoms Module (PedsQL™), Acute version
The PedsQL Gastrointestinal Sy mptom Module is a disease -specific 58- item module, comprised 
of 10 different s ymptom scales that assess gastrointestinal sy mptom -related quality of life: food 
and drink limits, trouble swallowing, heartburn and reflux, nausea and vomiting, gas and 
bloating, constipation, blood in poop, and diarrhea. The PedsQL Gastrointestinal Sy mptoms 
Module was designed to allow the selection and scoring of individual scales from the Module. 
The scales of Food and Drink L imits (6 items) and Diarrhea (7 items) were identified as 
clinically  relevant and appropriate for the s ymptoms experienced in this pediatric study  
population, and therefore, are the onl y scales u sed in this study . The scales will be completed by  
[CONTACT_385986] [ADDRESS_483404] a causal relationship with this 
treatme nt. An AE can therefore be an y unfavorable and unintended sign (including an abnormal 
laboratory  finding), s ymptom, or disease temporally  associated with the use of a medicinal 
(investigational) product, whether or not related to the medicinal (investigati onal) product (ICH 
Guidance E2A 1995). 
All AEs are collected from the time the informed consent is signed until the defined follow -up 
period stated in Section 7.1.[ADDRESS_483405] be followed to closure (the subject’s health has returne d to his/her baseline status 
or all variables have returned to normal), regardless of whether the subject is still participating in 
the study . Closure indicates that an outcome is reached, stabilization achieved (the investigator 
does not expect any  furthe r improvement or worsening of the event), or the event is otherwise 
explained. When appropriate, medical tests and examinations are performed so that resolution of 
event(s) can be documented.
8.1.[ADDRESS_483406] be 
recorded as new AEs (for example, if a subject experiences mild intermittent dy spepsia prior to 
dosing of investigational product, but the dy spepsia becomes severe and more frequent after first 
dose of investigational product has been administered, a new AE of sev ere dy spepsia [with the 
appropriate date of onset] is recorded on the appropriate eCRF).
The medical assessment of severit y is determined by [INVESTIGATOR_1477]:
Mild: A type of AE that is usually  transient and may  require only minimal treatment or 
therapeutic intervention. The event does not generally  interfere with usual 
activities of daily  living.
Moderate: A type of AE that is usually  alleviated with specific therapeutic intervention. The 
event interferes with usual activities of dai ly living, causing discomfort but poses 
no significant or permanent risk of harm to the research subject.
Severe: A type of AE that interrupts usual activities of daily  living, or significantl y affects 
clinical status, or may  require intensive therapeutic intervention.
For non-commercial use only
Shire CONFIDENTIAL Page 56
SHP633 -304 Protocol Amendment 3
Teduglutide 16 May 2018
In consideration of whether a treatment -emergent adverse event (TEAE) might lead to dose 
interruption (Section 8.4.1) or early  termination of the study  (Section 8.5), severe TEAEs will 
also be graded according to the National Cancer Institute
’s (NCI) Common Terminology  Criteria 
for Adverse Events (CTCAE) severit y grading criteria ( US Department of Health and Human 
Services et al., 2010 ).
8.1.2 Relationship Categorization
A phy sician/investigator must make the assessment of relationship to investigational product for 
each AE. The investigator should decide whether, in his or her medical judgment, there is a 
reasonable possibility  that the event may  have been caused b y the investigational product. If 
there is no valid reason for suggesting a relationship, then the AE should be classified as “not 
related”. Otherwise, if there is an y valid reason, even if undetermined or untested, for suspecting 
a possible cause -and-effect relationship between the invest igational product and the occurrence 
of the AE, then the AE should be considered “related”. The causality  assessment must be 
documented in the source document.
The following additional guidance may  be helpful:
Term Relationship Definition
RelatedThe temporal relationship between the event and the administration of 
the investigational product is compelling and/or follows a known or 
suspected response pattern to that product, and the event cannot be 
explained by  [CONTACT_423]’s medical condition, other therap ies, or 
accident.
Not RelatedThe event can be readil y explained by  [CONTACT_11260]’s underl ying medical condition, concomitant therapy , or 
accident and no plausible temporal or biologic relationship exists 
between the investigational product and the event.
AEs that are related to study  drug that are not resolved at EOT will be followed until the event 
resolves or stabilizes, as judged b y the investigator.
Laboratory  values, vital signs, and clinical findings at the scheduled ph ysicalexaminations must 
be reported as AEs if the investigator considers the finding to be a clinicall y significant change 
from the baseline. 
8.1.[ADDRESS_483407] be recorded during the course of the stud y in the eCRF. Outcomes are 
asfollows:
Fatal
Not Recovered/Not Resolved
Recovered/Resolved
Recovered/Resolved with Sequelae 
Recovering/Resolving
For non-commercial use only
Shire CONFIDENTIAL Page 57
SHP633 -304 Protocol Amendment 3
Teduglutide 16 May 2018
Unknown
8.1.4 Symptoms of the Disease under Study
Symptoms of the disease under study  should not be classed as AEs as long as they  are within the
normal day -to-day fluctuation or expected progression of the disease and are part of the efficacy  
data to be collected in the study; however, significant worsening of the s ymptoms should be 
recorded as an AE.
8.1.[ADDRESS_483408] be taken into consideration.
If, during the stud
y, there are abnormal clinical laboratory values or vital signs which were not 
present at the beginning of the study , further investigations should be performed until the values 
return to within the reference range or until a plausible explanation (eg, concomitant disease) is 
found for the abnormal values.
The investigator should decide, based on the above criteria and the clinical condition of a 
subject, whether a change in a clinical laboratory  or vital sign is clinicall y significant and 
therefore represents an AE.
8.1.[ADDRESS_483409] be reported within 24 hours to the 
Shire Global Drug Safety Department using the Shire Investigational and Marketed Products 
Pregnancy  Report Form. A copy  of the Shi re Investigational and Marketed Products Pregnancy 
Report Form (and an y applicable follow -
up reports) must also be sent to the Shire Medical 
Monitor using the details specified in the emergency  contact [CONTACT_1739]. 
In the event a subject becomes pregnant during the study , teduglutide administration must be 
discontinued immediately. 
Every  effort should be made to gather information regarding the pregnancy  outcome and 
condition of the infant. It is the responsibility  of the investigat or to obtain this information within 
[ADDRESS_483410] partum.
Pregnancy  complications such as spontaneous abortion/miscarriage or congenital abnormality  
are considered SAEs and must be reported using the Shire Clinical Study  Adverse Event Form 
for Serious Adverse Events and Non- serious AEs as Required b y the Protocol. Note: An elective 
abortion is not considered an SAE.
In addition to the above, if the investigator determines that the pr egnancy  meets serious criteria, 
it must be reported as an SAE using the Shire Clinical Study  Adverse Event Form for SAEs and 
Non-serious AEs as Required by
 [CONTACT_385987]-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_483411] positive serum/urine -HCG test or 
will determine the pregnancy  onset date.
8.1.7 Abuse, Misuse, Overdose, and Medication Error
Abuse, misuse, overdose, or medication error (as defined below) must be reported to the sponsor 
according to the SAE reporting procedure whether or not they  result in an AE/SAE as described 
in Section 8.2. Note: The 24 -hour reporting requirement for SAEs does not apply  to reports of 
abuse, misuse, overdose, or medication errors unless these result in an SAE. 
The ca tegories below are not mutually  exclusive; the event can meet more than 1 category .
Abuse –Persistent or sporadic intentional intake of investigatio nal product when used for 
a non -medical purpose (eg, to alter one’s state of consciousness or get high) in a manner 
that may  be detrimental to the individual and/or society .
Misuse –Intentional use of investigational product other than as directed or indicated at 
any dose (Note: this includes a situation where the investigational product is not used as 
directe d at the dose prescribed by  [CONTACT_760]).
Overdose –Administration of a dose greater than the allocated dose of the study  
medication or at a frequency  greater than the dosing interval specified by
 [CONTACT_760].
Medication Error – An error made in prescribing, dispensing, administration, and/or use 
of an investigational product. For studies, medication errors are reportable to the sponsor 
only as defined below.
Cases of subjects missing doses of the investigational product are not considered reportable as 
medication errors.
Medication errors should be collected/reported for all products under investigation.
The administration and/or use of an expi[INVESTIGATOR_10151] a 
reportable medication error. 
All investigational product provided to pediatric subjects should be supervised by  [CONTACT_31588]/legall y
-authorized representative/caregiver.
8.[ADDRESS_483412] awareness of 
the event. Note: The 24 -hour reporting requirement for SAEs does not apply  to reports of abuse, 
misuse, overdose, or medication errors (see Section 8.1.7) unless they  result in an SAE.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_483413] complete, sign, and date the Shire Clinical Study  Adverse Event Form for 
SAEs and Non- serious AEs as Required b y Protocol, and verify the accuracy of the information 
recorded on the form with the corresponding source documents (Note: Source docume nts are not 
to be sent unless requested). Fax or e -mail the completed form to the Shire Global Drug Safet y 
Department. A cop y of the completed Shire Clinical Study Adverse Event Form for Serious 
Adverse Events (SAEs) and Non -serious AEs as Required b y Prot ocol (and any  applicable 
follow -up reports) must also be sent to the Shire medical monitor or designee using the details 
specified in the emergency  contact [CONTACT_1739].
8.2.3 Serious Adverse Event Definition
Aserious adverse event ( SAE )is any  untoward medical occurrence (whether considered to be 
related to investigational product or not) that at any dose: 
Results in death
Is life -threatening. Note: The term 'life -threatening' in the definition of "serious" refers to 
an event in which th e subject was at risk of death at the time of the event; it does not refer 
to an event which h ypothetically might have caused death if it was more severe.
Requires inpatient hospi[INVESTIGATOR_1081]. Note: 
Hospi[INVESTIGATOR_059] s, which are the result of elective or previousl y scheduled surgery for pre 
existing conditions, which have not worsened after initiation of treatment, should not be 
classified as SAEs. For example, an admission for a previousl y scheduled ventral hernia 
repair would not be classified as an SAE; however, complication(s) resulting from a 
hospi[INVESTIGATOR_10153] y scheduled surgery  that meet(s) serious 
criteria must be reported as SAE(s).
Results in persistent or significant disability /inca pacity
Is a congenital abnormality /birth defect
Is an important medical event. Note: I mportant medical events that may not result in 
death, be life -threatening, or require hospi[INVESTIGATOR_12475], 
based upon appropriate medical judgme nt, they  may  jeopardize the subject and may  
require medical or surgical intervention to prevent 1 of the outcomes listed in this 
definition. Examples of such medical events include allergic bronchospasm requiring 
intensive treatment in an emergency  room or at home; blood dy scrasias or convulsions 
that do not result in inpatient hospi[INVESTIGATOR_059]; or the development of drug dependency  or 
drug abuse. 
8.2.4 Serious Adverse Event Collection Time Frame
All SAEs (regardless of relationship to study ) are collected from the time the subject signs the 
informed consent until the defined follow- up period stated in Section 7.1.4, and must be reported 
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_483414] awareness of the event. 
In addition, any SAE(s) considered “related” to the investigational product and discovered by  [CONTACT_10194] y interval after the study has completed must be reported to the Shire Glo bal 
Drug Safet y Department within [ADDRESS_483415]’s death (ie, the SAE was noted as the primary  cause of death) 
must have fatal checked as an outcome with the date of death recorded as the resolution date. For 
all other events ongoing at the time of death that did not contribute to the subject’s death, the 
outcome should be considered not resolved, without a resolution date recorded.
For an y SAE that results in the subject’s death or any ongoing events at the time of death, unless 
another investigational product action was previously  taken (eg, dr ug interrupted, reduced, 
withdrawn), the action taken with the investigational product should be recorded as “dose not 
changed” or “not applicable” (if the subject never received investigational product). The 
investigational product action of “withdrawn” should not be selected solel y as a result of the 
subject’s death.
8.2.[ADDRESS_483416], Ethics Committee, and Site 
Reporting 
The Sponsor and/or Clinical Contract Research Organization (CRO) is responsible for notify ing 
the relevant regulatory  authorities, and US central I nstitutional Review Boards (IRBs)/EU central 
ethics committees (ECs), of related, unexpected SAEs.
In addition, the Clinical CRO is responsible for notify ing active sites of all related, unexpected 
SAEs occu rring during all interventional studies across the SHP633 program.
The investigator is responsible for notifying the local IRB, local EC, or the relevant local 
regulatory  authorit y of all SAEs that occur at his or her site as required.
8.[ADDRESS_483417] is an AE (serious or nonserious) of scientific and medical concern 
specific to the sponsor’s product or program and for which ongoing monitoring and immediate 
notification by  [CONTACT_385988].
The AEs of special interest that require expedited regulatory  reporting include the following:
Growth of pre -existing poly ps of the colon
For non-commercial use only
Shire CONFIDENTIAL Page 61
SHP633 -304 Protocol Amendment 3
Teduglutide 16 May 2018
Benign neoplasia of the GI tract including the hepatobiliary  system
Tumor -promoting ability (eg, benign and/or ma lignant neoplasia of any  kind, not limited 
to those of the GI or hepatobiliary  system)
For AEs of special interest, the sponsor must be informed within [ADDRESS_483418] awareness as 
per the SAE notification instructions described in Section 8.2.2 even if the event does not fulfill 
the seriousness criteria.
8.4 Dose Interruption of Individual Subjects
The investigator is responsible for contact[CONTACT_20610]/designee when the subject’s 
teduglutide dosing regimen is interrupted. Attempts should be made to conta ct the 
sponsor/designee prior to dose interruption. Reasons for dosage interruptions may  include but are 
not limited to hospi[INVESTIGATOR_059], AEs, a lapse in investigational product delivery , etc.
Study  drug must be discontinued if any  of the following events occur:
Pregnancy
Severe h ypersensitivity , such as anaph ylaxis determined by  [CONTACT_319447]. This does not include the presence of anti- teduglutide antibodies, mild 
injection site reactions or mild sy mptoms that according to the investigator do not pose a 
significant risk to the subject.
An AE that is of NCI CTCAE severit y Grade 3 or 4 and considered to be related to study 
drug administration
Confirmed DILI related to teduglutide (see Section 8.4.2)
8.4.[ADDRESS_483419] experienced an AE that is of 
severit y ≥Grade [ADDRESS_483420]. 
In consideration of whether a TEAE might lead to dose interruption, severe TEAEs will also be 
graded according to the NCI  CTCAE severit y grading criteria ( US Department of Health and 
Human Services et al., 2010 ). All such TEAEs should be discussed with the Shire Medical 
Monitor or designee as soon as possible. The length of the dose interruptio n, and whether 
teduglutide administration resumes or is permanently  discontinued, depends on the clinical 
situation. 
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_483421] has 
clinical and laboratory  evidence of potential DILI, in the absence of an alternative explanation, 
as identified b y the following criteria:
ALT or AST >8x ULN
ALT or AST >5x ULN and >2x baseline value for more than 2 weeks
(ALT or AST >3x ULN and >2x baseline value) and (total bilirubin >2x ULN or 
INR>1.5)
ALT or AST >3x ULN and >2x baseline value with the appearance of fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)
All labora tory values suggestive of potentially  new DILI should be repeated and verified within 
[ADDRESS_483422] should be followed closely to determine the trajectory  of the 
laboratory  abnormalities and to evaluate the cause of liver injury . This evaluation may  include, 
as clinically  indicated, consideration o f sepsis, acute viral hepatitis (eg, hepatitis A 
immunoglobulin [IgM], hepatitis B surface antigen, hepatitis C antibodies, cy tomegalovirus IgM, 
Epstein- Barr virus antibody  panel), hepatobiliary  obstruction (ultrasound), autoimmune hepatitis 
(anti-nuclear, anti-smooth muscle, anti -actin, or anti -liver kidney  microsomal antibodies), 
intestinal failure associated liver disease, cardiovascular causes such as ischemic hepatitis, and 
concomitant hepatotoxic treatments.
Additional evaluations may  be performed at the discretion of the investigator in consultation 
with the Shire medical monitor.
Teduglutide administration must be permanentl y discontinued if DILI is confirmed and deemed 
related to stud y drug.
8.5 Early Termination of the Clinical Study
The data monitorin
g committee ( DMC )may recommend stoppi[INVESTIGATOR_319397]:
≥2subjects develop the same event of CTCAE severity  Grade [ADDRESS_483423]
or
[ADDRESS_483424].
For non-commercial use only
Shire CONFIDENTIAL Page 63
SHP633 -304 Protocol Amendment 3
Teduglutide 16 May 2018
9 DATA MANAGEMENT AND STATISTICAL METHODS
9.1 Data Collection
The investigators’ authorized site personnel must enter the information required by  [CONTACT_103365]. A study  monito r will visit each site in accordance with the monitoring plan and 
review the eCRF data against the source data for completeness and accuracy . Discrepancies 
between source data and data entered in the eCRF will be addressed b y qualified site personnel. 
When a data discrepancy warrants correction, the correction will be made by [CONTACT_59752]. Data collection procedures will be discussed with the site at the site initiation visit 
and/or at the investigator’s meeting. Unscheduled safet y follow up as sessments ( including visits 
conducted after EOS) are not to be collected unless requested.
9.2 Clinical Data Management 
Data are to be entered into a clinical database as specified in the CRO’s data management 
process. Quality  control and data validation proc edures are applied to ensure the validity  and 
accuracy  of the clinical database.
Data are to be reviewed and checked for omissions, errors, and values requiring further 
clarification using computerized and manual procedures. Data queries requiring clarific ation are 
to be communicated to the site for resolution. Only authorized personnel will make corrections to 
the clinical database, and all corrections are documented in an auditable manner.
9.3 Statistical Analysis Process 
The study  will be anal yzed by [CONTACT_385989]. All statistical anal yses will be performed 
using SAS®(SAS Institute, Cary , NC, [LOCATION_003]) version 9.3 or higher.
The statistical anal ysis plan (SAP) will provide the statistical methods and definitions for the 
analysis of the efficacy  and safet y data, as well as describe the approaches to be taken for 
summarizing other study  information such as subject disposition, d emographics and baseline 
characteristics, investigational product exposure, and prior and concomitant medications. 
9.[ADDRESS_483425] been collected for subjects 
entering from TED -C14-006. Additional interim analy ses may  be conducted as needed.
A DMC will be involved in the management of this study . The DMC members will review the 
data approximately  every 3 months according to the DMC Charter. The DMC rev iew will 
include all cumulative safety  data (ie, AEs, laboratory  assessments, phy sical examinations, etc.) 
from study  assessments through each cutoff period. Further details regarding the DMC can be 
found in the DMC charter, which will be available prior t o the administration of investigational 
product. 
The DMC for this study  will be conducted in accordance with the FDA Guidance for Clinical 
Trial Sponsors: Establishment and Operation of Clinical Trial Data Monitoring Committees 
(March 2006).
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_483426] may not be 
study  investigators or be employ ed at the same institution as a study  investigator, individuals 
employ ed by [CONTACT_456], independent contractors hired by  [CONTACT_456], or members of 
regulatory  agencies. The DMC may  make recommendations to the sponsor regarding stud y 
aspects including stoppi[INVESTIGATOR_007], modify ing or continuing the study ; however, the sponsor will have 
the final responsibility  to determine whe ther the study  should be modified or temporaril y or 
permanentl y stopped. 
9.5 Sample Size Calculation and Power Considerations 
The number of subjects in this study  is not based on statistical power considerations as this is an 
extension study  of the core studies, TED -C14-006 and SHP633- 301. The maximum number of 
subjects was determined by  [CONTACT_385990] -C14-006 and SHP633 -301.
9.6 Study Population
The safet y population includes all enrolled subjects in the study . Safet y population will be used 
for both safe ty and efficacy  anal yses.
9.7 Efficacy Analyses 
No claims of statistical significance will be made; however, 95% confidence intervals will be 
provided, if applicable. Continuous variables, including those assessed on a discrete scale, will 
be summarized using descriptive statistics including number of subjects, mean, median, standard 
deviation, maximum, and minimum. For categorical variables, statistical summaries will include 
number of subjects and percentages.
9.7.1 Efficacy Endpoints
Efficacy  endpoints will be analyzed at the end of each teduglutide tr eatment period (w eek 24 or 
EOT), and at each stud y visit, relative to the baseline of the core study  (TED -C14-006 or 
SHP633 -301) and/or first exposure to teduglutide. The following efficacy  endpoints will be 
analyzed: 
Reduction in PS volume of at least 20%
Absolute and relative change in PS volume
Complete weaning off PS
Change in day s per week of PS
9.8 Safety Analyses 
9.8.1 Safety Endpoints
The following safet y endpoints will be analy zed: 
For non-commercial use only
Shire CONFIDENTIAL Page 65
SHP633 -304 Protocol Amendment 3
Teduglutide 16 May 2018
Adverse events
Vital signs, incl uding temperature, heart rate, and blood pressure
Laboratory  safet y data (ie, clinical chemistry , hematology , and urinaly sis)
Urine output
Stool output 
Antibodies to teduglutide
Gastrointestinal -specific testing , including fecal occult blood testing and colonoscopy  or 
sigmoidoscop y
Z-scores for weight, height (or length), head circumference (up to 36 months of age), and 
BMI
Adverse events will be coded using the Medical Dictionary  for Regulatory  Activities 
(MedDRA). The number of events, incidence, and p ercentage of AEs will be calculated overall, 
by [CONTACT_1196] (SOC) and by  [CONTACT_11702]. SAEs will be further summarized by  
[CONTACT_11370] y and relationship to investigational product. Adverse events related to investigational 
product, AEs leading to withd rawal, SAEs, and deaths will be similarly  summarized/listed.
Prior and concomitant medications will be coded using the World Health Organization- Drug 
Dictionary  (WHO -DD) with regard to drug class and drug name. The number and percentage of 
subjects with sp
ecific prior medications will be summarized. Medical history (including 
surgical/procedural history ) will be coded using MedDRA. The number and percentage of 
subjects with specific histories will be summarized by  [CONTACT_6657]. 
Forclinical laboratory  tests, vital signs, body  weight, and fluid balance variables, descriptive 
statistics (mean, median, standard deviation, minimum and maximum values, the number and 
percentage of subjects in specified categories) will be calculated to su mmarize the observed 
values and change from baseline at each scheduled visit.
The number and percentage of subjects classified as having positive or neutralizing antibodies to 
teduglutide will be used to summarize the presence of antibodies. 
Additional sa fety parameters and measures will include change in bod y weight, height (or 
length) and head circumference (up to 36 months of age). Derived variables will include height 
z-score, weight z -score, BMI, and BMI z -score. Descriptive statistics (mean, median, standard 
deviation, minimum and maximum values, the number and percentage of subjects in specified 
categories) will be calculated to summarize the absolute values and change from baseline at each 
scheduled visit.
For non-commercial use only
Shire CONFIDENTIAL Page 66
SHP633 -304 Protocol Amendment 3
Teduglutide 16 May 2018
9.9 Other Analyses
9.9.1 Health -related Quality of Life Analyses 
Health economics and outcomes research endpoints will be analy zed at ap proximately  12-week 
intervals (w eeks 12 and 24 of each teduglutide treatment cy cle, and every  12 weeks for subjects 
not on teduglutide), relative to the study  baseline. The beginning of each treatment cy cle (CxD1) 
will be an additional baseline.
Change in Pediatric Quality  of Life Inventory  (PedsQL) score
Change in PedsQL Family  Impact Module score
Change in PedsQL Gastrointestinal Sy mptoms Module Sub
-Scales scores: 
Food and Drink L imits
Diarrhea 
For non-commercial use only
Shire CONFIDENTIAL Page 67
SHP633 -304 Protocol Amendment 3
Teduglutide 16 May 2018
10 SPONSOR’S AND INVEST IGATOR’S RESPONSIBIL ITIES
This study  is conducted in accordance with current applicable regulations, ICH, EU Directive 
2001/20/EC and its updates, and local ethical and legal requirements. 
The name [CONTACT_317368] y vendor (eg, CRO) used in this study  will be maintained 
in the investigator’s and sponsor’s files, as appropriate.
10.1 Sponsor’s Responsibilities
10.1.[ADDRESS_483427] been delegated will undertake their assigned roles for this study  in compliance with all 
applicable industry  regulations, I CH GCP Guideline E6 ( 1996), EU Directive 2001/20/EC, as 
well as all applicable national and loc al laws and regulations.
Visits to sites are conducted by  [CONTACT_10199]/or the company  
organizing/managing the research on behalf of the sponsor to inspect study  data, subjects’ 
medical records, and eCRFs in accordance with curre nt GCP and the respective local and 
(inter)national government regulations and guidelines. Records and data may additionall y be 
reviewed b y auditors or by  [CONTACT_10200].
The sponsor ensures that local regulatory  authority requirements are met befo re the start of the 
study . The sponsor (or a nominated designee) is responsible for the preparation, submission, and 
confirmation of receipt of an y regulatory  authority  approvals required prior to release of 
investigational product for shipment to the site .
10.1.2 Indemnity/Liability and Insurance
The sponsor of this research adheres to the recommendations of the Association of British 
Pharmaceutical Industry  Guidelines. If appropriate, a cop y of the indemnity document is 
supplied to the investigator before study  initiation, per local country  guidelines.
The sponsor ensures that suitable clinical study  insurance coverage is in place prior to the start of 
the study . An insurance certificate is supplied to the CRO as necessary . 
10.1.3 Public Posting of Study Information
The sponsor is responsible for posting appropriate study  information on applicable websites. 
Information included in clinical study  registries may  include participating investigators’ names 
and contact [CONTACT_3031].
10.1.4 Submission of Summary of Clinical Study Re port to Competent Authorities 
of Member States Concerned and Ethics Committees
The sponsor will provide a summary  of the clinical study  report to the competent authority  of the 
member state(s) concerned as required b y regulatory  requirement(s) and to compl y with the 
Community  guideline on GCP. This requirement will be fulfilled within 6 months of the end of 
the study  completion date for pediatric studies and within 1 y ear for non -pediatric studies as per 
guidance. The sponsor will provide the ECs with a cop y of the same summary.
For non-commercial use only
Shire CONFIDENTIAL Page 68
SHP633 -304 Protocol Amendment 3
Teduglutide 16 May 2018
10.1.5 Study Suspension, Termination, and Completion
The sponsor may  suspend or terminate the study , or part of the study , at any  time for any  reason. 
If the stud y is suspended or terminated, the sponsor will ensure that applicable sites, r egulatory  
agencies and IRBs/ECs are notified as appropriate. Additionally , the discontinuation of a 
registered clinical study  which has been posted to a designated public website will be updated 
accordingl y.
The sponsor will make an EOS declaration to the relevant competent authority  as required b y 
Article 10 (c) of Directive 2001/20/EC .
10.2 Investigator’s Responsibilities
10.2.[ADDRESS_483428] undertake to perform the study  in accordance with ICH GCP Guideline E6 
(1996), EU Di rective 2001/20/EC, and applicable regulatory  requirements and guidelines.
It is the investigator’s responsibility  to ensure that adequate time and appropriately  trained 
resources are available at the site prior to commitment to participate in this study . The 
investigator should also be able to estimate or demonstrate a potential for recruiting the required 
number of suitable subjects within the agreed recruitment period.
The investigator will maintain a list of appropriately  qualified persons to whom the investigator 
has delegated significant study -
related tasks, and shall, upon request of the sponsor, provide 
documented evidence of any  licenses and certifications necessar y to demonstrate such 
qualification. Curriculum vitae for investigators and sub- investigators are provided to the study  
sponsor (or designee) before starting the study .
If a potential research subject has a primary  care phy sician, the investigator should, 
with the 
subject’s consent, inform them of the subject’s participation in the study .
A coordinating principal investigator [INVESTIGATOR_319387]. Agreement with the final CSR is documented by  [CONTACT_385991] (single -site study ) or coordinating principal investigator (multicenter 
study ), in compliance with Directive 2001/83/EC as amended b y Directive 2003/63/EC and I CH 
Guidance E3 ( 1995). 
10.2.[ADDRESS_483429] met 
protocol eligibility  criteria. Investigators are required to sign an investigator agreement to 
confirm acceptance and willingness to comply  with the study  protocol.
If the investigator suspends or terminates the study  at their site, the investigator will promptly  
inform the sponsor and the IRB/EC and provide them with a d etailed written explanation. The 
investigator will also return all investigational products, containers, and other study materials to 
the sponsor. Upon study  completion, the investigator will provide the sponsor, I RB/EC, and 
regulatory  agency  with final reports and summaries as required by  (inter)national regulations.
Communication with local I RBs/ECs, to ensure accurate and timel y information is provided at 
all phases during the study , may  be done by  [CONTACT_456], applicable CRO, investigator, or for 
For non-commercial use only
Shire CONFIDENTIAL Page 69
SHP633 -304 Protocol Amendment 3
Teduglutide 16 May 2018
multic enter studies, the coordinating principal investigator [INVESTIGATOR_49106].
10.2.3 Documentation and Retention of Records
[IP_ADDRESS] Case Report Forms
The investigator is responsible for maintaining adequate and accurate medical records from 
which accurate information is recorded into eCRFs, which have been designed to record all 
observations and other data pertinent to the clinical investigation. Case report forms must be 
completed b y the investigator or desi gnee as stated in the site delegation log.
All data will have separate source documentation; no data will be recorded directly  into the 
eCRF.
eCRFs should be approved by  [CONTACT_385960].
The clini cal research associate (CRA)/study  monitor will verify  the contents against the source 
data per the monitoring plan. If the data are unclear or contradictory , queries are sent for 
corrections or verification of data.
[IP_ADDRESS] Recording, Access, and Retention of Sou rce Data and Study Documents
Original source data to be reviewed during this study  will include, but are not limited to: 
subject’s medical file, subject diary  cards, original clinical laboratory  reports, and histology  and 
pathology  reports.
All key  data mu st be recorded in the subject’s medical records.
The investigator must permit authorized representatives of the sponsor, the respective national, 
local, or foreign regulatory  authorities, the IRB/EC, and auditors to inspect facilities and to have 
direct ac cess to original source records relevant to this study, regardless of media.
The CRA/study  monitor (and auditors, IRB/EC or regulatory  inspectors) may  check the eCRF 
entries against the source documents. The consent form includes a statement by  [CONTACT_10203]/auditor from the sponsor or its representatives, national or local 
regulatory  authorities, or the I RB/EC, having access to source data (eg, subject’s medical file, 
appointment books, original laboratory reports, X -rays etc.). N on-study  site personnel will not 
disclose an y personal information or personal medical information.
These records must be made available within reasonable times for inspection and duplication, if 
required, b y a properly  authorized representative of any  regulatory  agency  (eg, the US FDA, 
EMA, [LOCATION_006] Medicines and Healthcare products Regulatory  Agency ) or an auditor.
Essential documents must be maintained according to ICH GCP requirements and may  not be 
destroy ed without written permission from the sponsor.
[IP_ADDRESS] Audit /Inspection
To ensure compliance with relevant regulations, data generated b y this study must be available 
for inspection upon request by  [CONTACT_1779], for example, the US FDA (as well as other US 
national and local regulatory
 authorities), the Europ ean Medicines Agency  (EMA), the 
For non-commercial use only
Shire CONFIDENTIAL Page 70
SHP633 -304 Protocol Amendment 3
Teduglutide 16 May 2018
Medicines and Healthcare products Regulatory  Agency , other regulatory  authorities, the sponsor 
or its representatives, and the I RB/EC for each site.
[IP_ADDRESS] Financial Disclosure
The investigator is required to disclose an y financial arrangement during the study  and for 1 year 
after, whereb y the outcome of the study  could be influenced by  [CONTACT_10204] , or other pay ments the investigator received from the sponsor. The 
following information is c ollected: an y significant payments from the sponsor or subsidiaries 
such as a grant to fund ongoing research, compensation in the form of equipment, retainer for 
ongoing consultation or honoraria; an y proprietary interest in investigational product; any 
significant equity  interest in the sponsor or subsidiaries as defined in 21 CFR 54 2(b) ( 1998).
10.[ADDRESS_483430]’s legall y
-authorized representative, as 
applicabl e, is requested to sign and date the subject informed consent form or a certified 
translation if applicable, after the subject has received and read (or been read) the written subject 
information and received an explanation of what the study involves, incl uding but not limited to: 
the objectives, potential benefits and risk, inconveniences, and the subject’s rights and 
responsibilities. A copy  of the informed consent and assent documentation (ie, a complete set of 
subject information sheets and fully  execut ed signature [CONTACT_1787]) must be given to the subject or the 
subject’s legall y-authorized representative, as applicable. This document may  require translation 
into the local language. Signed consent forms must remain in each subject’s study  file and must 
be ava ilable for verification at any  time.
Within the source documents, site personnel should document instruction of and understanding 
by [CONTACT_7071]/legall y-authorized representative/caregiver of the safe, responsible storage and 
administration of investigational product to the study  subject.
The principal investigator [INVESTIGATOR_1682] a cop y of the consent form, and assent form 
where applicable, thatwas reviewed by  [CONTACT_1201]/EC and which received their favorable 
opi[INVESTIGATOR_1649]/approval. A copy  of the IRB/EC’s written favorable opi[INVESTIGATOR_1649]/approval of these 
documents must be provided to the sponsor, prior to the start of the study  unless it is agreed to 
and docume nted (abiding by  [CONTACT_319428]) prior to study  start 
that another party  (ie, sponsor or coordinating principal investigator) is responsible for this 
action. Additionally , if the I RB/EC requires modification of the sample sub ject information and 
consent document provided by  [CONTACT_456], the documentation supporting this requirement must 
be provided to the sponsor.
10.3.[ADDRESS_483431] or Ethics Committee
For sites outside the EU, it is the responsibility  of the investiga tor to submit this protocol, the 
informed consent document (approved b y the sponsor or their designee), relevant supporting 
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_483432] recruitment information to the I RB/EC for review, and all 
must be approved prior to site initia tion.
For sites within the EU, the applicant for an EC opi[INVESTIGATOR_319376], the investigator, or 
for multicenter studies the coordinating principal investigator [INVESTIGATOR_10157], according to national 
provisions.
Responsibility  for coordinating with IRBs/ ECs is defined in the investigator agreement.
Prior to implementing changes in the study , the sponsor and the IRB/EC must approve any  
revisions of all informed consent documents and amendments to the protocol unless there is a 
subject safet y issue.
Investi gational product supplies will not be released until the Sponsor (or designee) has received 
written I RB/EC approval of and copi[INVESTIGATOR_10158].
For sites outside the EU, the investigator is responsible for keepi[INVESTIGATOR_1683]/EC apprised of the 
progres s of the stud y and of an y changes made to the protocol, but in an y case at least once a 
year; for sites within the EU, this can be done by  [CONTACT_456], the investigator or for multicenter 
studies the coordinating principal investigator, according to nation al provisions. The investigator 
must also keep the local IRB/EC informed of an y serious and significant AEs.
10.[ADDRESS_483433] (HIPAA) of 
1996. A site that is not a covered entity  as defined by  [CONTACT_385961] (or designee).
The confidentialit y of records that may be able to identif y subjects will be protected in 
accordance with applicable laws, regulations, and guidelines.
After subjects have consented to take part in the study , the sponsor and/or its representatives 
review their medical records and data collected during the stud y. These records and data may , in 
addition, be reviewed b y others including the following: independent auditors who validate the 
data on behalf of the sponsor; third parties with whom the sponsor may  develop, register, or 
market SHP633; national or local regu latory  authorities; and the I RBs/ECs which gave approval 
for the stud y to proceed. The sponsor and/or its representatives accessing the records and data 
will take all reasonable precautions in accordance with applicable laws, regulations, and 
guidelines to maintain the confidentialit y of subjects’ identities.
Subjects are assigned a unique identify ing number; however, their initials and date of birth may  
also be collected and used to assist the sponsor to verify  the accuracy  of the data (eg, to confirm 
thatlaboratory  results have been assigned to the correct subject).
The results of studies –containing subjects’ unique identify ing number, relevant medical 
records, and possibly  initials and dates of birth –will be recorded. They  may  be transferred to, 
and used in, other countries which may  not afford the same level of protection that applies within 
the countries where this study  is conducted. The purpose of an y such transfer would include: to 
support regulatory  submissions, to conduct new data anal yses to publish or present the study  
results, or to answer questions asked by  [CONTACT_1775].
For non-commercial use only
Shire CONFIDENTIAL Page 72
SHP633 -304 Protocol Amendment 3
Teduglutide 16 May 2018
10.5 Study Results / Publication Policy
Shire will endeavor to publish the results of all qualify ing, applicable, and covered studies 
according to external gu idelines in a timely  manner regardless of whether the outcomes are 
perceived as positive, neutral, or negative. Additionally , Shire adheres to external guidelines (eg, 
Good Publication Practices 2) when forming a publication steering committee, which is do ne for 
large, multicenter Phase [ADDRESS_483434] undergo appropriate technical and 
intellectual propert y review, with Shire agreement to publish prior to release of information. The 
review is aimed at protecting the sp onsor’s proprietary  information existing either at the 
commencement of the study  or generated during the study . To the extent permitted by  [CONTACT_10206], the principal investigator [INVESTIGATOR_59702] (or share with other authors) the 
copy right on his/her publications. To the extent that the principal investigator [INVESTIGATOR_10159], joint 
or shared rights, the principal investigator [INVESTIGATOR_10160] a perpetual, irrevocable, 
royalty-free license to make and distribute copi[INVESTIGATOR_10161].
The t erm “publication” refers to any public disclosure including original research articles, review 
articles, oral presentations, abstracts and posters at medical congresses, journal supplements, 
letters to the editor, invited lectures, opi[INVESTIGATOR_10162], book cha pters, electronic postings on 
medical/scientific websites, or other disclosure of the study  results, in printed, electronic, oral or 
other form.
Subject to the terms of the paragraph below, the investigator shall have the right to publish the 
study  results , and any  background information provided by  [CONTACT_10207] y publication of study results, or necessary for other scholars to verify such stud y 
results. Notwithstanding the foregoing, no publication that incorporates the spo nsor’s 
confidential information shall be submitted for publication without the sponsor’s prior written 
agreement to publish, and shall be given to the sponsor for review at least [ADDRESS_483435] publication of the study results shall be made 
by [CONTACT_10208]’s presentation of a joint, multicenter publication 
of the compi[INVESTIGATOR_10163]. If such a multicenter publication is not submitted to a 
journal for publication by  [CONTACT_385992] n an 18-month period after conclusion, abandonment, 
or termination of the study at all sites, or after the sponsor confirms there shall be no multicenter 
study  publication of the study  results, an investigator may individuall y publish the study results 
from the specific site in accordance with this section. The investigator must, however, 
acknowledge in the publication the limitations of the single -site data being presented.
Unless otherwise required by [CONTACT_10210], or the f orum in which 
it is made, authorship will comply  with the International Committee of Medical Journal Editors 
current standards. Participation as an investigator does not confer an y rights to authorship of 
publications.
For non-commercial use only
Shire CONFIDENTIAL Page 73
SHP633 -304 Protocol Amendment 3
Teduglutide 16 May 2018
11 REFERENCES
Drucker, D. J. & Yusta, B. 2014. Phy siology  and pharmacology  of the enteroendocrine hormone 
glucagon-like peptide-2. Annu Rev Physiol, 76,561- 83.
Khan, F. A., Squires, R. H., L itman, H. J., Balint, J., Carter, B. A., Fisher, J. G., Horslen, S. P., 
Jaksic, T., Koc oshis, S., Martinez, J. A., Mercer, D., Rhee, S., Rudolph, J. A., Soden, J., Sudan, 
D., Superina, R. A., Teitelbaum, D. H., Venick, R., Wales, P. W. & Duggan, C. 2015. Predictors 
of Enteral Autonom y in Children with I ntestinal Failure: A Multicenter Cohort Study . J Pediatr,
167, 29-34.e1.
Mouksassi, M. S., Marier, J. F., Cy ran, J. & Vinks, A. A. 2009. Clinical trial simulations in 
pediatric patients using realistic covariates: application to teduglutide, a glucagon -like peptide-2 
analog in neonates and infa nts with short -bowel s yndrome. Clin Pharmacol Ther, 86,667-71.
O'Keefe, S. J., Buchman, A. L ., Fishbein, T. M., Jeejeebhoy , K. N., Jeppesen, P. B. & Shaffer, J. 
2006. Short bowel sy ndrome and intestinal failure: consensus definitions and overview. Clin 
Gastroenterol Hepatol, 4,6-10.
Squires, R. H., Duggan, C., Teitelbaum, D. H., Wales, P. W., Balint, J., Venick, R., Rhee, S., 
Sudan, D., Mercer, D., Martinez, J. A., Carter, B. A., Soden, J., Horslen, S., Rudolph, J. A., 
Kocoshis, S., Superina, R., L awlor , S., Haller, T., Kurs- Lask y, M. & Belle, S. H. 2012. Natural 
history  of pediatric intestinal failure: initial report from the Pediatric Intestinal Failure 
Consortium. 
J Pediatr, 161, 723-8.e2.
Tappenden, K. A., Edelman, J. & Joelsson, B. 2013. Teduglutide enhances structural adaptation 
of the small intestinal mucosa in patients with short bowel sy ndrome. J Clin Gastroenterol, 47,
602-7.
Thymann, T., Stoll, B., Mecklenburg, L., Burrin, D. G., Vegge, A., Qvist, N., Eriksen, T.,
Jeppesen, P. B. & Sangild, P. T. 2014. Acute effects of the glucagon -like peptide 2 analogue, 
teduglutide, on intestinal adaptation in short bowel sy ndrome. J Pediatr Gastroenterol Nutr, 58,
694-702.
US Department of Health and Human Services, National In stitutes of Health & National Cancer 
Institute 2010. Common Terminology
 Criteria for Adverse Events (CTCAE).
Varni, J. W., Sherman, S. A., Burwinkle, T. M., Dickinson, P. E. & Dixon, P. 2004. The PedsQL  
Family  Impact Module: preliminary  reliability  and validity . Health Qual Life Outcomes, 2,55.
Wales, P. W., de Silva, N., Kim, J., L ecce, L., To, T. & Moore, A. 2004. Neonatal short bowel 
syndrome: population
-based estimates of incidence and mortality  rates. J Pediatr Surg, 39,690-
5.
For non-commercial use only
Shire CONFIDENTIAL Page 74
SHP633 -304 Protocol Amendment 3
Teduglutide 16 May 2018
12 APPENDICES
For non-commercial use only
Shire CONFIDENTIAL Page 75
SHP633 -304 Protocol Amendment 3
Teduglutide 16 May 2018
APPENDIX 1 PROTOCOL HISTORY
Document Date Global/Country/Site Specific
Original Protocol 08 April 2016 Global
Amendment 1 22 Nov 2016 Global
Amendment 2 23 Mar 2017 Global
Amendment 3 16 May 2018 Global
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 2 Amendment Date
23 Mar 2017Global
Description of Change and Rationale Section(s) Affected by [CONTACT_385970]; 
Section 8.1.6 ; Section 8.2.2 ; Section 
8.2.4
To allow  for approximately 7 days for subjects to transfer from Study 
TED -C14-006 to Study SHP633 -304 (instead of up to 7 days).Table 1 -1; Section 7.1.[ADDRESS_483436] pre treatment visit (P1) follow s the screening visit, it must occur 
within 12 w eeks of screening.Table 1 -3
Revised the language on abstinence as a contraceptive method for 
consistency with the Medicines and Healthcare Products Regulatory 
Agency (MHRA) Clinical Trial Facilitation Group's "Recommendations 
related to contraception and pregnancy testing in clinical trials."Section 4.7.1
Clarification that ancillary components, in addition to sterile w ater for 
injection syringes, will also be provided and labeled in accordance w ith 
the applicable regulatory requirements.Section 6.3.1
A footnote was added in Table 7 -2 to clarify that subjects older than 
18years of age will continue to use the Child Self Report and Parent 
Proxy -Report for Teens (ages 13 -18) when completing the Pediatric 
Quality of Life Generic Core Scale (PEDSQL™).Section [IP_ADDRESS] (Table 7-3)
Revised the text on severity categorization to specify that a severe 
treatment -emergent adverse event (TEAE) that might lead to dose 
interruption (Section 8.4.1) or early termination of the study 
(Section 8.5) w ill also be graded according to the National Cancer 
Institute’s (NCI) Common Terminology Criteria for Adverse Events 
(CTCAE) severity grading crite ria, in addition to the standard severity 
categorization. These events are no longer limited to only the events 
described in Table 8 -1, entitled “CTCAE Criteria for Adverse Events 
that May Lead to Dose Interruption (Prospective Period of Observation 
Only). ” Therefore, Table 8 -1 has been deleted.Sectio n 8.1.1 ; Section 8.4; Section 
8.4.1
Table 8 -1 (deleted)
For non-commercial use only
Shire CONFIDENTIAL Page 76
SHP633 -304 Protocol Amendment 3
Teduglutide 16 May 2018
Revised the criteria for early termination of the study: stoppi[INVESTIGATOR_385943] [ADDRESS_483437], and no longer limited to the 
events described in Table 8 -1, entitled “CTCAE Criteria for Adverse 
Events that May Lead to Dose Interruption (Prospective Period of 
Observation Only).”Section 8.5
Protocol Am endments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 1 Amendment Date
22 Nov 2016Global
Description of Change and Rationale Section(s) Affected by [CONTACT_385962].Protocol Signature [CONTACT_319504] [CONTACT_319431] -teduglutide treatment 
period, visits will take place approximately every 12 w eeks.Synopsis
Sections 3.1, 7.1.2
Figure 3 -1
The study design flow chart has been edited for clarity. Synopsis
Figure 3 -1
The collection of all actual and prescribed enteral nutrition data has been 
removed to reduce the burden on the subjects and investigators. Enteral 
nutrition data are not required as the efficac y endpoints are limited to 
parenteral support parameters.Synopsis
Table 1 -1, Table 1 -2, Table 1 -3
Sections 7.1.2, [IP_ADDRESS], [IP_ADDRESS], 7.1.5, 
[IP_ADDRESS], [IP_ADDRESS]
Exclusion criterion [ADDRESS_483438] been refined: 
exclusion/prohibition of treatment with growth hormone has been 
extended to [ADDRESS_483439] been clarified. Table 1 -2, Table 1 -3
Sections [IP_ADDRESS], 7.1.[ADDRESS_483440] required at the pretreatment visit should be performed at 
the local laboratory instead of the central laboratory. This will ensure 
timely results prior to starting treatment with teduglutide.Table 1 -3
Sections [IP_ADDRESS], 7.2.6
The requirement for urine specimen collection has been revised so that a 
lack of urinalysis will not constitute a protocol deviation for any pediatric 
subjects (not only for subjects wearing diapers).Table 1 -1, Table 1 -2, Table 1 -3
Section 7.2.4
For non-commercial use only
Shire CONFIDENTIAL Page 77
SHP633 -304 Protocol Amendment 3
Teduglutide 16 May 2018
Protocol Am endments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 1 Amendment Date
22 Nov 2016Global
Description of Change and Rationale Section(s) Affected by [CONTACT_385993] -teduglutide treatment visit 
after the screening visit will occur within 2 to 12 w eeks of the screening 
(formerly within 12 weeks of screening).Synopsis
Table [ADDRESS_483441] been clarified for visits during the no -teduglutide and 
teduglutide treatment periods.Table 1 -2, Table 1 -3
Section 7.1.2
‘Specific’ has been deleted from ‘positive/specific anti -teduglutide 
antibodies’ to eliminate the redundancy. By [CONTACT_108], positive samples 
must be specific (as assessed in the confirmatory assay), or otherwise 
considered negative.Table [ADDRESS_483442] been removed from 
medical history.Table 1 -1 (footnote b)
Section 7.2.1
For consistency within the protocol, sigmoidoscopy has been added as the 
alternate to colonoscopy throughout the protocol. Table 1 -1, Table 1 -2, Tab le 1-3
Sections 3.1, 7.1.2, [IP_ADDRESS]
Removal of former footnote i on fecal occult blood test for clarity. Table 1 -3
Clarification has been made on circumstances when the CxW28 visit ma y 
be combined with the next pretreatment or EOS/ET visit. Table 1 -3
Section 7.1.4
The text on PS support requirements over time in pediatric subjects w ith 
SBS has been clarified, and text on intestinal adaptation has been refined.Section 1.1
Status of current teduglutide approvals for use has been updated. Section 1.2, 3.1
The term ‘re -challenge’ has been replaced w ith ‘additional teduglutide 
treatment’ for clarity and consistency with other studies.Section 3.[ADDRESS_483443]’s completion of the study has been corrected for 
consistency within the protocol.Section 3.[ADDRESS_483444] been clarified.Sections 4.8.1, 4.8.2
Withdraw al by [CONTACT_7078]/guardian has been added as reason for 
discontinuation.Section 4.8.[ADDRESS_483445] i f deemed appropriate to ensure sufficient 
supplies between visits. Also, documentation of all dispensed study 
medication has been clarified.Section 6.4
Clarification has been made that local laboratory results are not required to 
be entered in the eCRFs.Section 7.2.4
Collection of urine sodium and urine osmolality has been removed. Section 7.2.4
For non-commercial use only
Shire CONFIDENTIAL Page 78
SHP633 -304 Protocol Amendment 3
Teduglutide 16 May 2018
Protocol Am endments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 1 Amendment Date
22 Nov 2016Global
Description of Change and Rationale Section(s) Affected by [CONTACT_385994] a follow -up period escape 
criterion.Secti on 7.2.5
Intake and output diaries (formerly in Sections 7.2.11 and 7.2.12, 
respectively) have been moved under a new Section 7.2.11 ‘Diaries’ for 
clarity, and are now Sections [IP_ADDRESS] and [IP_ADDRESS], respectively. 
Information on study drug administration diary has been added in Section 
[IP_ADDRESS]. Clarification has been made that only available diary data will be 
reviewed at each clinic and telephone visit.Sections 7.2.11, [IP_ADDRESS],  [IP_ADDRESS], 
[IP_ADDRESS] 
Performance of dipstick specific gravity tests by [CONTACT_385995]. It is 
now at the discretion of the investigator for all subjects, not just those in 
diapers. This change is to align with standard medical practice.Section 7.2. 11.[ADDRESS_483446] been made to the language on dose interruption. Sections 8.4, 8.4.1
Unscheduled safety follow  up assessments (including visits conducted 
after EOS) are not to be recorded. How ever, clarification has been made 
that they are to be collected where requested.Section 9.1
The protocol now  refers to the data monitoring committee (DMC) Charter 
for the schedule of DMC reviews.Section 9.[ADDRESS_483447] been made to the Health economics and outcomes research 
endpoints to include the begin ning of each treatment cycle (CxD1) as 
additional baseline. These changes are for clarity and consistency with 
other teduglutide studies. Synopsis
Section 9.9.[ADDRESS_483448] been made to the guidelines for nutritional support 
management during the study.Appendix 2
For non-commercial use only
Shire CONFIDENTIAL Page 79
SHP633 -304 Protocol Amendment 3
Teduglutide 16 May 2018
APPENDIX 2 GUIDELINES FOR NUTRI TIONAL SUPPORT MANAG EMENT 
DURING THE STUDY
Nutritional support adjustment in volume and calories should be considered at all planned visits. 
Please consider the following clinical parameters identified as markers for adequate management 
of pediatric SBS. These parameters should also be considered for managing nutritional support 
(PS and/or oral/enteral feeding) in terms of volume and calories during the treatment period. 
Growth trajectory , including weight, heigh t (or length), and head circumference (for pediatric 
subjects up to 36 months of age)
Other clinical evaluations
Serum electrol ytes
Blood urea nitrogen /creatinine levels
Changes in stool frequency  or volume, including mixed output
Stool consistency  (ie, Bristol Stool Scale)
Urine specific gravit y
General consideration to possible clinical deterioration in SBS
Inability  to maintain weight and growth velocity
Diarrhea ( ≥10 bowel movements per day , ≥80 mL/kg/day  from an ostomy, or 
≥75mL/kg/day  mixed output)
Colic/vomiting frequency increased
Electrol yte changes or imbalance
Skin breakdown 
Adjustments should be based on the actual nutritional support in volume and calories the 
subject infuses. Subjects should remain compliant with the nutritional support pre scription in 
volume and calories during the stud y.
Nutritional support constituents may  be adjusted at the discretion of the investigator.
During the [ADDRESS_483449]’s scheduled visit, no 
further changes to the prescr ibed nutritional support should be made.
If there is a change in EN or other food or fluid intake, the investigator should consider this 
when adjusting the PS/EN support in volume and calories.
For non-commercial use only
Shire CONFIDENTIAL Page 80
SHP633 -304 Protocol Amendment 3
Teduglutide 16 May 2018
Figure A -1 Weaning Algorithm for Subjects Who are NOT Toilet T rained and in 
Diapers
For non-commercial use only
Shire CONFIDENTIAL Page 81
SHP633 -304 Protocol Amendment 3
Teduglutide 16 May 2018
Figure A -2 Weaning Algorithm for Subjects Who are Toilet Trained and NOT in 
Diapers
For non-commercial use only
Shire CONFIDENTIAL Page 82
SHP633 -304 Protocol Amendment 3
Teduglutide 16 May 2018
Figure A -3 Clinical Dehydration Assessment and PS/EN Adjustment
For non-commercial use only
PROTOCOL: SHP633 -304
TITLE: A Prospective, Open -label, L ong-term Safety  and Efficacy  Study  of 
Teduglutide in Pediatric Patients with Short Bowel Sy ndrome Who 
Completed TED- C14-006 or SHP633 -301
DRUG: Teduglutide
IND: IND# [ADDRESS_483450] NO.: 2016-000849-30
SPONSOR: Shire Human Genetic Therapi[INVESTIGATOR_014], Inc.
[ADDRESS_483451] , Lexington, MA [ZIP_CODE] [LOCATION_003]
PROTOCOL 
HISTORY:Amendment 4: [ADDRESS_483452] 2019
Amendment 3: 16 May  2018
Amendment 2: 23 Mar 2017
Amendment 1: 22 Nov 2016
Original Protocol: [ADDRESS_483453] party without the express written 
consent of Shire.
For non-commercial use only
Shire CONFIDENTIAL Page2 
SHP633-304 Protocol Amendment 4 
Teduglutide 01Oct2019 
PROTOCOL SIGNATURE [CONTACT_64783]'s (Shire) Approval 
Signature: 
, 
 
Global Clinical Development 
Investigator's Acknowledgement 
I have read this protocol for Shire Study SHP633-304. 
Title: A prospective, open label, long-term safety and efficacy study of teduglutide in 
pediatric patients with short bowel syndrome who completed TED-Cl4-[ADDRESS_483454] fully discussed the objective(s) of this study and the contents of this protocol with the 
sponsor's representative. 
I understand that the information in this protocol is confidential and should not be disclosed, 
other than to those directly involved in the execution or the scientific/ethical review of the 
study, without written authorization from the sponsor. It is, however, permissible to provide 
the information contained herein to a subject in order to obtain their consent to participate. 
I agree to conduct this study according to this protocol and to comply with its requirements, 
subject to ethical and safety considerations and guidelines, and to conduct the study in 
accordance with International Conference on Harmonization (ICH) guidelines on Good 
Clinical Practice (GCP) and with the applicable regulatory requirements. 
I understand that failure to comply with the requirements of the protocol may lead to the 
termination of my participation as an investigator for this study. 
I understand that the sponsor may decide to suspend or prematurely terminate the study at 
any time for whatever reason; such a decision will be communicated to me in writing. 
Conversely, should I decide to withdraw from execution of the study I will communicate my 
intention immediately in writing to the sponsor. 
Investigator Name [CONTACT_1781]: 
(please hand print or type) 
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_483455] 2019
SUMMAR Y OF CHANGES F ROM PREVIOUS VERSION
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number [ADDRESS_483456] 2019Global
Description of Change and Rationale Section(s) Affected by [CONTACT_319487] S ponsor  was 
updated to . 
(Administrative letter dated [ADDRESS_483457] 2018)
The fax number of the S ponsor  was removed. 
(Administrative letter dated 15 Jan 2019)Emergency Contact [CONTACT_319488] w as updated to reflect Qui ntiles ’current 
name ,IQVIA ,and Dr. ’s email address as Emergency Contact [CONTACT_385996] 2020. Synopsis
Clarification of the follow -up period escape criteria and their use in 
combining the CxW24 and pretreatment visits was added.
(Clarification Memo dated 0 9 Apr 2019) Synopsis , Section 4.[ADDRESS_483458] dose of 
teduglutide in the study even if the EOS/ET occurs w ithin that timeframe.Table 1-1, Section 7.1.5 ,Section 8.1
An optional qualitative interview  to be conducted by [CONTACT_319490] 
14days after completion of the end of study/early termination visit was 
added. A single individual telephone interview will be conducted w ith 
English -speaking parents (or legal guardians) of subjects and subjects aged 
12 years or older who provide informed consent (and if applicable, informed 
assent) to participate in the interview. These interviews will be performed in 
selected countries participating in this trial.Table 1-1, Section 7.1.6, 
Section 7.2.13 , Section 9.9.2 ,
Appendix 3 , Appendix 4
Noted that CRP will not be measured in subjects <[ADDRESS_483459] at a dose or frequency greater than 0.05 mg/kg 
subcutaneous once daily. An overdose occu rs if any of the follow ing criteria 
are met: 
More than 0.05 mg/kg is given at any one time
Consecutive doses are spaced less than 12 hours apart
Any more than 0.05 mg/kg given in one day (a day is defined as 
beginning at 12:00 AMand ending at 11:59 PM)Section 8.1.[ADDRESS_483460] 2019
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number [ADDRESS_483461] 2019Global
Description of Change and Rationale Section(s) Affected by [CONTACT_319491] w ere updated to specify events 
leading to an interruption of teduglutide treatment and events leading to a 
permanent discontinuation of teduglutide treatment. 
Investigational product must be interr upted if any of the follow ing events 
occur:
An AE of special interest
An AE that is of NCI CTCAE severity Grade 3 or 4 and related to 
teduglutide
Intestinal obstruction
Biliary obstruction related to teduglutide
Pancreatic duct obstruction related to teduglutide
Heart failure with severe fluid overload related to teduglutide 
Investigational product must be permanently discontinued if any of the 
following events occur:
Pregnancy
Severe hypersensitivity, such as anaphylaxis determined by [CONTACT_192682] r to be related to study drug. This does not include the 
presence of anti -teduglutide antibodies, mild injection site reactions or 
mild symptoms that according to the investigator do not pose a 
significant risk to the subject.
Confirmed drug -induced liver injury (DILI) related to teduglutide 
Any malignancy
These clarifications were made for consistency with other teduglutide 
studies.Section 8.4, Section 8.4.1
Minor editorial changes and corrections to typographical errors (w hich do 
not modify content and/or intent of the original document) were made.Throughout the protocol
See Appendix [ADDRESS_483462] IN FORMA TION
In the event of a serious adverse event (SAE), the investiga tor must fax or e -mail the Shire 
Clinical Study  Adverse Event Form for Serious Adverse Events (SAEs) and Non -serious AEs as 
Required b y Protocol within 24 hours to the Shire Global Drug Safet y Department. Applicable 
fax numbers and e -mail address can be fo und on the form (sent under separate cover). A copy  of 
this form must also be sent to the S ponsor Medical Monitor by  e-mail using the details below.
, MD
Email: 
For protocol -or safety- related issues ,the investigator must contact [CONTACT_385997]:
Primary contact [CONTACT_385971] (NA) and backup contact [CONTACT_385972] (EU)
, MD, 
Mobile: 
US Toll Free number: 
Phone:  (medical emergencies –NA)
Email: 
Primary contact [CONTACT_385983]
, MD, 
Mobile: 
Phone: 
Phone:  (medical emergencies –EU)
Email: 
In addition, the investigator may also contact [CONTACT_941] S ponsor Medical Monitor (8:00 to 20:[ADDRESS_483463] Time):
, MD, 
Mobile: 
Email: 
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_483464](s) will be returned to the 
sponsor for inspection and anal ysis.
A product quality  complaint includes any  instances where there is an allegation or report relating 
to Shire licensed or investigational products, received in writing, electronically , or orall y, which 
indicates an impact to a product’s strength, identity , safet y, purit y, or quality, or which suggests 
that the product did not meet the criteria defined in the regulatory  applications, licenses, or 
marketing authorizations for the product. Examples of investigational product quality  complaints 
include, but ar e not limited to, the following:
Unit issues Capsule fill empty  or overage
Bottle/vial fill shortage or overage
Capsule/tablet damaged/broken
Syringe/vial cracked/brokenSyringe leakage
Missing components
Product discoloration
Device malfunction
Labeling Label missing
Leaflet or Instructions For Use 
(IFU) missing 
Label illegibleIncomplete, inaccurate, or 
misleading labeling
Lot number or serial number missing
Packaging Damaged packaging (eg, secondary , 
primary , bag/pouch)
Tampered seals
Inadequate or faulty  closureMissing components within package
Foreign 
materialContaminated product
Particulate in bottle/vial
Particulate in packaging
Please report the product quality complaint using the “Product Quality  Complaint Data 
Collection Form” via the email address:
Telephone number (provided for reference if needed):
Shire, Lexington, MA ([LOCATION_003])
For instruction on reporting AEs related to product complaints see Section 8.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_483465] OF APPENDICES ................................................................................................................11
ABBREVIAT IONS .......................................................................................................................12
STUDY SYNOPSI S ......................................................................................................................14
STUDY SCHEDULE(S) ................................................................
...............................................[ADDRESS_483466](s) ...........................................................[ADDRESS_483467] Compliance ..................................................................................................41
7 STUDY PROCEDURES........................................................................................................42
7.1 Study  Schedule ................................
.........................................................................42
7.1.1 Screening ................................................................................................................42
7.1.2 Visits for Subjects Not Receiving Teduglutide .....................................................42
7.1.3 Visits for Subjects Receiving Teduglutide ............................................................43
7.1.4 Teduglutide Follow -up Period ................................
...............................................46
7.1.5 Study  Completion/Earl y Termination Visit (EOS/ET Visit) .................................[ADDRESS_483468] 2019
9.9 Other Anal yses................................ ................................ ................................ ......... 71
9.9.1 Health- related Quality  of L ife Anal yses................................................................71
9.9.2 Qualitative Interviews ............................................................................................71
10SPONSOR’S AND I NVEST IGATOR’S RESPONSIBILIT IES...........................................72
10.1 Sponsor’s Responsibilities .......................................................................................72
10.1.1 Good Clinical Practice Compliance .......................................................................72
10.1.2 Indemnity /Liability  and Insurance .........................................................................72
10.1.3 Public Posting of Study  Information ......................................................................72
10.1.4 Submission of Summary  of Clinical Study  Report to Competent Authorities 
of Member States Concerned and Ethics Committees ...........................................72
10.1.5 Study  Suspension, Termination, and Completion..................................................73
10.2 Investigator’s Responsibilities ................................
.................................................[ADDRESS_483469] or Ethics Committee ..................................................76
10.4 Privacy  and Confidentiality ................................ ................................ ...................... 76
10.5 Study  Results / Publication Policy ...........................................................................[ADDRESS_483470]  OF TABLES
Table 1-1: Schedule of Events Required for All Subjects ..............................................19
Table 1- 2: Schedule of Events for Subjects Not Receiving Teduglutide .......................20
Table 1- 3: Schedule of Events for Subjects While Receiving Teduglutide....................21
Table 5- 1: Prohibited Treatment .....................................................................................37
Table 7
-1: List of Laboratory  Tests ................................
................................................49
Table 7-
2: Approximate Volume of Blood to be Drawn from Each Subject 
Annually ................................................................
........................................51
Table 7-3: Developmentally Appropriate PedsQL™Generic Core Scales .....................[ADDRESS_483471]  OF FIGURES
Figure 3 -1: Study  Design Flow Chart ................................
..............................................[ADDRESS_483472] aspartate aminotransferase
-HCG beta-human chorionic gonadotropin
BMI body  mass index
CRA clinical research associate
CRO contract research organization
CSR clinical study  report
CTCAE Common Terminology  Criteria for Adverse Events
DILI drug-induced livery  injury
DMC data monitoring committee
DPP-[ADDRESS_483473] 2019
Abbreviation Definition
IWRS interactive web -based response sy stem
MedDRA Medical Dictionary  for Regulatory  Activities
NA North America
NCI National Cancer Institute
NDA new drug application
NTT no-teduglutide treatment
PedsQL Pediatric Quality  of Life inventory
PS parenteral support
PT/INR prothrombin time/international normalized ratio
QD once dail y
SAE serious adverse event
SAP statistical analy sis plan
SBS short bowel sy ndrome
SC subcutaneous
SOC standard of care
t1/[ADDRESS_483474] upper limit of normal
US [LOCATION_002]
WHO -DD World Health Organization 
–Drug Dictionary
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_483475] 2019
STUDY  SYNOPSIS
Protocol num ber: SHP633 -304 Drug: Teduglutide
Title of the study: A Prospective, Open -label, Long -term Safety and Efficacy Study of Teduglutide in Pediatric 
Patients with Short Bowel Syndrome (SBS) Who Completed TED -C14-006 or SHP633 -301
Number of subjects (total and for each treatm ent arm):
Approximately [ADDRESS_483476] of care treatment arms, are expected to enroll in this extension study. This study will enroll up to as 
many subjects as complete the TED -C14-006 and SHP633 -301 studies.
Investigator(s): Multicenter study
Site(s) and Region(s ): 
Approximately 28 investigational sites in North America and Europe w ill participate in this extension study
Study period (planned):
October 2016 –December 2020Clinical phase: 3 Extension
Objectives:
Prim ary: To evaluate the long -term safety and tolerability of teduglutide treatment in pediatric subjects w ith SBS.
Secondary: To evaluate long -term efficacy of teduglutide treatment in pediatric subjects with SBS.
Rationale:
This is a Phase 3, prospective, open -label, long -term extension study to evaluate the safety and efficacy of 
teduglutide in pediatric subjects with short bow el syndrome (SBS) w ho completed either the TED -C14-006 or 
SHP633 -301 studies (the core studies). In addition to evaluating the long -term safety and durability of efficacy 
after [ADDRESS_483477] of care (SOC) treatment arms in TED -C14-[ADDRESS_483478], dose, and m ode of administration:
This study will allow repeat doses of teduglutide 0.05 mg/kg subcutaneous (SC) o nce daily (QD) injection for 
eligible pediatric subjects. There is no active comparator or reference product.
Methodology:
This is a Phase 3, prospective, open -label, long-term extension study to evaluate the safety and efficacy of 
teduglutide in pediatri c subjects who completed the TED -C14-006 or SHP633 -301 studies (core studies).
Once the informed consent (and if applicable, informed assent) have been reviewed and signed, demographics, 
and updates to medical history and short bow el syndrome history will be obtained .Subjects not receiving 
teduglutide treatment (ie, in a no -teduglutide treatment [NTT] period), w ill be seen approximately every 12 weeks 
for safety, parenteral support (PS) requ irements, and quality of life. The first NTT visit after the scree ning visit 
will occur within 2 to 12 w eeks of the screening visit . At any point after screening, including during a NTT 
period, subjects who meet ≥[ADDRESS_483479], and parent agree to proceed w ith teduglutide therapy .
After the pretreatment visit, subjects who meet ≥1 of the teduglutide treatment inclusion criteria, and meet none 
of the teduglutide treatment e xclusion criteria, will start a 28 -week cycle, consisting of 24 weeks of teduglutide 
treatment at 0.05 mg/kg SC once daily, followed by a 4 -week follow -up period (during which no teduglutide is 
administered) (Figure 3 -1). During the 28 -week cycle, clinic visits will occur at weeks 1, 2, 4, 6, 9, 12, 16, 20, 24, 
and 28. Phone visits are required approximately 1 w eek after adjustments in PS during the teduglutide treatment 
period (betw een weeks 1 and 24), and w eekly during the teduglutide follow -up period (be tween weeks 24 and 
28). Safety and PS requirements will be evaluated at every visit, and quality of life assessments will be made 
approximately every [ADDRESS_483480] may 
"escape" the follow -up period early and proceed immediately to another pretreatment visit. Follow ing completion 
of the [ADDRESS_483481] will proceed to an NTT visit or another pretreatment visit within 
approximately 12 weeks.
Atallsitevisits andtelephone contacts, safety willbemonitored andnutritional support willbereviewed and
adjusted asneeded. Tomaintain consistency across centers, allattempts should bemade tofollow thenutritional
support adjustment guideline s(developed withSBS expert input andprovided intheprotocol) fordecisions
regarding PSsupport reduction andadvances inenteral feeds based onweightgain, urine andstool output, and
clinical stability. Departure from theguidelines, however, isnotconsidered aprotocol deviation. (Appendix 2).
Study Design Flow Chart 
Figure legend: Safety and efficacy data for subjects not receiving teduglutide treatment are captured approximately every 
12 weeks, but subjects may proceed to the pretreatment visit at any time in order to assess eligibility for teduglutide 
therapy. Eligible subjects will enter a 28 -week teduglutide cycle. During this cycle, subjects will return to the site for 
safety and efficacy assessments at weeks 1, 2, 4, 6, 9, 12, 16, 20, and 24 ( solid black lines ). Phone visits are required 
approximately 1 week after adjustments in PS during the intervening weeks between weeks 2 and 24 ( dashed grey 
lines ). Subjects discontinue teduglutide at week 24 and enter a 4 -week follow -up (no-treatm ent) period, during which 
phone visits will be performed weekly ( solid grey lines ). If an escape criterion is met at week 24 or during the follow -up 
period, subjects may proceed directly to another pretreatment visit.
Study Inclusion Criteria: 
The subjec t will be considered eligible for the study if they meet allof the study inclusion criteria. Teduglutide 
treatment eligibility does not impact study eligibility.
1.Subject provides w ritten informed consent (subject, parent or legal guardian and, as appropriate, 
informed assent) to participate in the study before completing any study -related procedures.
2.Subject completed the TED -C14-006 or SHP633 -301 studies (including subjects in the standard of care 
treatment arms). Subjects are considered to have c ompleted SHP633 -[ADDRESS_483482] understands and is willing and able to fully adhere to study requirements as defined in this 
protocol. 
Study Exclusion Criteria: There are no exclusion criteria for this stud y.
Teduglutide Eligibility Criteria: Subjects are eligible for teduglutide treatment if at least one ( ≥1) of the 
teduglutide treatment inclusion criteria, and none of the teduglutide treatment exclusion criteria, are met. In 
addition, the investigator and the subject (and/or parent or legal guardian, as appropriate) must agree to proceed 
with treatment.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_483483] 2019
Teduglutide Treatment Inclusion Criteria :
1.Subject is teduglutide -naïve, receiving PS, and unable to significantly reduce PS or advance enteral feeds 
(eg, 10% or less change in PS or advance in feeds) for at least 3 months prior to and during the 
teduglutide pretreatment visit, as assessed by [CONTACT_093]. Transient instability for events such as 
interruption of central access or treatment for sepsis is allowed if the PS returns to within 10% of 
baseline prior to the event.
2.Subject w as previously treated w ith teduglutide and at least one of the following criteria is satisfied:
a.Increasing PS requirements follow ing teduglutide discontinuation.
b.Decreased PS requirement during prior teduglutide treatment, follow ed by  [CONTACT_319475].
c.Deteriorating nutritional status (eg, weight loss or growth failure) despi[INVESTIGATOR_319391] (EN) following teduglut ide discontinuation.
d.Deteriorating fluid or electrolyte status despi[INVESTIGATOR_319361].
e.Severe diarrhea related to teduglutide discontinuation.
Teduglutide Treatment Exclusion Cri teria:
1.Body  weight <5 kg at the pretreatment visit.
2.Unresected gastrointestinal (GI) polyp, known polyposis condition, premalignant change, or malignancy, 
in the GI tract.
3.History of cancer in the previous 5 years except surgically curative skin cancers.
4.Serial transverse enteroplasty or other major intestinal surgery within 3 months preceding the teduglutide 
pretreatment visit. Insertion of a feeding tube, anastomotic ulcer repair, minor intestinal resections 
≤10cm, and endoscopic procedures are allow ed.
5.Intestinal or other major surgery planned or scheduled to occur during the 28 -week cycle.
6.Clinically significant intestinal stricture or obstruction.
7.Clinically significant, active or recurrent pancreatic or biliary disease.
8.Active, severe, or unstable, cl inically significant hepatic impairment or injury, including the following 
laboratory values at the pretreatment visit:
a.Total bilirubin ≥2× upper limit of normal (ULN)
b.Aspartate aminotransferase (AST) ≥7 × ULN
c.Alanine aminotransferase (ALT) ≥7 × ULN
9.Renal dysfunction shown by [CONTACT_319476]  50mL/min/1.[ADDRESS_483484] repair, or patent ductus arteriosus ligation.
11.Participation in a clinical study using an experimental drug (other than glutamine, Omegaven, or 
Smoflipid) w ithin 3 months or 5.5 half -lives of the experimental drug, whichever is long er, prior to the 
pretreatment visit and for the duration of the 28 -week cycle.
12.Treatment with analogs of glucagon -like peptide -1 (GLP -1), glucagon -like peptide -2 (GLP -2) (not 
including teduglutide), insulin -like growth factor -1 (IGF -1), or grow th hormone, within 3 months 
preceding the teduglutide pretreatment visit.
13.Treatment with octreotide or dipeptidyl peptidase 4 (DPP -4) inhibitors within [ADDRESS_483485] 2019
15.Known history of alcohol or other substance abuse within 1 year prior to the pretreatment visit.
16.Pregnant or lactating female subjects.
17.Sexually active female subjects of child -bearing potential unwilling to use approved contraception 
during teduglutide treatment and for 30 days after the treatment period.
18.Any condition, disease, illness, or circumstance that in the investigator’s opi[INVESTIGATOR_319362], prevents comp letion of the study, or interferes with analysis of the study results.
Follow -up Period Escape Criteria: At the discretion of the investigator, the follow -up period may be interrupted 
(if the subject meets 1or more of escape criteria 1 to 4 during the fol low-up period) or omitted (if the subject 
meets escape criterion 5 at the CxW24 visit) and the subject may proceed directly to the pretreatment visit, if 
≥1of the following criteria is met:
1.Increasing PS requirements follow ing teduglutide discontinuation
2.Deteriorating nutritional status (eg, weight loss or growth failure) despi[INVESTIGATOR_319398].
3.Deteriorating fluid or electrolyte status despi[INVESTIGATOR_385949].
4.Severe diarrhea related to teduglutide discontinuation.
5.The subject escaped during the follow -up period of a previous teduglutide treatment cycle within 
SHP633 -[ADDRESS_483486] involvem ent in the study:
A subject w ill be considered enrolled in the study once the subject has provided signed consent and meets all of 
the Study Inclusion Criteria. Subjects may participate in multiple NTT periods and/or multiple [ADDRESS_483487] has access (as needed) to teduglutide. 
The subject’s maximum duration of participation is expected to be approximately [ADDRESS_483488] has not withdrawn early from the study for any reason 
prior to completing End of Study (EOS) visit.
Planned duration of no-teduglutide treatm ent periods : variable, depending o n disease course 
Planned duration of the teduglutide pretreatm ent visit: 1 to 21 days
Planned cycle duration : 28 weeks. Each cycle consists of 24 w eeks of teduglutide treatment followed 
by a 4 -week follow -up period (no treatment)
Endpoints and statistical analysis: 
The safety population will consist of all enrolled subjects. The safety population will be used for both 
safety and efficacy analysis.
Efficacy Endpoints
Efficacy endpoints will be analyzed at the end of each teduglutid e treatment period (w eek 24 or end of treatment 
[EOT]), and at each study visit, relative to the baseline of the core study (TED -C14-006 or SHP633 -301) and/or 
first exposure to teduglutide. The follow ing efficacy endpoints will be analyzed: 
Reduction in P S volume of at least 20%
Absolute and relative change in PS volume
Com plete weaning off PS
Change in days per w eek of PS
Health Econom ics and Outcom es Research Endpoints 
Health economics and outcomes research endpoints will be analyzed at approximately 12-week intervals 
(weeks 12 and 24 of each teduglutide treatment cycle, and every 12 w eeks for subjects not on teduglutide), 
relative to the study baseline. The beginning of each treatment cycle (CxD1) will be an additional baseline.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_483489] 2019
Change in Pediatric Quality of Life Inventory (PedsQL) score
Change in PedsQL Family Impact Module score
Change in PedsQL Gastrointestinal Symptoms Module Sub -Scales scores: 
Food and Drink Limits
Diarrhea 
Safety Endpoints 
The follow ing safety endpoints will be analyzed:
Adverse events
Vital signs, including temperature, heart rate, blood pressure
Laboratory safety data (ie, clinical chemistry, hematology, and urinalysis)
Urine output
Stool output
Antibodies to teduglutide
Gastrointestinal -specific testing, including fecal occult blood testing and colonoscopy or sigmoidoscopy
Z-scores for w eight, height (or length), head circumference (up to 36 months of age), and body mass index 
Statistical Methodology for Efficacy Analysis
No claims of statistical significance will be ma de; how ever, 95% confidence intervals will be provided, if 
applicable. Continuous variables, including those assessed on a discrete scale, will be summarized using 
descriptive statistics including number of subjects, mean, median, standard deviation , maxi mum, and minimum. 
For categorical variables, statistical summaries will include number of subjects and percentages.
Statistical Methodology for Safety Analysis 
Safety data, including laboratory tests and vital signs assessments, will be summarized by [CONTACT_22986] t. AEs will also be 
collected and summarized. Descriptive statistics will be calculated for quantitative safety data as w ell as for the 
difference from baseline, if applicable. Frequency counts will be compi[INVESTIGATOR_78415].
Sample Size Justification 
As this is an extension study, the maximum number of subjects was determined by [CONTACT_385985] -C14-[ADDRESS_483490] 2019
STUDY  SCHEDULE(S) 
Table 1-1: Schedule of Events Required for All Subjects 
PeriodScreening End of Study or Early Termination
Scr EOS/ET
Visit Type Site Site
Informed consent/assentaX
Study eligibility X
Demographics, medical historyb, SBS historycX
Dispense intake and output diaries X
Evaluate teduglutide treatment inclusion criteriadX
Adverse events X Xn
Concomitant medications and procedures X X
Physical examination and vital signs, including weight X
Height and head circumferenceeX
Review intake and output diariesf X
Record PS prescription and adjust as neededgX X
Safety laboratory testshX
PedsQL Generic Core Scale/ PedsQL Family Impact Module/ 
PedsQL Gastrointestinal Symptoms Module Sub -ScalesX
Antibodies to teduglutideiX
Fecal occult blood testingj(X)
Colonoscopy or sigmoidoscopyk(X)
Pregnancy testingl(X)
Qualitative interviewmX
FOBT = fecal occult blood testing; FOCBP = female of child-bearing potential; EOS =end of study; ET=early termination; 
GI=gastrointestinal; NTx=no treatment; PedsQL=Pediatric Quality of Life Inventory; PS=parenteral support; SBS=Short Bowel 
Syndrome; Scr =Screening
aInformed Consent (and informed assent, if applicable) must be obt ained prior to performing any study-related procedures; 
consent (and informed assent, if applicable) may be obtained anytime during the EOS visit for the TED -C14 -[ADDRESS_483491] has any changes to the SBS history that had been collected at the baseline of the TED -C14 -006 or SHP633- 301, 
then the updated SBS history will be collected.
dSubjects who meet ≥[ADDRESS_483492], 
and parent or legal guardian agrees to proceed with teduglutide therapy ( Table 1 -3).
eHead circumference will be measured in subjects 36 months of age and younger.
fThe intake diary should be completed daily for a minimum of 2 weeks prior to the EOS/ET visit. The output diary should be 
completed daily over a 48 -hour period of nutritional stabi lity before the EOS/ET visit.
gPS adjustments should be made after review of any available intake and output diaries and the safety lab data according to th e 
guidance for nutrition support adjustment provided in Appendix [ADDRESS_483493] of clinical chemistry, hematology, and urinalysis, with results processed 
by a central laboratory. Urine specimen collection should be attempted as part of the safety labs, but lack of urinalysis wil l not 
constitute a protocol deviation.
iRequired for all teduglutide -exposed subjects
jFOBT should be performed on teduglutide -exposed subjects on an annual basis, approximately every 48-60 weeks at a 
minimum.
kThe need for colonoscopy/sigmoidoscopy in response to a positive FOBT during a no -teduglutide treatment period is at the 
discretion of the investigator, but all teduglutide -exposed subjects will undergo colonoscopy/sigmoidoscopy after they have 
received the equivalent of 2 treatment cycles (48 weeks of study drug exposure), and subjects who continue to receive teduglutide 
will undergo colonoscopy/sigmoidoscopy at [ADDRESS_483494] 30 days after study 
drug discontinuation.
mOptional interview to be conducted by [CONTACT_1382] 14 days after completion of the EOS/ET visit (see Se ction 7.2.13 ).
nAEs will be collected for [ADDRESS_483495] dose of teduglutide in the study even if the EOS/ET occurs within that timef rame.
Note: (X) denotes conditional requirement for a given assessment if the subject meets certain conditions per protocol.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_483496] 2019
Table 1-2: Schedule of Events for Subjects Not Receiving Teduglutide 
Visit Number NTx
Visit Type Site
Visit FrequencyaEvery 12 weeks 
Window (days)b±[ADDRESS_483497] as neededfX
Safety laboratory testsgX
PedsQL Generic Core Scale/PedsQL Family Impact Module/ 
PedsQL Gastrointestinal Symptoms Module Sub -ScalesX
Antibodies to teduglutideh(X)
Fecal occult blood testingiAnnually 
Colonoscopy or sigmoidoscopyj(X)
Serum samplekEvery 24 w eeks
FOBT = fecal occult blood testing; NTT = no-teduglutide treatment; PedsQL = Pediatric Quality of Life Inventory; 
PS= parenteral support; TED = teduglutide
aThe first NTx visit following the screening visit must occur within [ADDRESS_483498] NTx visit in the current no- teduglutide treatment period.
cSubjects who meet ≥[ADDRESS_483499], 
and parent or guardian agree to proceed with teduglutide therapy ( Table 1 -3).
dHead circumference will be measured in subjects [ADDRESS_483500] ac tual PS volume and hours per day, completed daily for a minimum of 2 weeks prior to each study 
visit (see Section [IP_ADDRESS] ). Urine and stool output should be recorded in the output diary over a 48 -hour period of nutritional 
stability before every clinic vi sit (see Section [IP_ADDRESS] for more detail).
fPS adjustments should be made after review of the intake and output diaries and the safety lab data according to the guidance
for nutrition support adjustment provided in Appendix [ADDRESS_483501] of clinical chemistry, hematology, and urinalysis, with results processed 
by a central laboratory. Urine specimen collection should be attempted as part of the safety labs, but lack of urinalysis will not 
constitute a prot ocol deviation . CRP will not be measured in subjects <[ADDRESS_483502] follow -up samples collected 
every 12 weeks during the study until a negative result is obtaine d.
i FOBT should be performed on teduglutide -exposed subjects on an annual basis, approximately every 48-60 weeks at a 
minimum.
jThe need for colonoscopy/sigmoidoscopy in response to a positive FOBT during a no -teduglutide treatment period is at the 
discretion of the investigator, but all teduglutide -exposed subjects will undergo colonoscopy/sigmoidoscopy after they have 
received the equivalent of 2 treatment cycles (48 weeks of study drug exposure) and subjects who continue to receive teduglutide 
will un dergo colonoscopy/sigmoidoscopy at 5 year intervals or more oft
en as needed. See Section 7.2.9 for details.
kLack of collection of serum samples will not constitute a protocol deviation . Stored serum samples should be omitted for 
subjects weighing less than 15 kg and whenever local blood volume limitations are exceeded.
Note: (X) denotes conditional requirement for a given assessment if the subject meets certain conditions per protocol.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_483503] 2019
Table 1-3: Schedule of Events for Subjects While Receiving Teduglutide
PeriodPre-
treat mentTeduglutide Treat mentFollow -
up
Visit Number Pxa Cx
D1Cx
W1Cx
W2
Phone contact [CONTACT_319408] [ADDRESS_483504] is required approximately 1 week after PS adjustmentCxW24 
(EOT)CxW25 
CxW26 
CxW27CxW28c
Visit Type Site SiteSite Site Site Site Site Site Site Site Site PhonebSite
Cycle Day -21 to 0 1 8 15 29 43 64 85 113 141 169176
197 183
190
Window  (days)d-21 to 0 ±2 ±2 ±2 ±2 ±4 ±4 ±4 ±4 ±4 ±2 ±2
Evaluate teduglutide 
eligibility (inclusion 
and exclusion) criteriaX Xe
Dispense intake and 
output diariesX X X X X X X X X X X X
Adverse events X X X X X X X X X X X X X
Concomitant 
medications and 
proceduresX X X X X X X X X X X X X
Physical examination 
and vital signs, 
including weightX X X X X X X X X X X X
Height and head 
circumferencef X X X X
Review intake and 
output diariesg X X X X X X X X X X X X X
Record PS Rx and 
adjust as neededh X X X X X X X X X X X X X
Safety laboratory testsiXiX X X X X X X X X X (X) X
PedsQL Generic Core 
Scale/ Family Impact 
Module/ GI 
Symptoms M odule 
Sub-ScalesX X X
Antibodies to 
teduglutidej X X X X
Fecal occult blood 
testingX X X
Colonoscopy /
sigmoidoscopyk (X) (X) (X)
Pregnancy testinglX X X X X X X X X
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_483505] 2019
Table 1-3: Schedule of Events for Subjects While Receiving Teduglutide
PeriodPre-
treat mentTeduglutide Treat mentFollow -up
Serum samplemX X
Evaluate escape 
criterian XpX X
Dispense study drugoX X X X X X X X X
EOS =end of study; EOT = end of treatment; ET = early termination; FOBT = fecal occult blood test; FOCBP = female of child -bearing potential; FU = follow -up; 
GI=gastrointestinal; PedsQL = Pediatric Quality of Life Inventory; PS= parenteral support; SBS =Short Bowel Syndrome; SC = subcutaneous; Scr =Screening; 
TED =teduglutide; Tx = treatment
aIf the first pretreatment visit (P1) follows the screening visit, it must occur within 12 weeks of screening.
bPhone visits are required approximately 1 week after adjustments in PS. The assessments to be performed at phone visits are the same as those described for CxW25 -27 (except 
for evaluation of escape criteria). 
cThe investigator may combine the CxW28 visit with the next pretreatment visit if at least one escape criterion is met at the CxW28 visit, and the pretreatment assessments occur 
within [ADDRESS_483506] is completing the study at the CxW28 visit, the EOS/ET visit ( Table 1 -1) will take place in lieu of the CxW28 visit.
dVisit windows are relative to the CxD1 visit.
eEligibility will need to be re -confirmed prior to the first dose in the cycle. Negative urine pregnancy test is required prior to the first dose of teduglut ide, but results of other labs 
obtained at the CxD1 visit are not required to determine teduglutide treatment eligibility.
fHead circumference will be measured in subjects [ADDRESS_483507] actual PS volume and hours per day. Intake diaries should be completed daily for a minimum of 2 w eeks immediately prior t o each clinic visit (except 
at pretreatment visit), for [ADDRESS_483508] PT/INR at the pretreatment 
visit. Additional collection will occur if a potential drug -induced liver injury signal is observed. Urine specimen collection should be attempted as part of the safety labs, but lack 
of urinalysis will not constitute a protocol deviation . CRP will not be measured in subjects <[ADDRESS_483509] administration of teduglutide. Samples collected while subjects are re ceiving teduglutide (CxW12 and CxW24) must be 
drawn at least 14 hours after dosing.
kThe teduglutide -naïve subjects age 12 and older will undergo colonoscopy /sigmoidoscopy at the pretreatment visit if one has not been performed within 1 year. Subjects of any 
age with newly positive FOBT results at the pretreatment visit for which a readily detectable cause cannot be identified (eg, anal fissure) will undergo a 
colonoscopy /sigmoidoscopy prior to receiving teduglutide. If newly positive FOBT results (for which a readily detectable cause c annot be identified) are obtained at the end of a 
teduglutide treatment cycle (CxW24/EOT), colonoscopy /sigmoidoscopy will be performed. The need for colonoscopy /sigmoidoscopy in response to positive FOBTs at CxW12 is 
at the discretion of the investigator. Teduglutide -exposed subjects who have received the equivalent of 2 treatment cycles (48 weeks of study drug exposure) will undergo 
colonoscopy /sigmoidoscopy. See Section 7.2.9for details.
lA serum pregnancy test is performed on all FOCBP at the teduglutide pretreatment visit (when the pretreatment and screening visits are combined, the serum pregnancy test 
should be performed at the local laboratory). Urine pregnancy tests w ill be administered at all other visits according to the study schedules, or if pregnancy is suspected, or as 
specified per protocol upon withdrawal of the subject from the study.
mLack of collection of serum samples will not constitute a protocol deviati on. Stored serum samples should be omitted for subjects weighing less than [ADDRESS_483510] 2019
Table 1-3: Schedule of Events for Subjects While Receiving Teduglutide
PeriodPre-
treat mentTeduglutide Treat mentFollow -up
nIf escape criteria are met, the subject may proceed directly to another pretreatment visit at the discretion of the investigator.
oThe first SC injection of teduglutide in treatment -naïve subjects will be administered under the supervision of the investigator/designee after which the subject will be observ ed 
for hypersensitivity reactions for at least 4 hours. The sit e of administration (arm, thigh, abdomen) of the first teduglutide dose must be specified and recorded in the eCRF. See 
Section 6.2.[ADDRESS_483511] occur 
within 7 days of the CxW24 visit. 
Note: (X) denotes conditional requirement for a given assessment if the subject meets certain conditions per protocol.
For non-commercial use only
Shire CONFIDENTIAL Page 24
SHP633 -304 Protocol Am endment 4
Teduglutide 01Oct2019
1 BACKGROUND INFORMATI ON
1.1 Indication and Current Treatment Options 
Short bowel sy ndrome (SBS) is a rare disorder resulting from congenital abnormalities or severe 
intestinal diseases that result in major surgical resections of the small intestine. I t is estimated 
that, at most, there are a few hundred pediatric subjects 1 y ear and older with SBS ( Khan et al., 
2015; Wales et al ., 2004). Unlike the adult population, the majority  of cases of SBS in pediatric 
subjects are due to congenital anomalies or catastrophic events
 that occur during infancy . 
Although the small intestine is capable of remarkable adaptation, excessive loss of absorptive 
surface area or specialized functions can lead to dependence on parenteral nutrition or 
intravenous (IV) fluids (parenteral support [PS]). Treatment of both pediatric and adult patients 
is focused on achieving adequate intestinal absorption to allow for minimization or 
discontinuation of PS. About 30% of infants with SBS become independent of PS requirements 
within 12 months of the initial insult, and an additional 10% wean off PS within 24 mont hs. 
After this time, linear intestinal growth slows. About 60% of pediatric subjects with SBS are able 
to become independent of PS within 5 y ears of the initial diagnosis ( Khan et al., 2015). 
Nevertheless, despi[INVESTIGATOR_3062], many  pediatric subjects remain dependent 
on PS. Complications of long -term PS include liver disease, catheter -related blood stream 
infections, central line- associated venous thrombosis and dwindling central venous access. 
Sepsis is the leading cause of death in these patients and quality of life is poor ( Squires et al., 
2012). Accelerating the adaptive pro cess and achieving enteral autonomy  is an urgent goal for all 
patients with SBS who are dependent on PS ( Khan et al., 2015; Squires et al., 2012 ).
Intestinal adaptation is driven by  [CONTACT_319436] ( Drucker 
and Yusta, 2014 ).Chief among these is hormones glucagon -like peptide 2 (GL P
-2), which is 
secreted from L- type enteroendocrine cells that reside in the intestinal epi[INVESTIGATOR_319365]. Resection of these regions may  impair the adaptive response by  [CONTACT_319410] -2. 
1.[ADDRESS_483512] Background 
Teduglutide is a novel, recombinant analog of naturally  occurring human GLP -
2 that regulates 
the functional and structural integrity  of the cells lining the gastrointestinal (GI) tract. 
Teduglutide is a 33 -amino acid peptide that differs from native GLP- 2 in the substitution of 
glycine for alanine at the second position at the N -terminus. As a result, teduglutide demonstrates 
resistance to degradation by  [CONTACT_20597] l peptidase- IV (DPP -4) and therefor e maintains a longer 
elimination half -life (t 1/2) in adults of approximately 2 hours compared to the native peptide, 
which has a t 1/2 of approximately  7 minutes. Teduglutide has been shown in animal studies and 
previous human clinical trials to increase vi llus height and cry pt depth in the intestinal 
epi[INVESTIGATOR_2130], thereb y increasing the absorptive surface area of the intestines ( Tappenden et al., 
2013; Thymann et al. , 2014). The European Commission granted a centralized marketing 
authorization v alid throughout the European Union (EU) for teduglutide (Revestive™) on 
[ADDRESS_483513] 2012 and a New Drug Application (NDA) for teduglutide (Gattex®) was approved b y 
the [LOCATION_002] (US) Food and Drug Administration (FDA) on 21 December 2012 for the 
treatment of adult patients with SBS who are dependent on PS. 
For non-commercial use only
Shire CONFIDENTIAL Page 25
SHP633 -304 Protocol Am endment 4
Teduglutide 01Oct2019
Teduglutide hasalsobeen approved for use in adult patients with SBS in Canada and 
Switzerland. On 29 Jun 2016, the European Commission granted an extension of the Market 
Authorization for teduglutide ( REVESTIVE ™) for the treatment of patients aged 1 y ear and above 
with SBS; patients should be stable following a period of intestinal adaptation.
1.3 Clinical Studies with Teduglutide in Pediatric Subjects
One Phase 3 stud y, TED -C13-003, was completed in pedia tric SBS subjects in the US and 
[LOCATION_008] ([LOCATION_006]). In this study , teduglutide was administered to 3 cohorts of pediatric 
subjects from ages 1 -17. Thirty -seven pediatric subjects received teduglutide at doses of 
0.0125, 0.025, or 0.05 mg/kg/day  for [ADDRESS_483514] of care (SOC) cohort. There were clear dose -dependent effects of 
teduglutide seen at the 0.025 and 0.05 mg/kg/day  doses compared to SOC and the 
0.0125 mg/kg/day  dose. In the 0.025 mg/kg/day  cohort there was a reduction in PS volume at 
week 12 of 37%, including complete independence from PS support in [ADDRESS_483515], and a reduction 
of 3.94 hours per day  infusion time. I n the 0.05 mg/kg/day  cohort there was a reduction in PS 
volume at week 12 of 39%, including complete independence from PS support in 3 subjects, and 
a reduction of 4.18 hours per day  infusion time. Teduglutide was generall y safe and well 
tolerated b y pediatric subjects in all dosing cohorts. There were no deaths durin g the stud y and 
no treatment -
emergent serious adverse events (TESAEs) related to teduglutide were reported. No 
discontinuations from study  were due to adverse events (AEs).
TED -C14-006 is a recently  completed study  of pediatric subjects through 17 y ears which 
included 2 treatment arms: a teduglutide treatment arm and a SOC treatment arm. Subjects in 
both arms participated in a [ADDRESS_483516] 
medical therap y for SBS; while those in the teduglutide treatment arm received daily  
subcutaneous (SC) injections of teduglutide (study  drug) in addition to standard medical therapy . 
The subjects enrolling in the teduglutide treatment arm were randomized 1:1 in a double -blinded 
manner into 2 parallel dose groups: 0.025 mg/kg/day  or 0.05 mg/kg/day  of teduglutide 
administered subcutaneously  for 24 weeks. Compared to the SOC, treatment of pediatric subjects 
with SBS with teduglutide resulted in clinicall y meaningful reductions in PN/IV volume, 
calories, day s per week, and hours per day . A total 10% of subjects who received teduglutide 
achieved enteral autonomy  within 24 weeks despi[INVESTIGATOR_385950]/IV for several 
years. Teduglutide treatment also resulted in increases in EN volume and caloric intake as well 
as plasma citrulline. Although the differences in efficacy  between the 0.025 and 0.05 mg/kg dose 
groups were small, a consistently  greater effect was seen in the 0.05 mg/kg do se in all efficacy  
parameters. The PK properties were well characterized in this population and were consistent 
with the prior [ADDRESS_483517] medical therap y for SBS; while those in the 
teduglutide treatment arm will receive daily SC injections of 0.05 mg/kg teduglutide in addition 
to standard medical therapy . Similar to the treatment cy cles in SHP633-304, subjects in 
SHP633 -[ADDRESS_483518] version of the investigator’s brochure for the overall risk/benefit 
assessment and the most accurate and current information regarding the drug metabolism, 
pharmacokinetics, efficacy  and safet y of teduglutide (SHP633). 
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_483519]-time treatment of teduglutide- naïve 
subjects who par ticipated in the SOC treatment arms in TED -C14-006 or SHP633 -301.
2.2 Study Objectives
2.2.1 Primary Objectives
The primary  objective of the study  is to evaluate the long -term safet y and tolerability of 
teduglutide treatment in pediatric subjects with SBS who comple ted TED -C14-006 or 
SHP633 -301. 
2.2.2 Secondary Objectives
The secondary  objective of this study  is to evaluate the long -term efficacy  of teduglutide 
treatment in pediatric subjects with SBS who completed TED -C14-006 or SHP633-301.
For non-commercial use only
Shire CONFIDENTIAL Page 28
SHP633 -304 Protocol Am endment 4
Teduglutide 01Oct2019
3 STUDY DESIGN
3.1 Study Design and Flow Chart
This is a Phase 3, prospective, open -label, long -term extension study  to evaluate the safet y 
andefficacy  of teduglutide in pediatric subjects who completed the TED- C14-006 or 
SHP633 -301 studies (the "core studies"). At the time of entry  into TE D-C14-006, subjects were 
less than [ADDRESS_483520] 30% of their 
caloric or fluid needs and had not been able to significantly  reduce PS for at least [ADDRESS_483521] of care instead of 
teduglutide treatment. Subjects who elected to receive teduglutide were randomized to 
0.025 mg/kg or 0.05 mg/kg once dail y (QD) dosing in a double -blinded manner. 
At the time of entry  into SHP633- 304, subjects were [ADDRESS_483522] 35% of their caloric or fluid needs, and 
had not been able to significantly  reduce PS for at least [ADDRESS_483523] of care or teduglutide 0.05 mg/kg SC 
QD. 
Approximately  [ADDRESS_483524] meet ≥1 of the teduglutide treatment inclusion criteria and none o f 
the teduglutide treatment exclusion criteria. 
Additional Teduglutide Treatment
Subjects not receiving teduglutide treatment (ie, in a “no- teduglutide treatment period”), will be 
seen approximately  every  12 weeks for safety , parenteral support (PS) requi rements, and qualit y 
of life. At an y point during a no -teduglutide treatment period, subjects who meet ≥[ADDRESS_483525], and 
parent agree to proceed with teduglutide therapy .
Rationale: Some pediatric subjects may  have a durable beneficial effect after 24 weeks of 
teduglutide treatment and thus long -term follow -up without additional teduglutide treatment may  
be appropriate. However, there may  be some pediatric subjects who deteriorate or stop 
improving after discontinuation of teduglutide treatment. I n these pediatric subjects, additional 
teduglutide treatment may  be beneficial. 
Dose Selection 
Analy sis suggested that pediatric patients, ages 1 to 17 y ears old, are likel y to require the same 
dose as used in adults, namely  0.05 mg/kg/day  (Mouksassi et al., 2009 ).In this extension study , 
all subjects who enter a teduglutide treatment cy cle will receive 0.05 mg/kg SC QD.
For non-commercial use only
Shire CONFIDENTIAL Page 29
SHP633 -304 Protocol Am endment 4
Teduglutide 01Oct2019
Rationale: Teduglutide is approved for adult use in the US and EU, and for pediatric use in the 
EU, at a dose of 0.05 mg/kg SC once daily . The completed pediatric studies (TED -C13-003 and 
TED -C14-006) demonstrated that teduglutide dosing at 0.025 and 0.05 mg/kg/day  was 
associated with a fav orable benefit/risk profile. In addition, population pharmacokinetic 
modeling and simulations were conducted to determine the effective dose to be used in 
pediatric subjects using data from 8 adult clinical studies including adult Phase 1 studies and 
Phase s 2/3 studies as well as the pediatric study  (TED -C13-003) and suggested that the dose in 
pediatric subjects is likely to be same as the dose in adults ( O'Keefe et al., 2006 ). 
Further PK simulation was conducted based on the population PK model previously  established 
and a virtual population of 1000 pediatric patients created based on Centers for Disease Control 
(CDC) growth charts in the target age group (4 to 12 months) and taking into consideration 
body weights of pediatric patients with SBS enrolled in study  TED -C13-003 (approximately  
15% lower than health y subjects in the same age group). Monte Carlo simulations for all age 
groups were performed according to the SC dosing regimens of 0.0125, 0.025 and 0.05 mg/kg 
every  24hours. Rich concentration- time profiles were simulated with the customized population 
PK model to derive the exposure metrics area under the concentration curve at stead y state 
(AUC ss) and maximum concentration at steady state (C max,ss). Following 0.05 mg/kg dail y SC 
administration, the median C max,ss of teduglutide in infa nts (24.9 ng/mL ) was within 20% of that 
observed in the 2 to 4 and 4 to 6 y ears age groups (26.9 and 29.4 ng/mL , respectively ); and 
approximately  ~28% lower than that in adult patients with SBS. The clinical package in 
conjunction with C maxwas considered to support teduglutide dose of 0.05 mg/kg since AUC ss
was previousl y shown not to correlate with efficacy. Thus, the 0.05 mg/kg dose is proposed for 
testing in all age groups.
Duration of Treatment
The duration of teduglutide treatment in this study mirror s that of the TED -C14-[ADDRESS_483526] may  be 
evaluated immediatel y for additional teduglutide treatment. Subjects who clinically deteriorate or 
stop improving at an y time after the end of the follow- up period will also be assessed for 
additional treatment.
Rationale: During the teduglutide treatment cy cle, visit frequency  is similar to frequencies 
performed in TED -C13-003, TED -C14-006, and SHP633 -[ADDRESS_483527] deteriorated quickly  after treatment interruption (ie, escaped from a prior follow-up 
period) may  be evaluated immediately  for elig ibility  for additional treatment when they  reach the 
week 24 visit. 
For non-commercial use only
Shire CONFIDENTIAL Page 30
SHP633 -304 Protocol Am endment 4
Teduglutide 01Oct2019
Measures and Parameters
Following the review and signing of the informed consent (and informed assent, if applicable), 
screening visit procedures will begin including demographics, and up dates to medical history  
and SBS history . Subjects who meet ≥1 of the teduglutide treatment inclusion criteria may  
proceed to the pretreatment visit.
After the pretreatment visit, subjects who still meet ≥1 of the teduglutide treatment inclusion 
criteria, and meet none of the teduglutide treatment exclusion criteria, will start a 28 -week cy cle, 
consisting of 24 weeks of teduglutide treatment at 0.05 mg/kg SC once daily , followed by  a 
4-week follow -up (no treatment) period ( Figure 3-1). During the 28- week cy cle, clinic visits will 
occur at weeks 1, 2, 4, 6, 9, 12, 16, 20, 24, and 28. Phone visits are required approximately  
1
week after adjustments in PS during the teduglutide treatment period (between weeks 1 -24), 
and weekl y during the teduglutide follow -up p eriod (between weeks 24 and 28).
Safety  and PS requirements will be evaluated on a weekl y basis, and quality of life assessments 
will be made approximately  every  12 weeks. At all site visits and telephone contacts, safety  will 
be monitored ,and nutritional support will be reviewed and adjusted as needed. To maintain 
consistency  across centers, all attempts should be made to follow the nutritional support 
adjustment guidelines (developed with SBS expert input and provided in the protocol) for 
decisions regar ding PS reduction and advances in enteral feeds based on weight gain, urine and 
stool output, and clinical stability . Departure from the guidelines, however, is not considered a 
protocol deviation ( Appendix 2 ).
Rationale: Measures of long -term safety  will include AEs, growth parameters and anti -drug 
antibodies. Measure of long -term efficacy  will include durability  of effect as measured by  
[CONTACT_319495] (PedsQL , PedsQL Family  
Impact Module). A reduction in PS volume of at least 20% at end of treatment (EOT) was 
used as the primary  endpoint in pi[INVESTIGATOR_30338] 3 adult clinical trials and the completed 
phase 3pediatric study  (TED -C13-003) and will be used as an endpoint in this extension study . 
In previous c linical studies, a reduction of this magnitude was associated with a reduction in the 
number of day s per week of PS and increases in enteral intake. Reduction in volume and time of 
PS due to improved enteral absorption may  provide a pediatric subject with opportunities for 
more age -appropriate activities including oral rehabilitation. Quality  of life assessments will be 
performed in this study  to quantitate this effect.
Teduglutide has been found to have a targeted intestinotrophic effect. Taking into accou nt the 
patient population and the pharmacologic effect of teduglutide, GI -specific screening tests, 
including fecal occult blood testing and colonoscopy /sigmoidoscopy , which are commonl y part 
of the routine care of these subjects, will be performed to ensu re safet y. This study  captures 
long-term safet y data on poly ps and other colonic mucosal changes in teduglutide- exposed 
subjects using the surveillance strategy proposed in Section 7.2.9. 
For non-commercial use only
Shire CONFIDENTIAL Page 31
SHP633 -304 Protocol Amendment 4
Teduglutide 01Oct2019
Figure 3-1: Study Design Flow Chart
Figure legend: Safety and efficacy data for subjects not receiving teduglutide treatment are captured approximately every 
12weeks, but subjects may proceed to the pretreatment visit at any time in order to assess eligibility for tedugl utide therapy. 
Eligible subjects will enter a 28 -week teduglutide cycle. During this cycle, subjects will return to the site for safety and efficacy 
assessments at weeks 1, 2, 4, 6, 9, 12, 16, 20, and 24 ( solid black lines ). Phone visits are required appro ximately 1 week after 
adjustments in PS during the intervening weeks between weeks 2 and 24 ( dashed grey lines ). Subjects discontinue teduglutide at 
week 24 and enter a 4 -week follow-up (no -treatment) period, during which phone visits will be performed wee kly (solid grey 
lines ). If an escape criterion is met at week [ADDRESS_483528]’s maximum duration of participation is 
expected to be app roximately  [ADDRESS_483529] has not withdrawn 
early from the stud y for any reason prior to completing the End of Study (EOS) visit.
The study  completion date is defined as the date the final subject, across all sites, completes their 
final protocol -defined assessment. Please note that this includes the follow -up visit or contact 
(last safet y contact), whichever is later. The stud y comple tion date will be used to ascertain 
timing for study  results posting and reporting.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_483530] review and sign the informed consent (and informed assent, if applicable) 
before an y stud y-related procedures specified in the protocol are performed. Teduglutide 
treatment eligibility  does not impact study  eligibility .
4.[ADDRESS_483531] will not be considered eligible for the study  without meeting all of the criteria below:
1.Subject provides written informed consent (subject, parent or legal guardian and, as 
appropriate, subject informed assent) to participate in the study before completing an y 
study -related procedures. 
2.Subject completed the TED -C14-006 or SHP633 -301 studies (including subjects in the 
standar d of care treatment arms). Subjects are considered to have completed 
SHP633 -[ADDRESS_483532] 1 ( ≥1) of the teduglutide treatment 
inclusion criteria, and none of the teduglutide treat ment exclusion criteria are met. In addition, 
the investigator and the subject (and/or parent or legal guardian, as appropriate) must agree to 
proceed with treatment.
4.[ADDRESS_483533] is teduglutide -naïve, receiving PS, and unable to significantl y reduce PS or 
advance enteral feeds (eg, 10% or less change in PS or advance in feeds) for at least 
3months prior to and during the teduglutide pretreatment visit, as assessed by [CONTACT_1275]. Transient instability  for events su ch as interruption of central access or 
treatment for sepsis is allowed if the PS returns to within 10% of baseline prior to the 
event.
2.Subject was previousl y treated with teduglutide and at least 1 of the following criteria is 
satisfied:
Increasing PS req uirements following teduglutide discontinuation. a.
Decreased PS requirement during prior teduglutide treatment, followed b.
by [CONTACT_319412].
Deteriorating nutritional status eg, weight loss or growth failure) c.
despit e maximal tolerated enteral nutrition (EN) following teduglutide 
discontinuation.
For non-commercial use only
Shire CONFIDENTIAL Page 33
SHP633 -304 Protocol Amendment 4
Teduglutide 01Oct2019
Deteriorating fluid or electrolyte status despi[INVESTIGATOR_319382] d.
enteral fluid and electrolyte intake following teduglutide 
discontinuation.
Severe diarrhea related to teduglutide discontinuation. e.
4.5 Teduglutide Treatment Exclusion Criteria
1.Body weight <[ADDRESS_483534]
3.History  of cancer in the previous 5 y ears except surgically  curative skin cancers
4.Serial transverse enteroplasty or other major intestinal surgery within 3 months 
preceding the teduglutide pretreatment visit. Insertion of a feeding tube, anastomotic 
ulcer repair, minor intestinal resections ≤10 c m, and endoscopic procedures are allowed.
5.Intestinal or other major surgery planned or scheduled to occur during the 28 -week cy cle
6.Clinically  significant intestinal stricture or obstruction
7.Clinically  significant, active or recurrent pancreatic or biliary  disease
8.Active, severe, or unstable, clinically significant hepatic impairment or injury, including 
the following laboratory values at the pretreatment visit:
Total bilirubin ≥2× upper limit of normal (ULN) a.
Aspartate aminotransferase (AST) ≥7 × ULN b.
Alanin e aminotransferase (ALT) ≥7 × ULN c.
9.Renal dy sfunction shown by  [CONTACT_319476] 
50mL/min/1.[ADDRESS_483535] repair, or patent ductus 
arteriosus ligation
11.Participation in a clinical study  using an experimental drug (other than glutamine, 
Omegaven, or Smoflipid) within 3 months or 5.5 half -lives of the experimental drug, 
whichever is longer, prior to the pretreatment visit and for the duration of the 28 -week 
cycle
12.Treatment with analogs of glucagon -like peptide -1 (GL P-1), glucagon- like peptide -2 
(GLP-2) (not including teduglutide), insulin -like growth f actor -1 (IGF -1), or growth 
hormone, within 3 months preceding the teduglutide pretreatment visit.
13.Treatment with octreotide or dipeptidyl peptidase 4 (DPP -4) inhibitors within [ADDRESS_483536], 
closely -related compounds, or an y of the stated ingredients
For non-commercial use only
Shire CONFIDENTIAL Page 34
SHP633 -304 Protocol Am endment 4
Teduglutide 01Oct2019
15.Known history  of alcohol or other substance abuse within 1 y ear prior to the 
pretreatment visit
16. Pregnant or lactating female subjects 
17.Sexually  active female subjects of child -bearing potential unwilling to use approved 
contraception during teduglutide treatment and for 30 day s after the treatment period 
18.Any condition, disease, illness, or circumstance that in the investigator’s opi[INVESTIGATOR_319368] y undue risk, prevents completion of the study, or interferes with 
analysis of the study  results.
4.6 Follow -up Period Escape Criteria
At the discretion of the investigator, the follow- up period may  be interrupted (if the subject 
meets 1 or more of escape criteria 1 to 4 during the follow- up period) or omitted (if the subject 
meets escape criterion 5 at the CxW24 visit) and the subject may  proceed directly  to the 
pretreatment visit, if ≥1 of the following criteria is met:
1.Increasing PS requirements following teduglutide discontinuation.
2.Deteriorating nutritional status (eg, weight loss or growth failure) despi[INVESTIGATOR_319395].
3.Deteriorating fluid or electroly te status despi[INVESTIGATOR_385951] d and 
electrol yte intake following teduglutide discontinuation.
4. Severe diarrhea related to teduglutide discontinuation.
5.The subject escaped during the follow -up period of a previous teduglutide treatment 
cycle within SHP633- [ADDRESS_483537]. 
To be eligible for treatment with teduglutide, female pediatric subjects and adolescent subjects 
should be either:
Pre-menarchal and either Tanner Stage 1 or less than age 9 years, or
Females of child -bearing potential (FOCBP) with a negative serum beta- human chorionic 
gonadotropin ( -HCG) pregnancy  test at the teduglutide pretreatment visi t. 
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_483538] agree to abstain from sexual activity  that could 
result in pregnancy  or agree to use acceptable methods of contraception.
Acceptable methods of contraception are:
True abstinence: Abstention of sexual activity  that is in line with the preferred and usual 
lifesty le of the subject. (Periodic abstinence [eg, calendar, ovulation, sy mptothermal, 
post-ovulation methods] and withdrawal are not acceptable methods of contraception).
Intraut erine devices plus condoms
Double-barrier methods (eg, condoms and diaphragms with spermicidal gel or foam)
Hormonal contraceptives (oral, depot, patch, injectable, or vaginal ring), stabilized for at 
least 30 day s prior to the pretreatment visit, plus con doms. Note: if subject becomes 
sexually  active during the study , they  should use one of the other acceptable methods 
noted above in addition to the hormonal contraceptive until it has been stabilized for 
30days.
4.[ADDRESS_483539] wishes to remain in the study, the evaluations listed for the EOT visit are to be 
performed. A 4- week follow -up period will ensue, consisting of weekl y telephone visits 
(CxW25 -27) and the week 28 clinic visit (CxW28). The subject would then enter a 
no-teduglutide treatment (NTT) period and could be evaluated for subsequent teduglutide 
treatment eligibility  according to the study  sche dules. Comments (spontaneous or elicited) or 
complaints made by  [CONTACT_1706]. The reason for 
permanent treatment discontinuation, dates of investigational product administered (including 
last date of treatment), and amount of investigational product taken must be recorded in the 
electronic case report form (eCRF) and source documents, as described in Section 4.8.3. The 
investigator is encouraged to discuss withdrawal of a subject f
rom investigational product with 
the medical monitor, when possible.
4.8.[ADDRESS_483540] will 
then be asked to return 4 weeks later for the early termination (ET) visit, and will be contact[CONTACT_319413] y by [CONTACT_319445] -up.
If a subject withdraws from the study  during a NTT period, the evaluations listed for the ET visit 
are to be performed as soon and completel y as possible. 
For non-commercial use only
Shire CONFIDENTIAL Page 36
SHP633 -304 Protocol Am endment 4
Teduglutide 01Oct2019
Subjects who withdraw from the study will not be replaced.
4.8.3 Reasons for Discontinuation
The reason(s) for permanent discontinuation of treatment and/or withdrawal from the study  must 
be determined b y the investigator, and recorded in the subject’s medical record and in the eCRF. 
If a subject is withdrawn for more than [ADDRESS_483541] clinically  relevant reason should be entered in the eCRF.
Reasons for disconti nuation include, but are not limited to:
Adverse event 
Protocol deviation
Lack of efficacy  
Physician decision 
Withdrawal by  [CONTACT_1130] 
Withdrawal by  [CONTACT_7078]/guardian
Lost to follow -up
Pregnancy  (Discontinuation of treatment onl y) 
Death 
Other 
[IP_ADDRESS] Subjects ‘L ost to Follow -up’ Prior to Last Scheduled Visit
A minimum of [ADDRESS_483542] (office visit or telephone contact). At least [ADDRESS_483543]’s last 
known address via courier or mail (with an acknowledgement of receipt request) asking that they  
return to the site for final safet y evaluations, and return an y unused investigation al product.
For non-commercial use only
Shire CONFIDENTIAL Page 37
SHP633 -304 Protocol Am endment 4
Teduglutide 01Oct2019
5 CONCOMITANT TREATMENT
5.1 Concomitant Medications and Procedures
Concomitant treatment refers to all treatment taken between the dates of informed consent and 
EOS, inclusive. Concomitant medications and procedures will be assessed at each site vis it, and 
include all non -study  treatments (medications, herbal treatments, vitamins, invasive and 
diagnostic procedures). Concomitant treatment information must be recorded on the appropriate 
eCRF page. Details of medication changes and/or dosages will be r ecorded on the eCRF . 
5.1.[ADDRESS_483544] medical therapy for SBS should be continued.
5.1.2 Prohibited Treatment
The mechanism of action of teduglutide may  increase enteral absorption of drugs (eg, motility  
medication including narcotics and opi[INVESTIGATOR_20574], warfarin, 
psychotropi[INVESTIGATOR_1102], metronidazole, digoxin), so consideration should be given to modify ing 
concomitant enteral medication regimens. Down -titration of concomitant enteral medications 
should be considered when drugs, especially  those with a narrow therapeutic range, are given at 
dosages that are higher than usual.
The following medications are prohibited during teduglutide treatment and within the provided 
timeframe prior to the pretreatment visit:
Table 5-1: Prohibited Treatment
Prior Therapy Time Restriction Prior to 
the Pretreatment Visit
Native/synthetic glucagon -like peptide -2 (not -including teduglutide) Any
Glucagon-like peptide- [ADDRESS_483545] is teduglutide, which will be provided in sterile, single -use 3 mL  vials 
containing 5 mg or 1.25 mg teduglutide as a white ly ophilized powder to be reconstituted before 
use with 0.5 mL  sterile water for injection. In addition to the active ingredient (teduglutide), each 
vial of teduglutide contains L -histidine, mannitol, monobasic sodium phosphate monohy drate, 
and d ibasic sodium phosphate as excipi[INVESTIGATOR_840]. Additional information is provided in the current 
SHP633 investigator’s brochure.
6.1.[ADDRESS_483546](s)
6.2.[ADDRESS_483547] Management
An interactive web -based response s ystem (IWRS) will be used for screening and enrolling 
subjects, recording subject visits, investigational product supply dispensation and management, 
inventory  mana gement and supply  ordering, investigational product expi[INVESTIGATOR_49093], and return of investigational product. Please refer to the Study Manual for 
additional details regarding the IWRS. 
The I WRS will also be used for creating, tracking, and confirming investigational product 
shipments. A user manual with specific functions and instructions for the IWRS will be provided 
to the site, and site personnel will receive training.
6.2.[ADDRESS_483548], and/or 
parent/guardi an agree to proceed with treatment, a formal evaluation of teduglutide inclusion and 
exclusion criteria will be performed at the pretreatment visit ( Table 1-3). 
6.2.[ADDRESS_483549] will start a teduglutide treatment period, consisting of 24 weeks of 
teduglutide treatment at 0.05 mg/kg SC once daily. The initial dose will be calculated based on 
body  weight measured at the teduglutide pretreat ment visit, and adjusted as needed, based on 
body  weight measured at week 12 (CxW12). No other adjustments to dose will be made during 
the teduglutide treatment period, unless discussed with the sponsor’s medical monitor. 
Following reconstitution, teduglu tide will be administered by  [CONTACT_385955] 1 of the 
4 quadrants of the abdomen (in subjects without a stoma) or into either the thigh or arm. For 
subjects with a stoma, the quadrant of the abdomen containing the stoma should not be used. 
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_483550] 
4 hours during their initial dosing visit. The site of administration (arm, thigh, and abdomen) of 
the first teduglutide dose must be specified and recorded in the eCRF. 
Detailed instructions for reconstitution and injection of the investigational product can be found 
in the I nstructions for Use. 
Atthe end of each 24- week teduglutide treatment period, subjects will be evaluated for the need 
for additional teduglutide treatment. During the [ADDRESS_483551] may  proceed directly  to another pre treatment visit to assess treatment 
eligibility  for another cy cle (Section 4.6). Following the completion of the [ADDRESS_483552](s) conta iner. 
The study  drug will be packaged, labeled, and shipped to the study  site by  [CONTACT_98634]. Kits containing [ADDRESS_483553] is packaged in the following conditions:
Teduglutide will be provided in a sterile, single -use, glass vial as a l yophilized powder, to be 
reconstituted with 0.[ADDRESS_483554] be kept in a lo cked area with access restricted to specific study personnel. 
Study drug will be stored refrigerated at a temperature between 2 to 8°C (35.6 to 46.4°F) until 
dispensed to a subject. Once dispensed to a subject, the study  drug can be stored refrigerated 
or up to a controlled room temperature (acceptable range of 2 to 25°C, or 35.6 to 77°F). 
Parent/guardian will be instructed to keep the subject’s stud y drug and sterile water diluent at 
controlled room temperature. If there are concerns that the controlled ro om temperature cannot 
be maintained, the stud y drug may be refrigerated. The study  drug is for single use only , and 
should be used within [ADDRESS_483555] is maintained within an established temperature range. The investigator is responsible 
for ensuring that the temperature is monitored throughout the dur ation of the study  and that 
records are maintained; the temperature should be monitored continuously  by [CONTACT_3570]-house sy stem, a mechanical recording device such as a calibrated chart recorder, or by  [CONTACT_10179], such that both minimum and maxim um thermometric values over a specific time period 
can be recorded and retrieved as required. Such a device (ie, certified min/max thermometer) 
would require manual resetting upon each recording. The sponsor must be notified immediately  
upon discovery  of any excursion from the established range. Temperature excursions will require 
site investigation as to cause and remediation. The sponsor will determine the ultimate impact of 
excursions on the investigational product and will provide supportive documentati on as 
necessary . Under no circumstances should the product be dispensed to subjects until the impact 
has been determined and the product is deemed appropriate for use b y the sponsor.
The sponsor should be notified immediately  if there are an y changes to th e storage area of the 
investigational product that could affect the integrity  of the product(s), eg, fumigation of a 
storage room.
Investigational products are distributed b y the pharmacy or nominated member of the stud y 
team. The pharmacist/nominated team member will enter the unique subject identifier on the 
investigational product bottle/carton labels, as they are distributed. 
6.[ADDRESS_483556] will be made available to the sponsor’s site monitor for the purpose of accounting for 
all clinical supplies. Any  discrepancy  or deficiency  will be recorded and will include an 
explanation. All supplies sent to the invest igator must be accounted for and in no case will 
clinical supplies be used in any  unauthorized situation.
The investigator has overall responsibility  for administering/dispensing investigational product. 
Where permissible, tasks may  be delegated to a qualified designee (eg, a pharmacist) who is 
adequatel y trained in the protocol and who works under the direct supervision of the investigator. 
This delegation must be documented in the applicable study  delegation of authority  form.
The investigator or his/her designee (as documented by  [CONTACT_49121] y form) will dispense the investigational product only to subjects eligible 
for teduglutide treatment following the procedures set out in the study  protocol. All disp ensed 
study  medication will be documented in the interactive response technology  system and/or other 
investigational product record (eg, investigation product accountability  form). The investigator is 
responsible for assuring the retrieval of all stud y sup plies from subjects.
All used and unused study  drug vials must be returned by  [CONTACT_20608]/or parent/guardian, 
and will be retained at the site. If deemed appropriate, the investigator or his/her designee may  
dispense the unused study  drug vials to the same subject. All original containers, whether empty  
or containing stud y drug will be returned to the pharmacy. Returned stud y drugs will NOT be 
relabeled or reassigned for use b y other subjects. Contents of the study drug containers will not 
be combined. All used and unused vials must be returned to the distribution center according to 
the sponsor’s instruction. No vial/kit may  be destroy ed on site without approval by  [CONTACT_456]. 
Please see the Pharmacy  Manual for additional information.
6.[ADDRESS_483557] and empty /used 
investigational product packaging to every  visit. Drug accountability  will be assessed at the 
container/packaging level for unused investigational product that is contained within the original 
tamper -evident sealed container (eg, bottles, tray s, vials) or at the individual count level for 
opened containers/packaging. The pharmacist/nominated person will record details on the drug 
accountability  form.
Compliance with study  drug is calculated from subject diaries. Of those subjects eligible for 
teduglutide treatment, subjects who have received 80% of the planned doses administered will be 
assessed as being compliant with the study  protocol.
For non-commercial use only
Shire CONFIDENTIAL Page 42
SHP633 -304 Protocol Am endment 4
Teduglutide 01Oct2019
7 STUDY PROCEDURES
7.1 Study Sche dule
Detailed study  procedures and assessments to be performed for subjects throughout the study  are 
outlined in the Schedule of Assessments ( Table 1 -1,Table 1-2, and Table 1 -3) and must be 
referred to in conjunction with the instructions provided in this section. 
7.1.1 Screening 
Prior to performing an y study-related procedures (including those related to screening), the 
investigator or his/her designee must obtain written informed co nsent (and assent, as applicable) 
from the subject. A subject will have approximately [ADDRESS_483558] occ ur within 12 weeks of screening for a pretreatment visit, 
and within 2 to 12 weeks of screening for an NTx visit.
The screening visit (Scr) assessments and procedures, beginning with informed consent, will be 
performed as outlined in Table 1-1, and as deta iled below:
Informed consent, and informed assent (if applicable), is obtained
Study  eligibility  is determined. A screen failure is a subject who has given informed 
consent and failed to meet the Study  Inclusion Eligibility  Criteria. Subjects cannot be 
rescreened once they  have been designated as a screen failure. 
Demographics, updates to medical history  and SBS history
Intake and output diaries are dispensed
Evaluate teduglutide treatment inclusion criteria 
Adverse events, concomitant medications and con comitant procedures
7.1.2 Visits for Subjects Not Receiving Teduglutide
While outside of the 28- week teduglutide -treatment cy cle, subjects will be followed 
approximately  every  12weeks for safety  and efficacy  assessments. No -teduglutide treatment 
visits are numb ered sequentially  (NT1, NT2, etc.), even if interrupted by  [CONTACT_319415]. 
The visit window (±7 days) is relative to the first NTx visit in the current NTT period. 
Assessments will be performed as outlined in Table 1 -2and described below .
Intake and output diaries are dispensed
Evaluate teduglutide treatment inclusion criteria
Adverse events, concomitant medications and concomitant procedures
Physical examination and vital signs, including weight
Height and head circumference
Review intake and output diaries
For non-commercial use only
Shire CONFIDENTIAL Page 43
SHP633 -304 Protocol Am endment 4
Teduglutide 01Oct2019
Record PS prescription and adjust as needed
Safety  Laboratory  Tests (ie, clinical chemistry , hematology , and urinaly sis)
PedsQL  Generic Core Scale/PedsQL Family  Impact Module/ PedsQL  Gastrointestinal 
Symptoms Module Sub- Scales
Antibodies to teduglutide, if and when required
Fecal occult blood testing, as indicated (Section [IP_ADDRESS])
Colonoscopy /sigmoidoscopy , as indicated (see Section [IP_ADDRESS])
Serum sample, as indicated
Teduglutide treatment may  be considered at any  time during the NTT period. If the investigator 
and the subject (and parent or legal guardian, as appropriate) agrees to proceed with treatment if 
the subject is eligible, the subject may  proceed to the pretreatment visit immediately  to determine 
eligibility . 
7.1.3 Visits for Subjects Re ceiving Teduglutide
[IP_ADDRESS] Pretreatment Visit
Subjects who meet at least [ADDRESS_483559] dose administratio n (CxD1) during an y teduglutide treatment cy cle. I n general, 
pretreatment assessments may  occur over a period of up to 21 day s. The teduglutide pretreatment 
visit (Px) assessments and procedures will be performed as in Table 1-3 and as described below:
Evaluate teduglutide eligibility  (treatment inclusion/exclusion criteria) 
Dispense intake and output diaries
Adverse events, concomitant medications and concomitant procedures
Fecal occult blood testing 
Gastrointestinal -specific testing, including colono scopy  or sigmoidoscopy  as indicated
Physical examination and vital signs, including weight
Height and head circumference
Review intake and output diaries
Record PS prescription and adjust as needed
For non-commercial use only
Shire CONFIDENTIAL Page 44
SHP633 -304 Protocol Am endment 4
Teduglutide 01Oct2019
Safety  Laboratory  Tests 
(In addition to clinical chemistry, hematology, and urinaly sis, labs at this visit include 
prothrombin time [PT] international normalized ratio [I NR]. Subsequent prothrombin 
time/international normalized ratio [PT/I NR] measurement is only  required to evaluate 
for suspected drug -induced li ver injury  [DILI]). 
Serum pregnancy  testing, if applicable (when the pretreatment and screening visits are 
combined, the serum pregnancy  test should be performed at the local laboratory )
Serum sample 
[IP_ADDRESS] Teduglutide Treatment Period (CxD1 -CxW24)
The open -label teduglutide treatment period will comprise [ADDRESS_483560] administration (Visit CxD1). 
Visit CxD1
Assessments and procedures at this visit will be performed as outlined Table 1-3and as 
described below. 
Two weeks of intake diary data are required before drug is administered at CxD1.
Confirm teduglutide treatment eligibility
Dispense intake and output diaries
Adverse events, concomitant medications and concomitant procedures
Physical examination and vital signs, including weight 
Height and head circumference
Review intake and output diaries
Record PS prescription and adjust as needed 
Safety  laboratory  tests
Quality  of life measurements 
Antibodies to teduglutide
Pregnancy  testing (urine), if applicable
Dispense study  drug
For non-commercial use only
Shire CONFIDENTIAL Page 45
SHP633 -304 Protocol Am endment 4
Teduglutide 01Oct2019
Site Visits during Teduglutide Treatment Period
Subjects will return for clinic visits on cy cle weeks 1, 2, 4, 6, 9, 12, 16, 20, and 24/EOT. 
Assessments and procedures at these visits will be performed as outl ined in Table 1-3 and as 
described below:
Dispense/review intake and output diaries (every effort should be made to complete 
2weeks of intake diary  entries prior to each clinic visit and to complete 48 hours of 
output diary  entries during a period of nutr itional stability  prior to each clinic visit)
Physical examination and vital signs, including weight
Record PS prescription and adjust as needed
Safety  laboratory tests 
Urine pregnancy  testing for FOCBP (CxW4, CxW9, CxW12, CxW16, CxW20, CxW24)
Study  drug dispensation (except for CxW24)
Adverse events, concomitant medications and concomitant procedures
In addition, at CxW12 and CxW24 Visits ONLY , the following procedures will be performed:
Height and head circumference
Antibodies to teduglutide
Fecal occult blood testing (FOBT)
GI-specific testing, including colonoscop y or sigmoidoscopy  as indicated 
Quality  of life measurements 
At CxW24 ONLY , a serum sample is collected and stored for future analysis. This sample will 
not be used for genetic testing and la ck of collection will not constitute a protocol deviation.
Escape criteri a are also evaluated at CxW24. The investigator may  combine the CxW24 
assessments with the next pretreatment visit assessments if at least 1 escape criterion is met at the 
CxW24 visit and the pretreatment assessments occur within 7 days of the CxW24 visit.
Phone Visits 
Phone visits are required approximately  1 week after adjustments in PS during the teduglutide 
treatment period. Phone visit assessments and procedures are outlined in Table 1-3 and described 
below:
Review intake and output diaries
Safety  laboratory  tests (clinical chemistry  and urinaly sis)
Record PS prescription and adjust as needed
For non-commercial use only
Shire CONFIDENTIAL Page 46
SHP633 -304 Protocol Am endment 4
Teduglutide 01Oct2019
Obtain AEs, concomitant medications, and concomitant procedures  
Evaluate escape criteri a
7.1.4 Teduglutide Follow -up Period
The safet y follow -up period for this protocol is 4 weeks (weeks 25 – 28 of the cy cle). Phone 
visits will occur on cy cle weeks 25, 26, and [ADDRESS_483561] ly to another pretreatment visit at the investigator’s discretion. The investigator 
may combine the CxW24 or CxW28 visits with the next pretreatment visit if at least [ADDRESS_483562] is completing the study  at the CxW28 visit, the 
EOS/ET visit (Section 7.1.5 ) will take place in lieu of the CxW28 visit. Otherwise, following 
completion of the [ADDRESS_483563] will proceed to an NTT visit within 
approximately  12 weeks.
At cy cle week 28 (CxW28), subjects will return to the study  site. In addition to the assessments 
performed at weeks 25 -27, the following procedures will be performed at CxW28 ONLY:
Dispense int ake and output diaries 
Physical examination and vital signs, including weight
Antibodies to teduglutide
Pregnancy  testing (urine), if applicable
Evaluate escape criteria
7.1.5 Study Completion/Early Termination Visit (EOS/ET Visit) 
All subjects will return to the study  site for the end of study /early termination visit (EOS/ET). 
Assessments and procedures at this visit will be performed as outlined in Table 1-[ADDRESS_483564] discontinues the study prematurel y, the assessments for the EOS/ET 
Visit are to be performed as completel y as possible (see Section 4.8.2).
Adverse events -AEs will be collected for [ADDRESS_483565] dose of teduglutide in 
the study  even if the EOS/ET occurs within that timeframe.
Concom itant medications and concomitant procedures  
Physical examination and vital signs, including weight
Height and head circumference
Review intake and output diaries (the intake diary should be completed daily  for a 
minimum of 2 weeks prior to the EOS/ET visit. The output diary  should be completed 
daily  over a 48- hour period of nutritional stability  before the EOS/ET visit)
For non-commercial use only
Shire CONFIDENTIAL Page 47
SHP633 -304 Protocol Am endment 4
Teduglutide 01Oct2019
Record PS prescription and adjust as needed
Safety  laboratory tests 
Fecal occult blood testing, as indicated
Gastrointestinal -specifi c testing, including colonoscopy  or sigmoidoscopy  as indicated. 
Quality  of life measurements 
Antibodies to teduglutide
Pregnancy  testing, as needed
7.1.6 Qualitative Interview
An optional qualitative interview will be conducted by  [CONTACT_319490] 14 day s afte r 
completion of the EOS/ET visit (see Section 7.2.13). A single individual telephone interview will 
be conducted with English- speaking parents (or legal guardians) of subjects and subjects aged 
12years or older and who provide informed consent (and if app licable, informed assent) to 
participate in the interview. These interviews will be performed in selected countries.
7.[ADDRESS_483566] of the following:
Adverse events that were ongoing at the time of completion of TED- C14-006 or 
SHP633 -301
Events that occurred during the period between completion of TED -C14-[ADDRESS_483567] ory collected at the baseline visit of the TED -C14-006 or SHP633 -301 studies, that 
information (updated SBS history ) will be collected.
7.2.2 Physical Examination
Physical examinations will be performed according to the study  schedules. Any  new clinicall y 
signif icant findings noted during ph ysical examinations should be recorded on the appropriate 
AE page of the eCRF. 
7.2.3 Vital Signs, Body Weight, Height, Head Circumference and Body Mass 
Index
Vital signs will be measured according to the study  schedules. Measuremen ts will include 
systolic and diastolic blood pressure (mmHg), pulse (beats per minute), and body  temperature 
(°C/°F). Blood pressure should be determined b y cuff (using the same method, the same 
extremity , and in the same position throughout the study , whe never possible).
For non-commercial use only
Shire CONFIDENTIAL Page 48
SHP633 -304 Protocol Am endment 4
Teduglutide 01Oct2019
Body weight will also be recorded in the eCRF; subjects should be weighed on the same scale at 
each stud y visit. Height (or length) and head circumference (for subjects ≤36 months of age) will 
be measured at selected visits. A height z- score, weight z -score, BM I, and BMI z -score will be 
calculated b y the sponsor using the site -provided height and weight data collected at each site 
visit
New clinicall y significant vital sign abnormalities should be recorded on the appropriate AE 
page of the eCRF.
7.2.[ADDRESS_483568] of clinical chemistry , hematology , 
and urinal ysis and will be performed as outlined in the study  plan ( Table 1-1, Table 1-2, and 
Table 
1-3) Scheduled laboratory  testing will be processed by  a central lab. All laboratory  assay s 
will be performed according to the central laboratory ’s normal procedures. Reference ranges are 
to be supplied by  [CONTACT_25699] . The investigator should assess out-of- range clinical laborat ory 
values for clinical significance, indicating if the value(s) is/are not clinically  significant or 
clinically  significant. Abnormal clinical laboratory  values, which are unexpected or not 
explained by  [CONTACT_423]’s clinical condition, may , at the discre tion of the investigator or sponsor, 
be repeated as soon as possible until confirmed, explained, or resolved. 
During the teduglutide treatment period, subjects will also have safet y labs within approximately  
5-[ADDRESS_483569] of clinical chemistry  and urinal ysis and may  be processed by  [CONTACT_319438] a local laboratory . Local lab results are not required to be entered in the eCRFs; however, if 
the local lab results indicate an y new clinicall y significant changes, they must be reported as an 
AE(see Section 8.1). Urine specimen collection should be attempted as part of the safety  labs, 
but lack of urinal ysis will not constitute a protocol deviation.
New clinicall y significant labs should be reported as AEs.
For non-commercial use only
Shire CONFIDENTIAL Page 49
SHP633 -304 Protocol Am endment 4
Teduglutide 01Oct2019
The following clinical laboratory assessments will be performed according to the study  
schedules: 
Table 7-1: List of Laboratory Tests 
Hematology :
Hematocrit 
Hemoglobin 
Platelet count
Red blood cell count 
Red blood cell morphology, if needed
White blood cell count with differential
Coagulation :
Prothrombin time/I nternational normalized ratio 
Urinalysis : 
Blood
Glucose
Leukocytes
Microscopic analysis
pH 
Protein
Specific gravity
Pregnancy tests (females of childbearing potential):
oSerum β -HCG ( teduglutide pretreatment visit )
oUrine β -HCG (all other visits)Biochemistry :
Albumin 
Alkaline phosphatase 
Alanine aminotransferase 
Amy lase
Aspartate aminotransferase 
Bicarbonate
Bilirubin (total, direct, and indirect)
Blood urea nitrogen 
Calcium (total)
Chloride
Cholesterol
C-reactive proteina
Creatinine
Estimated Glomerular Filtration Rate 
(Schwartz formula)
Gamma -glutamyl transferase 
Glucose
Lipase
Magnesium
Phosphorus
Potassium 
Sodium 
Triglycerides
Uric acid
aC-reactive protein will not be measured  in subjects <10 kg.
7.2.5 Serum Sampling
Serum samples will be collected and stored for future anal ysis at the following times: 
At the pretreatment visit. If the subject arrived at the pretreatment visit by [CONTACT_319478], the serum sample will not be repeated at the pretreatment visit, because 
it will have been collected recentl y at the CxW24 visit.
At the CxW24 (EOT) visit
During NTT: Approximately  every  24 weeks 
Stored serum samples should be omitted for subjects weighing less than 15 kg and whenever 
local blood volume limitations are exceeded.
For non-commercial use only
Shire CONFIDENTIAL Page 50
SHP633 -304 Protocol Am endment 4
Teduglutide 01Oct2019
The serum sample will not be used for genetic testing. Lack of collection will not constitute a 
protocol deviation.
The sponsor, sponsor’s representatives, biorepositories, and an y specialt y laboratories will be 
blinded to the subject’s identity . The sample and/or extracted material will otherwise be stored 
for up to [ADDRESS_483570] their 
sample and/or extracted material destro yed. An y results alread y generated from the samples will 
not be removed from an y anal yses that have already  been performed.
7.2.[ADDRESS_483571] is performed on all FOCBP at the teduglutide pretreatment visit (when 
the pretreatment and screening visits are combined, the serum preg nancy  test should be 
performed at the local laboratory ). Urine pregnancy  tests will be administered at all other visits 
according to the stud y schedules, or if pregnancy is suspected, or as specified per protocol upon 
withdrawal of the subject from the study . 
7.2.7 Antibody Testing
Blood samples will be drawn for the anal ysis of antibodies to teduglutide according to the 
Schedule of Assessments ( Table 1-1
, Table 1 -
2, and Table 1-3). Blood samples for antibodies 
may be drawn from a central line or from peripheral access. The sample drawn on CxD1 must be 
drawn prior to administration of the first dose of teduglutide. Once the subject has started 
teduglutide treatment, samples must be drawn at least [ADDRESS_483572] 
annually  are shown in Table 7-2.
For non-commercial use only
Shire CONFIDENTIAL Page 51
SHP633 -304 Protocol Am endment 4
Teduglutide 01Oct2019
Table 7-2: Approximate Volume of Blood to be Drawn from Each Subject Annually
AssessmentSample 
Volume (mL)No. Sam ples per two 28 -week 
Teduglutide CyclesTotal 
Volume (mL)
Subjects ≥10kg Receiving Teduglutide Treatm ent 
Safety Biochemistry and -hCGa2.5 24 60
Hem atology 2 24 48
Coagulation Parameters 2 2 4
Antibodies 2 8 16
Serum storage samplesb3 4 12
Total mL per 2, 28 -week Treatment Cycles (Approximate Annual Volume): 140
Subjects < 10kg Receiving Teduglutide Treatm ent
Safety Biochemistryc1 24 24
Hem atology 1 24 24
Coagulation Parameters 2 2 4
Antibodies 1 8 8
Total mL per 2, 28 -week Treatment Cycles (Approximate Annual Volume): 60
Subjects ≥10kg Not Receiving Teduglutide Treatmentd
AssessmentSample 
Volume (mL)No. Sam ples per 4 NTT VisitsTotal 
Volume (mL)
Safety Biochemistry 2.5 4 10
Hem atology 2 4 8
Serum storage samplesb3 2 6
Total mL per 4 “No Teduglutide Treatment” Visits 48 -week period: 24
Subjects < 10kg Not Receiving Teduglutide Treatmentd,
AssessmentSample 
Volume (mL)No. Sam ples per 4 NTT VisitsTotal 
Volume (mL)
Safety Biochemistryc1 4 4
Hem atology 1 4 4
Total mL per 4 “No Teduglutide Treatment” Visits 48 -week period: 8
β-hCG=beta -human chorionic gonadotropin; NTT=no -teduglutide treatment
a β-hCG testing will only be administered to females who are eligible for teduglutide treatment.
bStored serum samples should be omitted for subjects weighing less than 15 kg and whenever local blood volume limitations are 
exceeded.
cCRP will not be measured in subjects <[ADDRESS_483573] negative.
Note: The amount of blood to be drawn for each assessment is an estimate. The amount of blood 
to be drawn may  vary  according to the instructions provided by  [CONTACT_10190]. When more than 1 blood assessment is to be done at the time 
point/period, if they  require the same t ype of tube, the assessme nts should be combined. Blood 
volume estimates do not include safet y labs performed after PS adjustment, and anti -teduglutide 
antibody  testing du ring no -teduglutide treatment. Stored serum samples should be omitted for 
subjects weighing less than 15 kg and whenever local blood volume limitations are exceeded. 
For non-commercial use only
Shire CONFIDENTIAL Page 52
SHP633 -304 Protocol Am endment 4
Teduglutide 01Oct2019
Maximum blood volume at an y given visit occurs when the pretreatment and Week 24 visits are 
combined. For subjects <10 kg this is 5.0 mLand for subjects ≥10 kg this is 8.5mL . 
7.2.9 Gastrointestinal- specific Testing
[IP_ADDRESS] Fecal Occult Blood Testing
Fecal occult blood testing must be performed on all subjects at the pretreatment visit, week 12, 
and week [ADDRESS_483574] be performed on 
teduglutide -exposed subjects (subjects who have received teduglutide an y time in the past 
andare therefore not teduglutide -naïve) on a roughly  annual basis (approximately  every  
48-60 weeks). Actions to be taken in respo nse to a positive FOBT are described below.
[IP_ADDRESS]
Colonoscopy or Sigmoidoscopy
Teduglutide -naïve subjects age 12 and older will undergo colonoscopy  or sigmoidoscopy  at the 
pretreatment visit if one has not been performed within 1 y ear. 
Subjects of an y age with newly  positive FOBT results at the pretreatment visit for which a 
readil y detectable cause cannot be identified (eg, anal fissure) will undergo a colonoscop y or 
sigmoidoscop y prior to receiving teduglutide. If newly positive FOBT results (for which a 
readi ly detectable cause cannot be identified) are obtained at the end of a teduglutide treatment 
cycle (CxW24/EOT), colonoscopy  or sigmoidoscopy  will be performed. The need for 
colonoscop y or sigmoidoscopy in response to positive FOBTs at an y other point durin g the 
study , or to re -evaluate persistently  positive FOBTs is at the discretion of the investigator. 
Teduglutide -exposed subjects who have received the equivalent of 2 treatment cy cles (48 weeks 
of study  drug exposure) will undergo colonoscopy  or sigmoido scopy. While receiving additional 
teduglutide treatment, subjects will undergo colonoscopy  or sigmoidoscopy at 5 y ear intervals or 
more often as needed. 
Upper endoscop y ma y be performed along with any colonoscop y or sigmoidoscopy at the 
investigator’s dis cretion. If a pol yp is found, adherence to current pol yp follow -up guidelines is 
recommended. Subjects with unresected GI pol yps, poly posis conditions, premalignant change 
or malignancy  in the GI tract will be excluded from teduglutide treatment.
7.2.10 Nutrition al Support
Nutritional support includes PS, EN, and other food and fluids. Advances in EN and/or 
reductions to PS will be based on clinical status, including weight, linear growth, hy dration 
status, and safet y laboratory  results. Intake and output diaries will include data to be considered 
in the adjustment of each subject’s nutritional support. Guidelines for nutritional support 
management and weaning algorithms are provided in Appendix 2 .
For non-commercial use only
Shire CONFIDENTIAL Page 53
SHP633 -304 Protocol Am endment 4
Teduglutide 01Oct2019
7.2.11 Diaries
[IP_ADDRESS] Study Drug Administration Diary
A study  drug administration diary  will record administration of teduglutide. This diary  should be 
completed b y the subject (or parent/legal guardian, as applicable) dail y during the teduglutide 
treatment periods (between visits CxD1 and CxW24).
[IP_ADDRESS] Intake Diary
Intake diaries will be us ed to collect and evaluate each subject’s nutritional support. The 
subject/parent/guardian will complete the appropriate fields of the PS section of the intake diary  
2 weeks prior to ALL scheduled site visits (except at pretreatment visit). During the 24 -week 
teduglutide treatment period, the intake diary  will also be completed for 1 week following PS 
adjustments. The intake diary  will also be completed daily  during the 4 -week follow -up period. 
The following data will be captured in the intake diaries:
Parenteral support volume and infusion duration
Site personnel will determine the actual PS daily  calories based on diary  entries.
All available diary  data will be reviewed by  [CONTACT_319479].
[IP_ADDRESS] Output Diary
Urine and stool output should be recorded in the output diary  over a 48- hour period of nutritional 
stability  before every  clinic visit; in addition, output should be record ed for subjects that are in a 
teduglutide treatment cy cle within 1 week of implementing a change in the PS prescription, 
regardless of previous teduglutide exposure.
Urine data:
Toilet -trained subjects (who do not wear diapers)
Measure and record all urine output in mL  or cc 
Nontoilet- trained subjects (who wear diapers)
Measure and record the weight of all urine -only diapers. Urine volume will be calculated 
using the following formula: 1 g (scale weight) = 1 mL  or 1 cc
At the discretion of the investigator , the parent may  be asked to collect the first void after 
the daily  PS infusion to measure specific gravity
Stool data (includes diapers with mixed urine and stool):
Toilet -trained subjects (who do not wear diapers)
Record the occurrence of each bowel move ment and score the stool consistency  using the 
Bristol Stool Form Scale (see Output diary )
For non-commercial use only
Shire CONFIDENTIAL Page 54
SHP633 -304 Protocol Am endment 4
Teduglutide 01Oct2019
Nontoilet- trained subjects (who wear diapers)
Record the weight of diapers containing stool (including diapers with mixed urine and 
stool) as stool output and score the stool consistency  using the Bristol Stool Form Scale 
(see Output diary ). Stool volume will be calculated using the formula: 1 g (scale weight) 
= 1mLor [ADDRESS_483575] s younger than 2 y ears of age. If a child is 
unable to complete the age -appropriate questionna ire (eg, due to developmental delay  or other 
illness) it will not constitute a protocol deviation, but the parent should continue to complete the 
appropriate parent -specific forms.
Field trials have shown that the internal consistency  reliability  of the Pe dsQL  was excellent, with 
alphas for the generic core scales in both self -and proxy -report greater than the 0.[ADDRESS_483576] month, and parent- report 
of problems pursuing their normal work routine and concentrating at work. The PedsQL Generic 
Core Scales are also responsive to clinical change, as demonstrated in field trials.
[IP_ADDRESS] Pediatric Q uality of Life Generic Core Scale (PedsQL™), Acute V ersion
The PedsQL Generic Core Scale is designed to measures health -related quality  of life (HRQoL) 
in pediatric subjects and adolescents (2 -18 years of age). The developmentally  appropriate 
PedsQL  Generi c Core Scale will be completed b y either the parent or legal guardian and subject 
as indicated in Table 7 -3at the time points as outlined in Table 1
-1, Table 1 -2,and Table 1 -3.
For non-commercial use only
Shire CONFIDENTIAL Page 55
SHP633 -304 Protocol Am endment 4
Teduglutide 01Oct2019
Table 7-3: Developmentally App ropriate PedsQL™Generic Core Scales
Report Completed by
[CONTACT_319417] (ages 2 -4) Parent or Legal Guardian
Child Self Report and Parent Proxy -Report for Young Pediatric subjects 
(ages 5 -7)Subject and Parent or Legal Guardian
Child Self Report and Parent Proxy -Report for Pediatric subjects 
(ages 8 -12)Subject and Parent or Legal Guardian
Child Self Report and Parent Proxy -Report for Teens (ages 13 -18)aSubject and Parent or Legal Guardian
Abbreviations: PedsQL=Pediatric Quality of Life Inventory
a The Child Self Report and Parent Proxy -Report for Teens (ages 13 -18) w ill also be completed for subjects older 
than 18 years of age .
The Parent Report for Toddlers (ages 2 -4) of the PedsQL Generic Core Scale is composed of 
21 items comprising 4 dimensions as follows: 1) Physical Functioning (8 items), 2) Emotional 
Functioning (5 items), 3) Social Functioning (5 items), 4) School Functioning (3 items). 
The Child and Parent Reports of the PedsQL Generic Core Scale for Young Pediatric subjects 
(ages 5 -7), Pediatric subjects (ages 8- 12), and Teens (ages 13 -18) are composed of 23 items 
comprising 4 dimensions as follows: 1) Physical Functioning (8 items), 2) Emotional 
Functioning (5 items), 3) Social Functioning (5 items), 4) School Functioning (5 items).
[IP_ADDRESS] Pediatric Quality of Life Family Impact Module (PedsQL™), Acute Version
The PedsQL Family  Impact Module is a parent -report multidimensional instrument that will be 
completed b y the parent or legal guardian, as outlined in Table 1-1, Table [ADDRESS_483577] of pediatric chronic health conditions on parents and the family  (Varni et al., 2004). 
The 36- item PedsQL Family  Impact Modul e consists of 6 scales measuring parent self- reported 
functioning as follows: 1) Physical Functioning (6 items), 2) Emotional Functioning (5 items), 
3) Social Functioning (4 items), 4) Cognitive Functioning (5 items; worries about treatment and 
disease), 5) Communication (3 items), 6) Worry  (5items). Two additional scales measure 
parent -reported family  functioning as follows: 1) Daily  Activities (3 items), and 2) Family  
Relationships (5 items). The PedsQL Family  Impact Module should take the parent or lega l 
guardian approximately  5 to 10 minutes to complete.
[IP_ADDRESS] PedsQL Gastrointestinal Symptoms Module (PedsQL™), Acute 
Version
The PedsQL Gastrointestinal Sy mptom Module is a disease -specific 58- item module, comprised 
of 10 different s ymptom scales that assess gastrointestinal sy mptom -related quality  of life: food 
and drink limits, trouble swallowing, heartburn and reflux, nausea and vomiting, gas and 
bloating, constipation, blood in poop, and diarrhea. The PedsQL Gastrointestinal Sy mptoms 
Module was designed to allow the selection and scoring of individual scales from the Module. 
The scales of Food and Drink L imits (6 items) and Diarrhea (7 items) were identified as 
clinically  relevant and appropriate for the s ymptoms experienced in this pediatric study  
populati on, and therefore, are the onl yscales used in this study . 
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_483578] of teduglutide on the 
caregiver burden experienced during th e stud y. 
The interviews will be offered to English -speaking parents or legal guardians of subjects and 
subjects aged 12 years or older in selected countries. At the qualified subjects’ clinic sites, 
subjects and caregivers will be provided with a descript ion of the qualitative interview and be 
offered the opportunit y to participate. Subjects and caregivers who agree to participate will be 
asked to provide written informed consent (for caregiver interviews) and written assent and 
parental permission (for subject interviews) using forms developed specifically  for the 
interviews.
The format will be a single individual telephone interview using a semistructured interview 
guide. Each interview will be approximately  45 minutes and will be completed within 14 day s
after completion of the EOS/ET visit. Subjects and caregivers will be interviewed individually 
and separatel y and will be instructed to take the interview at a private setting.
Two interview guides have been developed, one for the caregiver interviews ( Appendix 3 ) and 
one for the subject interviews ( Appendix 4 ). Interview guides for [LOCATION_006] sites will be reviewed b y a 
native speaker of the local dialect. The guides will begin with a brief overview of the interview 
process and very  general questions intended to get the participants talking about their 
experiences (and the impacts of these experiences) associated with SBS prior to entering the 
study . These questions will then be followed by  a thorough probi ng of subject and caregiver 
experience during the study  and the importa nce of the treatment outcomes. Topi[INVESTIGATOR_319401]:
Subjects: SBS- related s ymptoms and impacts 
oSymptoms due to SBS
oSymptoms due to parenteral support
oImpact of SBS on dail y activities, physical functioning and social functioning
oImpact of parenteral support on daily  activities, phy sical functioning, and social 
functioning
For non-commercial use only
Shire CONFIDENTIAL Page 57
SHP633 -304 Protocol Am endment 4
Teduglutide 01Oct2019
Subjects: experience of teduglutide treatment in relation to SBS sy mptoms and impa cts 
during the stud y
oChanges of SBS -related sy mptoms relating to teduglutide
oChanges of parenteral support- related s ymptoms relating to teduglutide
oChanges o fdaily activities, physical functioning ,and social functioning relating to 
teduglutide
Caregivers : 
oSBS-related s ymptoms and impacts described as an observer
Symptoms due to SBS 
Symptoms due to parenteral support
Impact of SBS on dail y activities, physical functioning ,and social functioning
Impact of parenteral support on daily  activities, phy sical functioning, and social 
functioning
oChanges in SBS -related sy mptoms and impacts in relation to teduglutide treatment 
during the study described as an observer
Changes of SBS -related sy mptoms relating to teduglutide 
Changes of parenteral support- related s ymptoms relating to teduglutide
Changes o fdaily activities, physical functioning ,and social functioning relating 
to teduglutide
oDescription of care provided and impacts on caregivers of pediatric patients with SBS 
requiring parenteral support
Impact on ability  to complete activities of dail y living
Impact on emotional and social functioning
Financial impact
oChanges of caregiver impact in relation to teduglutide treatment during the study
Impact on ability  to complete activities of dail y living
Impact on em otional and social functioning
Financial impact
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_483579], as well as any  perceived treatment benefits in 
these areas and the meaningfulness of these changes from the perspective of the parent/legal 
guardian and/or subject. Site personnel will obtain consent, assent, and permission for those 
individuals that agree to participate in the qualitative interviews.
All interviews w ill be conducted by  [CONTACT_385998]. 
Interviews with subjects and caregivers from [LOCATION_006] sites will be conducted by a moderator who is a 
native speaker. The content of the interview will be transcribed, and the audio recording will be 
destroy ed to protect patient privacy . All personal information will be removed from the 
transcripts. Using the interview transcripts, dominant trends will be identified in each interview 
and then compared across the results of the other interviews to generate themes or patterns in the 
way subjects and caregivers describe their/their child’s treatment experiences and observations 
during the clinical trial as well as their perceptions of treatment benefit over the trial period. 
Should an interviewer become aware of any  potential AEduring the telephone interview, the 
interviewer will share the relevant information with the subject’s clinical site staff within 1day. 
The clinical site will be responsible for follow -up with the subject. The investigator will be 
responsible for determining the clinical significance of the event and the reporting of the event as 
outlined in Section 8.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_483580] a causal relationship with this 
treatment. An AE can therefore be an y unfavorable and unintended sign (including an abnormal 
laboratory  finding), s ymptom, or disease temporally  associated with the use of a medicinal 
(investigational) product, whether or not related to the medicinal (investigational) product (ICH 
Guidance E2A 1995). 
All AEs are collected from the time the informed consent is signed until the [ADDRESS_483581] be followed to closure (the subject’s health has returned to his/her baseline status 
or all variables have returned to normal), regardless of whether the subject is still participating in 
the study . Closure indicates that an outcome is reached, stabilization achieved (the investigator 
does not expect any further improvement or worsening of the event), or the event is otherwise 
explained. When appropriate, medical tests and examinations are performed so that resolution of 
event(s) can be documented.
8.1.[ADDRESS_483582] be 
recorded as new AEs ( for example, if a subject experiences mild intermittent dy spepsia prior to 
dosing of investigational product, but the dy spepsia becomes severe and more frequent after first 
dose of investigational product has been administered, a new AE of severe dy spepsia [with the 
appropriate date of onset] is recorded on the appropriate eCRF).
The medical assessment of severit y is determined by [INVESTIGATOR_1477]:
Mild:  A ty pe of AE that is usually  transient and may  require onl y minimal treatment or 
therape uticintervention. The event does not generally  interfere with usual activities of daily  
living.
Moderate:   A type of AE that is usually  alleviated with specific therapeutic intervention. The 
event interferes with usual activities of daily  living, causing 
discomfort but poses no significant 
or permanent risk of harm to the research subject.
For non-commercial use only
Shire CONFIDENTIAL Page 60
SHP633 -304 Protocol Am endment 4
Teduglutide 01Oct2019
Severe:  A type of AE that interrupts usual activities of dail y living, or significantly affects 
clinical status, or may  require intensive therapeutic intervention.
In consideration of whether a treatment-emergent adverse event (TEAE) might lead to dose 
interruption (Section 8.4.1) or early  termination of the study  (Section 8.5), severe TEAEs will 
also be graded according to the National Cancer Institute’s (NCI) Common Te rminology  Criteria 
for Adverse Events (CTCAE) severit y grading criteria ( US Department of Health and Human 
Services et al., 20 10).
8.1.2 Relationship Categorization
A phy sician/investigator must make the assessment of relationship to investigational product for 
each AE. The investigator should decide whether, in his or her medical judgment, there is a 
reasonable possibility  that the event may  have been caused b y the investigational product. If 
there is no valid reason for suggesting a relationship, then the AE should be classified as “not 
related”. Otherwise, if there is an y valid reason, even if undetermined or untested, for suspect ing 
a possible cause -and-effect relationship between the investigational product and the occurrence 
of the AE, then the AE should be considered “related”. The causality  assessment must be 
documented in the source document.
The following additional guidance may be helpful:
Term Relationship Definition
RelatedThe temporal relationship between the event and the administration of 
the investigational product is compelling and/or follows a known or 
suspected response pattern to that product, and the event cannot be 
explained by  [CONTACT_423]’s medical condition, other therapi[INVESTIGATOR_014], or 
accident.
Not RelatedThe event can be readil y explained by  [CONTACT_11260]’s underl ying medical condition, concomitant therapy , or 
accident and no plausible temporal or biologic relationship exists 
between the investigational product and the event.
AEs that are related to study  drug that are not resolved at EOT will be followed until the event 
resolves or stabilizes, as judged b y the investigator.
Laboratory values, vital signs, and clinical findings at the scheduled ph ysical examinations must 
be reported as AEs if the investigator considers the finding to be a clinicall y significant change 
from the baseline. 
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_483583] be recorded during the course of the stud y in the eCRF. Outcomes are 
as follows:
Fatal
Not Recovered/Not Resolved
Recovered/Resolved
Recovered/Resolved with Sequelae 
Recovering/Resolving
Unknown
8.1.4 Symptoms of the Disease under Study
Symptoms of the disease under study  should not be classed as AEs as long as they  are within the 
normal day -to-day fluctuation or expected progression of the disease and are part of the efficacy  
data to be collected in the study; however, significant worsening of the s ymptoms should be 
recorded as an AE.
8.1.[ADDRESS_483584] be taken into consideration.
If, during the stud y, there are abnormal clinical laboratory values or vital s igns which were not 
present at the beginning of the study , further investigations should be performed until the values 
return to within the reference range or until a plausible explanation (eg, concomitant disease) is 
found for the abnormal values.
The investigator should decide, based on the above criteria and the clinical condition of a 
subject, whether a change in a clinical laboratory  or vital sign is clinicall y significant and 
therefore represents an AE.
8.1.[ADDRESS_483585] be reported within 24 hours to the 
Shire Global Drug Safety Department using the Shire Investiga tional and Marketed Products 
Pregnancy  Report Form. A copy  of the Shire Investigational and Marketed Products Pregnancy 
Report Form (and an y applicable follow -up reports) must also be sent to the S ponsor Medical 
Monitor using the details specified in the e mergency  contact [CONTACT_1739]. 
In the event a subject becomes pregnant during the study , teduglutide administration must be 
discontinued immediately. 
Every  effort should be made to gather information regarding the pregnancy  outcome and 
condition of the infant. It is the responsibility  of the investigator to obtain this information within 
30 calendar day s after the initial notification and approximately  30 calendar day s postpartum.
Pregnancy  complications such as spontaneous abortion/miscarriage or congenital abnormality  
are considered SAEs and must be reported using the Shire Clinical Study  Adverse Event Form 
for Serious Adverse Events and Non- serious AEs as Required b y the Protocol. Note: An elective 
abortion is not considered an SA E.
In addition to the above, if the investigator determines that the pregnancy  meets serious criteria, 
it must be reported as an SAE using the Shire Clinical Study  Adverse Event Form for SAEs and 
Non-serious AEs as Required by  [CONTACT_385999] S hire Investigational and Marketed 
Products Pregnancy  Report Form. The test date of the first positive serum/urine -HCG test or 
will determine the pregnancy  onset date.
8.1.7 Abuse, Misuse, Overdose, and Medication Error
Abuse, misuse, overdose, or medication er ror (as defined below) must be reported to the sponsor 
according to the SAE reporting procedure whether or not they  result in an AE/SAE as described 
in Section 8.2. Note: The 24 -hour reporting requirement for SAEs does not apply  to reports of 
abuse, misuse , overdose, or medication errors unless these result in an SAE. 
The categories below are not mutually  exclusive; the event can meet more than 1 category .
Abuse –Persistent or sporadic intentional intake of investigational product when used for 
a non -medi cal purpose (eg, to alter one’s state of consciousness or get high) in a manner 
that may  be detrimental to the individual and/or society .
Misuse –Intentional use of investigational product other than as directed or indicated at 
any dose (Note: this includes a situation where the investigational product is not used as 
directed at the dose prescribed by  [CONTACT_760]).
Overdose –Administration of the investigational product at a dose or frequency  greater 
than 0.05 mg/kg subcutaneous once dail y. An overdose occurs if an y of the following 
criteria are met: 
oMore than 0.05 mg/kg is given at an y one time
oConsecutive doses are space d less than 12 hours apart
oAny more than 0.05 mg/kg given in one day  (a day  is defined as beginning at 
12:00 AMand ending at 11:59 PM)
For non-commercial use only
Shire CONFIDENTIAL Page 63
SHP633 -304 Protocol Am endment 4
Teduglutide 01Oct2019
Medication Error –An error made in prescribing, dispensing, administration, and/or use 
of an investigational product. F or studies, medication errors are reportable to the sponsor 
only as defined below.
Cases of subjects missing doses of the investigational product are not considered reportable as 
medication errors.
Medication errors should be collected/reported for all pro ducts under investigation.
The administration and/or use of an expi[INVESTIGATOR_10151] a 
reportable medication error. 
All investigational product provided to pediatric subjects should be supervised by  [CONTACT_31588]/legall y-authorized representative/caregiver.
8.[ADDRESS_483586] awareness 
of the event. Note: The 24- hour reporting requireme nt for SAEs does not apply  to reports of 
abuse, misuse, overdose, or medication errors (see Section 8.1.7) unless they result in an SAE.
All Adverse Events of Special Interest, as defined in Section 8.3, must be reported by [CONTACT_386000] y Department and the S ponsor Medical Monitor 
within [ADDRESS_483587] complete, sign, and date the Shire Clinical Study  Adverse Event Form for 
SAEs and Non- serious AEs as Required b y Protocol and verify the accuracy of the information 
recorded on the form with the corresponding source documents (Note: Source documents are not 
to be sent unless requested). Fax or e -mail the completed form to the Shire Global 
Drug Safet y 
Department. A cop y of the completed Shire Clinical Study Adverse Event Form for Serious 
Adverse Events (SAEs) and Non -serious AEs as Required b y Protocol (and any applicable 
follow -up reports) must also be sent to the Sponsor medical monitor or designee using the details 
specified in the emergency  contact [CONTACT_1739].
8.2.3 Serious Adverse Event Definition
Aserious adverse event ( SAE) is any  untoward medical occurrence (whether considered to be 
related to investigational product or not) that at any dose: 
Results in death
For non-commercial use only
Shire CONFIDENTIAL Page 64
SHP633 -304 Protocol Am endment 4
Teduglutide 01Oct2019
Is life -threatening. Note: The term 'life -threatening' in the definition of "serious" refers to 
an event in which t he subject was at risk of death at the time of the event; it does not refer 
to an event which h ypothetically might have caused death if it was more severe.
Requires inpatient hospi[INVESTIGATOR_1081]. Note: 
Hospi[INVESTIGATOR_48181], which are the result of elective or previousl y scheduled surgery for 
pre-existing conditions, which have not worsened after initiation of treatment, should not 
be classified as SAEs. For example, an admission for a previously  scheduled ventral 
hernia r epair would not be classified as an SAE; however, complication(s) resulting from 
a hospi[INVESTIGATOR_230476](s) serious 
criteria must be reported as SAE(s).
Results in persistent or significant disability /incapacity
Is a congenital abnormality /birth defect
Is an important medical event. Note: I mportant medical events that may not result in 
death, be life -threatening, or require hospi[INVESTIGATOR_12475], 
based upon appropriate medical judgm ent, they  may  jeopardize the subject and may  
require medical or surgical intervention to prevent 1 of the outcomes listed in this 
definition. Examples of such medical events include allergic bronchospasm requiring 
intensive treatment in an emergency  room or at home; blood dy scrasias or convulsions 
that do not result in inpatient hospi[INVESTIGATOR_059]; or the development of drug dependency  or 
drug abuse. 
8.2.4 Serious Adverse Event Collection Time Frame
All SAEs (regardless of relationship to study ) are collected from the time the subject signs the 
informed consent until the defined follow- up period stated in Section 7.1.4, and must be reported 
to the Shire Global Drug Safety  Department andthe S ponsor Medical Monitor within [ADDRESS_483588] awareness of the event.
In addition, any SAE(s) considered “related” to the investigational product and discovered by  [CONTACT_10194] y interval after the study has completed must be reported to the Shire Global 
Drug Safet y Department within [ADDRESS_483589]’s death (ie, the SAE was noted as the primary  cause of death) 
must have fatal checked as an outcome with the date of death recorded as the resolution date. For 
all other events ongoing at the time of death that did not contribute to the subject’s death, the 
outcome should be considered not resolved, wi thout a resolution date recorded.
For an y SAE that results in the subject’s death or any ongoing events at the time of death, unless 
another investigational product action was previously  taken (eg, drug interrupted, reduced, 
withdrawn), the action taken wi th the investigational product should be recorded as “dose not 
changed” or “not applicable” (if the subject never received investigational product). The 
investigational product action of “withdrawn” should not be selected solel y as a result of the 
subject’ s death.
8.2.[ADDRESS_483590], Ethics Committee, and Site 
Reporting 
The Sponsor and/or Clinical Contract Research Organization (CRO) is responsible for notify ing 
the relevant regulatory  authorities, and US central I nstitutional R eview Boards (IRBs)/EU central 
ethics committees (ECs), of related, unexpected SAEs.
In addition, the Clinical CRO is responsible for notify ing active sites of all related, unexpected 
SAEs occurring during all interventional studies across the SHP633 progr am.
The investigator is responsible for notifying the local IRB, local EC, or the relevant local 
regulatory  authorit y of all SAEs that occur at his or her site as required.
8.[ADDRESS_483591] is an AE (serious or n onserious) of scientific and medical concern 
specific to the sponsor’s product or program and for which ongoing monitoring and immediate 
notification by  [CONTACT_230013].
The AEs of special interest that require expedited regulat ory reporting include the following:
Growth of pre -existing poly ps of the colon
Benign neoplasia of the GI tract including the hepatobiliary  system
Tumor -promoting ability (eg, benign and/or malignant neoplasia of any  kind, not limited 
to those of the GI or hepatobiliary  system)
For AEs of special interest, the sponsor must be informed within [ADDRESS_483592] awareness as 
per the SAE notification instructions described in Section 8.2.2 even if the event does not fulfill 
the seriousness criteria.
8.4 Dose Inte rruption of Individual Subjects
The investigator is responsible for contact[CONTACT_20610]/designee when the subject’s 
teduglutide dosing r egimen is interrupted. 
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_483593] thesponsor/designee prior to dose interruption. Reasons fo r 
dosage interruptions may include but are not limited to hospi[INVESTIGATOR_059], AEs, a lapse in 
investigational product delivery , etc. The length of the dose interruption, and whether teduglutide 
administration resumes or is permanentl y discontinued, depends on the clinical situation.
Investigational product must be interrupted if any of the following events occur:
An AE of special interest (see Section 8.3)
An AE that is of NCI CTCAE severit y Grade 3 or 4 and related to teduglutide
Intestinal obstruction
Biliar y obstruction related to teduglutide
Pancreatic duct obstruction related to teduglutide
Heart failure with severe fluid overload related to teduglutide
Investigational product must be permanentl y discontinued if an y of the following events occur:
Pregnancy
Severe h ypersensitivity , such as anaph ylaxis determined by  [CONTACT_319447]. This does not include the presence of anti- teduglutide antibodies, mild 
injection site reactions or mild sy mptoms that according to the investigator d o not pose a 
significant risk to the subject.
Confirmed DILI related to teduglutide (see Section 8.4.2)
Any malignancy .
8.4.[ADDRESS_483594] experienced an AE that is of 
severit y ≥Grade [ADDRESS_483595]. 
In consideration of whether a TEAE might lead to dose interruption, severe TEAEs will also be 
graded according to the NCI  CTCAE severit y grading criteria ( US Department of Health and 
Human S ervices et al., 2010 ). All such TEAEs should be discussed with the S ponsor Medical 
Monitor or designee as soon as possible. The length of the dose
 interruption, and whether 
teduglutide administration resumes or is permanently  discontinued, depends on th e clinical 
situation. 
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_483596] has 
clinical and laboratory  evidence of potential DILI, in the absence of an alternative explanation, 
as identified b y the following criteria:
ALT or AST >8x ULN
ALT or AST >5x ULN and >2x baseline value for more than 2 weeks
(ALT or AST >3x ULN and >2x baseline value) and (total bilirubin >2x ULN or 
INR>1.5)
ALT or AST >3x ULN and >2x baseline value with the appearance of fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)
All laboratory  values suggestive of potentially  new DILI should be repeated and verified within 
[ADDRESS_483597] should be followed closel y to determine the trajectory  of the 
laboratory  abnormalities and to evaluate the cause of liver injury . This evaluation may  include, 
as clinically  indicated, consideration of sepsis, acute viral hepatitis (eg, hepatitis A 
immunoglobulin [IgM], hepatitis B surface anti gen, hepatitis C antibodies, cy tomegalovirus IgM, 
Epstein- Barr virus antibody  panel), hepatobiliary  obstruction (ultrasound), autoimmune hepatitis 
(anti-nuclear, anti -smooth muscle, anti -actin, or anti -liver kidney  microsomal antibodies), 
intestinal failur
e associated liver disease, cardiovascular causes such as ischemic hepatitis, and 
concomitant hepatotoxic treatments.
Additional evaluations may  be performed at the discretion of the investigator in consultation 
with the S ponsor medical monitor.
Teduglutide administration must be permanentl y discontinued if DILI is confirmed and deemed 
related to stud y drug.
8.5 Early Termination of the Clinical Study
The data monitoring committee (DMC) may  recommend stoppi[INVESTIGATOR_319397]:
≥2subjects develop the same event of CTCAE severity  Grade [ADDRESS_483598]
or
1subject develops an event of CTCAE severity Grade [ADDRESS_483599].
For non-commercial use only
Shire CONFIDENTIAL Page 68
SHP633 -304 Protocol Am endment 4
Teduglutide 01Oct2019
9 DATA MANAGEMENT AND STATISTICAL METHODS
9.1 Data Collection
The investigators’ authorized site personnel must enter the information required by  [CONTACT_103365]. A study  monitor will visit each site in accordance with the monitoring plan and 
review the eCRF data against the source data for completeness and accuracy. Discrepancies 
between source data and data entered in the eCRF will be addressed b y qualified site personnel. 
When a data discrepancy warrants correction, the correction will be made by [CONTACT_59752]. Data collection procedures will be discussed with the site at the site initiation visit 
and/or at the investigator’s meeting. Unscheduled safet y follow up assessments ( including visits 
conducted after EOS) are not to be collected unless requested.
9.2 C linical Data Management 
Data are to be entered into a clinical database as specified in the CRO’s data management 
process. Quality  control and data validation procedures are applied to ensure the validity  and 
accuracy  of the clinical database.
Data are to be reviewed and checked for omissions, errors, and values requiring further 
clarification using computerized and manual procedures. Data queries requiring clarification are 
to be communicated to the site for resolution. Only authorized personnel will make corrections to 
the clinical database, and all corrections are documented in an auditable manner.
9.3 Statistical Analysis Process 
The study  will be anal yzed by  [CONTACT_10196]. All statistical anal yses will be performed 
using SAS®(SAS Institute, Ca ry, NC, [LOCATION_003]) version 9.3 or higher.
The statistical anal ysis plan (SAP) will provide the statistical methods and definitions for the 
analysis of the efficacy  and safet y data, as well as describe the approaches to be taken for 
summarizing other study  inform ation such as subject disposition, demographics and baseline 
characteristics, investigational product exposure, and prior and concomitant medications. 
9.[ADDRESS_483600] been collected for subjects 
entering from TED -C14-006. Additional interim analy ses may  be conducted as needed.
A DMC will be involved in the management of this study . The DMC members will review the 
data approximately  every 3 months according to the DMC Charter. The DMC review will 
include all cumulative safety  data (ie, AEs, laboratory  assessments, phy sical examinations, etc.) 
from study  assessments through each cutoff period. Further details regarding the DMC can be 
found in the DMC char ter, which will be available prior to the administration of investigational 
product. 
For non-commercial use only
Shire CONFIDENTIAL Page 69
SHP633 -304 Protocol Am endment 4
Teduglutide 01Oct2019
The DMC for this study  will be conducted in accordance with the FDA Guidance for Clinical 
Trial Sponsors: Establishment and Operation of Clinical Trial Data Monitoring Co mmittees 
(March 2006).
The DMC will be an external, independent board comprised of ph ysicians with relevant training. 
The DMC will be restricted to individuals free of significant conflicts of interest, including, but 
not limited to, financial, scientific, or regulatory  in nature. The DMC will be governed by  a 
Charter agreed to b y members of the Board and the sponsor. Members of the Board may not be 
study  investigators or be employ ed at the same institution as a study  investigator, individuals 
employ ed by [CONTACT_456], independent contractors hired by  [CONTACT_456], or members of 
regulatory  agencies. The DMC may  make recommendations to the sponsor regarding stud y 
aspects including stoppi[INVESTIGATOR_007], modify ing or continuing the study ; however, the sponsor will have 
the final responsibility  to determine whether the study  should be modified or temporaril y or 
permanentl y stopped. 
9.5 Sample Size Calculation and Power Considerations 
The number of subjects in this study  is not based on statistical power considerations as this is an 
extension study  of the core studies, TED -C14-006 and SHP633- 301. The maximum number of 
subjects was determined by  [CONTACT_385990] -C14-006 and SHP633 -301.
9.6 Study Population
The safet y population includes all enrolled subjects in the study . Safet y population will be used 
for both safet y and efficacy  anal yses.
9.7 Efficacy Analyses 
No claims of statistical significance will be made; however, 95% confidence intervals will be 
provided, if applicable. Continuous variables, including those assessed on a disc rete scale, will 
be summarized using descriptive statistics including number of subjects, mean, median, standard 
deviation, maximum, and minimum. For categorical variables, statistical summaries will include 
number of subjects and percentages.
9.7.1 Efficacy End points
Efficacy  endpoints will be anal yzed at the end of each teduglutide treatment period (week 24 or 
EOT), and at each stud y visit, relative to the baseline of the core study  (TED -C14-006 or 
SHP633 -301) and/or first exposure to teduglutide. The following effica cy endpoints will be 
analyzed: 
Reduction in PS volume of at least 20%
Absolute and relative change in PS volume
Complete weaning off PS
Change in day s per week of PS
For non-commercial use only
Shire CONFIDENTIAL Page 70
SHP633 -304 Protocol Am endment 4
Teduglutide 01Oct2019
9.8 Safety Analyses 
9.8.1 Safety Endpoints
The following safet y endpoints will be analy zed: 
Adverse events
Vital signs, including temperature, heart rate, and blood pressure
Laboratory  safet y data (ie, clinical chemistry , hematology , and urinaly sis)
Urine output
Stool output 
Antibodies to teduglutide
Gastrointestinal -specific testing , including fecal occult blood testing and colonoscopy  or 
sigmoidoscop y
Z-scores for weight, height (or length), head circumference (up to 36 months of age), and 
BMI 
Adverse events will be coded using the Medical Dictionary  for Regulatory  Activities 
(MedDRA). The number of events, incidence, and percentage of AEs will be calculated overall, 
by [CONTACT_1196] (SOC) and by  [CONTACT_11702]. SAEs will be further summarized by  
[CONTACT_11370] y and relationship to investigational product. Adverse events related to investigation al 
product, AEs leading to withdrawal, SAEs, and deaths will be similarly  summarized/listed.
Prior and concomitant medications will be coded using the World Health Organization- Drug 
Dictionary  (WHO -DD) with regard to drug class and drug name. The number an d percentage of 
subjects with specific prior medications will be summarized. Medical history  (including 
surgical/procedural history ) will be coded using MedDRA. The number and percentage of 
subjects with specific histories will be summarized by  [CONTACT_386001] n class and preferred term. 
For clinical laboratory  tests, vital signs, body  weight, and fluid balance variables, descriptive 
statistics (mean, median, standard deviation, minimum and maximum values, the number and 
percentage of subjects in specified cate gories) will be calculated to summarize the observed 
values and change from baseline at each scheduled visit.
The number and percentage of subjects classified as having positive or neutralizing antibodies to 
teduglutide will be used to summarize the presen ce of antibodies. 
Additional safet y parameters and measures will include change in bod y weight, height (or 
length) and head circumference (up to 36 months of age). Derived variables will include height 
z
-score, weight z -score, BMI, and BMI z -score. Descri ptive statistics (mean, median, standard 
deviation, minimum and maximum values, the number and percentage of subjects in specified 
categories) will be calculated to summarize the absolute values and change from baseline at each 
scheduled visit.
For non-commercial use only
Shire CONFIDENTIAL Page 71
SHP633 -304 Protocol Am endment 4
Teduglutide 01Oct2019
9.9 Other Analyses
9.9.1 Health -related Quality of Life Analyses 
Health economics and outcomes research endpoints will be analy zed at approximately  12-week 
intervals (weeks 12 and 24 of each teduglutide treatment cy cle, and every  12 weeks for subjects 
not on teduglutide), relative to the study  baseline. The beginning of each treatment cy cle (CxD1) 
will be an additional baseline.
Change in Pediatric Quality  of Life Inventory  (PedsQL) score
Change in PedsQL Family  Impact Module score
Change in PedsQL Gastrointestinal Sy mptoms Mo dule Sub- Scales scores: 
oFood and Drink L imits
oDiarrhea 
9.9.2 Qualitative Interviews
A final report will be developed for the qualitative interviews and will be included in the CSR of 
the study .
For non-commercial use only
Shire CONFIDENTIAL Page 72
SHP633 -304 Protocol Am endment 4
Teduglutide 01Oct2019
10 SPONSOR’S AND INVEST IGATOR’S RESPONSIBIL ITIES
This study  is conducted in accordance with current applicable regulations, ICH, EU Directive 
2001/20/EC and its updates, and local ethical and legal requirements. 
The name [CONTACT_317368] y vendor (eg, CRO) used in this study  will be maintained 
in the investigator’s and sponsor’s files, as appropriate.
10.1 Sponsor’s Responsibilities
10.1.[ADDRESS_483601] been delegated will undertake their assigned roles for this study  in compliance with all 
applicable industry  regulations, I CH GCP Guideline E6 ( 1996), EU Directive 2001/20/EC, as 
well as all applicable national and local laws and regulations.
Visits to sites are conducted by  [CONTACT_10199]/or the company  
organizing/managing the research on behalf of the sponsor to inspect study  data, subjects’ 
medical records, and eCRFs in accordance with current GCP and the respective local and 
(inter)national government regulation s and guidelines. Records and data may additionall y be 
reviewed b y auditors or by  [CONTACT_10200].
The sponsor ensures that local regulatory  authority requirements are met before the start of the 
study . The sponsor (or a nominated designee) is responsible for the preparation, submission, and 
confirmation of receipt of an y regulatory  authority  approvals required prior to release of 
investigational product for shipment to the site.
10.1.2 Indemnity/Liability and Insurance
The sponsor of this research adh eres to the recommendations of the Association of British 
Pharmaceutical Industry  Guidelines. If appropriate, a cop y of the indemnity document is 
supplied to the investigator before study  initiation, per local country  guidelines.
The sponsor ensures that s uitable clinical study  insurance coverage is in place prior to the start of 
the study . An insurance certificate is supplied to the CRO as necessary . 
10.1.3 Public Posting of Study Information
The sponsor is responsible for posting appropriate study  information o
n applicable websites. 
Information included in clinical study  registries may  include participating investigators’ names 
and contact [CONTACT_3031].
10.1.4 Submission of Summary of Clinical Study Report to Competent Authorities 
of Member States Concerned and Ethics Committees
The sponsor will provide a summary  of the clinical study  report to the competent authority  of the 
member state(s) concerned as required b y regulatory  requirement(s) and to comply  with the 
Community  guideline on GCP. 
For non-commercial use only
Shire CONFIDENTIAL Page 73
SHP633 -304 Protocol Am endment 4
Teduglutide 01Oct2019
This requirement willbefulfilled within 6months oftheendofthe study  completion date for 
pediatric studies and within 1 y ear for non-pediatric studies as per guidance. The sponsor will 
provide the ECs with a copy of the same summary .
10.1.5 Study Suspension, Termination, and Completion
The sponsor may  suspend or terminate the study , or part of the study , at any  time for any  reason. 
If the stud y is suspended or terminated, the sponsor will ensure that applicable sites, regulatory 
agencies and IRBs/ECs are notified as appropriate. Additio nally , the discontinuation of a 
registered clinical study  which has been posted to a designated public website will be updated 
accordingl y.
The sponsor will make an EOS declaration to the relevant competent authority  as required b y 
Article 10 (c) of Direct ive 2001/20/EC .
10.2 Investigator’s Responsibilities
10.2.[ADDRESS_483602] undertake to perform the study  in accordance with ICH GCP Guideline E6 
(1996), EU Directive 2001/20/EC, and applicable regulatory  requirements and guide lines.
It is the investigator’s responsibility  to ensure that adequate time and appropriately  trained 
resources are available at the site prior to commitment to participate in this study . The 
investigator should also be able to estimate or demonstrate a po tential for recruiting the required 
number of suitable subjects within the agreed recruitment period.
The investigator will maintain a list of appropriately  qualified persons to whom the investigator 
has delegated significant study -related tasks, and shall , upon request of the sponsor, provide 
documented evidence of any  licenses and certifications necessary  to demonstrate such 
qualification. Curriculum vitae
for investigators and sub- investigators are provided to the study  
sponsor (or designee) before start ing the study .
If a potential research subject has a primary  care phy sician, the investigator should, with the 
subject’s consent, inform them of the subject’s participation in the study .
A coordinating principal investigator [INVESTIGATOR_319387]. Agreement with the final CSR is documented by  [CONTACT_319426] (single -site study ) or coordinating principal inv estigator (multicenter 
study ), in compliance with Directive 2001/83/EC as amended b y Directive 2003/63/EC and I CH 
Guidance E3 ( 1995). 
10.2.[ADDRESS_483603] met 
protocol eligibility  criteria. Investigators 
arerequired to sign an investig ator agreement to 
confirm acceptance and willingness to comply  with the study  protocol.
For non-commercial use only
Shire CONFIDENTIAL Page 74
SHP633 -304 Protocol Am endment 4
Teduglutide 01Oct2019
If the investigator suspends or terminates the study  at their site, the investigator will promptly  
inform the sponsor and the I RB/EC and provide them with a detailed wr itten explanation. The 
investigator will also return all investigational products, containers, and other study materials to 
the sponsor. Upon study  completion, the investigator will provide the sponsor, I RB/EC, and 
regulatory  agency  with final reports and summaries as required by  (inter)national regulations.
Communication with local I RBs/ECs, to ensure accurate and timel y information is provided at 
all phases during the study , may  be done by  [CONTACT_456], applicable CRO, investigator, or for 
multicenter studies, the coordinating principal investigator [INVESTIGATOR_49106].
10.2.3 Documentation and Retention of Records
[IP_ADDRESS] Case Report Forms
The investigator is responsible for maintaining adequate and accura te medical records from 
which accurate information is recorded into eCRFs, which have been designed to record all 
observations and other data pertinent to the clinical investigation. Case report forms must be 
completed b y the investigator or designee as st ated in the site delegation log.
All data will have separate source documentation; no data will be recorded directly  into the 
eCRF.
eCRFs should be approved by  [CONTACT_385960].
The clinical resear ch associate (CRA)/study  monitor will verify  the contents against the source 
data per the monitoring plan. If the data are unclear or contradictory , queries are sent for 
corrections or verification of data.
[IP_ADDRESS] Recording, Access, and Retention of Source Data a nd Study Documents
Original source data to be reviewed during this study  will include, but are not limited to: 
subject’s medical file, subject diary  cards, original clinical laboratory  reports, and histology  and 
pathology  reports.
All key  data must be reco rded in the subject’s medical records.
The investigator must permit authorized representatives of the sponsor, the respective national, 
local, or foreign regulatory  authorities, the IRB/EC, and auditors to inspect facilities and to have 
direct access to or iginal source records relevant to this study , regardless of media.
The CRA/study  monitor (and auditors, IRB/EC or regulatory  inspectors) may  check the eCRF 
entries against the source documents. The consent form includes a statement by  [CONTACT_386002]/auditor from the sponsor or its representatives, national or local 
regulatory  authorities, or the I RB/EC, having access to source data (eg, subject’s medical file, 
appointment books, original laboratory reports, X -rays etc.). Non- study  site personnel will not 
disclose an y personal information or personal medical information.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_483604] be made available within reasonable times for inspection and duplication, if 
required, b y a properly  authorized representative of any  regulatory  agency  (eg, the US FDA, 
EMA, [LOCATION_006] Medicines and Healthcare products Regulatory  Agency ) or an auditor.
Essential documents must be maintained according to ICH GCP requirements and may  not be 
destroy ed without written permission from the sponsor.
[IP_ADDRESS] Audit/Inspection
To ensure compliance with relevant regulations, data generated b y this study must be available 
for inspection upon request by  [CONTACT_1779], for example, the US FDA (as well as other US 
national and local regulatory  authorities), the European Medici nes Agency  (EMA), the 
Medicines and Healthcare products Regulatory  Agency , other regulatory  authorities, the sponsor 
or its representatives, and the I RB/EC for each site.
[IP_ADDRESS] Financial Disclosure
The investigator is required to disclose an y financial arrangeme nt during the study  and for 1 year 
after, whereb y the outcome of the study  could be influenced by  [CONTACT_10204] , or other pay ments the investigator received from the sponsor. The 
following information is collected: any significant payments from the sponsor or subsidiaries 
such as a grant to fund ongoing research, compensation in the form of equipment, retainer for 
ongoing consultation or honoraria; an y proprietary interest in investigational product; any 
significant equity  interest in the sponsor or subsidiaries as defined in 21 CFR 54 2(b) ( 1998).
10.[ADDRESS_483605]’s legall y
-authorized representative, as 
applicable, is requ ested to sign and date the subject informed consent form or a certified 
translation if applicable, after the subject has received and read (or been read) the written subject 
information and received an explanation of what the study  involves, including but not limited to: 
the objectives, potential benefits and risk, inconveniences, and the subject’s rights and 
responsibilities. A copy  of the informed consent and assent documentation (ie, a complete set of 
subject information sheets and fully  executed signature [CONTACT_1787]) must be given to the subject or the 
subject’s legall y-authorized representative, as applicable. This document may  require translation 
into the local language. Signed consent forms must remain in each subject’s study  file and must 
be available for verification at any  time.
Within the source documents, site personnel should document instruction of and understanding 
by [CONTACT_7071]/legall y-authorized representative/caregiver of the safe, responsible storage and 
administration of investigational product to the study  subject.
For non-commercial use only
Shire CONFIDENTIAL Page 76
SHP633 -304 Protocol Am endment 4
Teduglutide 01Oct2019
The principal investigator [INVESTIGATOR_1682] a cop y of the consent form, and assent form 
where applicable, that was reviewed b y the IRB/EC and which received their favorable 
opi[INVESTIGATOR_1649]/approval. A copy  of the IRB/EC’s written fa vorable opi[INVESTIGATOR_1649]/approval of these 
documents must be provided to the sponsor, prior to the start of the study  unless it is agreed to 
and documented (abiding by  [CONTACT_319428]) prior to study  start 
that another party  (ie, sponsor or coordinating principal investigator) is responsible for this 
action. Additionally , if the I RB/EC requires modification of the sample subject information and 
consent document provided by  [CONTACT_456], the documentation supporting this requirement must 
be provided to the sponsor.
10.3.[ADDRESS_483606] or Ethics Committee
For sites outside the EU, it is the responsibility  of the investigator to submit this protocol, the 
informed consent document (approved b y the sponsor or their designee), relevant supporting 
information and all ty pes of subject recruitment information to t he IRB/EC for review, and all 
must be approved prior to site initiation .
For sites within the EU, the applicant for an EC opi[INVESTIGATOR_319376], the investigator, or 
for multicenter studies the coordinating principal investigator [INVESTIGATOR_10157], according to national 
provisions.
Responsibility  for coordinating with IRBs/ECs is defined in the investigator agreement.
Prior to implementing changes in the study , the sponsor and the IRB/EC must approve any  
revisions of all informed consent documents and amendme nts to the protocol unless there is a 
subject safet y issue.
Investigational product supplies will not be released until the Sponsor (or designee) has received 
written I RB/EC approval of and copi[INVESTIGATOR_10158].
For sites outside the EU, the investigator is responsible for keepi[INVESTIGATOR_1683]/EC apprised of the 
progress of the stud y and of an y changes made to the protocol, but in an y case at least once a 
year; for sites within the EU, this can be done by  [CONTACT_456], the investigator or for multicenter 
studies the coordinating principal investigator, according to national provisions. The investigator 
must also keep the local IRB/EC informed of an y serious and significant AEs.
10.[ADDRESS_483607] (HIPAA) of 
1996. A site that is not a covered entity  as defined by  [CONTACT_385961] (o r designee).
The confidentialit y of records that may be able to identify subjects will be protected in 
accordance with applicable laws, regulations, and guidelines.
After subjects have consented to take part in the study , the sponsor and/or its representatives 
review their medical records and data collected during the stud y. 
For non-commercial use only
Shire CONFIDENTIAL Page 77
SHP633 -304 Protocol Am endment 4
Teduglutide 01Oct2019
These records anddata may,inaddition, be reviewed by  [CONTACT_1774]: 
independent auditors who validate the data on behalf of the sponsor; third parties with whom the 
sponsor may  develop, register, or market SHP633; national or local regulatory  authorities; and 
the IRBs/ECs which gave approval for the stud y to proceed. The sponsor and/or its 
representatives accessing the records and data will take all reasonable precaut ions in accordance 
with applicable laws, regulations, and guidelines to maintain the confidentiality  of subjects’ 
identities.
Subjects are assigned a unique identify ing number; however, their initials and date of birth may  
also be collected and used to ass ist the sponsor to verify  the accuracy  of the data (eg, to confirm 
that laboratory  results have been assigned to the correct subject).
The results of studies –containing subjects’ unique identify ing number, relevant medical 
records, and possibly  initials and dates of birth –will be recorded. They  may  be transferred to, 
and used in, other countries which may  not afford the same level of protection that applies w ithin 
the countries where this study  is conducted. The purpose of an y such transfer would includ e: to 
support regulatory  submissions, to conduct new data anal yses to publish or present the study  
results, or to answer questions asked by  [CONTACT_1775].
10.5 Study Results / Publication Policy
Shire will endeavor to publish the results of a ll qualify ing, applicable, and covered studies 
according to external guidelines in a timely  manner regardless of whether the outcomes are 
perceived as positive, neutral, or negative. Additionally, Shire adheres to external guidelines 
(eg,Good Publication Practices 2) when forming a publication steering committee, which is 
done for large, multicenter Phase [ADDRESS_483608] undergo appropriate technical and 
intellectual propert y review, with Shire agreement to publish pr ior to release of information. The 
review is aimed at protecting the sponsor’s proprietary  information existing either at the 
commencement of the study  or generated during the study . To the extent permitted by  [CONTACT_10206], the principal investigator [INVESTIGATOR_59702] (or share with other authors) the 
copy right on his/her publications. To the extent that the principal investigator [INVESTIGATOR_10159], joint 
or shared rights, the principal investigator [INVESTIGATOR_10160] a perpetual, irrevocable, 
royalty-free license to make and distribute copi[INVESTIGATOR_10161].
The term “publication” refers to an y public disclosure including original research articles, review 
articles, oral presentations, abstracts and posters at medical congresses, journal supplem ents, 
letters to the editor, invited lectures, opi[INVESTIGATOR_10162], book chapters, electronic postings on 
medical/scientific websites, or other disclosure of the study  results, in printed, electronic, oral or 
other form.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_483609] the right to publish the 
study  results, and any  background information provided by  [CONTACT_10207] y publication of study results, or necessary for other scholars to verify such stud y 
results. Notwithstanding the foregoing, no publication that incorporates the sponsor’s 
confidential information shall be submitted for publication without the sponsor’s prior written 
agreement to publish and shall be given to the sponsor for review at least [ADDRESS_483610] publication of the study  results shall be made 
by [CONTACT_10208]’s presentation of a joint, multicenter publication 
of the compi[INVESTIGATOR_10163]. If such a multicenter publicat ion is not submitted to a 
journal for publication by  [CONTACT_10209] 18-month period after conclusion, abandonment, 
or termination of the study at all sites, or after the sponsor confirms there shall be no multicenter 
study  publication of the study  results, an investigator may  individuall y publish the study results 
from the specific site in accordance with this section. The investigator must, however, 
acknowledge in the publication the limitations of the single -site data being presented.
Unless otherw ise required by  [CONTACT_10210], or the forum in which 
it is made, authorship will comply  with the International Committee of Medical Journal Editors 
current standards. Participation as an investigator does not confer an y right s to authorship of 
publications.
For non-commercial use only
Shire CONFIDENTIAL Page 79
SHP633 -304 Protocol Am endment 4
Teduglutide 01Oct2019
11 REFERENCES
Drucker, D. J. and Yusta, B. 2014. Physiology  and pharmacology  of the enteroendocrine 
hormone glucagon- like peptide -2. Annu Rev Physiol, 76, 561 -83.
Khan, F. A., Squires, R. H., Litman, H. J., Balint, J., Carter, B. A., Fisher, J. G., Horslen, S. P., 
Jaksic, T., Kocoshis, S., Martinez, J. A., Mercer, D., Rhee, S., Rudolph, J. A., Soden, J., 
Sudan, D., Superina, R. A., Teitelbaum, D. H., Venick, R., Wales, P. W. and Duggan, C. 
2015. Predictors of Enteral Autonomy  in Children with Intestinal Failure: A Multicenter 
Cohort Study . J Pediatr, 167, 29 -34.e1.
Mouksassi, M. S., Marier, J. F., Cyran, J. and Vinks, A. A. 2009. Clinical trial simulations in 
pediatric patients using realistic covariates: application to teduglutide, a glucagon- like 
peptide-2 analog in neonates and infants with short- bowel syndrome. Clin Pharmacol 
Ther, 86, 667-71.
O'Keefe, S. J., Buchman, A. L., Fishbein, T. M., Jeejeebho y, K. N., Jeppesen, P. B. and Shaffer, 
J. 2006. Short bowe l syndrome and intestinal failure: consensus definitions and overview. 
Clin Gastroenterol Hepatol, 4, 6-10.
Squires, R. H., Duggan, C., Teitelbaum, D. H., Wales, P. W., Balint, J., Venick, R., 
Rhee, S., 
Sudan, D., Mercer, D., Martinez, J. A., Carter, B. A., Soden, J., Horslen, S., Rudolph, J. 
A., Kocoshis, S., Superina, R., Lawlor, S., Haller, T., Kurs -Lask y, M.and Belle, S. H. 
2012. Natural history  of pediatric intestinal failure: initial report from the Pediatric 
Intestinal Failure Consortium. J Pediatr, 161, 723- 8.e2.
Tappenden, K. A., Edelman, J. and Joelsson, B. 2013. Teduglutide enhances structural 
adaptat ion of the small intestinal mucosa in patients with short bowel syndrome. J Clin 
Gastroenterol, 47, 602-7.
Thymann, T., Stoll, B., Mecklenburg, L., Burrin, D. G., Vegge, A., Qvist, N., Eriksen, T., 
Jeppesen, P. B. and Sangild, P. T. 2014. Acute effects of the glucagon
-like peptide 2 
analogue, teduglutide, on intestinal adaptation in short bowel syndrome. J Pediatr 
Gastroenterol Nutr, 58, 694-702.
US Department of Health and Human Services, National Institutes of Health and National 
Cancer Institute 2010. Common Terminology  Criteria for Adverse Events (CTCAE).
Varni, J. W., Sherman, S. A., Burwinkle, T. M., Dickinson, P. E. and Dixon, P. 2004. The 
PedsQL  Family Impact Module: preliminary  reliability  and validity . Health Qual Life 
Outcomes, 2, 55.
Wales, P. W., de Silva, N., Kim, J., Lecce, L., To, T. and Moore, A. 2004. Neonatal short bowel 
syndrome: population -based estimates of incidence and mortality  rates. J Pediatr Surg,
39, 690-5.
For non-commercial use only
Shire CONFIDENTIAL Page 80
SHP633 -304 Protocol Am endment 4
Teduglutide 01Oct2019
APPENDIX 1 PROTOCOL HISTORY
Document Date Global/Country/Site Specific
Original Protocol [ADDRESS_483611] 2019 Global
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 3 Amendment Date
16 May 2018Global
Description of Change and Rationale Section(s) Affected by [CONTACT_319472] 
.Emergency Contact [CONTACT_385982]633 -[ADDRESS_483612] been modified to accommodate 
younger children completing SHP633 -301. 
SHP633 -304 w ill evaluate long -term safety and efficacy in subjects who 
completed SHP633 -301 and will provide a mechanism for subjects who 
complete SHP633 -301 to receive additional teduglutide treatment if 
clinically indicated . Synopsis; Table 1 -1; Section 2; 
Section 3.1; Section 4.1; Section 4.5; 
Section 6.2.2; Section 7.1.1; 
Section [IP_ADDRESS]; Section 7.2.1; 
Section 9.5; Section 9.7.1
To minimize risk to subjects, a new escape criterion was added, allow ing 
those who had escaped during the follow -up period of a previous teduglutide 
treatment to omit the follow -up period during subsequent teduglutide 
treatment cycles . 
For subjects who previously escaped the follow -up period, CxW24 
assessments can be combined with the next pretreatment visit assessments.Syno psis; Table 1 -3; Figure 3 -1; 
Section 3.1; Section 4.6; 
Section 6.2.3; Section [IP_ADDRESS]; 
Section [IP_ADDRESS]; Section 7.1.4; 
Section 7.2.[ADDRESS_483613] gastrointestinal procedures.Table 1 -1; Table 1 -2; Table 1 -3, 
Section 5.1; Section 7.1.1; 
Section 7.1.2; Section [IP_ADDRESS]; 
Section [IP_ADDRESS]; Section 7.1.5
Updated the information on the clinical studies with teduglutid e in pediatric 
subjects to include the results of TED -C14-006 and a description of the 
additional core study, SHP633 -301. Section 1.3
Added new PK simulation data to further support dosing. Section 3.1
Deleted text that was duplicated in other sentences of sections. Section 5.1
Deleted biological therapy (eg, antitumor necrosis factor) from the table of 
prohibited treatments as it was included in error.Table [ADDRESS_483614] of laboratory tests. Table 7 -1
For non-commercial use only
Shire CONFIDENTIAL Page 81
SHP633 -304 Protocol Am endment 4
Teduglutide 01Oct2019
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 3 Amendment Date
16 May 2018Global
Description of Change and Rationale Section(s) Affected by [CONTACT_386003].Section 7.2.3
Specified that saved serum samples should be omitted for subjects w eighing 
less than 10 kg and whenever local blood volume limitations are exceeded.Section 7.2.8
Clarified that if a child is under 2 years of age or unable to complete a 
quality of life questionnaire (due to developmental delay or other illness) it 
will not constitute a protocol deviation.Section 7.2.[ADDRESS_483615] been collected for subjects entering from TED -C14-006. Additional 
interim analyses may be conducted as needed.Section 9.4
Minor editorial changes and corrections to typographical errors (w hich do 
not modify content and/or intent of the original document) were made.Throughout protocol
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 2 Amendment Date
23 Mar 2017Global
Description of Change and Rationale Section(s) Affected by [CONTACT_385970]; 
Section 8.1.6; Section 8.2.2; 
Section 8.2.4
To allow  for approximately 7 days for subjects to transfer from Study 
TED -C14-006 to Study SHP633 -304 (instead of up to 7 days).Table 1 -1; Section 7.1.[ADDRESS_483616] pretreatment visit (P1) follow s the screening visit, it must occur 
within 12 w eeks of screening.Table 1 -3
Revised the language on abstinence as a contraceptive method for 
consistency with the Medicines and Healthcare Products Regulatory 
Agency (MHRA) Clinical Trial Facilitation Group's "Recommendations 
related to contraception and pregnancy testing in clinical trials."Section 4.7.1
Clarification that ancillary components, in addition to sterile w ater for 
injection syringes, will also be provided and labeled in accordance w ith 
the applicable regulatory requirements.Section 6.3.1
A footnote was added in Table 7 -2 to clarify that subjects older than 
18years of age will con tinue to use the Child Self Report and Parent 
Proxy -Report for Teens (ages 13 -18) when completing the Pediatric 
Quality of Life Generic Core Scale (PEDSQL™).Section [IP_ADDRESS] (Table 7 -3)
For non-commercial use only
Shire CONFIDENTIAL Page 82
SHP633 -304 Protocol Am endment 4
Teduglutide 01Oct2019
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 2 Amendment Date
23 Mar 2017Global
Description of Change and Rationale Section(s) Affected by [CONTACT_319483] a severe 
treatment -emergent adverse event (TEAE) that might lead to dose 
interruption (Section 8.4.1) or early termination of the study (Section 8.5) 
will also be graded according to the National Cancer Institute’s (NCI) 
Common Terminology Criteria for Adverse Events (CTCAE) severity 
grading criteria, in addition to the standard severity categorization. These 
events are no longer limited to only the events described in Table 8 -1, 
entitled “CTCAE Cr iteria for Adverse Events that May Lead to Dose 
Interruption (Prospective Period of Observation Only).” Therefore, Table 
8-1 has been deleted.Sectio n 8.1.1; Section 8.4; 
Section 8.4.1
Table 8 -1 (deleted)
Revised the criteria for early termination of the study: stoppi[INVESTIGATOR_385943] [ADDRESS_483617], and no longer limited to the 
events described in Table 8 -1, entitled “CTCAE Criteria for Adverse 
Events that May Lead to Dose Interruption (Prospective Period of 
Observation Only).”Section 8.5
Protocol Am endments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 1 Amendment Date
22 Nov 2016Global
Description of Change and Rationale Section(s) Affected by [CONTACT_385962].Protocol Signature [CONTACT_319504] [CONTACT_319431] -teduglutide treatment 
period, visits will take place approximately every 12 w eeks.Synopsis
Sections 3.1, 7.1.2
Figure 3 -1
The study design flow chart has been edited for clarity. Synopsis
Figure 3 -1
The co llection of all actual and prescribed enteral nutrition data has been 
removed to reduce the burden on the subjects and investigators. Enteral 
nutrition data are not required as the efficacy endpoints are limited to 
parenteral support parameters.Synopsis
Table 1- 1, Table 1 -2, Table 1 -3
Sections 7.1.2, [IP_ADDRESS], [IP_ADDRESS], 7.1.5, 
[IP_ADDRESS], [IP_ADDRESS]
Exclusion criterion [ADDRESS_483618] been refined: 
exclusion/prohibition of treatment with growth hormone has been 
extended to 3 months for consistency with other teduglutide studies. Synopsis
Section 4.5
Table 5 -1
For non-commercial use only
Shire CONFIDENTIAL Page 83
SHP633 -304 Protocol Am endment 4
Teduglutide 01Oct2019
Protocol Am endments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 1 Amendment Date
22 Nov 2016Global
Description of Change and Rationale Section(s) Affected by [CONTACT_386004]. Synopsis
Section 4.[ADDRESS_483619] been clarified. Table 1- 2, Table 1 -3
Sections [IP_ADDRESS], 7.1.[ADDRESS_483620] required at the pretreatment visit should be performed at the 
local laboratory instead of the central laboratory. This will ensure timely 
results prior to starting treatment with teduglutide .Table 1 -3
Sections [IP_ADDRESS], 7.2.6
The requirement for urine specimen collection has been revised so that a 
lack of urinalysis will not constitute a protocol deviation for any pediatric 
subjects (not only for subjects wearing diapers).Table [ADDRESS_483621] no -teduglutide treatment visit 
after the screening visit will occur within 2 to 12 w eeks of the screening 
(formerly within 12 w eeks of screening).Synopsis
Table [ADDRESS_483622] been clarified for visits during the no -teduglutide and 
teduglutide treatment periods.Table 1 -2, Table 1 -3
Section 7.1.2
‘Specific’ has been deleted from ‘positive/specific ant i-teduglutide 
antibodies’ to eliminate the redundancy. By [CONTACT_108], positive samples 
must be specific (as assessed in the confirmatory assay), or otherwise 
considered negative.Table [ADDRESS_483623] been removed from 
medical history.Table 1 -1 (footnote b)
Section 7.2.1
For consistency within the protocol, sigmoidoscopy has been added as the 
alternate to colonoscopy throughout the protocol. Table 1 -1, Table 1 -2, Table 1 -3
Sections 3.1, 7.1.2, [IP_ADDRESS]
Removal of former footnote i on fecal occult blood test for clarity. Table 1 -3
Clarification has been made on circumstances when the CxW28 visit may 
be combined with the next pretreatment or EOS/ET visit. Table 1 -3
Section 7.1.4
The text on PS support requirements over time in pediatric subjects w ith 
SBS has been clarified, and text on intestinal adaptation has been refined.Section 1.1
Status of current teduglutide approvals for use has been updated. Section 1.2, 3.1
The term ‘re -challenge’ has been replaced w ith ‘additional teduglutide 
treatment’ for clarity and consistency with other studies.Section 3.[ADDRESS_483624]’s completion of the study has been corrected for 
consistency within the protocol.Section 3.[ADDRESS_483625] been clarified.Sections 4.8.1, 4.8.2
For non-commercial use only
Shire CONFIDENTIAL Page 84
SHP633 -304 Protocol Am endment 4
Teduglutide 01Oct2019
Protocol Am endments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 1 Amendment Date
22 Nov 2016Global
Description of Change and Rationale Section(s) Affected by [CONTACT_386005]/guardian has been added as reason for 
discontinuation.Section 4.8.[ADDRESS_483626] met a follow -up period escape 
criterion.Section 7.2.5
Intake and output diaries (formerly in Sections 7.2.11 and 7.2.12, 
respectively) have been moved under a new Section 7.2.11 ‘Diaries’ for 
clarity, and are now Sections [IP_ADDRESS] and [IP_ADDRESS], respectively. 
Information on study drug administration diary has been added in Section 
[IP_ADDRESS]. Clarification has been made that only available diary data will be 
reviewed at each clinic and telephone visit.Sections 7.2.11, [IP_ADDRESS], [IP_ADDRESS], 
[IP_ADDRESS] 
Performance of dipstick specific gravity tests by [CONTACT_385995]. It is 
now at the discreti on of the investigator for all subjects, not just those in 
diapers. This change is to align with standard medical practice.Section [IP_ADDRESS]
Clarifications have been made to the language on dose interruption. Sections 8.4, 8.4.1
Unscheduled safety follow up assessments (including visits conducted 
after EOS) are not to be recorded. How ever, clarification has been made 
that they are to be collected where requested.Section 9.1
The protocol now  refers to the data monitoring committee (DMC) Charter 
for the s chedule of DMC reviews.Section 9.[ADDRESS_483627] been made to the Health economics and outcomes research 
endpoints to include the beginning of each treatment cycle (CxD1) as 
additional baseline. These changes are for clarity and consistency with 
other ted uglutide studies. Synopsis
Section 9.9.[ADDRESS_483628] been made to the guidelines for nutritional support 
management during the study.Appendix 2
For non-commercial use only
Shire CONFIDENTIAL Page 85
SHP633 -304 Protocol Am endment 4
Teduglutide 01Oct2019
APPENDIX 2 GUIDELINES FOR NUTRI TIONAL SUPPORT MANAG EMENT 
DURING THE STUDY
Nutritional support adjustment in volume and calories should be considered at all planned visits. 
Please consider the following clinical parameters identified as markers for adequate management 
of pediatric SBS. These parameters should also be considered f or managing nutritional support 
(PS and/or oral/enteral feeding) in terms of volume and calories during the treatment period. 
Growth trajectory , including weight, height (or length), and head circumference (for pediatric 
subjects up to 36 months of age)
Other clinical evaluations
Serum electrol ytes
Blood urea nitrogen /creatinine levels
Changes in stool frequency  or volume, including mixed output
Stool consistency  (ie, Bristol Stool Scale)
Urine specific gravit y
General consideration to possible clinical deterioration in SBS
Inability  to maintain weight and growth velocity
Diarrhea ( ≥10 bowel movements per day , ≥80 mL/kg/day  from an ostomy, or 
≥75mL/kg/day  mixed output)
Colic/vomiting frequency increased
Electrol yte changes or imbalance
Skin breakdown 
Adjustments should be based on the actual nutritional support in volume and calories the 
subject infuses. Subjects should remain compliant with the nutritional support prescription in 
volume and calories during the stud y.
Nutritional support constituents may be adjusted at the discretion of the investigator.
During the [ADDRESS_483629]’s scheduled visit, no 
further changes to the prescribed nutritional support should be made.
If there is a change in EN or other food or fluid intake, the investigator should consider this 
when adjusting the PS/EN support in volume and calories.
For non-commercial use only
Shire CONFIDENTIAL Page 86
SHP633 -304 Protocol Am endment 4
Teduglutide 01Oct2019
Figure A -1 Weaning Algorithm for Subjects Who are NOT Toilet Trained and in 
Diapers
For non-commercial use only
Shire CONFIDENTIAL Page 87
SHP633 -304 Protocol Am endment 4
Teduglutide 01Oct2019
Figure A -2 Weaning Algorithm for Subjects Who are Toilet Traine d and NOT in 
Diapers
For non-commercial use only
Shire CONFIDENTIAL Page 88
SHP633 -304 Protocol Am endment 4
Teduglutide 01Oct2019
Figure A -3 Clinical Dehydration Assessment and PS/EN Adjustment
For non-commercial use only
Shire CONFIDENTIAL Page 89
SHP633 -304 Protocol Am endment 4
Teduglutide 01Oct2019
APPENDIX 3 CAREGIVER INTERVIEW GUIDE
Exit Interv iews With Caregiv ers
Follow ing Participation in a
Short Bow el Sy ndrome Clinical T rial
1.Introduction (5Minutes)
Introduce interviewers
Confirm caregiver’s first name [CONTACT_386006] w
We are interested in learning more about your child’s symptoms and impacts due to short 
bowel syndrome and parenteral support. W e would also like to understand your experiences 
caring for your child as well as you and your child’s experiences with regard to treatment 
during the clinical trial.
The information you share with us will help the study sponsors learn more about potential 
treatment benefits of the clinical trial drug.
As we go along, please feel comfortable to speak openly and share your opi[INVESTIGATOR_319403]. 
There are no wrong answers. You are the expert.
Unless you report a side effect potentially related to a medication that our study sponsors 
produce during today’s call, your name [CONTACT_386007].
If you doreport a side effect during today’s call, I have to let the study sponsors know. I 
may ask you some follow -up questions to fully understand the nature of the experience 
so I can fully communicate information to the study sponsor.
**REMEMBER TO TURN ON THE AUDIO RECORDER ONCE CONSENT I S PROVIDED. 
INTERVIEWER WILL VERBALLY NOTE STUDY ID AND INTERVIEW DATE**
2.History and Symptoms (10 minutes)
Just briefly, please tell us about your child’s history with SBS.
How old is your child?
How long has your child had SBS?
How long has your child received parenteral support?
For non-commercial use only
Shire CONFIDENTIAL Page 90
SHP633 -304 Protocol Am endment 4
Teduglutide 01Oct2019
What symptoms of SBS does your child experience? W hat symptoms due to parenteral 
support does your child experience? Are there other symptoms your child experienced in th e 
past but doesn’t experience currently? W hat are those? [Probe for complete list and write 
down each symptom provided by [CONTACT_2299]; for each symptom, probe to understand 
whether due to SBS, parenteral support, or both]
Symptom 1: ________________________________
Symptom 2: ________________________________
Symptom 3: ________________________________
Symptom 4: ________________________________
Symptom 5: ________________________________
[If not provided spontaneously by [CONTACT_2299], specific symptoms will be probed.]
Now we would like to discuss other symptoms that some patients or caregivers have described 
to see whether or not they are things your child has experienced as well.
As I read each symptom, please let me know if your child has experienced this symptom in 
relation to his or her SBS or parenteral support. [Only read those symptoms not already 
provided by [CONTACT_2299]; probe to understand whether due to SBS, parenteral support, or 
both]
Pain/discomfort
Fatigue
Frequent need to empty bowels/bag
Diarrhea
Of the symptoms you have described which would you say is the most bothersome for your 
child? W hy?
3.Impacts (10 minutes)
How does your child’s SBS and parenteral support affect his or her life? [Probe for complete 
list and write down each impact provided by [CONTACT_18629]; probe to understand whether 
impact of SBS, parenteral support, or both]
Impact 1: ________________________________
Impact 2: ________________________________
Impact 3: ________________________________
Impact 4: __________ ______________________
Impact 5: ________________________________
[If not provided spontaneously by [CONTACT_2299], specific impacts will be probed.]
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_483630] 
described to see whether or not they are things your child has experienced as well.
As I read each impact, please let me know if you have experienced this in relation to your 
child’s SBS and parenteral support. [Only read those impacts not already provided by [CONTACT_2416]. For endorsed impacts, ask the participant to describe their experiences with the 
impact and whether they feel it is due to SBS or parenteral therapy or both]
Daily activities, including school if applicable
-Need to know /plan for bathroom facilities when leaving home
Physical functioning
Social functioning
Emotional functioning
Sleep
Of the impacts you have described, which would you say is the most bothersome to your 
child? W hy?
4.Clinical Trial Experiences (10 minut es)
Now we would like to talk about your experience during the clinical trial.
What were your expectations of treatment prior to entering the clinical trial?
Thinking back to before you started the clinical trial, what were some of the reasons you 
decided to enroll your child in the trial?
Were there specific symptoms/issues which you most wanted treatment to help? W hich 
ones? W hy?
How frequently was your child receiving parenteral therapy at the beginning of the trial? 
[Probe on how many times a week, for how many hours, and when administered] .
What improvements, if any, have you noticed in your child since starting the study? [Have 
caregivers describe each improvement reported]
Improvement 1: ________________________________
Impro vement 2: ________________________________
Improvement 3: ________________________________
Improvement 4: ________________________________
Improvement 5: ________________________________
For non-commercial use only
Shire CONFIDENTIAL Page 92
SHP633 -304 Protocol Am endment 4
Teduglutide 01Oct2019
What were the biggest improvements you noticed? How important, if at all, were these 
improvements to you?
Were there smaller or other improvements that you noticed that were also meaningful to 
you? If so, please describe these improvements. [Add these improvements to the list above]
I would like to review each of the improvements that you noticed. Thinking about [a 
symptom from the list] , how would you describe them before the study? [Probe mild, 
moderate , or severe , as applicable]
How would you describe them after the study? [Probe none , mild, moderate , or severe , as 
applicable]
[If not reported] Were there any improvements in your child’s parenteral therapy during the 
study? How important, if at all, was this change to you? [Probe to capture current parenteral 
frequency]
Of all of the improvements we have talked about, which do you think was the most important 
to your child? Why? W hich was the most important to you? W hy?
How would you describe the change in yo ur child’s SBS overall after participating in the 
study? [Probe: very much better , much better , a little better, no change , a little worse , much 
worse , or very much worse]
5.Caregiver Experiences (10 minutes)
Now we would like to talk about your experience as a caregiver of a child with SBS.
How has having a child with SBS impacted your life? [Probe for complete list and write down 
each impact provided by [CONTACT_18629]; probe to understand whether impact of SBS, 
parenteral support, or both]
Impact 1: ________________________________
Impact 2: ________________________________
Impact 3: ________________________________
Impact 4: ________________ ________________
Impact 5: ________________________________
[If not provided spontaneously by [CONTACT_2299], specific impacts will be probed.]
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_483631] experienced as well.
As I read each impact, please let me know if you have experienced this in relation to caring 
for your child with SBS [Only read those impacts not already provided by [CONTACT_2299]. For 
endorsed impacts, ask participants to describe their experiences with the impact and 
whether they feel it is due to their child’s SBS, parenteral therapy for the SBS, or both.]
Caregiver’s daily activities
-Need to know/plan for bathroom facilities when leaving home with child
Caregiver’s physical functioning
Caregiver’s emotional functioning
Caregiver’s social functioning
Caregiver’s sleep
Financial impact
Of the impacts you have described which would you say is the most bothersome for you? 
Why?
Which, if any, of the above do you feel was improved during your child’s participation in the 
clinical trial? How important, if at all, was this improvement?
6.Closing
Is there anything else you would like to add about your child’s SBS?
Thank you for taki ng the time to meet with us today. Your input has been very helpful and will 
also be helpful for the patients that will participate in further research on SBS. Thank you again.
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_483632] INTERVIEW GUIDE
Exit Interv iews With Pediatric Subjects
Following Participation in a
Short Bow el Sy ndrome Clinical T rial
7.Introduction (5Minutes)
Introduce interviewers
Confirm subject’s first name [CONTACT_386008] w
We are interested in learning more about your symptoms and impacts due to short bowel 
syndrome and parenteral support (the nutrition and fluids you get because of your short 
bowel). W e would also like to understand your experiences during the study you were in. 
The information you share with us will help the study sponsors learn more about potential 
treatment benefits of the clinical trial drug.
As we go along, please feel free to speak openly and share your opi[INVESTIGATOR_319403]. There are 
no wrong answers. You are the expert.
Unless you report a side effect that might be related to a medication that our study sponsors 
produce during today’s call, your name [CONTACT_386009] r be associated with anything you share 
with us.
If you doreport a side effect during today’s call, I have to let the study sponsors know. I 
may ask you some follow -up questions to fully understand what happened so I can fully 
share this with the study sp onsor.
**REMEMBER TO TURN ON THE AUDIO RECORDER ONCE CONSENT I S PROVIDED. 
INTERVIEWER WILL VERBALLY NOTE STUDY ID AND INTERVIEW DATE**
8.History and Symptoms (15 minutes)
Just briefly, please tell us about history with SBS.
How old are you? 
How long have you had SBS?
How long have you been getting parenteral support? [Confirm participant understanding 
of term and use term if understood/used or use the participant preferred term throughout 
the interview]
For non-commercial use only
Shire CONFIDENTIAL Page 95
SHP633 -304 Protocol Am endment 4
Teduglutide 01Oct2019
What symptoms of SBS do you experience? W hat symp toms due to parenteral support do 
you experience? Are there other symptoms you have had in the past but do not experience 
today? W hat are those? [Probe for complete list and write down each symptom provided by 
[CONTACT_2299]; for each symptom, probe to un derstand whether due to SBS, parenteral 
support, or both]
Symptom 1: ________________________________
Symptom 2: ________________________________
Symptom 3: ________________________________
Symptom 4: ________________________________
Symptom 5: ________________________________
[If not provided spontaneously by [CONTACT_2299], specific symptoms will be pr obed.]
Now we would like to discuss other symptoms that some patients have described to see 
whether or not they are things you have experienced as well.
As I read each symptom, please let me know if you have experienced this symptom in 
relation to your SBS or parenteral support. [Only read those symptoms not already provided 
by [CONTACT_2299]; probe to understand whether due to SBS, parenteral support, or both]
Pain/discomfort
Fatigue
Frequent need to empty bowels/bag
Diarrhea
Of the symptoms you have described which would you say is the most bothersome for you? 
Why?
9.Impacts (15 minutes)
How does your SBS and parenteral support affect your life? [Probe for complete list and 
write down each impact provided by [CONTACT_2299]; probe to understand whether impact of 
SBS, parenteral support, or both]
Impact 1: ________________________________
Impact 2: ________________________________
Impact 3: __________________________ ______
Impact 4: ________________________________
Impact 5: ________________________________
[If not provided spontaneously by [CONTACT_2299], specific impacts will be probed.]
For non-commercial use only
Shire CONFIDENTIAL Page [ADDRESS_483633] experienced as well.
As I read each impact, please let me know if you have experienced this in relation to your 
SBS and parenteral support. [Only read those impacts not already provided by [CONTACT_2416]. For endorsed impacts, ask the participant to describe their experiences with the 
impact and whether they feel it is due to SBS or parenteral therapy or both]
Daily activities, including school if appl icable
-Need to know/plan for bathroom facilities when leaving home
Physical functioning
Social functioning
Emotional functioning
Sleep
Of the impacts you have described, which would you say is the most bothersome to? W hy?
10. Clinical Trial Experiences (10 
minutes)
Now we would like to talk about your experience during the clinical trial.
What did you think the study would be like before you started it? 
Thinking back to before you started the study, what were some of the reasons you decided 
to be a part of the study? 
Were there specific symptoms/issues which you most wanted treatment to help? W hich 
ones? W hy?
How frequently were you child receiving parenteral therapy at the beginning of the trial? 
[Probe on how many times a week, for how many hours, and when administered] .
What improvements, if any, have you noticed since you started the study? [Have 
participants describe each improvement reported]
Improvement 1: ________________________________
Improvement 2: ________________________________
Improvement 3: ________________________________
Improvement 4: ________________________________
Improvement 5: ________________________________
For non-commercial use only
Shire CONFIDENTIAL Page 97
SHP633 -304 Protocol Am endment 4
Teduglutide 01Oct2019
What were the biggest improvements you noticed? How important, if at all, were these 
improvements to you?
Were there smaller or other improvements that you noticed that were also meaningful to 
you? If so, please describe these improvemen ts. [Add these improvements to the list above]
I would like to review each of the improvements that you noticed. Thinking about [a 
symptom from the list] , how would you describe them before the study? [Probe mild, 
moderate , or severe , as applicable]
How would you describe them after the study? [Probe none , mild, moderate , or severe , as 
applicable]
[If not reported] Were there any improvements in your parenteral therapy during the study? 
How important, if at all, was this change to you? [Probe to capture cur rent parenteral 
frequency]
Of all of the improvements we have talked about, which do you think was the most important 
to you? W hy? 
How would you describe the change in your SBS overall after being in the study? [Probe: 
very much better , much better , a little better, no change , a little worse, much worse , or very 
much worse ]
11. Closing
Is there anything else you would like to add about your SBS?
Thank you for taking the time to meet with us today. Your input has been very helpful and will 
also be he lpful for the patients that will participate in further research on SBS. Thank you again.
For non-commercial use only